

**Universitäres Centrum für Tumorerkrankungen
der Universitätsmedizin Mainz**

BESONDERE AUFGABEN UND QUALITÄTSBERICHT | BERICHTSJAHRE 2019 – 2021

Vorwort

Dieser Bericht wird im Rahmen der „Regelungen des G-BA zur Konkretisierung der besonderen Aufgaben von Zentren und Schwerpunkten gemäß § 136c Absatz 5 SGB V (Zentrums-Regelungen)“ auf der Datengrundlage der Jahre 2019-2021 erstellt und öffentlich zugänglich gemacht. Er dient der Darstellung der qualitätsverbessernden Maßnahmen und Ergebnisse.

Die strukturelle Gliederung aus der „Zentrums-Regelung“ wurde in diesem Bericht weitgehend übernommen. Die qualitätsverbessernden Maßnahmen sind dort in der Anlage 2 – Anforderungen an Onkologische Zentren unter § 2 Nummer 3 aufgeführt.

Kennzahlen aus den Jahren 2019-2021 bilden die Grundlage des Berichts.

Inhalt

Vorwort	1
Inhalt	2
1. Darstellung des UCT und seiner Netzwerkpartner	3
Leitung UCT Mainz	3
Interdisziplinäre Zusammenarbeit	3
Zertifizierte Zentren (Stand 12/2021)	4
Beteiligung an nationalen Netzwerken	5
2. Anzahl der im Zentrum tätigen Fachärztinnen und Fachärzte für Onkologie, Chirurgie, Pathologie und Radiologie bzw. der Fachärzte mit einer entsprechenden Zusatzweiterbildung	6
3. Art und Anzahl der pro Jahr erbrachte besonderen Aufgaben	7
Interdisziplinäre Fallkonferenzen	8
Externe Beratung – Unterstützung anderer im stationären und ambulanten Bereich durch Fachexpertise	9
Strukturiertes Vorhalten begleitender supportiver Maßnahmen im stationären und ambulanten Sektor	10
Behandlungspfade SOPs	10
Konzentration außergewöhnlicher Fachexpertise in besonderen Versorgungsbereichen der Onkologie	10
4. Maßnahmen zur Qualitätssicherung und Qualitätsverbesserung der besonderen Aufgabenwahrnehmung	11
5. Fort- und Weiterbildungsveranstaltungen	15
6. Onkologisches Netzwerk Rheinland-Pfalz – Maßnahmen zum strukturierten Austausch mit onkologischen Zentren, Krankenhäusern, Schwerpunktpraxen und Hausärzt*innen	16
7. Selbsthilfegruppen, Krebsgesellschaft Rheinland-Pfalz und Patientenbeteiligung	17
8. Mitarbeit an Leitlinien und Konsensuspapieren	18
9. Beteiligung des Zentrums an klinischen Studien	18
10. Wissenschaftliche Publikationen	18
11. Forschungstätigkeit am UCT Mainz	18
Translationale Forschung - Organisation	18
UCT Infrastruktur	19
UCT Nachwuchsförderung	19
UCT-Projekte und Drittmittel	20
External Advisory Board	20
Anhang	21

1. Darstellung des UCT und seiner Netzwerkpartner

Das Universitäre Centrum für Tumorerkrankungen der Universitätsmedizin (UCT) Mainz ist ein Zusammenschluss aller onkologisch tätigen Einrichtungen der Universitätsmedizin Mainz. Es hat es sich als Onkologisches Spitzenzentrum (Anerkennung der Deutschen Krebshilfe 2016 und 2021) zur Aufgabe gemacht, die Versorgung onkologischer Patienten auf allen Ebenen optimal zu gestalten. Gemäß dem Motto der Universitätsmedizin "Unser Wissen für Ihre Gesundheit" streben wir nach stetiger Verbesserung und Anpassung unseres Handelns an modernste Versorgungsmöglichkeiten. Dies schließt die enge Kooperation in einem Netzwerk mit niedergelassenen Kolleginnen und Kollegen, Krankenhäusern, Patientenverbänden, Selbsthilfegruppen, Hospizen und anderen ein. Darüber hinaus entwickelt und koordiniert das UCT translationale Forschungsprogramme, um neue innovative Forschungsergebnisse zeitnah in die klinische Praxis zu transferieren.

Leitung UCT Mainz

Leiter	Univ.-Prof. Dr. Thomas Kindler
Stellvertreter	Univ.-Prof. Dr. Hauke Lang (Klinik für Abdominal-, Viszeral- und Transplantationschirurgie) Univ.-Prof. Dr. Ugur Sahin (Forschungszentrum für Immuntherapie) Univ.-Prof. Dr. Heinz Schmidberger (Klinik und Poliklinik für Radioonkologie und Strahlentherapie) Univ.-Prof. Dr. Matthias Theobald (III. Medizinische Klinik & Poliklinik)
Koordination Onkologisches Zentrum	Dr. Friederike Mildemberger

Tabelle 1: Leitung und UCT-Geschäftsführung

Übergeordnetes Entscheidungsgremium ist der UCT-Lenkungsausschuss. Diesem Gremium gehören alle an der Versorgung onkologischer Patient*innen und an der Krebsforschung beteiligten Klinik- und Institutsleiter an. Darüber hinaus wird der Lenkungsausschuss durch gewählte Mitglieder der Selbsthilfe (n=2) und Netzwerkvertretern (n=4) ergänzt. Die Mitglieder des Lenkungsausschusses treffen sich 1x/Quartal und stimmen über Vorschläge der UCT-Geschäftsführung (Leitung und Koordination) ab. Der Lenkungsausschuss wird durch das „External Advisory Board“ (siehe 11.) und von Mitgliedern des externen Patienten Boards beraten.

Interdisziplinäre Zusammenarbeit

Die interdisziplinäre Zusammenarbeit zwischen den einzelnen Kliniken und dem UCT ist durch Kooperationsverträge geregelt. Eine Aufstellung der internen Kooperationspartner ist in *Anhang 1* dargestellt. Zentrale Aufgabe des UCT ist die Koordination der interdisziplinären Zusammenarbeit. Die Leitung des UCT Mainz wird hierbei durch Schnittstellenkoordinator*innen und Bereichsleiter unterstützt (Tabelle 2). Zusammen mit der UCT-Geschäftsführung ist das Koordinationsteam für die strukturelle und konzeptionelle Weiterentwicklung des UCT Mainz sowie für die Umsetzung beschlossener Maßnahmen verantwortlich.

Bereiche	Leitung / Koordination / Ansprechpartner
Interdisziplinäre UCT Ambulanz	Prof. Dr. Thomas Kindler Ingrid Schülke
IT-Management	Diogo Alexandre Georg Vollmar
Netzwerkkoordination	Dr. Karin Dietrich Dr. Alexander Desuki
Personalisierte Onkologie Molekulares Tumorboard	Dr. Alexander Desuki Dr. Marius Fried
Selbsthilfe und Patientenbeteiligung	Dr. Karin Dietrich Prof. Dr. Jörg Wiltink
Sektion Psychoonkologie	Prof. Dr. Jörg Wiltink
Tumorboard-Koordination	Marie Meinert
Wissenschaftliche Koordination	Dr. Ann-Kathrin-Herrmann
Zentrales QM des UCT Mainz	Dr. Friederike Mildenerberger Pia Fischer
Zentrale Tumordokumentation	Rosi Klingler Ursula Sudhof
Zentrale UCT Studienabteilung	Prof. Dr. Georg Heß Christina van Oordt

Tabelle 2: Zentrale Bereiche des UCT und Ansprechpartner

Abbildung 1 zeigt einen Überblick über derzeit zertifizierte Zentren, intern beteiligte Organisationsstrukturen sowie zentrale Tätigkeitsfelder des UCT Mainz.




Abbildung 1: Darstellung der am UCT beteiligten Einrichtungen und Organisationsbereiche

Zertifizierte Zentren (Stand 12/2021)

Im Onkologischen Zentrum UCT Mainz sind derzeit 14 Krebserkrankungen nach Vorgaben der Deutschen Krebsgesellschaft (DKG) zertifiziert.

Organkrebszentrum/ Modul	Leitung des Zentrums (Stand 10-2022)
Brustkrebs	Univ.-Prof. Dr. Marcus Schmidt
Gyn. Krebserkrankungen	PD Dr. Marco Battista
Hautkrebs	Univ.-Prof. Dr. Stephan Grabbe
Viszeralonkologie - Darmkrebs/ HCC - Magen/ Pankreas	Univ.-Prof. Dr. Peter Galle
Neuroonkologie	Univ.-Prof. Dr. Florian Ringel
Uroonkologisches Zentrum - Prostata - Modul Niere	Univ.-Prof. Dr. Axel Haferkamp
Kopf- Hals-Tumoren	Univ.-Prof. Dr. Christoph Matthias
Kinderonkologie	Univ.-Prof. Dr. Jörg Faber
Leukämie- und Lymphom-Centrum	Univ.-Prof. Dr. Matthias Theobald
Weichteilsarkome incl. GIST	Univ.-Prof. Dr. Dr. Traub

Tabelle 3: DKG-zertifizierte Organkrebszentren und Leitung (Stand 01/2022)

Alle zertifizierten DKG-Zentren des UCT Mainz inkl. Kooperationspartner sind auf der Webseite www.oncomap.de/centers gelistet.

Neben den in Tabelle 3 gelisteten DKG-zertifizierten Zentren / Modulen bestehen weitere Zertifizierungen im Bereich Onkologie:

- *Interdisziplinäres Endokrine und Neuroendokrine Tumorzentrum (IENET-Zentrum)* ausgezeichnet von der European Neuroendocrine Tumor Society (ENETS) als Center of Excellence
- DKG-zertifizierte *Gynäkologische Dysplasie-Einheit*
- DAGV-zertifiziertes *Exzellenzzentrum Oberer Gastrointestinaltrakt*

Beteiligung an nationalen Netzwerken

Das UCT Mainz ist als Onkologisches Spitzenzentrum an zahlreichen nationalen Netzwerken aktiv beteiligt.

- Als eines von 15 durch die Deutsche Krebshilfe ausgezeichnetes Onkologisches Spitzenzentrum Mitglied des **CCC-Netzwerkes der Deutschen Krebshilfe**
- Mitglied des Deutschen Konsortiums für Translationale Krebsforschung (**DKTK**; als Partnerstandort Frankfurt a.M.)
- Nationales Netzwerk Genomische Medizin (**nNGM**)
- Deutsches Netzwerk Genomische Medizin (**DNPM**)
- Medizininformatik-Initiative **MIRACUM**
- Netzwerk **OnkoAktiv** für onkologische Sport- und Bewegungsangebote
- Deutsches Konsortium für Familiären Brust- und Eierstockkrebs (**FBREK**)

2. Anzahl der im Zentrum tätigen Fachärztinnen und Fachärzte für Onkologie, Chirurgie, Pathologie und Radiologie bzw. der Fachärzte mit einer entsprechenden Zusatzweiterbildung

Anzahl der im Zentrum tätigen Fachärztinnen und Fachärzte für Onkologie, Chirurgie, Pathologie und Radiologie¹ bzw. der Fachärzte mit einer entsprechenden Zusatzweiterbildung ¹ angegeben in VK im Jahresdurchschnitt				
Einrichtung / Bereich	2019	2020	2021	Zusatzweiterbildungen (2020)
ONKOLOGEN²				
III. Medizinische Klinik & Poliklinik - Hämatologie / medizinische Onkologie / Pneumologie	21,08	20,95	18,06	Allergologie, Hämostaseologie, Infektiologie, Medikamentöse Tumorthherapie, Notfallmedizin, Palliativmedizin, Schlafmedizin, Spezielle Schmerztherapie, Flugmedizin
Klinik und Poliklinik für Kinder- und Jugendmedizin - SP Kinder-Hämatologie und -Onkologie -	5	4	4,45	Palliativmedizin
Universitäres Centrum für Tumorerkrankungen (UCT)	3	3	3	Palliativmedizin
² In weiteren Kliniken sind Fachärzte mit Zusatzbezeichnung "Medikamentöse Tumorthherapie" onkologisch tätig.				
CHIRURGISCHE KLINIKEN und weitere chirurgisch tätige Kliniken				
Klinik für Allgemein-, Viszeral- und Transplantationschirurgie	13,38	10,79	12,92	Ärztliches Qualitätsmanagement, Notfallmedizin, Proktologie, Spezielle Viszeralchirurgie
Hals-, Nasen-, Ohren-Klinik und Poliklinik – Plastische Operationen inkl. Stimm- u Sprachstörungen	9,82	8,62	8,04	Medikamentöse Tumorthherapie, Spezielle Hals- Nasen- Ohrenchirurgie, Plastische Operationen, Ärztliches Qualitätsmanagement, Allergologie
Hautklinik und Poliklinik	14	7,82	9,45	Ärztliches Qualitätsmanagement, Akupunktur, Allergologie, Dermatohistologie, Labordiagnostik – fachgebunden –, Medikamentöse Tumorthherapie, Naturheilverfahren, Palliativmedizin, Phlebologie, Proktologie.
Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie – Plastische Operationen	6,25	7,35	8,11	Plastische Operationen
Klinik und Poliklinik für Geburtshilfe und Frauengesundheit	13,44	14,66	17,97	SP Gynäkologische Onkologie. Ärztliches Qualitätsmanagement, Akupunktur, Labordiagnostik – fachgebunden –, Medikamentöse Tumorthherapie, Medizinische Informatik, Naturheilverfahren, Palliativmedizin, Psychotherapie – fachgebunden –
Klinik und Poliklinik für Herz- Thorax- und Gefäßchirurgie	20,17	19,3	23,49	Intensivmedizin
Klinik und Poliklinik für Kinderchirurgie	5,54	5,12	4,88	Sportmedizin

Klinik und Poliklinik für Urologie und Kinderurologie	9,97	10,35	11,85	Medikamentöse Tumorthherapie, Röntgendiagnostik – fachgebunden –, Andrologie [Die Inhalte der Zusatzweiterbildung Medikamentöse Tumorthherapie sind in der Facharztanerkennung bereits enthalten.]
Neurochirurgische Klinik und Poliklinik	13,83	15,29	12,34	Intensivmedizin, Notfallmedizin
Zentrum für Orthopädie und Unfallchirurgie	16,58	17,76	14,53	Handchirurgie, Spezielle Orthopädische Chirurgie, Spezielle Unfallchirurgie, Orthopädische Rheumatologie,
PATHOLOGIE				
Institut für Neuropathologie	1	0,9	0,9	//
Institut für Pathologie	7,82	6,81	9,51	Ärztliches Qualitätsmanagement
RADIOLOGIE				
Klinik und Poliklinik für Neuroradiologie inkl. Schwerpunkt Neuroradiologie	6,24	8,07	9,08	//
Klinik und Poliklinik für diagnostische und interventionelle Radiologie inkl. Schwerpunkt Kinderradiologie	18,49	17,79	18,01	Ärztliches Qualitätsmanagement
Nachrichtlich³				
I. Medizinische Klinik und Poliklinik (u.a. Gastroenterologie, Endokrinologie)	18,27	17,90	16,47	Medikamentöse Tumorthherapie, Palliativmedizin, Ärztliches Qualitätsmanagement, Notfallmedizin, Intensivmedizin, Infektiologie, Diabetologie, Tropenmedizin, Medizinische Informatik
Klinik und Poliklinik für Radioonkologie und Strahlentherapie	8,1	6,48	6,76	[Die Inhalte der Zusatzweiterbildung Medikamentöse Tumorthherapie sind in der Facharztanerkennung bereits enthalten.]
³ In mehreren weiteren Kliniken und Polikliniken der Universitätsmedizin werden Patienten onkologisch betreut.				

Tabelle 4: Fachärzte am UCT Mainz. Nachrichtlich: Vollkräfte Ärztlicher Dienst im Bereich Forschung und Lehre und Drittmittel sind nicht berücksichtigt.

3. Art und Anzahl der pro Jahr erbrachte besonderen Aufgaben

Das UCT der Universitätsmedizin Mainz steht als Haus der Maximalversorgung als Ansprechpartner und Tertiärversorger allen Zuweisern und Patient*innen von Rheinland-Pfalz und darüber hinaus zur Verfügung. Das UCT Mainz ist in Rheinland-Pfalz der größte Versorger in den Bereichen Onkologie und Hämatologie und übernimmt neben den klassischen universitären Aufgaben „Klinik, Forschung & Lehre“ die Funktion eines Koordinators des regionalen onkologischen Netzwerks. In den Jahren 2019 – 2021 wurden am UCT Mainz jährlich knapp 20.000 onkologische Patient*innen behandelt (Tabelle 5).

	2019	2020	2021
Erstvorstellungen	3.817	3.664	3.813
Alle Patienten	19.822	19.059	19.751

Tabelle 5: Anzahl der im entsprechenden Jahr behandelten Patienten mit Erstvorstellung einer onkologischen Erkrankung und alle onkologischen Patienten (gemäß den Kriterien der Deutschen Krebshilfe eines onkologischen Spitzenzentrums).

Interdisziplinäre Fallkonferenzen

Interdisziplinäre Fallkonferenzen (Tumorboards) stellen die Basis für die Erstellung eines leitliniengerechten Behandlungsplans für onkologische Patient*innen dar. Die individualisierte Behandlung wird von Expert*innen für Diagnostik, onkologische Chirurgie, konservativer onkologischer Therapie und interventioneller Therapie gemeinsam mit der primär patientenführenden Einrichtung diskutiert. Die Teilnahme eines/r Facharztes oder Fachärztin für Hämatologie und medizinische Onkologie, Radiologie bzw. Neuroradiologie, Strahlentherapie und Pathologie bzw. Neuropathologie ist gemäß OnkoZert-Kriterien der Deutschen Krebsgesellschaft verpflichtend. Die Teilnahme der Fachdisziplinen wird in jedem Tumorboardprotokoll dokumentiert. Am UCT Mainz finden wöchentlich 16 Tumorkonferenzen für jede Tumorentität statt (siehe Abb. 2).

Tag	Zeit	Tumorkonferenz
Montag	15:00 Uhr	Molekulares Tumorboard (MolTubo)
	15:15 Uhr	Kolloquium für Hepatozelluläre Karzinome (HCC)
Dienstag	14:00 Uhr	Pädiatrisches Tumorboard (Koordination dezentral)
	16:10 Uhr	Thorax-onkologisches Board (TOB)
Mittwoch	14:00 Uhr	Interdisziplinäres onkologisches Forum (IOF)
	15:15 Uhr	Kolonrektale Tumorkonferenz (KRT)
	15:45 Uhr	Tumorboard für Kopf-Hals-Tumore (KHT)
Donnerstag	13:30 Uhr	Gynäkologisches und Senologisches Tumorboard (Gyn + IST)
	14:30 Uhr	Urologisches interdisziplinäres Tumorboard (UIT)
	15:15 Uhr	Gastrointestinales Tumorboard (GI)
	anschließend	Weichteil-Tumorboard (WT)
	15:15 Uhr	Hämatologisches Forum (HämFor)
	15:30 Uhr	Interdisziplinäres neuroonkologisches Forum (INOF)
Freitag	16:15 Uhr	Interdisziplinäres endokrines und neuroendokrines Tumorboard (IENET)
	08:15 Uhr	Interdisziplinäres Hauttumor-Board (IHB)
	14:30 Uhr	Tumorboard Stammzelltransplantation (SZT)

Abbildung 2: Wochenplan aller Tumorboards des UCT Mainz

In den Berichtsjahren 2019, 2020 und 2021 wurden am UCT Mainz 11.083, 11.833 und 12.123 Patientenfälle besprochen und konsentiert (siehe Abb. 3).




Abbildung 3: Anzahl der besprochenen Patientenfälle pro Kalenderjahr.

Niedergelassene Kolleg*innen aus Schwerpunktpraxen und Krankenhäuser haben über ein Web-basiertes Anmeldeformular (<https://www.unimedizin-mainz.de/uct/fuer-aerzte/interdisziplinaere-tumorboards/iof/iof.html>) die Möglichkeit Krebspatient*innen im jeweiligen Tumorboard anzumelden sowie in Präsenz oder per Videokonferenz am Tumorboard teilzunehmen. Das erstellte Protokoll wird von der zentralen Tumordokumentation automatisch an den/die externe/n Anmelder*in verschickt.

Externe Beratung – Unterstützung anderer im stationären und ambulanten Bereich durch Fachexpertise

Insbesondere für Krankenhausärzt*innen besteht die Möglichkeit Patient*innen in entitätsspezifischen Tumorboards zur Zweitmeinung / externen Beratung vorzustellen. In den Jahren 2019, 2020 und 2021 wurden 1.014, 1.313 und 1.358 externe Patientenfälle aus Krankenhäusern und von Schwerpunktpraxen in den Tumorboards des UCT Mainz diskutiert und konsentiert (Abb. 4).




Abbildung 4: Anzahl der diskutierten externen Patientenfälle in UCT-Tumorboards pro Kalenderjahr.

Schwerpunktpraxen haben zudem die Möglichkeit Krebspatient*innen in den spezialisierten interdisziplinären Tumorsprechstunden zur Zweitmeinung vorzustellen. Der Anmeldevorgang ist niederschwellig und kann entweder über direkte Kontaktaufnahme mit dem/r zuständigen Kollegen/in oder über die zentrale UCT-Hotline.

Strukturiertes Vorhalten begleitender supportiver Maßnahmen im stationären und ambulanten Sektor

Die interdisziplinäre UCT-Ambulanz und Ambulanzen für gynäkologische, hämatologische, gastrointestinale und pädiatrische Tumorerkrankungen stellen die zentralen Anlaufstationen für Krebspatient*innen dar. In den Ambulanzen erfolgt ein Belastungsscreening, um den individuellen Bedarf von Supportivmaßnahmen (psychoonkologische Betreuung, sozialmedizinische Beratung, Ernährungstherapie, Sport- und Bewegungstherapie, palliativmedizinische Betreuung, Fertilitätsberatung, humangenetische Beratung) zu ermitteln. In der interdisziplinären UCT-Ambulanz stehen den Patient*innen außerdem Patientenlotsen als Ansprechpartner*innen und ambulanten Betreuung zur Verfügung. Das UCT Mainz ist Mitglied und Zentrum des NCT-Programms OnocAktiv. Im Rahmen des Programms wird Patienten die Möglichkeit einer heimatnahen Bewegungs- und Sporttherapie in zertifizierten Kooperationspartnern angeboten (koordiniert durch das Institut für Physikalische Therapie, Prävention und Rehabilitation). Ausgehend von den Ambulanzen wird i.d.R. der gesamte individuelle Behandlungsablauf organisiert und koordiniert (inkl. stationärer Therapien wie Tumoroperationen, stationäre Chemo- oder Strahlentherapie, zelluläre Therapieverfahren). Für Patient*innen, welche sich primär stationär vorstellen oder für welche im Verlauf eine stationäre Behandlung erforderlich ist, steht ebenfalls eine strukturierte Erfassung der individuellen Belastungssituation mittels Screeningbögen zur Verfügung. Zudem wird von Seiten der Sektion Psychoonkologie ein Liaisondienst in definierten Bereichen mit bekannt hohem Bedarf angeboten. Jährlich erfolgt eine flächendeckende Auswertung des Screenings und der daraus resultierenden Beratung / Intervention. Die Ergebnisse werden im Qualitätszirkeln des UCT Mainz vorgestellt, diskutiert und ggf. werden erforderliche Maßnahmen zur Verbesserung eingeleitet.

Behandlungspfade | SOPs

Für eine Vielzahl an Tumorentitäten wurden am UCT Mainz Behandlungspfade (BHPF) erstellt. BHPF werden regelmäßig bei neuen wissenschaftlichen Erkenntnissen oder Änderungen in den Leitlinien angepasst. Neben entitätsspezifischen BHPF stellt das UCT Mainz zahlreiche BHPF zur Supportivtherapie sowie für onkologische Patient*innen relevante Verfahrensanweisungen (z.B. Impfen bei Tumorerkrankungen) bereit. Alle BHPF sind außerdem für UCT-Netzwerkpartner über die Passwort-geschützte Partnerwebseite verfügbar. Eine Zusammenstellung aller UCT-BHPFs ist in *Anhang 2* dargestellt.

Konzentration außergewöhnlicher Fachexpertise in besonderen Versorgungsbereichen der Onkologie

Programm für Personalisierte Onkologie

Um die zeitnahe Umsetzung neuer innovativer Therapien in der klinischen Routine zu ermöglichen und der zunehmend individualisierten, tumoragnostischen Therapie gerecht zu werden, wurde im Jahr 2020 das Programm für Personalisierte Onkologie entwickelt (Leitung: Dr. A. Desuki). In der Sprechstunde für Personalisierte Onkologie werden Patient*innen individuell zu einer erweiterten molekularen Diagnostik, verfügbaren Studienoptionen, insbesondere Phase I, Basket- und Umbrella-Studien oder Teilnahme an wissenschaftlichen Programmen beraten. Das Programm ist eng mit der molekularen / immunonkologischen Diagnostik Plattform des Instituts für Pathologie, dem Molekularen Tumorboard, der UCT-Studienzentrale und den wissenschaftlichen Programmen des UCT Mainz (siehe Punkt 11) verknüpft.

Zentrum für Kinderonkologie

Das UCT Mainz unterhält an der Universitätsmedizin Mainz das einzige zertifizierte Zentrum für Kinderonkologie in Rheinland-Pfalz. Damit verknüpft ist ein überregionales Studienangebot für onkologische Erkrankungen im Kindesalter. Das Zentrum für Kinderonkologie koordiniert außerdem die spezialisierte ambulante pädiatrische Palliativversorgung (SAPPV) in Rheinland-Pfalz. Weitere Informationen sind unter <https://www.unimedizin-mainz.de/kinderklinik/onkologie/uebersicht.html> zu finden.

Zentrum für Zelluläre Immuntherapie und Stammzelltransplantation

Das Zentrum innerhalb der 3. Medizinischen Klinik & Poliklinik bietet allen Patient*innen in Rheinland-Pfalz Zugang zu innovativen Immuntherapien wie z.B. der CAR-T-Zell-Therapie oder hämatopoetischen Stammzelltransplantationen mit patienteneigenen (autologen) oder fremden (allogenen) Stammzellen. Diese komplexen Therapien erfordern die enge und koordinierte Zusammenarbeit in einem interdisziplinären Team. Weiter Informationen sind unter folgenden Link zu finden: <https://www.unimedizin-mainz.de/3-med/startseite/zentrum-fuer-zellulaere-immuntherapie-und-stammzelltransplantation.html>.

Zertifizierte Zentren für Seltene Erkrankungen

i) neu in 2021 wurde am UCT Mainz das *Zentrum für Weichteilsarkome (inkl. GIST)* zertifiziert. Die seltene Tumorerkrankung erfordert die Vorhaltung eines interdisziplinären, spezialisierten Teams bestehend aus Tumororthopäden, Strahlentherapeuten, Pathologen und Medizinischen Onkologen. Sarkome sind im Kindesalter häufige Tumoren, insofern besteht außerdem eine enge Anbindung an das Zentrum für Kinderonkologie. Das Zentrum ist zentrale Anlaufstelle für alle Patient*innen in Rheinland-Pfalz mit Weichteil- und Knochensarkomen

ii) das *Interdisziplinäre Endokrine und Neuroendokrine Tumorzentrum (IENET-Zentrum)* der Universitätsmedizin Mainz ist als eine von lediglich 4 weiteren deutschen Kliniken von der European Neuroendocrine Tumor Society (ENETS) als Center of Excellence ausgezeichnet und zertifiziert worden (ENETS - Center of Excellence). Um einen optimalen Behandlungserfolg zu gewährleisten, steht die interdisziplinäre Zusammenarbeit der verschiedenen Fachdisziplinen wie Endokrinologie, Endokrine Chirurgie, Nuklearmedizin, Gastroenterologie, Onkologie, Radiologie, Pathologie und Strahlentherapie im Vordergrund. Weitere Informationen sind unter <https://www.unimedizin-mainz.de/endokrinologie/interdisziplinaeres-endokrines-und-neuroendokrines-tumor-zentrum.html> zu finden.

Weitere Spezialsprechstunden

i) *Kardio-onkologische Sprechstunde*: Ziel der Sprechstunde ist das frühzeitige Erkennen potenziell schädlicher Einflüsse einer Krebstherapie auf das Herz-Kreislaufsystem, das Einleiten einer prophylaktischen Therapie zum Schutz des Herzens, um Langzeit-Nebenwirkungen zu verhindern, ohne aber den Therapieerfolg zu gefährden.

ii) *Sprechstunde für Komplementärmedizin*: In der komplementärmedizinischen Sprechstunde für gynäkologische Onkologie wird universitäre Schulmedizin mit von uns anerkannte, wissenschaftlich belegte Naturheilkunde ergänzt.

4. Maßnahmen zur Qualitätssicherung und Qualitätsverbesserung der besonderen Aufgabenwahrnehmung

Zur Evaluation der Qualität werden eine Vielzahl von Instrumenten genutzt.

Adhärenzprüfungen

Um die Umsetzung der in den Tumorboards ausgesprochenen Therapieempfehlungen zu evaluieren, wird seit 2015 anhand einer Stichprobe der Empfehlungen (2. Halbjahr, mind. 5% der Empfehlungen) über alle entitätsbezogenen Tumorboards eine Prüfung der Adhärenz durchgeführt. In den Jahren 2019-2021 lagen für nahezu 90% (rd. 87-89%) entsprechende Informationen über den weiteren Verlauf vor. Davon wurde in konstant rd. 96% (95,5-96,01%) die Therapie adhärenz zur Empfehlung umgesetzt (Abb. 5). Lediglich rd. 4% der Empfehlungen wurden aufgrund medizinischer Ergebnisse oder des Patientenwunsches abgeändert ohne erneut im Tumorboard besprochen worden zu sein.




Abbildung 5: Adhärenz an Tumorboardbeschlüsse.

Evaluation der Tumorboardmaske

Zur Anmeldung einer Besprechung in einem Tumorboard wird eine für alle Tumorboards 2108 entwickelte vereinheitlichte Anmeldemaske im klinischen Informationssystem genutzt. In einem jährlichen Treffen der Tumorboardleiter wird die Zweckmäßigkeit der Anmeldeangaben evaluiert und ggf. durch neue (Pflicht-)Felder optimiert. Gelegentlich wird die Anmeldemaske auch durch Streichung von im Verlaufe der Zeit obsoleten Feldern gestrafft. Dies betrifft sowohl Angaben zur Erkrankung der Patientinnen und Patienten als auch notwendige Angaben zur Dokumentation. Dadurch wird die zielgerichtete Qualität der Anmeldung (und damit auch der Protokollierung) anhaltend optimiert sowie die Tumordokumentation unterstützt.

Behandlungspfade und SOPs

Für die unterschiedlichen Entitäten liegen jeweils Behandlungspfade vor, die in den Organkrebszentren und Modulen unter Einbeziehung der interdisziplinären Diagnostik und Therapie auf Facharzzebene erstellt werden. Sie werden seit mehreren Jahren routinemäßig einmal jährlich geprüft und ggf. überarbeitet, z.B. aufgrund neuer wissenschaftlicher Erkenntnisse, die sich aus Studien oder aktuellen externen Leitlinien (z.B. S3-Leitlinien der AWMF und DKG oder internationalen Leitlinien) ergeben.

In 2018/2019 wurden Behandlungspfade (SOPs) zu Begleit- und Folgeerkrankungen und zum Nebenwirkungsmanagement anhand der S3-Leitlinie Supportive Therapie entwickelt. Sie können übergreifend, UCT-weit genutzt werden (derzeit insgesamt 14, zusätzlich Anlagen). Sie betreffen z.B. die Themen Neutropenisches Fieber, Prophylaxe tiefer Beinvenenthrombosen bei malignen Erkrankungen, Antiemese, periphere Neuropathie, Polyneuropathie, Antiresorptiva/Osteoprotektion, Tumoranämie etc. Zusätzlich sind supportive Therapien in den Chemotherapieschemata in CATO (s. unten) verankert.

Die Prüfung der Aktualität der Behandlungspfade wird durch die automatische Erinnerungsfunktion (Aufforderung zum Review) im Dokumentenmanagementsystem unterstützt.

Auf die Behandlungspfade kann nicht nur in der ganzen Universitätsmedizin intern über das Dokumentenmanagementsystem zugegriffen werden, sondern sie stehen auch seit 2020 für externe

Kooperationspartner über einen passwortgeschützten Bereich der Homepage (Log In - Bereich) zur Verfügung.

Regelhaft in den Zentren und Modulen durchgeführte Morbiditäts- und Mortalitätskonferenzen unterstützen u.a. auch die Prüfung und ggf. Aktualisierung von Behandlungspfaden.

Darüber hinaus liegen für eine Vielzahl relevanter Prozesse SOPs vor, die in den jeweiligen onkologischen Bereichen, aber zum Teil auch übergreifend erstellt und ggf. aktualisiert werden. Übergreifend relevante SOPs (i.A. Verfahrensanweisungen) betreffen z. B. folgende Themen: Tumorboards, Leitlinienverantwortliche (Bestellung, Aufgaben), Fertilitätserhalt-Angebot der Beratung, Behandlungspfade im UCT, Zusammenarbeit mit Selbsthilfegruppen, Patientenbefragungen, Einweiserbefragungen und (für die gesamte UM) Morbiditäts- und Mortalitätskonferenzen. Die SOPs unterliegen im Dokumentenmanagementsystem ebenfalls der o.g. Review-Funktion.

Interne und externe Audits

Das Onkologische Zentrum ist seit 2015 nach den Vorgaben der Deutschen Krebsgesellschaft zertifiziert. Dabei sind seit verschiedenen Jahren auch zahlreiche Organkrebszentren bzw. Module zertifiziert (siehe Organigramm/Übersicht unter Punkt 1). Das Onkologische Zentrum stellt sich jährlich einem externen Audit durch Fachexperten der Deutschen Krebsgesellschaft in dem die Erfüllung der Anforderungen der Deutschen Krebsgesellschaft bewertet wird. Die im jeweiligen Bericht dargestellten Ergebnisse werden intern besprochen und dienen ggf. der Ableitung von Maßnahmen zur Optimierung. Im Folgeaudit wird die Umsetzung von Verbesserungen geprüft.

Im Jahresverlauf erfolgen zahlreiche interne Audits in den einzelnen Bereichen, auch ein jährliches internes Audit des Onkologischen Zentrums. Hier werden die Erfüllung von Vorgaben übergeprüft, Potentiale ermittelt und die Umsetzung von Maßnahmen bewertet. Über jedes Audit ein Protokoll angefertigt. Die Ergebnisse werden in der Folge in den jeweiligen Leitungszirkel der Zentren besprochen und ggf. Maßnahmen abgeleitet.

Qualitätszirkel

Das Onkologische Zentrum führt – neben ca. 10 kleineren auf QMB-Ebene- seit 2016 drei größere Qualitätszirkel jährlich durch, die für alle Organkrebszentren und Module sowie Hauptkooperationspartner offen sind. Zusätzlich erfolgen Qualitätszirkel in den Zentren und Modulen und im Bereich Stammzelltherapie (2x / Jahr mit allen rheinland-pfälzischen Blutstammzelltransplantationszentren). Die Bereiche der begleitenden Angebote (u.a. Psychoonkologie, Palliativmedizin, Ernährungsmedizin, Seelsorge, Physikalische Therapie und Rehabilitation, Tumorzentrum RLP) treffen sich 3 - 4 Mal jährlich zum Qualitätszirkel. Treffen mit allen kooperierenden Selbsthilfegruppen finden seit 2017 regelmäßig einmal im Quartal statt und werden zum Teil durch die begleitenden Angebote zum übergreifenden Qualitätszirkel erweitert. Im Zeitraum 2019 – 2021 fanden folgende Qualitätszirkel statt:

Große Qualitätszirkel Onkologisches Zentrum			Qualitätszirkel Begleitende Dienste		
2019	2020	2021	2019	2020	2021
01.04.2019	05.03.2020	22.04.2021	14.03.2019	13.02.2020	25.03.2021
06.06.2019	*	22.07.2021	23.05.2019	03.09.2020	09.09.2021
16.09.2019	19.11.2020	22.11.2021	29.08.2019	06.11.2020	02.12.2021
			14.11.2019		

Tabelle 6: Qualitätszirkel des onkologischen Zentrums und begleitender Dienste. Pandemiebedingt fanden zwischen April und Oktober 2020 nur die zusätzlichen monatlichen, „kleinen“ QZ statt.

Ermittlung der Patienten- und Einweiser-/Zuweiserzufriedenheit, Wartezeiterhebungen

Mindestens alle drei Jahre führen alle Organkrebszentren und Module eine Befragung der Patientinnen und Patienten sowie zu-/einweisender Ärztinnen und Ärzte durch. In den jeweiligen Bereichen werden die Befragungen ausgewertet und analysiert sowie ggf. Maßnahmen abgeleitet und die Umsetzung überprüft. Zusätzlich wird anhand ausgewählter Fragen seit 2016 eine Gesamtbewertung für das Onkologische Zentrum erstellt, woraus ebenfalls bei Bedarf Maßnahmen in Qualitätszirkeln abgeleitet werden.

Die Wartezeiterhebungen in den Organkrebszentren und Modulen erfolgen i.A. über einen Zeitraum von 4 Wochen jährlich. Die jeweilige Auswertung und Analyse wird auch hier zur Identifikation und Umsetzung von Verbesserungsmöglichkeiten genutzt.

Jahresreview

Im seit 2015 jährlich erarbeiteten Jahresreview wird ein Überblick über die Weiterentwicklung des Onkologischen Zentrums und des UCT gegeben. Damit sind u.a. eine jährliche Bewertung der Vorjahresziele, aktualisierte Zieldefinitionen, ggf. mit Neuausrichtung, sowie die Betrachtung von Auditergebnissen verbunden (PDCA-Zyklus). Das Jahresreview wird vom Lenkungsausschuss des UCT beschlossen und enthält sowohl einen tabellarischen Überblick der Vorjahresziele mit Bewertung als auch einen neuen Ziel- und Maßnahmenplan. Grundlegende Ziele sind der Erhalt der Anerkennung als Onkologisches Spitzenzentrum / CCC im Verfahren der Deutsche Krebshilfe, die weitere Anerkennung als Onkologisches Spitzenzentrum im Landeskrankenhausplan sowie die Fortführung der Zertifizierung als Onkologisches Zentrum nach den Vorgaben der DKG.

Netzwerktreffen und –befragungen

Durch Kooperationen hat das UCT ein regionales Netzwerk mit Kliniken und Praxen aufgebaut. Mindestens 2 Mal jährlich finden Netzwerktreffen statt, die im Sinne eines Qualitätszirkels der gegenseitigen Information und übergreifenden Abstimmungen dienen. Im ein- bis dreijährigen Turnus werden seit 2019 durch eine Netzwerkbefragung die Zufriedenheit und Wünsche der Partner ermittelt, analysiert und ggf. Maßnahmen abgeleitet. Gewählte Vertreter der Praxen und Kliniken sind -ebenso wie Vertreter der Selbsthilfegruppen- Mitglied im Lenkungsausschuss des UCT.

Patient Participation Board

Zusätzlich zum Patientenbeirat auf Ebene der Selbsthilfegruppen konnte das UCT 2020 vier externe Persönlichkeiten für ein Patient Participation Board (PPB) gewinnen, um so die Patientensicht aktiv in strategische Projektentscheidungen einzubringen (z.B. Beteiligung an der Entwicklung von Studieninformationen für Patienten, Outreachprogrammen und Öffentlichkeitsarbeit). Mission Statement and Rules of Procedures sowie ein Working Plan wurden entwickelt. Seit Gründung des PPBs

finden regelmäßig alle 4 Monate Treffen der Mitglieder statt. Ein Patient Reported Outcome (PRO)-Office soll in enger Kooperation mit dem PPB 2023 aufgebaut werden.

CATO®

Das elektronische System CATO® (computer aided therapy for oncology) dient der standardisierten und sicheren Verordnung und Herstellung von Chemotherapeutika. Nach der Implementierung zunächst in der Apotheke erfolgt seit Anfang 2021 die Herstellung von Chemotherapeutika dort generell computergesteuert über CATO® und in der Folge die flächendeckende Ausrollung von CATO® als Verordnungssystem in der Onkologie der Universitätsmedizin (inkl. Kinderonkologie!). Dieser Prozess konnte in 07/2022 erfolgreich abgeschlossen werden. Die Eingaben zur Dokumentation der Applikation in CATO® sind über eine Eingabe am stationären PC möglich. Zur zeitsparenderen, sicheren Nutzbarkeit als Gabe-Dokumentationssystem über Handgeräte mit Scanfunktion am Patientenbett wird die Software BD Cato™ ReadyMed eingerichtet werden.

Besonderer Versorgungsbereich Psychoonkologie und Palliativstation

Neben Fortbildungs-/Schulungsangeboten ist in beiden Bereichen Supervision als Merkmal der Qualitätssicherung Bestandteil. Eine externe Supervision erfolgt jeweils monatlich, die interne Supervision regelmäßig wöchentlich und zusätzlich bei Bedarf.

Lob- und Beschwerdemanagement

Das zentrale Lob- und Beschwerdemanagement der Universitätsmedizin Mainz ist der Stabsstelle Qualitätsmanagement und Klinisches Risikomanagement zugeordnet und steht damit auch onkologischen Patienten zur Verfügung. Meinungsäußerungen sind persönlich, telefonisch, schriftlich oder per E-Mail möglich. Eingehende Meinungsäußerungen werden mithilfe einer Software erfasst und in Zusammenarbeit mit den Einrichtungen bearbeitet. Ein strukturiertes Beschwerdecontrolling findet statt. Nach Möglichkeit werden Verbesserungsmaßnahmen abgeleitet. Patienten erhalten Rückmeldungen, wenn die Meldungen mit Namen und Anschriften versehen sind. In regelmäßigen Abständen -jedoch mind. ein Mal jährlich- erhalten alle Einrichtungen eine Auswertung.

Critical Incident Reporting System (CIRS)

Das Critical Incident Reporting-System (CIRS) ist zur - meist anonymen - Meldung von kritischen Ereignissen (critical incident) und Beinahe-Schäden als klinikweites und einheitliches System eingerichtet. Jeder meldenden Person wird im Rahmen von CIRS-Meldungen Anonymität und Sanktionsfreiheit zugesichert, Daten von Patientinnen oder Patienten dürfen dabei nicht angegeben werden. Im Vordergrund steht die Analyse. Es geht um die Fragestellung "Wie können wir ein ähnliches Ereignis in Zukunft vermeiden, damit kein Patient zu Schaden kommt?" Zur Bearbeitung wurden bereichsbezogene Auswertungsteams etabliert. Gemeinsam mit den Verantwortlichen werden ggf. vorbeugende Maßnahmen abgeleitet. Ziel ist das Lernen aus Fehlern und Beinahe-Fehlern.

5. Fort- und Weiterbildungsveranstaltungen

Das UCT Mainz bietet regelmäßig Fort- und Weiterbildungsveranstaltungen für interne und externe Partner an. Die Veranstaltungen sind i.d.R. von der Ärztekammer Rheinhessen zertifiziert, die Teilnahme wird erfasst und Teilnahmebescheinigungen werden ausgestellt.

Die Finanzierung der Veranstaltungen erfolgt entweder aus dem Budget des UCT Mainz oder durch externe Sponsoren. Veranstaltungen mit finanzieller Unterstützung durch externe Partner sind ausgewiesen. Die Veranstaltungen sind für Teilnehmer kostenfrei.

Eine Übersicht der angebotenen Veranstaltungen für die Jahre 2019 – 2021 zeigt *Anhang 3*.

Im Rahmen der ärztlichen Weiterbildung bietet das UCT seit Juli 2020 ein für externe Partner zugängliches, wöchentliches Online-Seminar an. In diesem moderierten Seminar werden im Rahmen eines onkologischen Curriculums alle relevanten Themen zu Prävention, Diagnostik, Therapie und Nachsorge von Tumorerkrankungen von Experten des UCT Mainz vorgestellt und diskutiert [<https://www.unimedizin-mainz.de/index.php?id=41471>]. Mehr als 120 Seminare konnten bisher angeboten werden. Die Veranstaltungen werden aufgezeichnet und stehen allen UCT-Netzwerkpartnern dauerhaft über die passwortgeschützte interne Webseite des UCT Mainz zur Verfügung.

6. Onkologisches Netzwerk Rheinland-Pfalz – Maßnahmen zum strukturierten Austausch mit onkologischen Zentren, Krankenhäusern, Schwerpunktpraxen und Hausärzt*innen

Mit dem Ziel jeder/m Krebspatient*in in Rheinland-Pfalz eine flächendeckende und heimatnahe Versorgung auf höchstem Niveau zukommen zu lassen, hat das UCT Mainz im Jahr 2015 ein regionales onkologisches Netzwerk gegründet. Die Zusammenarbeit zwischen dem UCT Mainz und Netzwerkpartnern ist durch Kooperationsverträge geregelt. Inhalte des Kooperationsvertrags sind u.a.:

- Verpflichtung zur Leitlinien-gerechten Therapie in Diagnostik, Therapie und Nachsorge
- Gegenseitige Teilnahme an Tumorkonferenzen
- Vorstellung zur Einholung von Zweitmeinungen
- Teilnahme an klinischen Studien; gemeinsame Studienwebseite
- Zugang zu internen UCT-Behandlungspfaden
- Austausch von Kennzahlen zur Qualitätssicherung im Netzwerk
- Zusammenarbeit bei Fort- und Weiterbildung

Derzeit bestehen sektorübergreifend mit 22 Kliniken inkl. ihrer onkologischen Zentren und 32 Schwerpunktpraxen in Rheinland-Pfalz und angrenzenden Bundesländern Kooperationsverträge. Alle externen Kooperationspartner sind unter <https://www.unimedizin-mainz.de/uct/das-uct-mainz/organisation/regionale-partner.html> gelistet.

Jeweils zwei gewählte Partner des UCT-Netzwerks aus dem niedergelassenen Sektor (Dr. T. Flohr (Mainz) und Prof. Dr. R. Weide (Koblenz); Stand 01/2022) und Krankenhaus (Prof. Dr. G. Held (Kaiserslautern); Dr. W. Blau (Wiesbaden); Stand 01/2022) sind Mitglieder des UCT Lenkungsausschuss, dem zentralen Entscheidungsgremium des UCT Mainz. Alle Netzwerkpartner sind Mitglied des UCT-Mainz und berechtigt, an der UCT-Mitgliederversammlung (1 x jährlich) teilzunehmen.

Zum strukturierten Austausch über Themen der regionalen Versorgung von Krebspatient*innen (Diagnostik, Therapieempfehlungen, strukturierte Nachsorge), Vorstellung neuer Diagnostik- und Therapieangebote (z.B. Studienangebote, molekulare Diagnostik, zelluläre Therapieverfahren) oder übergeordneten politischen Anliegen (Onkologiekonzept RLP) finden seit 2016 2 x jährlich Netzwerktreffen statt. Eine Liste der Veranstaltungen zeigt *Anhang 4*. Im Rahmen der Netzwerktreffen findet auch die Wahl der Vertreter der Netzwerkpartner statt.

Mit Schwerpunktversorgern in der Region (Westpfalzkrankenhaus Kaiserslautern, Klinikum Ludwigshafen, Klinikum Mutterhaus der Borromäerinnen Trier, Krankenhaus der Barmherzigen Brüder Trier, Gemeinschaftsklinikum Mittelrhein Koblenz, Katholisches Klinikum Koblenz-Montabaur) finden zudem regelmäßige 1:1 Treffen (zuletzt digital) statt. Zur Verbesserung der Zusammenarbeit im direkten regionalen Umfeld des UCT Mainz wurde zudem der Onkologische Arbeitskreis Mainz-Wiesbaden

gegründet. Der Arbeitskreis bespricht sich seit 2018 1 x/Jahr. Die Arbeit des UCT-Netzwerks wird zentral von 2 Netzwerkkoordinatoren unterstützt (siehe auch Tabelle 2, Kapitel 1).

Um einen permanenten Zugang zu UCT-Behandlungspfaden, Aufzeichnungen von Weiterbildungsveranstaltungen, zentralen Dokumenten und Kontaktinformationen für Fachkolleg*innen zu ermöglichen, steht den UCT-Netzwerkpartner*innen seit 2020 Zugriff auf ein passwortgeschütztes Webportal zu Verfügung.

Aktuelle Informationen werden zudem über den UCT-Newsletter, welcher seit 2017 mehrmals pro Jahr publiziert wird, kommuniziert.

7. Selbsthilfegruppen, Krebsgesellschaft Rheinland-Pfalz und Patientenbeteiligung

Die Einbindung und Beteiligung von Patientinnen und Patienten an der Entwicklung des UCT Mainz stellt ein zentrales Anliegen dar. Das UCT Mainz hat hierfür Kooperationsverträge mit derzeit 19 Selbsthilfegruppen abgeschlossen (*Stand 01/2022*), welche die Zusammenarbeit zwischen dem UCT Mainz und der Selbsthilfe regeln. Seit 2016 und seit 2018 regelmäßig 1 x /Quartal (Ausnahme 2020 aufgrund der Corona-Pandemie) finden moderierte Treffen (Dr. K. Dieterich; Prof. Dr. J. Wiltink) mit den Sprecher*innen der Selbsthilfegruppen statt (*siehe Anhang 5*). Auf das Angebot der Selbsthilfegruppen werden alle Patient*innen des UCT Mainz hingewiesen, Selbsthilfegruppen können sich über die UCT-Webseite präsentieren.

Das UCT Mainz bietet überregional allen Patient*innen regelmäßige Informationsveranstaltungen zu wichtigen Themen der Supportivtherapie in Form von monatlich stattfindenden Online-Seminaren an. Das Programm der Veranstaltung sowie weitere Veranstaltungen für Patient*innen sind in *Anhang 6* dargestellt.

Unter enger Einbindung und Beteiligung der Selbsthilfegruppen veranstaltet das UCT Mainz jährlich einen Patiententag. Alle 4 Jahre findet am UCT Mainz zudem der rheinlandpfälzische Krebstag in enger Zusammenarbeit mit der Krebsgesellschaft Rheinland-Pfalz statt (zuletzt 2019).

Um die psychoonkologische Versorgung und sozialmedizinische Beratung im regionalen Netzwerk zu unterstützen und weiterzuentwickeln, wurde mit der Krebsgesellschaft RLP eine Kooperationsvereinbarung beschlossen. Prof. Dr. Buhl und Prof. Dr. Kindler (beide UCT) sind zudem Mitglieder des Vorstands der Krebsgesellschaft RLP und gleichzeitig Vertreter der Universitätsmedizin Mainz.

Um die Beteiligung von Patient*innen und Angehörigen an der strukturellen und konzeptionellen Entwicklung des Krebszentrums zu verbessern, wurde im Jahr 2020 das UCT *Patient Participation Board* (PPB) gegründet. Das Board setzt sich aus ausgewählten Mitgliedern mit Bezug zur Versorgung onkologischer Patient*innen und translationaler / klinischer Forschung zusammen. Das Board trifft sich 3 x /Jahr und bespricht zentrale Themen wie Vertretung von Patienteninteressen bei der Planung des CCC-Neubaus, patientenrelevante Endpunkte klinischer Studien oder Öffentlichkeitsarbeit des UCT Mainz. Um die Arbeit des PPBs zu unterstützen und auch Patienten-relevante Endpunkte in klinischen Studien zu integrieren, wurde im Jahr 2021 das Patient-reported Outcome (PrO) Office am UCT Mainz gegründet (koordiniert durch das Institut für Medizinische Biometrie, Epidemiologie und Informatik (IMBEI)).

8. Mitarbeit an Leitlinien und Konsensuspapieren

Zahlreiche Vertreter*innen des UCT Mainz sind an der Erstellung und Aktualisierung von Leitlinien und Konsensuspapieren beteiligt. Eine Übersicht zeigt *Anhang 7*.

9. Beteiligung des Zentrums an klinischen Studien

Das Vorhalten innovativer klinischer Studien, sowohl für Patient*innen des UCT Mainz als auch als Angebot für externe Netzwerkpartner ist ein zentrales Anliegen des UCT Mainz. Ziel ist es, für jede Tumorentität und jede Erkrankungsphase eine Studienoption, mit Fokus auf frühe klinische Studien, anzubieten. Ergänzt wird das Angebot durch zahlreiche Studien zur Verbesserung der Diagnostik, Entwicklung von Medizinprodukten, Identifikation von prädiktiven Biomarkern, Erfassung von Fragen zur Lebensqualität, u.a. Eine vollständige Übersicht über das aktuelle Angebot an klinischen Studien bietet die Studienwebseite des UCT Mainz (<https://www.unimedizin-mainz.de/uct/studien/tumorthherapie-studien.html>).

Tabelle 7 zeigt die Anzahl der aktiven klinischen Studien für die Jahre 2019 – 2021.

2019		2020		2021	
Alle aktiven Studien	Phase I-III Therapiestudien	Alle aktiven Studien	Phase I-III Therapiestudien	Alle aktiven Studien	Phase I-III Therapiestudien
221	136	226	127	236	132

Tabelle 7: aktive Studien am UCT Mainz sowie davon Therapiestudien der Phase I-III.

10. Wissenschaftliche Publikationen

Das UCT Mainz publiziert jährlich zahlreiche wissenschaftliche Arbeiten in internationalen, *peer-reviewed* Zeitschriften. Tabelle 8 zeigt die Anzahl aller Publikationen mit Beteiligung von Vertretern des UCT Mainz sowie Veröffentlichungen, welche federführend am UCT Mainz durchgeführt wurden (Erst- u/o Letztautor des UCT Mainz) für die Jahre 2019 – 2021. Eine Liste aller Publikationen der Jahre 2019 – 2021 ist in *Anhang 8* zu finden.

2019		2020		2021	
Gesamtzahl	Erst- u/o Letztautor	Gesamtzahl	Erst- u/o Letztautor	Gesamtzahl	Erst- u/o Letztautor
289	159	374	191	517	265

Tabelle 8: Publikationen des UCT Mainz.

11. Forschungstätigkeit am UCT Mainz

Translationale Forschung - Organisation

Das Forschungsprogramm des UCT Mainz setzt sich aus 4 Schwerpunktbereichen zusammen:

- Genomic Instability & Resistance (Sprecher: Prof. Dr. T. Hoffmann)
- Immunooncology (Sprecher: Prof. Dr. T. Bopp)
- Molecular Diagnostics & Early Detection (Sprecher: Prof. Dr. T. Kindler)
- Outcome Research & Cancer Epidemiology (Sprecherin: Prof. Dr. S. Singer)

Jeder Schwerpunktbereich wird durch eine*n Sprecher*in und Stellvertreter*in vertreten. Schwerpunktsprechertreffen finden 1x/Quartal statt, um die Erfüllung der Zielvorgaben zu prüfen und ggf. Maßnahmen einzuleiten.

Das UCT Mainz stellt eine Schnittstelle zwischen translationaler Forschung und klinischer Routine dar. Um den interdisziplinären Austausch zu fördern, wurden am UCT Mainz Disease Management Groups (DMG) etabliert. Diese setzen sich aus Clinician Scientists, Forscher*innen, Epidemiolog*innen, Studienärzt*innen und Fachärzt*innen aus verschiedenen Facheinrichtungen zusammen. DMG-Treffen finden alle 6-8 Wochen statt. Derzeit existieren folgende DMGs:

- DMG Weichgewebe- und Knochentumoren
- DMG Uroonkologie
- DMG Thoraxonkologie
- DMG Kopf-Hals-Tumore
- DMG Gastrointestinale Tumore

Der Sprecher der jeweiligen DMG berichtet in regelmäßigen Abständen der UCT-Geschäftsführung.

UCT Infrastruktur

Das UCT Mainz hält für Clinician und Medical Scientists folgende Strukturen vor:

- Biobank der Universitätsmedizin Mainz (BBM): die BBM umfasst i) eine Gewebebiobank für FFPE-Blöcke sowie native Tumormaterialien (Betreiber: Institut für Pathologie); ii) eine Liquid Biobank (Betreiber: Zentrum für Kardiologie und Präventive Kardiologie); und iii) eine zelluläre Biobank (Betreiber: III. Medizinische Klinik & Poliklinik).
- Zentrale Tumordokumentation: Alle Fälle von Tumorpatient*innen werden nach dem einheitlichen onkologischen Basisdatensatz, festgelegt durch die Arbeitsgemeinschaft Deutscher Tumorzentren (ADT) und der Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID) dokumentiert. Die Kennzahlen werden an das zuständige Krebsregister Rheinland-Pfalz gemäß Landeskrebsregistergesetzes (LKrebsRG §4) gemeldet. Erfasste Daten werden außerdem in die Datenbank CentraXX transferiert und verfügbaren Biobankproben abgeglichen. CentraXX dient zukünftig auch für den Export von Daten an den DKTK-Brückenkopf sowie nNGM.
- UCT-Studienzentrale inkl. Phase I-Einheit: Das UCT-Studienteam stellt allen Mitgliedern des UCT Mainz für Fragen zu Studien zur Verfügung. Zentrale Aufgabe des UCT-Studienteams ist die Koordination früher Phase I/II-Studien sowie sogenannter *investigator initiated trials* (IITs) am Zentrum. Diese Studien bieten onkologischen Patient*innen neue, innovative Therapieoptionen, die in der Routineversorgung nicht zur Verfügung stehen und stellen einen substantiellen Mehrwert des UCT Mainz für das gesamte regionale Netzwerk dar. Das Phase-I/II Studienprogramm ist zudem eng an die molekulare Diagnostikplattform (500-Gen *next generation sequencing* (NGS) Panel; Multiplex Immunoprofilierung) sowie der Sprechstunde „Personalisierte Onkologie“ gekoppelt. Alle klinischen Studien für onkologische Patient*innen werden vom UCT-Studienteam zentral in der Datenbank For.UM erfasst und regelmäßig ausgewertet. Die strukturelle und konzeptionelle Weiterentwicklung erfolgt im interdisziplinären Arbeitskreis klinische Studien (AKKS).

UCT Nachwuchsförderung

Das UCT bietet seit 2016 regelmäßig zusammen mit Mainz Research School of Translational Biomedicine (TransMed) ein Förderprogramm ausschließlich für Clinician Scientists mit onkologischem Schwerpunkt an. Weiterhin stehen Clinician und Medical Scientists zentrale Programme aus TransMed und Drittmittel-geförderten Forschungskollegiaten zu Verfügung. Tabelle 9 zeigt die geförderten Wissenschaftler*innen mit onkologischem Schwerpunkt.

	2019	2020	2021
Clinician Scientists	4	12	15
Medical Scientists	26	34	28

Tabelle 9: Anzahl geförderter Wissenschaftler*innen am UCT Mainz

UCT-Projekte und Drittmittel

	2019	2020	2021
Bewilligte Projekte (N)	37	21	20
Verfügbare Drittmittel (in € Mio.)	14,5	13,0	12,9

Tabelle 10: Anzahl der bewilligten Projekte und verfügbaren Drittmittel am UCT Mainz

External Advisory Board

Das UCT Mainz wird seit 2015 regelmäßig von einem wissenschaftlichen Beirat (*External Advisory Board (EAB)*) mit nationalen und internationalen Experten beraten.

Mitglieder des EAB 2022:

- Andree Blaukat, PhD, Senior Vice President - Head Translational Innovation Platform Oncology, Merck KGaA, Darmstadt, Germany
- Stefan Fröhling, MD, Professor of Hematology & Oncology, Managing Director NCT Heidelberg, Head of Division for Translational Medical Oncology, DKFZ, Heidelberg, Germany
- Cornelis Melief, MD, PhD, Emeritus Professor and Head of the Department of Immunohematology and Blood Transfusion, Leiden University Medical Center; CSO of ISA Pharmaceuticals, Leiden, Netherlands
- Ira Mellman, PhD, Vice President Cancer Immunology at Genentech, San Francisco, CA, USA
- Stephan Mielke, MD, Professor of Haematology and Cellular Therapy, Scientific Director of the Cancer Center, Head of Department of Cell Therapy and allogeneic stem cell transplantation, Member of Board of Directors Karolinska Comprehensive Cancer Center, Karolinska University Hospital and Institute, Stockholm, Sweden
- Andreas Neubauer, MD, Professor of Medicine, Director Department of Hematology, Oncology and Immunology, Universitätsklinikum Gießen/Marburg, Germany
- Tobias Sjöblom, MD, PhD, Professor and Head of Department of Immunology, Genetics and Pathology, Cancer Precision Medicine; Uppsala University, Sweden
- Lonneke van de Poll, MS, PhD, Professor of Cancer Epidemiology and Survivorship, Tilburg University, Group Leader at the Netherlands Cancer Institute, Senior Researcher at the Comprehensive Cancer Organisation Netherlands, Tilburg, Netherlands

Anhang

- Anlage 1 – Liste der internen Kooperationspartner
- Anlage 2 – Behandlungspfade
- Anlage 3 – Fort- und Weiterbildungsveranstaltungen
- Anlage 4 – Netzwerktreffen 2019 – 2021
- Anlage 5 – Selbsthilfegruppen-Treffen 2016 – 2021
- Anlage 6 – Programm Patientenveranstaltungen
- Anlage 7 – Mitarbeit an Leitlinienpapieren
- Anlage 8 – Publikationen 2019 / 2020 / 2021

Anhang 1 – Interne Kooperationspartner

Name der Einrichtung
1. Med. Klinik und Poliklinik (inkl. Ernährungsberatung)
3. Med. Klinik und Poliklinik
Klinik für Anästhesiologie
Apotheke
Augenklinik und Poliklinik
Klinik für Allgemein-, Viszeral- und Transplantationschirurgie
Brustzentrum
Klinik und Poliklinik für Geburtshilfe und Frauengesundheit
Gyn. Dysplasie-Einheit
Interdisziplinäres Gyn. Krebszentrum
Hautklinik und Poliklinik
Hautklinik und Poliklinik - Sektion Plastische und Ästhetische Chirurgie
Hautkrebszentrum Rhein-Main
Hals-Nasen-Ohren-Klinik und Poliklinik
Klinik und Poliklinik für Herz- und Gefäßchirurgie
Institut für Humangenetik
Institut für Medizinische Mikrobiologie und Hygiene
Institut für Physikalische Therapie, Prävention und Rehabilitation
Interdisziplinäres Zentrum Klinische Studien
Zentrum für Kardiologie, Kardiologie I - Allgemeine und interventionelle Kardiologie und internistische Intensivmedizin
Klinik und Poliklinik für Kinderchirurgie
Klinik und Poliklinik für Kinder- und Jugendmedizin
Klinik und Poliklinik für diagnostische und interventionelle Radiologie - Sektion Kinderradiologie
Kinderonkologisches Zentrum
Leukämie- und Lymphom-Centrum Mainz
Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie
Neurochirurgische Klinik und Poliklinik
Institut für Neuropathologie
Klinik und Poliklinik für Neuroradiologie
Neuroonkologisches Zentrum
Neuroonkologisches Zentrum
Klinik und Poliklinik für Nuklearmedizin
Interdisziplinäre Abteilung für Palliativmedizin
Institut für Pathologie
Prostatakrebszentrum
Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie
Klinik und Poliklinik für diagnostische und interventionelle Radiologie
Klinik und Poliklinik für Radioonkologie und Strahlentherapie
Sozial- und Pflegeberatung
Thoraxchirurgie
Transfusionszentrale

Kopf-Hals-Tumorzentrum
Zentrum für Orthopädie und Unfallchirurgie (ZOU)
Zentrum für Orthopädie und Unfallchirurgie (ZOU) - Tumororthopädie
Klinik und Poliklinik für Urologie und Kinderurologie
Uroonkologisches Zentrum
Viszeralonkologisches Zentrum
Institut für Klinische Chemie und Laboratoriumsmedizin

Kapitel	Name
	UCT_BPFAD_Sarkome [KP]
	UCT_BPFAD_Gastrointestinale Tumore [KP]
	UCT_BPFAD_A_Patienteninformation
	UCT_BPFAD_Tumore der Bronchien/Pleura/Mediastinum [KP]
	UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]
	UCT_BPFAD_Supportiv-SOPs
	UCT_BPFAD_Neuroonkologische Tumore [KP]
	UCT_BPFAD_Urogenitale Tumore [KP]
	UCT_BPFAD_Tumore im Kindesalter [KP]
	UCT_BPFAD_Tumore der Haut [KP]
	UCT_BPFAD_Gynäkologische Tumore [KP]
	UCT_BPFAD_Endokrin aktive Tumore [KP]
	UCT_BPFAD_Leukämien und Lymphome [KP]
UCT_BPFAD_A_Patienteninformation	UCT_BPFAD_A_Patienteninformation_Schutzimpfungen für Krebspatienten
UCT_BPFAD_A_Patienteninformation	UCT_BPFAD_A_Patienteninformation_Schutzimpfungen für Krebspatienten - allgemeine Hinweise
UCT_BPFAD_A_Patienteninformation	Patienteninfo Anagrelid
UCT_BPFAD_A_Patienteninformation	Patienteninfo Dabrafenib + Trametinib
UCT_BPFAD_A_Patienteninformation	Patienteninfo Lenalidomid
UCT_BPFAD_A_Patienteninformation	Patienteninfo Everolimus
UCT_BPFAD_A_Patienteninformation	Patienteninfo Ruxolitinib
UCT_BPFAD_A_Patienteninformation	Patienteninfo Abirateron
UCT_BPFAD_A_Patienteninformation	Patienteninfo Temozolomid
UCT_BPFAD_A_Patienteninformation	Patienteninfo Midostaurin
UCT_BPFAD_A_Patienteninformation	Patienteninfo Osimertinib
UCT_BPFAD_A_Patienteninformation	Patienteninfo Capecitabin
UCT_BPFAD_A_Patienteninformation	Patienteninfo Dasatinib
UCT_BPFAD_A_Patienteninformation	Patienteninfo Palbociclib
UCT_BPFAD_A_Patienteninformation	Patienteninfo Hydroxycarbamid
UCT_BPFAD_A_Patienteninformation	Patienteninfo Nilotinib
UCT_BPFAD_A_Patienteninformation	Patienteninfo Venetoclax
UCT_BPFAD_A_Patienteninformation	Patienteninfo Ibrutinib
UCT_BPFAD_A_Patienteninformation	Patienteninfo Vermurafenib
UCT_BPFAD_Endokrin aktive Tumore [KP]	NEN Colon Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	Insulinom Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	NEN Appendix Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	NET Dünndarm Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	Seltene funktionelle pNET Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	NEN Rektum Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	NEN Schilddrüse Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	NET NEN duodenal, gastral und ileum Behandlungspfad

UCT_BPFAD_Endokrin aktive Tumore [KP]	Fortgeschrittene nicht operable nicht pNET G1 G2 Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	Multiple Endokrine Neoplasie Typ 1(MEN1) pNEN Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	Fortgeschrittene nicht operable pNET G1,G2 Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	Fortgeschrittenes NET Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	NEN Pankreas Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	Phäochromozytom und Paragangliom Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	Gastrinom Behandlungspfad
UCT_BPFAD_Endokrin aktive Tumore [KP]	Lebermetastasen NEN1 Behandlungspfad
UCT_BPFAD_Gastrointestinale Tumore [KP]	Behandlungsalgorithmus Pankreaskarzinom
UCT_BPFAD_Gastrointestinale Tumore [KP]	Behandlungsalgorithmus Ösophaguskarzinom
UCT_BPFAD_Gastrointestinale Tumore [KP]	Behandlungsalgorithmus Hepatozelluläres Karzinom
UCT_BPFAD_Gastrointestinale Tumore [KP]	Behandlungsalgorithmus Analkarzinom C21
UCT_BPFAD_Gastrointestinale Tumore [KP]	Behandlungsalgorithmus Gallenblasenkarzinom
UCT_BPFAD_Gastrointestinale Tumore [KP]	Behandlungsalgorithmus Rektumkarzinom C20
UCT_BPFAD_Gastrointestinale Tumore [KP]	Behandlungsalgorithmus Colonkarzinom C18
UCT_BPFAD_Gastrointestinale Tumore [KP]	Behandlungsalgorithmus Dünndarmkarzinom C17
UCT_BPFAD_Gastrointestinale Tumore [KP]	Behandlungsalgorithmus Gallengangskarzinom
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26a1 Patientenpfad Radiologie-Gynäkologie
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26.b2 Patientenpfad RezMed GYN
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26.c5 Patientenpfad Zervixkarzinom
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26.c3 Patientenpfad Mammakarzinom
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26.c6 Patientenpfad Uterine Sarkome
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26.c2 Patientenpfad Ovarialkarzinom epitheliales
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26.c4 Patientenpfad Vulvakarzinom
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26.b1 Patientenpfad Primär GYN
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26 Patientenpfad Diagnostik und Behandlung operativer Primär- und Rezidivfälle im BZ
UCT_BPFAD_Gynäkologische Tumore [KP]	IV.2.26.c1 Patientenpfad Endometriumkarzinom
UCT_BPFAD_Leukämien und Lymphome [KP]	BP Chronisch myeloische Leukämie (CML)
UCT_BPFAD_Leukämien und Lymphome [KP]	BP Aggressive Lymphome
UCT_BPFAD_Leukämien und Lymphome [KP]	BP Akute myeloische Leukämie (AML)
UCT_BPFAD_Leukämien und Lymphome [KP]	BP ZNS-Lymphom
UCT_BPFAD_Leukämien und Lymphome [KP]	BP Akute Lymphatische Leukämie (ALL)
UCT_BPFAD_Leukämien und Lymphome [KP]	BP Morbus Hodgkin
UCT_BPFAD_Leukämien und Lymphome [KP]	Chronisch Lymphatische Leukämie (CLL)
UCT_BPFAD_Leukämien und Lymphome [KP]	BP Multiples Myelom
UCT_BPFAD_Leukämien und Lymphome [KP]	BP Indolente Lymphome (NHL)
UCT_BPFAD_Neuroonkologische Tumore [KP]	UCT BPFAD Behandlungspfad Myelonkompression
UCT_BPFAD_Neuroonkologische Tumore [KP]	UCT BPFAD Behandlungspfad Glioblastom
UCT_BPFAD_Neuroonkologische Tumore [KP]	UCT BPFAD Behandlungspfad Rezidiv Glioblastom

UCT_BPFAD_Neuroonkologische Tumore [KP]	UCT_BPFAD_Behandlungspfad_Intraaxiale Raumforderung
UCT_BPFAD_Neuroonkologische Tumore [KP]	BP_ZNS-Lymphom
UCT_BPFAD_Neuroonkologische Tumore [KP]	Postoperative Management Neuroonkologischer Patienten
UCT_BPFAD_Neuroonkologische Tumore [KP]	NOZ Therapie und Nachsorge bei primären Hirntumoren
UCT_BPFAD_Sarkome [KP]	UCT_BPFAD_Sarkome_CL_Checkliste genetisches Risiko Sarkome
UCT_BPFAD_Sarkome [KP]	UCT_BPFAD_VA_Gastrointestinale Stromatumore (GIST)
UCT_BPFAD_Sarkome [KP]	BP_Ewing-Sarkom
UCT_BPFAD_Sarkome [KP]	BP_Weichteilsarkom
UCT_BPFAD_Sarkome [KP]	BP_Osteosarkome
UCT_BPFAD_Supportiv-SOPs	Gastrointestinale Komplikationen (Schwerpunkt Diarrhoe und Colitis) bei Patienten mit hämatologischen und onkologischen Erkrankungen
UCT_BPFAD_Supportiv-SOPs	Schutzimpfungen - Leitlinie Onkopedia
UCT_BPFAD_Supportiv-SOPs	Impfen bei Immundefizienz - Artikel
UCT_BPFAD_Supportiv-SOPs	Immundefekte, sekundär
UCT_BPFAD_Supportiv-SOPs	Schutzimpfungen - Leitlinie AGIHO (Anhang)
UCT_BPFAD_Supportiv-SOPs	Venöse Thrombembolien (VTE) bei Tumorpatienten
UCT_BPFAD_Supportiv-SOPs	Impfen bei Immundefizienz - Veröffentlichung
UCT_BPFAD_Supportiv-SOPs	Schutzimpfungen - Leitlinie AGIHO
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_Antiemese
UCT_BPFAD_Supportiv-SOPs	Risiko Febrile Neutropenie
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_Diagnostik bei klinisch dokumentierten Infektionen
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_Supportive Tumoranämie
UCT_BPFAD_Supportiv-SOPs	Antiemese bei CINV mit Aprepitant/Emend
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_Applikation von G-CSF
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_Paravasate_Zytostatika Paravasation - Wie ist vorzugehen?
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_chemoinduzierte Polyneuropathie
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_Paravasate
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Anwendung von Dexrazoxan zur Behandlung von Anthrazyklin-Paravasaten
UCT_BPFAD_Supportiv-SOPs	Anwendung von Dexrazoxan zur Behandlung von Anthrazyklin-Paravasaten
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_Tumorlysesyndrom
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_Paravasate Paravasation - spezifische Maßnahmen
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_Neutropenisches Fieber
UCT_BPFAD_Supportiv-SOPs	Chemoinduzierte periphere Neuropathie (CIN/CIPN)
UCT_BPFAD_Supportiv-SOPs	Schutzimpfungen für Krebspatienten
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_begleitende Hydrierung bei Tumorthherapie

UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_ossäre Komplikationen
UCT_BPFAD_Supportiv-SOPs	UCT_BPFAD_AA_Supportiv_Antiresorptiva/Osteoprotektion
UCT_BPFAD_Tumore der Bronchien/Pleura/Mediastinum [KP]	BP_NSCLC_Stadium_I-III
UCT_BPFAD_Tumore der Bronchien/Pleura/Mediastinum [KP]	BP_NSCLC_Stadium_IV
UCT_BPFAD_Tumore der Bronchien/Pleura/Mediastinum [KP]	BP_Kleinzelliges_Lungenkarzinom
UCT_BPFAD_Tumore der Haut [KP]	Leitlinie_Dermatofibrosarkoma_protuberans_der_Haut
UCT_BPFAD_Tumore der Haut [KP]	Leitlinie_Basalzellkarzinom
UCT_BPFAD_Tumore der Haut [KP]	Leitlinie_Merkelzellkarzinom
UCT_BPFAD_Tumore der Haut [KP]	Leitlinie_Melanom - Diagnostik, Therapie, Nachsorge
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Checkliste Therapie Larynx tumor / Hypopharynx tumor
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Oropharynxkarzinom
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Therapie von Patienten mit Mundhöhlenkarzinomen in der MKG
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	SOP Staging Bildgebung KHT
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Speicheldrüsenkarzinom
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	BP_Kopf-Hals-Tumore
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Versorgungspfad Tumor
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Nachsorge von Patienten mit Mundhöhlenkarzinomen in der MKG
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Mundhöhlenkarzinom
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Postoperatives Management von Patienten mit Mundhöhlenkarzinomen in der MKG
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Nasopharynxkarzinom
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Larynxkarzinom
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Betreuung von Patienten mit tumortherapeutischer Bestrahlung
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Behandlungspfad für das CUP-Syndrom
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Zusammenarbeit Epithetik
UCT_BPFAD_Tumore des Kopf- Hals- Bereiches [KP]	Hypopharynxkarzinom
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Osteosarkome_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Niedrigmaligne Gliome_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Hirntumore im Kindesalter_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Hochmaligne Gliome_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Ewing-Sarkom_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Akute Leukaemie im Kindesalter_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Neuroblastom_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Medulloblastom_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Nephroblastom_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Non-Hodgkin-Lymphome_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Keimzelltumoren_PaedOnk
UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Hodgkin-Lymphom_PaedOnk

UCT_BPFAD_Tumore im Kindesalter [KP]	UCT_BPFAD_VA_Weichteilsarkome_PaedOnk
UCT_BPFAD_Urogenitale Tumore [KP]	Behandlungspfad Prostatakarzinom
UCT_BPFAD_Urogenitale Tumore [KP]	Behandlungspfad Peniskarzinom
UCT_BPFAD_Urogenitale Tumore [KP]	Patientenpfad RezMed Uro
UCT_BPFAD_Urogenitale Tumore [KP]	Behandlungspfad Nierentumor
UCT_BPFAD_Urogenitale Tumore [KP]	Patientenpfad Primär Uro
UCT_BPFAD_Urogenitale Tumore [KP]	Behandlungspfad Hodentumor
UCT_BPFAD_Urogenitale Tumore [KP]	Behandlungspfad Blasenkarzinom

2019 - Veranstaltungen für Ärzte, Zuweiser und Fachpersonal	Datum	Format	Veranstalter
9. Mainzer Post San Antonio	16.01.2019	Präsenz	Gyn
Post ASH (*)	23.01.2019	Präsenz	III. Med. Klinik
Mainzer Kopf- und Hals-Sonografiekurse 2019 / Grundkurs (zweitägig)	25.01.2019	Präsenz	HNO
DGAV OP-Workshop: Minimal-invasive / robotisch-assistierte Magen- und Ösophaguschirurgie (*) (zweitägig)	04.02.2019	Präsenz	I. Med. Klinik
12. Symposium des Thoraxonkologischen Kompetenzzentrums Mainz (TOM) (*)	06.02.2019	Präsenz	III. Med. Klinik
Rheumatologische Symptome in der Onkologie (*)	13.02.2019	Präsenz	UCT Mainz / I. Med. Klinik
9. Mainzer Hautkrebsymposium (*)	13.02.2019	Präsenz	Derma
Experten-Forum - Update Mamma- und Ovarialkarzinom (*)	13.02.2019	Präsenz	Gyn
Jahrestagung Forum Urodynamikum (zweitägig) (*)	22.02.2019	Präsenz	Uro
2. Mainzer Palliative Care Symposium	08.03.2019	Präsenz	III. Med. Klinik
Was ist neu (WIN) 2019? Die I. Medizinische Klinik lädt ein (*)	20.03.2019	Präsenz	I. Med. Klinik
Auftaktsymposium Else Kröner-Forschungskolleg Mainz „Von chronischer Inflammation zur Krebsentstehung in der Leber	04.04.2019	Präsenz	I. Med. Klinik, TransMed, UCT Mainz
KontroVERSEN 14 - Symposium Maligne Lymphome (*)	05.04.2019	Präsenz	III. Med. Klinik
1st UCT Mainz Mini-Symposium in Translational Oncology (MiTraC): "A View to a Kill: Target Discovery in Cancer Research" (*)	12.04.2019	Präsenz	UCT Mainz
CAR-T-Zellen	08.05.2019	Präsenz	Transfusionszentrale
Mainzer Kopf- und Hals-Sonografiekurse 2019 / Aufbaukurs (zweitägig)	17.05.2019	Präsenz	HNO
Neues vom Amerikanischen Krebskongress (*)	12.06.2019	Präsenz	I. Med. Klinik
Wiesbaden - Chicago - Mainz, Neues vom amerikanischen Krebskongress (*)	12.06.2019	Präsenz	Gyn
Gynäko-Onkologischer Stammtisch: Das Ovarialkarzinom heute! (*)	14.08.2019	Präsenz	Gyn
Pädiatrie Aktuell 2019 - Kinderonkologie	04.09.2019	Präsenz	ZKJM
Thementag klinische Forschung	13.09.2019	Präsenz	IZKS
Strahlenschutz bei der SLN-Diagnostik	20.09.2019	Präsenz	NUK
14. Mainzer Klinisch-Pathologisches Seminar: Molekulare Diagnostik und neue Therapien bei Lungenkarzinomen (*)	25.09.2019	Präsenz	Patho
MEDEA - Herausforderung gynäkologische Tumoren (*)	25.09.2019	Präsenz	Gyn
Gespräche mit onkologischen Patienten	15.10.2019	Präsenz	Fort- und Weiterbildung
Mainzer Kopf- und Hals-Sonografiekurse 2019 / Abschlusskurs (zweitägig)	25.10.2019	Präsenz	HNO
Multiples Myelom Mainzer Update 8 (*)	06.11.2019	Präsenz	III. Med. Klinik
4. Symposium der AGO Kommission Integrative Medizin (zweitägig) (*)	08.11.2019	Präsenz	Gyn
4. Mainzer Update Hämatologie & Onkologie (*)	16.11.2019	Präsenz	UCT Mainz

Interdisziplinäres Kopf-Hals-Tumorsymposium Mainz 2019: Therapiestandards und neue Perspektiven (*)	04.12.2019	Präsenz	HNO
Interdisziplinäre psychoonkologische Fallsupervision (IPF)	13.06.2019 19.09.2019 17.10.2019 21.11.2019 19.12.2019	Präsenz	PSO
Onkologie-Seminar des UCT Mainz	immer Montags	Hybrid	UCT Mainz

* Veranstaltung mit externer finanzieller Unterstützung

2020 - Veranstaltungen für Ärzte, Zuweiser und Fachpersonal	Datum	Format	Veranstalter
10. Mainzer Post San Antonio Symposium (*)	15.01.2020	Präsenz	Gyn
13. Symposium des Thoraxonkologischen Kompetenzzentrums Mainz (TOM) (*)	15.01.2020	Präsenz	III. Med. Klinik
Wege zwischen Klinik und Praxis, Thema: Krebs und COVID-19	20.01.2021	digital	Gyn
Post ASH-Symposium (*)	22.01.2020	Präsenz	III. Med. Klinik
40 Jahre Deutsches Kinderkrebsregister: Wissenschaftliches Symposium (zweitägig) (*)	23.01.2020	Präsenz	Deutsches Kinderkrebsregister, IMBEI
Mainzer Kopf- und Hals-Sonografiekurse 2019 (Grundkurs) (zweitägig)	07.02.2020	Präsenz	HNO
DGAV OP-Workshop: Minimal-invasive / Robotisch-assistierte Magen- und Ösophaguschirurgie (zweitägig) (*)	10.02.2020	Präsenz	Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e.V.
2. Info-Abend: Brustkrebs(-prävention) im Alltag	24.02.2021	digital	Gyn
Gespräche mit onkologischen Patienten	03.03.2020	Präsenz	Fort- und Weiterbildung
5. Gynäko-Onkologischer Stammtisch - Für Frauen gegen Krebs (*)	04.03.2020	Präsenz	Gyn
3. Mainzer Palliative Care Symposium	06.03.2020	Präsenz	Palliativmedizin, Interdisziplinäre Gesellschaft für Palliativmedizin (iGP)
Wege zwischen Klinik und Praxis, Thema: PARPP - wann und für wen und in welcher Kombination	22.03.2021	digital	Gyn
Neues vom Amerikanischen Krebskongress (*)	17.06.2020	digital	I. Med. Klinik
Plötzlich ist alles anders	25.08.2020		Fort- und Weiterbildung
13. Kongress der Deutschen Gesellschaft für Palliativmedizin (viertägig) (*)	09.09.2020	digital	Deutsche Gesellschaft für Palliativmedizin + UCT Mainz
2nd UCT Mainz Mini-Symposium in Translational Oncology (MiTraC): "Targeting Resistance in Cancer Immunotherapy" (*)	10.09.2020	digital	UCT Mainz
MEDEA - Herausforderung gynäkologische Tumoren (*)	16.09.2020	digital	Gyn
Update: 1 Jahr CAR-T-Zelltherapie in RLP (*)	28.10.2020	digital	III. Med. Klinik
Wege zwischen Klinik und Praxis	28.10.2020	Hybrid	Gyn
5. Mainzer Update Hämatologie & Onkologie	18.11.2020	digital	UCT Mainz
Gespräche mit onkologischen Patienten	19.11.2020		Fort- und Weiterbildung
3. Forum Onkologie in Mainz (*)	20.11.2020	digital	RG Gesellschaft für Information und Organisation mbH

Interdisziplinäre psychoonkologische Fallsupervision (IPF)	08.10.2020 19.11.2020	digital	PSO
Onkologie-Seminar des UCT Mainz	immer Montags	Hybrid	UCT Mainz

* Veranstaltung mit externer finanzieller Unterstützung

2021 - Veranstaltungen für Ärzte, Zuweiser und Fachpersonal	Datum	Format	Veranstalter
11. Mainzer Post San Antonio Symposium (*)	13.01.2021	digital	Gyn
Post ASH-Symposium (*)	13.01.2021	digital	III. Med. Klinik
Krebs und COVID-19	20.01.2021	digital	Gyn
2. Info-Abend: Brustkrebs (-prävention) im Alltag	24.02.2021	digital	Gyn
Wege zwischen Klinik und Praxis, Thema: PARPP - wann und für wen und in welcher Kombination	22.03.2021	digital	Gyn
Experten-Meeting Ovar „Ihre Themen - unsere Mission“ (*)	18.05.2021	digital	Gyn
Neues vom Amerikanischen Krebskongress (*)	16.06.2021	digital	I. Med. Klinik
3. Mainz - Chicago - Wiesbaden - Neues vom amerikanischen Krebskongress (*)	26.06.2021	digital	Gyn
Mainzer Kopf- und Hals-Sonografiekurse 2021 / Aufbaukurs (zweitägig)	24.09.2021	Präsenz	HNO
3rd UCT Mainz Mini-Symposium in Translational Oncology (MiTraC): "Emerging Concepts in Immuno-Oncology & DNA Damage" (*)	28.09.2021	digital	UCT Mainz
Multiprofessionelle Sarkomtherapie am UCT Mainz	06.10.2021	digital	UCT Mainz, Sarkomzentrum
3. Uro-Onkologischer Weiterbildungszirkel - Multimodales Teaching für Assistenzärzte	27.10.2021	digital	Urologie
4. Forum Onkologie in Mainz (*)	29.10.2021	Präsenz	RG Gesellschaft für Information und Organisation mbH
Clovis Experten-Meeting Ovar „Ihre Themen - unsere Mission“ (*)	03.11.2021	Präsenz	Gyn
Symposium Interdisziplinäre Immunonkologie	05.11.2021	Hybrid	UCT Mainz & Derma
11. Mainzer Update Dermatologie (*)	10.11.2021	digital	
FANTA 4, Therapie des Mammakarzinoms (*)	11.11.2021	digital	Gyn
Neues vom Europäischen Krebskongress 2020 (*)	27.11.2021	digital	I. Med. Klinik
6. Mainzer Update Hämatologie & Onkologie	13.11.2021	digital	UCT Mainz
Mainzer Kopf- und Hals-Sonografiekurse 2021 / Abschlusskurs (zweitägig)	19.11.2021	Präsenz	HNO
Wind of Change - Neues aus der Gynäkologie und Senologie (*)	24.11.2021	Präsenz	Gyn
Interdisziplinäre (psycho)-onkologische Fallbesprechung	23.09.2021 28.10.2021 25.11.2021	digital	PSO
Onkologie-Seminar des UCT Mainz	immer Montags	Hybrid	UCT Mainz

* Veranstaltung mit externer finanzieller Unterstützung

UCT-Netzwerktreffen		
Datum	Uhrzeit	Format, Veranstaltungsort
15.06.2016	15:30 – 16:30 Uhr	Präsenz, UM
23.11.2016	17:30 – 19:30 Uhr	Präsenz, UM
18.10.2017	17:00 – 18:30 Uhr	Präsenz, UM
21.03.2018	17:00 – 18:30 Uhr	Präsenz, UM
07.11.2018	17:00 – 18:30 Uhr	Präsenz, UM
26.06.2019	17:00 – 18:30 Uhr	Präsenz, UM
06.11.2019	16:30 – 18:00 Uhr	Präsenz, UM
17.06.2020	15:45 – 17:00 Uhr	Digital
09.12.2020	16:00 – 17:00 Uhr	Digital
09.06.2021	16:00 – 17:30 Uhr	Digital
27.10.2021	16:30 – 18:00 Uhr	Digital
29.06.2022	17:00 – 18:30 Uhr	Digital
30.11.2022	17:00 – 18:30 Uhr	Digital

Onkologischer Arbeitskreis Mainz / Wiesbaden		
Datum	Uhrzeit	Format, Veranstaltungsort
29.08.2018 (Kick-Off)	17:00 – 18:30 Uhr	Präsenz, UM
03.04.2019	17:00 – 18:30 Uhr	Präsenz, UM
14.08.2019	17:00 – 18:30 Uhr	Präsenz, UM
18.03.2020	17:00 – 18:30 Uhr	Präsenz, UM, abgesagt
22.09.2021	17:00 – 18:30 Uhr	Favorite Parkhotel Mainz
11.05.2022	17:00 – 18:30 Uhr	Digital

Selbsthilfegruppentreffen im UCT Mainz		
Datum	Uhrzeit	Format, Veranstaltungsort
27.09.2016	16:00 – 17:30 Uhr	Präsenz, UM
26.06.2017	16:00 – 17:30 Uhr	Präsenz, UM
25.09.2017	17:00 – 18:30 Uhr	Präsenz, UM
29.01.2018	16:00 – 17:30 Uhr	Präsenz, UM
23.04.2018	16:00 – 17:30 Uhr	Präsenz, UM
23.07.2018	16:00 – 17:30 Uhr	Präsenz, UM
08.10.2018	16:00 – 17:30 Uhr	Präsenz, UM
28.01.2019	16:00 – 17:30 Uhr	Präsenz, UM
28.05.2019	16:00 – 17:30 Uhr	Präsenz, UM
22.08.2019	16:30 – 18:00 Uhr	Präsenz, UM
02.12.2019	16:00 – 17:30 Uhr	Präsenz, UM
20.10.2020	16:00 – 17:30 Uhr	Digital
07.12.2020	17:00 – 18:30 Uhr	Digital
08.03.2021	17:00 – 18:30 Uhr	Digital
21.06.2021	17:00 – 18:30 Uhr	Digital
13.09.2021	17:00 – 18:30 Uhr	Digital
06.12.2021	17:00 – 18:30 Uhr	Digital
14.03.2022	17:00 – 18:30 Uhr	Digital
27.06.2022	17:00 – 18:30 Uhr	Hybrid
05.09.2022	17:00 – 18:30 Uhr	Hybrid
05.12.2022	17:00 – 18:30 Uhr	Hybrid

Anhang 6 – Programm Patientenveranstaltungen

Veranstaltung	Datum	Veranstalter	Veranstaltungsformat
MDS-Patienten Tag (*)	16.02.19	Leukämiehilfe Rhein-Main, III. Med. Klinik	Präsenz
Arzt-Patienten Tag: Gut leben mit Magen- oder Darmkrebs! (*)	20.03.19	I. Med. Klinik	Präsenz
Krebsforschung am Standort Mainz – von der Vision zur Therapie der Zukunft	10.04.19	CI3	Präsenz
Wie entsteht Krebs und wie kann er bekämpft werden?	09.05.19	Prostatatakrebs-SHG	Präsenz
Hirntumortag 2019 - Aktuelle Therapien bei Gliomen	11.06.19	Neurochirurgie	Präsenz
Diagnose Krebs! Neue Therapien - neue Wege - neue Antworten	11.06.19	UCT Mainz	Präsenz
UCT-Patiententag (*)	19.10.19	UCT Mainz	Präsenz
Arzt-Patienten-Seminar: Nierenkarzinom	26.10.19	I. Med. Klinik	Präsenz
TTP-Patiententag (*)	15.11.19	III. Med. Klinik	Präsenz
Roboterchirurgie an der Universitätsmedizin Mainz	22.01.20	Medizinische Gesellschaft Mainz, Friedrich-Naumann-Stiftung	Präsenz
Telefonaktion zum Weltkrebstag 2020	07.02.20	UCT Mainz	digital
allo-Transplantation - und dann? Patiententag 2020 (*)	04.07.20	III. Med. Klinik, Leukämiehilfe Rhein-Main e.V.	digital
Thrombotisch-Thrombozytopenische Purpura - Patiententag	06.11.20	III. Med. Klinik	digital
COVID 19 - was nun bei Stammzelltransplantation und CAR-T-Zell-Therapie?	06.02.21	III. Med. Klinik	digital
Patiententag 2021: Stammzell-Transplantation und CAR-T-Zell-Therapie (*)	19.06.21	III. Med. Klinik, LHRM	digital
UCT-Patiententag	30.10.21	UCT Mainz	digital
Patiententag Thrombotisch-Thrombozytopenische Purpura	05.11.21	III. Med. Klinik	digital
Ambulante Rehabilitationsgruppe für Krebspatienten: Tumor krank – und trotzdem fit!	jeden Donnerstag	IPTPR, Gesundheitssportverein Mainz e.V.	Präsenz

* Veranstaltung mit externer finanzieller Unterstützung

Thema – Wiederkehrende Veranstaltungen 2021	Datum	Bereich (drop-down Menu)	Format
Seelische Belastungen (z.B. Stress und Ängste) im Rahmen der Krebserkrankung. Wie kann es nach der Klinik weitergehen?	21.04.21	Psychoonkologie	digital
Psychosoziale Krebsberatung - Möglichkeiten der Unterstützung im veränderten Alltag	19.05.21	Psychosoziale Krebsberatungsstelle, Tumorzentrum RLP	digital
Individuelle Begleitung von Krebspatienten durch OncoCoaches	16.06.21	OncoCoaches	digital
Körperliche Aktivität bei Krebs - wie komme ich wieder in Gang?	21.07.21	Ergotherapie, Logopädie, Physiotherapie	digital

Was hilft bei Übelkeit und Erbrechen - vor, während und nach der Therapie?	18.08.21	Onkologische Fachpflege	digital
Krebsdiagnose - was ist aus sozialrechtlicher Sicht zu beachten?	15.09.21	Sozial- und Pflegeberatung	digital
Kann man mit Ernährung die Krebstherapie unterstützen bzw. Nebenwirkungen lindern?	20.10.21	Ernährungsmedizin	digital
Mit Leid leben - Seelsorgliche Perspektiven	17.11.21	Klinikseelsorge	digital
Palliativmedizin – Unterstützungsangebote in unterschiedlichen Krankheitsphasen	15.12.21	Palliativmedizin	digital

Offener psychoonkologischer Abend für Patienten	Termin	Format
Psychoonkologie stellt sich vor	13.03.19	Präsenz
Wie finde ich in den Alltag zurück?	10.04.19	Präsenz
Kommunikation mit Behandlern	08.05.19	Präsenz
Bewältigung und Ressourcen	12.06.19	Präsenz
Chronische Erschöpfung (Fatigue)	11.09.19	Präsenz
Angst vor Wiedererkrankung	09.10.19	Präsenz
Krankheit und Familie	13.11.19	Präsenz
Partnerschaft und Nähe	11.12.19	Präsenz
Offener psychoonkologischer Abend für Patienten	09.12.20	digital
Kommunikation über die Erkrankung	12.05.21	digital
Chronische Erschöpfung (Fatigue) und ihre Bewältigung	09.06.21	digital
Angst vor Wiedererkrankung	06.10.21	digital
Krankheit, Familie und Partnerschaft	10.11.21	digital

Experten	Mitarbeit an Leitlinien*– nicht abschließend
Gynäkologie	
PD Dr. Marco Battista	Endometriumkarzinom (S3) Uterine Sarkome (S2k)
Prof. Dr. Annette Hasenburg	Ovarialkarzinom (S3), Komplementärmedizin (S3) Psychoonkologie (S3)
Prof. Dr. Marcus Schmidt	Mammakarzinom (S3) Antiresorptiva-assoziierte Kiefernekrosen (S3)
Hämatologie	
Dr. Eva Wagner-Drouet	Patienten Blut Management in der Hämatologie und Onkologie (S2k) Leitlinien Onkopedia / DAG-HSZT*: Deutsche Leitlinie Spenderauswahl allogene Stammzelltransplantation" (2021) Leitlinie Stammzelltransplantation und CAR T Zell-Therapie: Indikationen in der Behandlung hämatologischer Erkrankungen bei Erwachsenen (2022) Leitlinie Langzeitnachsorge nach allogener SZT (2018 und aktuelle Überarbeitung) Leitlinie zur autologen Stammzelltransplantation – supportive Therapie und Nachsorge (2018) *: DAG-HSZT: Deutsche Arbeitsgemeinschaft für Hämatopoetische Stammzell-transplantation und Zelluläre Therapie
Prof. Dr. Georg Heß	Follikuläre Lymphome (S3)
Prof. Dr. Markus Munder	Multiples Myelom (S3)
Dermatologie	
Prof. Dr. Stephan Grabbe	Basalzellkarzinom (S2k) Aktinische Keratose und Plattenepithelkarzinom der Haut (S3) Kaposi-Sarkom (S1) Dermatofibrosarkoma protuberans (S1) Pleomorphes kutanes Sarkom Angiosarkom der Haut (S1) Kutane Lymphome (S2k) Merkelzellkarzinom der Haut (S2k)
Allgemein- Viszeral-Transplantationschirurgie	
Prof. Dr. Hauke Lang	Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome (S3) Kolorektales Karzinom (S3) Lebertransplantation (S2k)
Mund-, Kiefer- und Gesichts-Chirurgie	
Prof. Dr. Dr. Bilal Al-Nawas	Implantat-Versorgung zur oralen Rehabilitation im Zusammenhang mit Kopf-Hals-Bestrahlung (S3)Infizierte Osteoradionekrose (IORN) der Kiefer (S2k) Zahnimplantate bei medikamentöser Behandlung mit Knochenantiresorptiva (inkl. Bisphosphonate) (S3)Antiresorptiva-assoziierte Kiefernekrosen (S3)Diagnostik und Therapie des Mundhöhlenkarzinoms (S3)Supportive Therapie bei onkologischen PatientInnen - interdisziplinäre Querschnittsleitlinie (S3)

Dr. Dr. Maximilian Krüger	Infizierte Osteoradionekrose der Kiefer (S2k), Supportive Therapie (S3)
PD Dr. Dr. Eik Schiegnitz	Antiresorptiva-assoziierte Kiefernekrosen (S3)
Kinderonkologie	
Prof. Dr. Jörg Faber	Bewegungsförderung und Bewegungstherapie in der pädiatrischen Onkologie (S2k)
Gastroenterologie	
Prof. Dr. Peter R. Galle	Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome (S3) Clinical Practice Guideline "Management of Hepatocellular Carcinoma" der European Association for the Study of Liver Diseases (EASL) International Liver Cancer Association (ILCA) Transarterial Chemoembolization (TACE) Consensus Paper Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Prof. Dr. Markus Möhler	Magenkarzinom (S3) Perioperatives Management bei gastrointestinalen Tumoren (S3) Ösophaguskarzinom (Onkopedia) Magenkarzinom (Onkopedia)
Endokrinologie	
PD Dr. Christian Fottner	Neuroendokrine Tumore (S2k)
Prof. Dr. Matthias M. Weber	Neuroendokrine Tumore (S2k) Diagnostik und Therapie klinisch hormoninaktiver Hypophysentumoren (S2k)
Thoraxchirurgie	
Prof. Dr. Eric Rößner	Europäische Leitlinie der EACTS/ESTS (Thoraxchirurgie) für „Ground glass opacities“ der Lunge
Orthopädie	
Prof. Dr. Dr. Frank Traub	Osteosarkome (S3) - geplante Leitlinie
Radioonkologie und Strahlentherapie	
Prof. Dr. Heinz Schmidberger	Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (S3) Diagnostik, Therapie und Nachsorge des Hodgkin Lymphoms bei erwachsenen Patienten (S3) Diagnostik, Therapie und Nachsorge für erwachsene Patienten mit einem diffusen groß-zelligen B-Zell-Lymphom und verwandte Entitäten (S3) Diffuses großzelliges B-Zell-Lymphom (Onkopedia) Diagnostik, Therapie und Nachsorge für Patienten mit einem follikulären Lymphom (S3) Kolorektales Karzinom (S3) (bis 2017)
Dr. Tilman Bostel	Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (S3)
Nicht primär onkologische Leitlinien	
	Leitlinien, mit ggf. Bezug zu onkologischen Erkrankungen / Patienten (Beispiele): S2k-Leitlinie Nicht-alkoholische Fettlebererkrankung (Prof. J. Schattenberg) S2k-Leitlinie Chron. obstruktive Bronchitis und Lungenemphysem (Prof. R. Buhl) S3-Leitlinie Behandlung von Angststörungen (Prof. J. Wiltink) S2k-Leitlinie Harninkontinenz der Frau (Prof. A. Haferkamp) Europäischen Leitlinie der EACTS & ESTS & ERS „Pneumothorax“ (Prof. E. Rößner)

Publikationen UCT Mainz 2019

* Erst- und/oder Letztautor UCT Mainz

1. *Aasland, D, Götzinger, L, Hauck, L, Berte, N, Meyer, J, Effenberger, M, Schneider, S, Reuber, EE, Roos, WP, Tomicic, MT, Kaina, B, & Christmann, M. (2019). Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB. *Cancer Res*, 79(1), 99-113. doi:10.1158/0008-5472.Can-18-1733
2. Adebahr, S, Hechtner, M, Schröder, N, Schimek-Jasch, T, Kaier, K, Duncker-Rohr, V, Gkika, E, Momm, F, Gaertner, J, Becker, G, Grosu, AL, & Nestle, U. (2019). Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial). *J Thorac Oncol*, 14(3), 408-419. doi:10.1016/j.jtho.2018.10.170
3. *Ahmed, S, Galle, PR, & Neumann, H. (2019). Molecular endoscopic imaging: the future is bright. *Ther Adv Gastrointest Endosc*, 12, 2631774519867175. doi:10.1177/2631774519867175
4. Ahmetlić, F, Riedel, T, Hömberg, N, Bauer, V, Trautwein, N, Geishauser, A, Sparwasser, T, Stevanović, S, Röcken, M, & Mocikat, R. (2019). Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape. *Cancer Immunol Res*, 7(4), 600-608. doi:10.1158/2326-6066.Cir-18-0419
5. Akbaba, S, Oelmann-Avendano, JT, Krug, D, Arians, N, Bostel, T, Hoerner-Rieber, J, Nicolay, NH, Debus, J, Lindel, K, & Foerster, R. (2019). The impact of vaginal dilator use on vaginal stenosis and sexual quality of life in women treated with adjuvant radiotherapy for endometrial cancer. *Strahlenther Onkol*, 195(10), 902-912. doi:10.1007/s00066-019-01466-1
6. Al-Batran, SE, Homann, N, Pauligk, C, Goetze, TO, Meiler, J, Kasper, S, Kopp, HG, Mayer, F, Haag, GM, Luley, K, Lindig, U, Schmieg, W, Pohl, M, Stoecklacher, J, Folprecht, G, Probst, S, Prasnikar, N, Fischbach, W, Mahlberg, R, Trojan, J, Koenigsmann, M, Martens, UM, Thuss-Patience, P, Egger, M, Block, A, Heinemann, V, Illerhaus, G, Moehler, M, Schenk, M, Kullmann, F, Behringer, DM, Heike, M, Pink, D, Teschendorf, C, Löhr, C, Bernhard, H, Schuch, G, Rethwisch, V, von Weikersthal, LF, Hartmann, JT, Kneba, M, Daum, S, Schulmann, K, Weniger, J, Belle, S, Gaiser, T, Oduncu, FS, Güntner, M, Hozaeel, W, Reichart, A, Jäger, E, Kraus, T, Mönig, S, Bechstein, WO, Schuler, M, Schmalenberg, H, & Hofheinz, RD. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. *Lancet*, 393(10184), 1948-1957. doi:10.1016/s0140-6736(18)32557-1
7. Allodji, RS, Hawkins, MM, Bright, CJ, Fidler-Benaoudia, MM, Winter, DL, Alessi, D, Fresneau, B, Journy, N, Morsellino, V, Bárdi, E, Bautz, A, Byrne, J, Feijen, ELA, Teepe, JC, Vu-Bezin, G, Rubino, C, Garwicz, S, Grabow, D, Gudmundsdottir, T, Guha, J, Hau, EM, Jankovic, M, Kaatsch, P, Kaiser, M, Linge, H, Muraca, M, Llanas, D, Veres, C, Øfstaas, H, Diallo, I, Mansouri, I, Ronckers, CM, Skinner, R, Terenziani, M, Wesenberg, F, Wiebe, T, Sacerdote, C, Jakab, Z, Haupt, R, Lähteenmäki, P, Zaletel, LZ, Kuehni, CE, Winther, JF, Michel, G, Kremer, LCM, Hjorth, L, Haddy, N, de Vathaire, F, & Reulen, RC. (2019). Risk of subsequent primary leukaemias among 69,460 five-year survivors of childhood cancer diagnosed from 1940 to 2008 in Europe: A cohort study within PanCareSurFup. *Eur J Cancer*, 117, 71-83. doi:10.1016/j.ejca.2019.05.013
8. *Altmann, C, Keller, S, & Schmidt, MHH. (2019). The Role of SVZ Stem Cells in Glioblastoma. *Cancers (Basel)*, 11(4). doi:10.3390/cancers11040448
9. Alwers, E, Bläker, H, Walter, V, Jansen, L, Kloor, M, Arnold, A, Sieber-Frank, J, Herpel, E, Tagscherer, KE, Roth, W, Chang-Claude, J, Brenner, H, & Hoffmeister, M. (2019). External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS. *BMC Cancer*, 19(1), 681. doi:10.1186/s12885-019-5842-7
10. Amant, F, Berveiller, P, Boere, I, Cardonick, E, Fruscio, R, Fumagalli, M, Halaska, MJ, Hasenburg, A, Johansson, ALV, Lambertini, M, Lok, C, Maggen, C, Morice, P, Peccatori, F, Poortmans, P, Van Calsteren, K, Vandenbroucke, T, van Gerwen, M, van den Heuvel-Eibrink, M, Zagouri, F, & Zapardiel, I. (2019). Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. *Ann Oncol*. doi:10.1093/annonc/mdz228

11. Amitay, EL, Carr, PR, Jansen, L, Walter, V, Roth, W, Herpel, E, Kloor, M, Bläker, H, Chang-Claude, J, Brenner, H, & Hoffmeister, M. (2019). Association of Aspirin and Nonsteroidal Anti-Inflammatory Drugs With Colorectal Cancer Risk by Molecular Subtypes. *J Natl Cancer Inst*, 111(5), 475-483. doi:10.1093/jnci/djy170
12. Andreiuolo, F, Varlet, P, Tauziède-Espariat, A, Jünger, ST, Dörner, E, Dreschmann, V, Kuchelmeister, K, Waha, A, Haberler, C, Slavic, I, Corbacioglu, S, Riemenschneider, MJ, Leipold, A, Rüdiger, T, Körholz, D, Acker, T, Russo, A, Faber, J, Sommer, C, Armbrust, S, Rose, M, Erdlenbruch, B, Hans, VH, Bernbeck, B, Schneider, D, Lorenzen, J, Ebinger, M, Handgretinger, R, Neumann, M, van Buiren, M, Prinz, M, Roganovic, J, Jakovcovic, A, Park, SH, Grill, J, Puget, S, Messing-Jünger, M, Reinhard, H, Bergmann, M, Hattingen, E, & Pietsch, T. (2019). Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features. *Brain Pathol*, 29(2), 205-216. doi:10.1111/bpa.12659
13. Aubreville, M, Stoeve, M, Oetter, N, Goncalves, M, Knipfer, C, Neumann, H, Bohr, C, Stelzle, F, & Maier, A. (2019). Deep learning-based detection of motion artifacts in probe-based confocal laser endomicroscopy images. *Int J Comput Assist Radiol Surg*, 14(1), 31-42. doi:10.1007/s11548-018-1836-1
14. *Auer, TA, Breit, HC, Marini, F, Renovanz, M, Ringel, F, Sommer, CJ, Brockmann, MA, & Tanyildizi, Y. (2019). Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse. *J Neuroradiol*, 46(1), 36-43. doi:10.1016/j.neurad.2018.04.002
15. Baechler, SA, Factor, VM, Dalla Rosa, I, Ravji, A, Becker, D, Khiati, S, Miller Jenkins, LM, Lang, M, Sourbier, C, Michaels, SA, Neckers, LM, Zhang, HL, Spinazzola, A, Huang, SN, Marquardt, JU, & Pommier, Y. (2019). The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis. *Nat Commun*, 10(1), 83. doi:10.1038/s41467-018-07922-3
16. *Bahr, K, Zimmer, S, Springer, E, Fottner, C, Becker, S, Ernst, BP, Matthias, C, & Künzel, J. (2019). High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression. *ORL J Otorhinolaryngol Relat Spec*, 81(5-6), 309-316. doi:10.1159/000502325
17. Bakhtiar, S, Salzmann-Manrique, E, Hutter, M, Krenn, T, Duerken, M, Faber, J, Reinhard, H, Kreyenberg, H, Huenecke, S, Cappel, C, Bremm, M, Pfirrmann, V, Merker, M, Barnbrock, A, Schöning, S, Willasch, AM, Rettinger, E, Soerensen, J, Klingebiel, TE, Jarisch, A, & Bader, P. (2019). AlloHSCT in paediatric ALL and AML in complete remission: improvement over time impacted by accreditation? *Bone Marrow Transplant*, 54(5), 737-745. doi:10.1038/s41409-018-0341-z
18. Balmus, G, Pilger, D, Coates, J, Demir, M, Sczaniecka-Clift, M, Barros, AC, Woods, M, Fu, B, Yang, F, Chen, E, Ostermaier, M, Stankovic, T, Ponstingl, H, Herzog, M, Yusa, K, Martinez, FM, Durant, ST, Galanty, Y, Beli, P, Adams, DJ, Bradley, A, Metzakopian, E, Forment, JV, & Jackson, SP. (2019). ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks. *Nat Commun*, 10(1), 87. doi:10.1038/s41467-018-07729-2
19. *Bartsch, F, Baumgart, J, Tripke, V, Hoppe-Lotichius, M, Heinrich, S, & Lang, H. (2019). Resection of intrahepatic cholangiocarcinoma in elderly patients - is it reasonable? *BMC Surg*, 19(1), 157. doi:10.1186/s12893-019-0620-7
20. *Bartsch, F, Heinrich, S, Roth, W, & Lang, H. (2019). [Lymphadenectomy in oncological visceral surgery-Part 1 : Hepatobiliary tumors and pancreatic cancer]. *Chirurg*, 90(5), 423-438. doi:10.1007/s00104-019-0956-7
21. *Bartsch, F, Paschold, M, Baumgart, J, Hoppe-Lotichius, M, Heinrich, S, & Lang, H. (2019). Surgical Resection for Recurrent Intrahepatic Cholangiocarcinoma. *World J Surg*, 43(4), 1105-1116. doi:10.1007/s00268-018-04876-x
22. *Bartsch, F, Tripke, V, Baumgart, J, Hoppe-Lotichius, M, Heinrich, S, & Lang, H. (2019). Extended resection of intrahepatic cholangiocarcinoma: A retrospective single-center cohort study. *Int J Surg*, 67, 62-69. doi:10.1016/j.ijsu.2019.05.006
23. *Baumgart, J, Jungmann, F, Bartsch, F, Kloth, M, Mittler, J, Heinrich, S, & Lang, H. (2019). Two-Stage Hepatectomy and ALPPS for Advanced Bilateral Liver Metastases: a Tailored Approach Balancing Risk and Outcome. *J Gastrointest Surg*. doi:10.1007/s11605-019-04145-9
24. *Beck, O, Muensterer, O, Hofmann, S, Rossmann, H, Poplawski, A, Faber, J, & Gödeke, J. (2019). Central Venous Access Devices (CVAD) in Pediatric Oncology Patients-A Single-Center Retrospective Study Over More Than 9 Years. *Front Pediatr*, 7, 260. doi:10.3389/fped.2019.00260
25. Beckmann, MW, Lotz, L, Toth, B, Baston-Büst, DM, Fehm, T, Frambach, T, Germeyer, A, Goeckenjan, M, Häberlin, F, Henes, M, Hirchenhain, J, Hübner, S, Korell, M, Krüssel, JS, Müller, A, Reinsberg, J, Schwab, R, Seitz, S, Sütterlin, M, van

- der Ven, H, van der Ven, K, Winkler-Crepaz, K, Wimberger, P, von Wolff, M, Liebenthron, J, & Dittrich, R. (2019). Concept Paper on the Technique of Cryopreservation, Removal and Transplantation of Ovarian Tissue for Fertility Preservation. *Geburtshilfe Frauenheilkd*, 79(1), 53-62. doi:10.1055/a-0664-8619
26. *Beltz, A, Gösswein, D, Zimmer, S, Limburg, I, Wünsch, D, Gribko, A, Deichelbohrer, M, Hagemann, J, Stauber, RH, & Künzel, J. (2019). Staging of oropharyngeal squamous cell carcinoma of the head and neck: Prognostic features and power of the 8th edition of the UICC staging manual. *Eur J Surg Oncol*, 45(6), 1046-1053. doi:10.1016/j.ejso.2019.02.032
 27. *Beyer, M, Romanski, A, Mustafa, AM, Pons, M, Büchler, I, Vogel, A, Pautz, A, Sellmer, A, Schneider, G, Bug, G, & Krämer, OH. (2019). HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β -catenin, MYC, and WT1. *Cancers (Basel)*, 11(10). doi:10.3390/cancers11101436
 28. *Bialojan, A, Sohl, J, Rausch, J, Aranda Lopez, P, Denny, M, Langguth, P, Hartmann, AK, Yagita, H, Probst, HC, Schild, H, & Radsak, MP. (2019). Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice. *Eur J Immunol*. doi:10.1002/eji.201848039
 29. Bischoff, J, Barinoff, J, Mundhenke, C, Bauerschlag, DO, Costa, SD, Herr, D, Lübke, K, Marmé, F, Maass, N, von Minckwitz, G, Grischke, EM, Müller, V, Schmidt, M, Gerber, B, Kümmel, S, Schumacher, C, Krabisch, P, Seiler, S, Thill, M, Nekljudova, V, & Loibl, S. (2019). A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). *Anticancer Drugs*, 30(4), 394-401. doi:10.1097/cad.0000000000000722
 30. Bisschops, R, East, JE, Hassan, C, Hazewinkel, Y, Kamiński, MF, Neumann, H, Pellisé, M, Antonelli, G, Bustamante Balen, M, Coron, E, Cortas, G, Iacucci, M, Yuichi, M, Longcroft-Wheaton, G, Mouzyka, S, Pilonis, N, Puig, I, van Hooft, JE, & Dekker, E. (2019). Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. *Endoscopy*, 51(12), 1155-1179. doi:10.1055/a-1031-7657
 31. Bläker, H, Alwers, E, Arnold, A, Herpel, E, Tagscherer, KE, Roth, W, Jansen, L, Walter, V, Kloor, M, Chang-Claude, J, Brenner, H, & Hoffmeister, M. (2019). The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage. *Clin Gastroenterol Hepatol*, 17(3), 455-462.e456. doi:10.1016/j.cgh.2018.04.015
 32. Bossler, F, Kuhn, BJ, Günther, T, Kraemer, SJ, Khalkar, P, Adrian, S, Lohrey, C, Holzer, A, Shimobayashi, M, Dürst, M, Mayer, A, Rösl, F, Grundhoff, A, Krijgsveld, J, Hoppe-Seyler, K, & Hoppe-Seyler, F. (2019). Repression of Human Papillomavirus Oncogene Expression under Hypoxia Is Mediated by PI3K/mTORC2/AKT Signaling. *MBio*, 10(1). doi:10.1128/mBio.02323-18
 33. *Bostel, T, Förster, R, Schlamp, I, Sprave, T, Akbaba, S, Wollschläger, D, Debus, J, Mayer, A, Schmidberger, H, Rief, H, & Nicolay, NH. (2019). Stability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy : Results from a large multicenter cohort. *Strahlenther Onkol*, 195(12), 1074-1085. doi:10.1007/s00066-019-01482-1
 34. *Bostel, T, Sachpazidis, I, Splinter, M, Bougatf, N, Fechter, T, Zamboglou, C, Jäkel, O, Huber, PE, Baltas, D, Debus, J, & Nicolay, NH. (2019). Dosimetric Impact of Interfractional Variations in Prostate Cancer Radiotherapy-Implications for Imaging Frequency and Treatment Adaptation. *Front Oncol*, 9, 940. doi:10.3389/fonc.2019.00940
 35. *Boutas, I, Potiris, A, Brenner, W, Lebrecht, A, Hasenburg, A, Kalantaridou, S, & Schmidt, M. (2019). The expression of galectin-3 in breast cancer and its association with chemoresistance: a systematic review of the literature. *Arch Gynecol Obstet*. doi:10.1007/s00404-019-05292-9
 36. *Buchmann, N, Gempt, J, Ryang, YM, Pyka, T, Kirschke, JS, Meyer, B, & Ringel, F. (2019). Can Early Postoperative O-(2-(18F)Fluoroethyl)-L-Tyrosine Positron Emission Tomography After Resection of Glioblastoma Predict the Location of Later Tumor Recurrence? *World Neurosurg*, 121, e467-e474. doi:10.1016/j.wneu.2018.09.139
 37. *Burghardt, J, Klein, E, Brähler, E, Ernst, M, Schneider, A, Eckerle, S, Neu, MA, Wingerter, A, Henninger, N, Panova-Noeva, M, Prochaska, J, Wild, P, Beutel, M, & Faber, J. (2019). Prevalence of mental distress among adult survivors of childhood cancer in Germany-Compared to the general population. *Cancer Med*, 8(4), 1865-1874. doi:10.1002/cam4.1936

38. *Büttner, M, König, HH, Löbner, M, Briest, S, Konnopka, A, Dietz, A, Riedel-Heller, S, & Singer, S. (2019). Out-of-pocket-payments and the financial burden of 502 cancer patients of working age in Germany: results from a longitudinal study. *Support Care Cancer*, 27(6), 2221-2228. doi:10.1007/s00520-018-4498-1
39. Cadenas, C, Vosbeck, S, Edlund, K, Grgas, K, Madjar, K, Hellwig, B, Adawy, A, Glotzbach, A, Stewart, JD, Lesjak, MS, Franckenstein, D, Claus, M, Hayen, H, Schriewer, A, Gianmoena, K, Thaler, S, Schmidt, M, Micke, P, Pontén, F, Mardinoglu, A, Zhang, C, Käfferlein, HU, Watzl, C, Frank, S, Rahnenführer, J, Marchan, R, & Hengstler, JG. (2019). LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer. *Int J Cancer*, 145(4), 901-915. doi:10.1002/ijc.32138
40. *Cámara, RJA, Schwentner, L, Friedl, TWP, Deniz, M, Fink, V, Lato, K, Widschwendter, P, Rack, B, Janni, W, Singer, S, & Bekes, I. (2019). Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial. *Breast Cancer Res Treat*, 175(3), 627-635. doi:10.1007/s10549-019-05171-6
41. Cammann, VL, Sarcon, A, Ding, KJ, Seifert, B, Kato, K, Di Vece, D, Szawan, KA, Gili, S, Jurisic, S, Bacchi, B, Micek, J, Frangieh, AH, Napp, LC, Jaguszewski, M, Bossone, E, Citro, R, D'Ascenzo, F, Franke, J, Noutsias, M, Knorr, M, Heiner, S, Burgdorf, C, Koenig, W, Thiele, H, Tschöpe, C, Rajan, L, Michels, G, Pfister, R, Cuneo, A, Jacobshagen, C, Karakas, M, Banning, A, Cuculi, F, Kobza, R, Fischer, TA, Vasankari, T, Airaksinen, KEJ, Dworakowski, R, Kaiser, C, Osswald, S, Galiuto, L, Dichtl, W, Delmas, C, Lairez, O, Horowitz, JD, Kozel, M, Widimský, P, Tousek, P, Winchester, DE, Gilyarova, E, Shilova, A, Gilyarov, M, El-Battrawy, I, Akin, I, Ukena, C, Bauersachs, J, Pieske, BM, Hasenfuß, G, Rottbauer, W, Braun-Dullaeus, RC, Opolski, G, MacCarthy, P, Felix, SB, Borggrefe, M, Di Mario, C, Crea, F, Katus, HA, Schunkert, H, Münzel, T, Böhm, M, Bax, JJ, Prasad, A, Shinbane, J, Lüscher, TF, Ruschitzka, F, Ghadri, JR, & Templin, C. (2019). Clinical Features and Outcomes of Patients With Malignancy and Takotsubo Syndrome: Observations From the International Takotsubo Registry. *J Am Heart Assoc*, 8(15), e010881. doi:10.1161/jaha.118.010881
42. *Campana, LG, Kis, E, Botlyán, K, Orlando, A, de Terlizzi, F, Mitsala, G, Careri, R, Curatolo, P, Snoj, M, Sersa, G, Valpione, S, Quaglini, P, Mowatt, D, Brizio, M, & Schepler, H. (2019). Electrochemotherapy for advanced cutaneous angiosarcoma: A European register-based cohort study from the International Network for Sharing Practices of electrochemotherapy (InspECT). *Int J Surg*, 72, 34-42. doi:10.1016/j.ijsu.2019.10.013
43. *Castven, D, Becker, D, Czauderna, C, Wilhelm, D, Andersen, JB, Strand, S, Hartmann, M, Heilmann-Heimbach, S, Roth, W, Hartmann, N, Straub, BK, Mahn, FL, Franck, S, Pereira, S, Haupts, A, Vogel, A, Wörns, MA, Weinmann, A, Heinrich, S, Lang, H, Thorgeirsson, SS, Galle, PR, & Marquardt, JU. (2019). Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification. *Int J Cancer*, 144(11), 2782-2794. doi:10.1002/ijc.32026
44. *Christmann, M, & Kaina, B. (2019). Epigenetic regulation of DNA repair genes and implications for tumor therapy. *Mutat Res*, 780, 15-28. doi:10.1016/j.mrrev.2017.10.001
45. Clemens, E, Meijer, AJ, Broer, L, Langer, T, van der Kooi, AL, Uitterlinden, AG, de Vries, A, Kuehni, CE, Garrè, ML, Kepak, T, Kruseova, J, Winther, JF, Kremer, LC, van Dulmen-den Broeder, E, Tissing, WJ, Reznitz, C, Kenborg, L, Hasle, H, Grabow, D, Parfitt, R, Binder, H, Carleton, BC, Byrne, J, Kaatsch, P, Am Zehnhoff-Dinnesen, A, Zolk, O, & van den Heuvel-Eibrink, MM. (2019). Genetic Determinants of Ototoxicity During and After Childhood Cancer Treatment: Protocol for the PanCareLIFE Study. *JMIR Res Protoc*, 8(3), e11868. doi:10.2196/11868
46. Cortes, JE, Khaled, S, Martinelli, G, Perl, AE, Ganguly, S, Russell, N, Krämer, A, Dombret, H, Hogge, D, Jonas, BA, Leung, AY, Mehta, P, Montesinos, P, Radsak, M, Sica, S, Arunachalam, M, Holmes, M, Kobayashi, K, Namuyinga, R, Ge, N, Yver, A, Zhang, Y, & Levis, MJ. (2019). Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncol*, 20(7), 984-997. doi:10.1016/s1470-2045(19)30150-0
47. *Czauderna, C, Castven, D, Mahn, FL, & Marquardt, JU. (2019). Context-Dependent Role of NF-kappaB Signaling in Primary Liver Cancer-from Tumor Development to Therapeutic Implications. *Cancers (Basel)*, 11(8). doi:10.3390/cancers11081053
48. *Dau, M, Kraeft, SK, & Kämmerer, PW. (2019). Unique manifestation of a multifocal adult rhabdomyoma involving the soft palate-case report and review of literature. *J Surg Case Rep*, 2019(4), rjz116. doi:10.1093/jscr/rjz116
49. Deltour, I, Schlehofer, B, Massardier-Pilonchery, A, Schläfer, K, Armstrong, B, Giles, GG, Siemiatycki, J, Parent, ME, Krewski, D, McBride, M, Johansen, C, Auvinen, A, Salminen, T, Hours, M, Montestrucq, L, Blettner, M, Berg-Beckhoff, G, Sadetzki, S, Chetrit, A, Lagorio, S, Iavarone, I, Yamaguchi, N, Takebayashi, T, Woodward, A, Cook, A, Tynes, T, Klæboe, L, Feychting, M, Lonn, S, Fleming, S, Swerdlow, AJ, Schoemaker, MJ, Moissonnier, M, Kesminiene, A, Cardis, E, Schuz, J, Vrijheid, M, Evrard, AS, Sanchez, M, Brown, J, Nadon, L, Christensen, HC, Kurtio, P, Lahkola, A, Bernard, M,

- Jarus-Hakak, A, Pearce, N, Blaasaas, K, Ahlbom, A, McKinney, PA, Muir, KR, & Grp, IS. (2019). Exposure to loud noise and risk of vestibular schwannoma: results from the INTERPHONE international case-control study. *Scandinavian Journal of Work Environment & Health*, 45(2), 183-193. doi:10.5271/sjweh.3781
50. Denschlag, D, Ackermann, S, Battista, MJ, Cremer, W, Egerer, G, Follmann, M, Haas, H, Harter, P, Hettmer, S, Horn, LC, Juhasz-Boess, I, Kast, K, Köhler, G, Kröncke, T, Lindel, K, Mallmann, P, Meyer-Steinacker, R, Mustea, A, Petru, E, Reichardt, P, Schmidt, D, Strauss, HG, Tempfer, C, Thiel, F, Ulrich, U, Vogl, T, Vordermark, D, Gass, P, & Beckmann, MW. (2019). Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019). *Geburtshilfe Frauenheilkd*, 79(10), 1043-1060. doi:10.1055/a-0882-4116
 51. *Desuki, A, Staib, F, Gockel, I, Moehler, M, Lang, H, Biesterfeld, S, Maderer, A, Galle, PR, Berger, MR, & Schimanski, CC. (2019). Loss of LLGL1 Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. *Can J Gastroenterol Hepatol*, 2019, 2920493. doi:10.1155/2019/2920493
 52. *Diehl, E, Rieger, S, Letzel, S, Nienhaus, A, & Escobar Pinzon, LC. (2019). [Burdens and resources of nurses working in the specialist palliative care: an explorative cross-sectional study]. *Pflege*, 32(4), 209-223. doi:10.1024/1012-5302/a000680
 53. Dimopoulos, MA, Gay, F, Schjesvold, F, Beksac, M, Hajek, R, Weisel, KC, Goldschmidt, H, Maisnar, V, Moreau, P, Min, CK, Pluta, A, Chng, WJ, Kaiser, M, Zweegman, S, Mateos, MV, Spencer, A, Iida, S, Morgan, G, Suryanarayan, K, Teng, ZY, Skacel, T, Palumbo, A, Dash, AB, Gupta, N, Labotka, R, Rajkumar, SV, Bar, D, Basso, A, Fantl, D, He, S, Horvath, N, Lee, C, Rowlings, P, Taylor, K, Cochrane, T, Kwok, F, Ramanathan, S, Agis, H, Zojer, N, Kentos, A, Offner, F, Van Droogenbroeck, J, Wu, KL, Maiolino, A, Martinez, G, Zanella, K, Capra, M, Araujo, S, Gregora, E, Pour, L, Scudla, V, Spicka, I, Abildgaard, N, Andersen, N, Jensen, BA, Helleberg, C, Plesner, T, Salomo, M, Svirskaitė, A, Delarue, R, Blau, I, Schieferdecker, A, Teleanu, V, Munder, M, Rollig, C, Salwender, HJ, Fuhrmann, S, Weisel, K, Duerig, J, Zeis, M, Klein, S, Reimer, P, Schmidt, C, Scheid, C, Mayer, K, Hoffmann, M, Sosada, M, Dimopoulos, A, Delimpasi, S, Kyrtsionis, MC, Anagnostopoulos, A, Nagy, Z, Illes, A, Egyed, M, Borbenyi, Z, Mikala, G, Dally, N, Horowitz, N, Gutwein, O, Nemets, A, Vaxman, I, Shvets, O, Trestman, S, Ruchlemer, R, Nagler, A, Tadmor, T, Rouvio, O, Preis, M, Cavo, M, De Rosa, L, Musto, P, Cafró, A, Tosi, P, Offidani, M, Corso, A, Rossi, G, Liberati, AM, Bosi, A, Suzuki, K, Nakaseko, C, Ishikawa, T, Matsumoto, M, Nagai, H, Sunami, K, Chou, T, Akashi, K, Takezako, N, Hagiwara, S, Eom, HS, Jo, DY, Kim, JS, Lee, JH, Yoon, SS, Yoon, DH, Kim, K, Levin, MD, Vellenga, E, Minnema, M, Waage, A, Haukas, E, Grosicki, S, Pluta, A, Robak, T, Marques, H, Bergantim, R, Campilho, F, Chng, WJ, Goh, YT, McDonald, A, Rapoport, B, Rivas, MAA, de La Fuente, FD, Montes, YG, Sanchez, JM, Mateos, MV, Rocafiguera, AO, Rosinol, L, San Miguel, J, de Oteyza, JP, Encinas, C, Alegre-Amor, A, Lopez-Guía, A, Axelsson, P, Carlson, K, Stromberg, O, Hansson, M, Blimark, CH, Mueller, R, Chen, CC, Liu, TC, Huang, SY, Wang, PN, Nakorn, TN, Prayongratana, K, Unal, A, Goker, H, Sonmez, M, Korenkova, S, Chaidos, A, Oakervee, H, Sati, H, Benjamin, R, Wechalekar, A, Garg, M, Ramasamy, K, Cook, G, Chantry, A, Jenner, M, Buadi, F, Berryman, R, Janakiram, M, & Grp, T-MS. (2019). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*, 393(10168), 253-264. doi:10.1016/s0140-6736(18)33003-4
 54. *Ditsch, N, & Schmidt, M. (2019). Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer. *Geburtshilfe Frauenheilkd*, 79(12), 1328-1335. doi:10.1055/a-1037-5205
 55. Ditsch, N, Untch, M, Thill, M, Müller, V, Janni, W, Albert, US, Bauerfeind, I, Blohmer, J, Budach, W, Dall, P, Diel, I, Fasching, PA, Fehm, T, Friedrich, M, Gerber, B, Hanf, V, Harbeck, N, Huober, J, Jackisch, C, Kolberg-Liedtke, C, Kreipe, HH, Krug, D, Kühn, T, Kümmel, S, Loibl, S, Lüftner, D, Lux, MP, Maass, N, Möbus, V, Müller-Schimpfle, M, Mundhenke, C, Thitz, U, Rhiem, K, Rody, A, Schmidt, M, Schneeweiss, A, Schütz, F, Sinn, HP, Solbach, C, Solomayer, EF, Stickeler, E, Thomssen, C, Wenz, F, Witzel, I, & Wöckel, A. (2019). AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. *Breast Care (Basel)*, 14(4), 224-245. doi:10.1159/000501000
 56. Dmitrieva-Posocco, O, Dzutsev, A, Posocco, DF, Hou, V, Yuan, W, Thovarai, V, Mufazalov, IA, Gunzer, M, Shilovskiy, IP, Khaitov, MR, Trinchieri, G, Waisman, A, & Grivennikov, SI. (2019). Cell-Type-Specific Responses to Interleukin-1 Control Microbial Invasion and Tumor-Elicited Inflammation in Colorectal Cancer. *Immunity*, 50(1), 166-180.e167. doi:10.1016/j.immuni.2018.11.015
 57. Dong, J, Gharahkhani, P, Chow, WH, Gammon, MD, Liu, G, Caldas, C, Wu, AH, Ye, W, Onstad, L, Anderson, LA, Bernstein, L, Pharoah, PD, Risch, HA, Corley, DA, Fitzgerald, RC, Iyer, PG, Reid, BJ, Lagergren, J, Shaheen, NJ, Vaughan, TL, MacGregor, S, Love, S, Palles, C, Tomlinson, I, Gockel, I, May, A, Gerges, C, Anders, M, Böhmer, AC, Becker, J, Kreuser, N, Thieme, R, Noder, T, Venerito, M, Veits, L, Schmidt, T, Schmidt, C, Izbicki, JR, Hölscher, AH, Lang, H, Lorenz, D, Schumacher, B, Mayershofer, R, Vashist, Y, Ott, K, Vieth, M, Weismüller, J, Nöthen, MM, Moebus, S, Knapp, M, Peters, WHM, Neuhaus, H, Rösch, T, Ell, C, Jankowski, J, Schumacher, J, Neale, RE, Whiteman, DC, & Thrift, AP. (2019). No Association Between Vitamin D Status and Risk of Barrett's Esophagus or Esophageal Adenocarcinoma: A Mendelian Randomization Study. *Clin Gastroenterol Hepatol*, 17(11), 2227-2235.e2221. doi:10.1016/j.cgh.2019.01.041

58. Ebner, F, Wöckel, A, Schwentner, L, Blettner, M, Janni, W, Kreienberg, R, & Wischnewsky, M. (2019). Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival? *BMC Cancer*, 19(1), 90. doi:10.1186/s12885-019-5292-2
59. *Echchannaoui, H, Petschenka, J, Ferreira, EA, Hauptrock, B, Lotz-Jenne, C, Voss, RH, & Theobald, M. (2019). A Potent Tumor-Reactive p53-Specific Single-Chain TCR without On- or Off-Target Autoimmunity In Vivo. *Mol Ther*, 27(1), 261-271. doi:10.1016/j.ymthe.2018.11.006
60. *Eichler, M, Hechtner, M, Wehler, B, Buhl, R, Stratmann, J, Sebastian, M, Schmidberger, H, Kortsik, C, Nestle, U, Wirtz, H, Wehler, T, Blettner, M, & Singer, S. (2019). Use of psychosocial services by lung cancer survivors in Germany : Results of a German multicenter study (LARIS). *Strahlenther Onkol*, 195(11), 1018-1027. doi:10.1007/s00066-019-01490-1
61. Emons, G, Tempfer, C, Battista, MJ, Mustea, A, & Vordermark, D. (2019). Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO). *Geburtshilfe Frauenheilkd*, 79(12), 1273-1277. doi:10.1055/a-1019-7720
62. *Erb, HHH, Ebert, M, Kuhn, R, Donix, L, Haferkamp, A, Seed, RI, & Jüngel, E. (2019). PIAS1 is not suitable as a urothelial carcinoma biomarker protein and pharmacological target. *PLoS One*, 14(10), e0224085. doi:10.1371/journal.pone.0224085
63. *Ernst, M, Brähler, E, Klein, EM, Jünger, C, Wild, PS, Faber, J, Schneider, A, & Beutel, ME. (2019). Parenting in the face of serious illness: Childhood cancer survivors remember different rearing behavior than the general population. *Psychooncology*, 28(8), 1663-1670. doi:10.1002/pon.5138
64. *Ernst, M, Tibubos, AN, Unterrainer, J, Burghardt, J, Brähler, E, Wild, PS, Jünger, C, Faber, J, Schneider, A, & Beutel, ME. (2019). Status and predictors of planning ability in adult long-term survivors of CNS tumors and other types of childhood cancer. *Sci Rep*, 9(1), 7290. doi:10.1038/s41598-019-43874-4
65. *Ernst, M, Wiltink, J, Tibubos, AN, Brähler, E, Schulz, A, Wild, PS, Burghardt, J, Münzel, T, König, J, Lackner, K, Pfeiffer, N, Michal, M, & Beutel, ME. (2019). Linking cancer and mental health in men and women in a representative community sample. *J Psychosom Res*, 124, 109760. doi:10.1016/j.jpsychores.2019.109760
66. Fako, V, Martin, SP, Pomyen, Y, Budhu, A, Chaisaingmongkol, J, Franck, S, Lee, JM, Ng, IO, Cheung, TT, Wei, X, Liu, N, Ji, J, Zhao, L, Liu, Z, Jia, HL, Tang, ZY, Qin, LX, Kloeckner, R, Marquardt, J, Greten, T, & Wang, XW. (2019). Gene signature predictive of hepatocellular carcinoma patient response to transarterial chemoembolization. *Int J Biol Sci*, 15(12), 2654-2663. doi:10.7150/ijbs.39534
67. *Federici, M, Raffaelli, J, Paolucci, D, Schierl, R, & Krämer, I. (2019). Efficacy of four cleaning solutions for the decontamination of selected cytotoxic drugs on the different surfaces of an automated compounding system. *J Occup Environ Hyg*, 16(1), 6-15. doi:10.1080/15459624.2018.1526384
68. *Ferrata, M, Schad, A, Zimmer, S, Musholt, TJ, Bahr, K, Kuenzel, J, Becker, S, Springer, E, Roth, W, Weber, MM, & Fottner, C. (2019). PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity. *Front Oncol*, 9, 343. doi:10.3389/fonc.2019.00343
69. Filmann, N, Walter, D, Schadde, E, Bruns, C, Keck, T, Lang, H, Oldhafer, K, Schlitt, HJ, Schön, MR, Herrmann, E, Bechstein, WO, & Schnitzbauer, AA. (2019). Mortality after liver surgery in Germany. *Br J Surg*, 106(11), 1523-1529. doi:10.1002/bjs.11236
70. Finkelmeier, F, Czauderna, C, Perkhofer, L, Ettrich, TJ, Trojan, J, Weinmann, A, Marquardt, JU, Vermehren, J, & Waidmann, O. (2019). Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. *J Cancer Res Clin Oncol*, 145(1), 253-259. doi:10.1007/s00432-018-2780-8
71. *Foerster, F, Hoppe-Lotichius, M, Vollmar, J, Marquardt, JU, Weinmann, A, Wörns, MA, Otto, G, Zimmermann, T, & Galle, PR. (2019). Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. *United European Gastroenterol J*, 7(6), 838-849. doi:10.1177/2050640619840221
72. *Frees, SK, Kamal, MM, Nestler, S, Levien, PM, Bidnur, S, Brenner, W, Thomas, C, Jaeger, W, Thüroff, JW, & Roos, FC. (2019). Risk-adjusted proposal for >60 months follow up after surgical treatment of organ-confined renal cell carcinoma according to life expectancy. *Int J Urol*, 26(3), 385-390. doi:10.1111/iju.13882

73. Frick, M, Chan, W, Arends, CM, Hablesreiter, R, Halik, A, Heuser, M, Michonneau, D, Blau, O, Hoyer, K, Christen, F, Galan-Sousa, J, Noerenberg, D, Wais, V, Stadler, M, Yoshida, K, Schetelig, J, Schuler, E, Thol, F, Clappier, E, Christopheit, M, Ayuk, F, Bornhäuser, M, Blau, IW, Ogawa, S, Zemojtel, T, Gerbitz, A, Wagner, EM, Spriewald, BM, Schrezenmeier, H, Kuchenbauer, F, Kobbe, G, Wiesneth, M, Koldehoff, M, Socié, G, Kroeger, N, Bullinger, L, Thiede, C, & Damm, F. (2019). Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. *J Clin Oncol*, 37(5), 375-385. doi:10.1200/jco.2018.79.2184
74. *Futterer, JJ, Surcel, C, van den Bergh, R, Borgmann, H, Briganti, A, Gandaglia, G, Kretschmer, A, Ost, P, Sooriakumaran, P, Tilki, D, Valerio, M, Ploussard, G, De Visschere, PJL, & Tsaur, I. (2019). Imaging modalities in synchronous oligometastatic prostate cancer. *World J Urol*, 37(12), 2573-2583. doi:10.1007/s00345-018-2416-2
75. *Galle, PR, Foerster, F, Kudo, M, Chan, SL, Llovet, JM, Qin, S, Schelman, WR, Chintharlapalli, S, Abada, PB, Sherman, M, & Zhu, AX. (2019). Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. *Liver Int*, 39(12), 2214-2229. doi:10.1111/liv.14223
76. Garlipp, B, Gibbs, P, Van Hazel, GA, Jeyarajah, R, Martin, RCG, Bruns, CJ, Lang, H, Manas, DM, Ettorre, GM, Pardo, F, Donckier, V, Benckert, C, van Gulik, TM, Goéré, D, Schoen, M, Pratschke, J, Bechstein, WO, de la Cuesta, AM, Adeyemi, S, Rieke, J, & Seidensticker, M. (2019). Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIFLOX trial. *Br J Surg*, 106(13), 1837-1846. doi:10.1002/bjs.11283
77. Gérard, C, Di-Luoffo, M, Gonay, L, Caruso, S, Couchy, G, Lorient, A, Castven, D, Tao, J, Konobrocka, K, Cordi, S, Monga, SP, Hanert, E, Marquardt, JU, Zucman-Rossi, J, & Lemaigre, FP. (2019). Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. *J Hepatol*, 71(2), 323-332. doi:10.1016/j.jhep.2019.03.024
78. Gerardo-Ramírez, M, Lazzarini-Lechuga, R, Hernández-Rizo, S, Jiménez-Salazar, JE, Simoni-Nieves, A, García-Ruiz, C, Fernández-Checa, JC, Marquardt, JU, Coulouarn, C, Gutiérrez-Ruiz, MC, Pérez-Aguilar, B, & Gomez-Quiroz, LE. (2019). GDF11 exhibits tumor suppressive properties in hepatocellular carcinoma cells by restricting clonal expansion and invasion. *Biochim Biophys Acta Mol Basis Dis*, 1865(6), 1540-1554. doi:10.1016/j.bbdis.2019.03.003
79. *Gerlach, C, Alt-Epping, B, & Oechsle, K. (2019). Specific challenges in end-of-life care for patients with hematological malignancies. *Curr Opin Support Palliat Care*, 13(4), 369-379. doi:10.1097/spc.0000000000000470
80. *Gerlach, C, Goebel, S, Weber, S, Weber, M, & Sleeman, KE. (2019). Space for intuition - the 'Surprise'-Question in haemato-oncology: Qualitative analysis of experiences and perceptions of haemato-oncologists. *Palliat Med*, 33(5), 531-540. doi:10.1177/0269216318824271
81. *Goepfert, K, Dinsart, C, Rommelaere, J, Foerster, F, & Moehler, M. (2019). Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing. *Front Oncol*, 9, 425. doi:10.3389/fonc.2019.00425
82. *Goetze, E, Moergel, M, Gielisch, M, & Kämmerer, PW. (2019). Safety of resection margins in CAD/CAM-guided primarily reconstructed oral squamous cell carcinoma-a retrospective case series. *Oral Maxillofac Surg*, 23(4), 459-464. doi:10.1007/s10006-019-00797-8
83. Gogas, HJ, Flaherty, KT, Dummer, R, Ascierto, PA, Arance, A, Mandalá, M, Liszkay, G, Garbe, C, Schadendorf, D, Krajsova, I, Gutzmer, R, Sileni, VC, Dutriaux, C, de Groot, JWB, Yamazaki, N, Loquai, C, Gollerkeri, A, Pickard, MD, & Robert, C. (2019). Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. *Eur J Cancer*, 119, 97-106. doi:10.1016/j.ejca.2019.07.016
84. Gomarteli, K, Fleckenstein, J, Kirschner, S, Bobu, V, Brockmann, MA, Henzler, T, Meyer, M, Riffel, P, Schönberg, SO, Veldwijk, MR, Kränzlin, B, Hoerner, C, Glatting, G, Wenz, F, Herskind, C, & Giordano, FA. (2019). Radiation-induced malignancies after intensity-modulated versus conventional mediastinal radiotherapy in a small animal model. *Sci Rep*, 9(1), 15489. doi:10.1038/s41598-019-51735-3
85. González, J, Gaynor, JJ, Martínez-Salamanca, JI, Capitanio, U, Tilki, D, Carballido, JA, Chantada, V, Daneshmand, S, Evans, CP, Gasch, C, Gontero, P, Haferkamp, A, Huang, WC, Espinós, EL, Master, VA, McKiernan, JM, Montorsi, F, Pahernik, S, Palou, J, Pruthi, RS, Rodríguez-Faba, O, Russo, P, Scherr, DS, Shariat, SF, Spahn, M, Terrone, C, Vera-Donoso, C, Zigeuner, R, Hohenfellner, M, Libertino, JA, & Ciancio, G. (2019). Association of an organ transplant-based approach with a dramatic reduction in postoperative complications following radical nephrectomy and tumor thrombectomy in renal cell carcinoma. *Eur J Surg Oncol*, 45(10), 1983-1992. doi:10.1016/j.ejso.2019.05.009

86. *Gothe, HJ, Bouwman, BAM, Gusmao, EG, Piccinno, R, Petrosino, G, Sayols, S, Drechsel, O, Minneker, V, Josipovic, N, Mizi, A, Nielsen, CF, Wagner, EM, Takeda, S, Sasanuma, H, Hudson, DF, Kindler, T, Baranello, L, Papantonis, A, Crosetto, N, & Roukos, V. (2019). Spatial Chromosome Folding and Active Transcription Drive DNA Fragility and Formation of Oncogenic MLL Translocations. *Mol Cell*, 75(2), 267-283.e212. doi:10.1016/j.molcel.2019.05.015
87. *Graf, C, Wilgenbus, P, Pagel, S, Pott, J, Marini, F, Reyda, S, Kitano, M, Macher-Göppinger, S, Weiler, H, & Ruf, W. (2019). Myeloid cell-synthesized coagulation factor X dampens antitumor immunity. *Sci Immunol*, 4(39). doi:10.1126/sciimmunol.aaw8405
88. *Gribko, A, Künzel, J, Wünsch, D, Lu, Q, Nagel, SM, Knauer, SK, Stauber, RH, & Ding, GB. (2019). Is small smarter? Nanomaterial-based detection and elimination of circulating tumor cells: current knowledge and perspectives. *Int J Nanomedicine*, 14, 4187-4209. doi:10.2147/ijn.S198319
89. *Grimminger, PP, Tagkalos, E, Hadzijusufovic, E, Corvinus, F, Babic, B, & Lang, H. (2019). Change from Hybrid to Fully Minimally Invasive and Robotic Esophagectomy is Possible without Compromises. *Thorac Cardiovasc Surg*, 67(7), 589-596. doi:10.1055/s-0038-1670664
90. *Grivas, P, Monk, BJ, Petrylak, D, Reck, M, Foley, G, Guenther, S, Hennessy, D, Makris, C, & Moehler, M. (2019). Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. *Target Oncol*, 14(5), 505-525. doi:10.1007/s11523-019-00665-1
91. *Gronke, K, Hernández, PP, Zimmermann, J, Klose, CSN, Kofoed-Branzk, M, Guendel, F, Witkowski, M, Tizian, C, Amann, L, Schumacher, F, Glatt, H, Triantafyllopoulou, A, & Diefenbach, A. (2019). Interleukin-22 protects intestinal stem cells against genotoxic stress. *Nature*, 566(7743), 249-253. doi:10.1038/s41586-019-0899-7
92. *Grunwitz, C, Salomon, N, Vascotto, F, Selmi, A, Bukur, T, Diken, M, Kreiter, S, Türeci, Ö, & Sahin, U. (2019). HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. *Oncoimmunology*, 8(9), e1629259. doi:10.1080/2162402x.2019.1629259
93. Guo, H, Treude, F, Krämer, OH, Lüscher, B, & Hartkamp, J. (2019). PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1. *Sci Rep*, 9(1), 8755. doi:10.1038/s41598-019-45209-9
94. *Hadzijusufovic, E, Tagkalos, E, Neumann, H, Babic, B, Heinrich, S, Lang, H, & Grimminger, PP. (2019). Preoperative endoscopic pyloric balloon dilatation decreases the rate of delayed gastric emptying after Ivor-Lewis esophagectomy. *Dis Esophagus*, 32(6). doi:10.1093/dote/doy097
95. Haffa, M, Holowatyj, AN, Kratz, M, Toth, R, Benner, A, Gigic, B, Habermann, N, Schrotz-King, P, Böhm, J, Brenner, H, Schneider, M, Ulrich, A, Herpel, E, Schirmacher, P, Straub, BK, Nattenmüller, J, Kauczor, HU, Lin, T, Ball, CR, Ulrich, CM, Glimm, H, & Scherer, D. (2019). Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal Cancer. *J Clin Endocrinol Metab*, 104(11), 5225-5237. doi:10.1210/jc.2019-00461
96. Hagens, ERC, van Berge Henegouwen, MI, van Sandick, JW, Cuesta, MA, van der Peet, DL, Heisterkamp, J, Nieuwenhuijzen, GAP, Rosman, C, Scheepers, JGG, Sosef, MN, van Hillegersberg, R, Lagarde, SM, Nilsson, M, Räsänen, J, Nafteux, P, Pattyn, P, Hölscher, AH, Schröder, W, Schneider, PM, Mariette, C, Castoro, C, Bonavina, L, Rosati, R, de Manzoni, G, Mattioli, S, Garcia, JR, Pera, M, Griffin, M, Wilkerson, P, Chaudry, MA, Sgromo, B, Tucker, O, Cheong, E, Moorthy, K, Walsh, TN, Reynolds, J, Tachimori, Y, Inoue, H, Matsubara, H, Kosugi, SI, Chen, H, Law, SYK, Pramesh, CS, Puntambekar, SP, Murthy, S, Linden, P, Hofstetter, WL, Kuppasamy, MK, Shen, KR, Darling, GE, Sabino, FD, Grimminger, PP, Meijer, SL, Bergman, J, Hulshof, M, van Laarhoven, HWM, Mearadji, B, Bennink, RJ, Annema, JT, Dijkgraaf, MGW, & Gisbertz, SS. (2019). Distribution of lymph node metastases in esophageal carcinoma [TIGER study]: study protocol of a multinational observational study. *BMC Cancer*, 19(1), 662. doi:10.1186/s12885-019-5761-7
97. *Hahn, F, Müller, L, Stöhr, F, Mähringer-Kunz, A, Schotten, S, Düber, C, Bartsch, F, Lang, H, Galle, PR, Weinmann, A, & Kloeckner, R. (2019). The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter? *Liver Int*, 39(7), 1307-1314. doi:10.1111/liv.14132
98. *Hanf, A, Oelze, M, Manea, A, Li, H, Münzel, T, & Daiber, A. (2019). The anti-cancer drug doxorubicin induces substantial epigenetic changes in cultured cardiomyocytes. *Chem Biol Interact*, 313, 108834. doi:10.1016/j.cbi.2019.108834
99. Harter, P, Sehoul, J, Lorusso, D, Reuss, A, Vergote, I, Marth, C, Kim, JW, Raspagliesi, F, Lampe, B, Aletti, G, Meier, W, Cibula, D, Mustea, A, Mahner, S, Runnebaum, IB, Schmalfeldt, B, Burges, A, Kimmig, R, Scambia, G, Greggi, S, Hilpert,

- F, Hasenburger, A, Hillemanns, P, Giorda, G, von Leffern, I, Schade-Brittinger, C, Wagner, U, & du Bois, A. (2019). A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. *N Engl J Med*, 380(9), 822-832. doi:10.1056/NEJMoa1808424
100. *He, Y, & Kaina, B. (2019). Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide? *Int J Mol Sci*, 20(7). doi:10.3390/ijms20071562
 101. *He, Y, Roos, WP, Wu, Q, Hofmann, TG, & Kaina, B. (2019). The SIAH1-HIPK2-p53ser46 Damage Response Pathway is Involved in Temozolomide-Induced Glioblastoma Cell Death. *Mol Cancer Res*, 17(5), 1129-1141. doi:10.1158/1541-7786.Mcr-18-1306
 102. *Hechtner, M, Eichler, M, Wehler, B, Buhl, R, Sebastian, M, Stratmann, J, Schmidberger, H, Gohrbandt, B, Peuser, J, Kortsik, C, Nestle, U, Wiesemann, S, Wirtz, H, Wehler, T, Bals, R, Blettner, M, & Singer, S. (2019). Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study. *J Thorac Oncol*, 14(3), 420-435. doi:10.1016/j.jtho.2018.11.019
 103. Heidegger, I, Tsaur, I, Borgmann, H, Surcel, C, Kretschmer, A, Mathieu, R, Visschere, P, Valerio, M, van den Bergh, RCN, Ost, P, Tilki, D, Gandaglia, G, & Ploussard, G. (2019). Hereditary prostate cancer - Primetime for genetic testing? *Cancer Treat Rev*, 81, 101927. doi:10.1016/j.ctrv.2019.101927
 104. *Heimes, AS, & Schmidt, M. (2019). Atezolizumab for the treatment of triple-negative breast cancer. *Expert Opin Investig Drugs*, 28(1), 1-5. doi:10.1080/13543784.2019.1552255
 105. *Heimes, AS, Schmidt, M, Jäkel, J, Almstedt, K, Gebhard, S, Weyer-Eiberich, V, Elger, T, Krajnak, S, Brenner, W, Hasenburger, A, & Battista, MJ. (2019). A retrospective analysis of immunohistochemically determined IRF4 (interferon regulating factor 4) expression in a consecutive cohort of 114 ovarian cancer patients. *Arch Gynecol Obstet*, 299(1), 239-246. doi:10.1007/s00404-018-4941-z
 106. *Heinrich, S, Besselink, M, Moehler, M, van Laethem, JL, Ducreux, M, Grimminger, P, Mittler, J, Lang, H, Lutz, MP, & Lesurtel, M. (2019). Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. *BMC Cancer*, 19(1), 675. doi:10.1186/s12885-019-5889-5
 107. Heppt, MV, Amaral, T, Kähler, KC, Heinzerling, L, Hassel, JC, Meissner, M, Kreuzberg, N, Loquai, C, Reinhardt, L, Utikal, J, Dabrowski, E, Gesierich, A, Pföhler, C, Terheyden, P, Thoms, KM, Zimmer, L, Eigentler, TK, Kirchberger, MC, Stege, HM, Meier, F, Schlaak, M, & Berking, C. (2019). Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. *J Immunother Cancer*, 7(1), 299. doi:10.1186/s40425-019-0800-0
 108. Herr, D, Wischnewsky, M, Joukhadar, R, Chow, O, Janni, W, Leinert, E, Fink, V, Stüber, T, Curtaz, C, Kreienberg, R, Blettner, M, Wollschläger, D, & Wöckel, A. (2019). Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study. *PLoS One*, 14(7), e0218434. doi:10.1371/journal.pone.0218434
 109. Herrlinger, U, Tzaridis, T, Mack, F, Steinbach, JP, Schlegel, U, Sabel, M, Hau, P, Kortmann, RD, Krex, D, Grauer, O, Goldbrunner, R, Schnell, O, Bähr, O, Uhl, M, Seidel, C, Tabatabai, G, Kowalski, T, Ringel, F, Schmidt-Graf, F, Suchorska, B, Brehmer, S, Weyerbrock, A, Renovanz, M, Bullinger, L, Galldiks, N, Vajkoczy, P, Misch, M, Vatter, H, Stuplich, M, Schäfer, N, Kebir, S, Weller, J, Schaub, C, Stummer, W, Tonn, JC, Simon, M, Keil, VC, Nelles, M, Urbach, H, Coenen, M, Wick, W, Weller, M, Fimmers, R, Schmid, M, Hattingen, E, Pietsch, T, Koch, C, & Glas, M. (2019). Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. *Lancet*, 393(10172), 678-688. doi:10.1016/s0140-6736(18)31791-4
 110. Hilf, N, Kuttruff-Coqui, S, Frenzel, K, Bukur, V, Stevanović, S, Gouttefangeas, C, Platten, M, Tabatabai, G, Dutoit, V, van der Burg, SH, Thor Straten, P, Martínez-Ricarte, F, Ponsati, B, Okada, H, Lassen, U, Admon, A, Ottensmeier, CH, Ulges, A, Kreiter, S, von Deimling, A, Skardelly, M, Migliorini, D, Kroep, JR, Idorn, M, Rodon, J, Piró, J, Poulsen, HS, Shraibman, B, McCann, K, Mendrzyk, R, Löwer, M, Stieglbauer, M, Britten, CM, Capper, D, Welters, MJP, Sahuquillo, J, Kiesel, K, Derhovanessian, E, Rusch, E, Bunse, L, Song, C, Heesch, S, Wagner, C, Kemmer-Brück, A, Ludwig, J, Castle, JC, Schoor, O, Tadmor, AD, Green, E, Fritsche, J, Meyer, M, Pawlowski, N, Dorner, S, Hoffgaard, F, Rössler, B, Maurer, D, Weinschenk, T, Reinhardt, C, Huber, C, Rammensee, HG, Singh-Jasuja, H, Sahin, U, Dietrich, PY, & Wick, W. (2019). Actively personalized vaccination trial for newly diagnosed glioblastoma. *Nature*, 565(7738), 240-245. doi:10.1038/s41586-018-0810-y

111. *Hillen, B, Simon, P, Grimminger, PP, Gockel, I, & Pfirrmann, D. (2019). Use of a Perioperative Web-Based Exercise Program for a Patient with Barrett's Carcinoma Scheduled for Esophagectomy. *Case Rep Oncol*, 12(3), 755-764. doi:10.1159/000503558
112. *Hoffmann, MA, Buchholz, HG, Wieler, HJ, Höfner, T, Müller-Hübenthal, J, Trampert, L, & Schreckenberger, M. (2019). The positivity rate of 68Gallium-PSMA-11 ligand PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. *Oncotarget*, 10(58), 6124-6137. doi:10.18632/oncotarget.27239
113. *Hoffmann, MA, Wieler, HJ, Baues, C, Kuntz, NJ, Richardsen, I, & Schreckenberger, M. (2019). The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer. *Urology*, 130, 1-12. doi:10.1016/j.urology.2019.04.004
114. *Hofmann, M, Thieringer, F, Nguyen, MA, Månsson, W, Galle, PR, & Langguth, P. (2019). A novel technique for intraduodenal administration of drug suspensions/solutions with concurrent pH monitoring applied to ibuprofen formulations. *Eur J Pharm Biopharm*, 136, 192-202. doi:10.1016/j.ejpb.2019.01.010
115. Holch, JW, Ricard, I, Stintzing, S, Fischer von Weikersthal, L, Decker, T, Kiani, A, Vehling-Kaiser, U, Heintges, T, Kahl, C, Kullmann, F, Scheithauer, W, Moehler, M, Jelas, I, Modest, DP, Westphalen, CB, von Einem, JC, Michl, M, & Heinemann, V. (2019). Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial). *Eur J Cancer*, 106, 115-125. doi:10.1016/j.ejca.2018.10.001
116. *Huber, T, Hadzijušufovic, E, Hansen, C, Paschold, M, Lang, H, & Kneist, W. (2019). Head-Mounted Mixed-Reality Technology During Robotic-Assisted Transanal Total Mesorectal Excision. *Dis Colon Rectum*, 62(2), 258-261. doi:10.1097/dcr.0000000000001282
117. Huiskens, J, Schadde, E, Lang, H, Malago, M, Petrowsky, H, de Santibañes, E, Oldhafer, K, van Gulik, TM, & Olthof, PB. (2019). Avoiding postoperative mortality after ALPPS-development of a tumor-specific risk score for colorectal liver metastases. *HPB (Oxford)*, 21(7), 898-905. doi:10.1016/j.hpb.2018.11.010
118. Iavarone, M, Invernizzi, F, Czauderna, C, Sanduzzi-Zamparelli, M, Bhoori, S, Amadeo, G, Manini, MA, López, MF, Anders, M, Pinter, M, Rodríguez, MJB, Cristóbal, MR, Soteras, GA, Piñero, F, Villadsen, GE, Weinmann, A, Crespo, G, Mazzaferro, V, Regnault, H, Giorgio, M, González-Díéguez, ML, Donato, MF, Varela, M, Wörns, MA, Bruix, J, Lampertico, P, & Reig, M. (2019). Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. *Am J Transplant*, 19(11), 3176-3184. doi:10.1111/ajt.15551
119. Iwamoto, Y, Kaucher, S, Lorenz, E, Bärnighausen, T, & Winkler, V. (2019). Development of breast cancer mortality considering the implementation of mammography screening programs - a comparison of western European countries. *BMC Public Health*, 19(1), 823. doi:10.1186/s12889-019-7166-6
120. Jia, M, Zhang, Y, Jansen, L, Walter, V, Edelmann, D, Gündert, M, Tagscherer, KE, Roth, W, Bewerunge-Hudler, M, Herpel, E, Kloor, M, Ulrich, A, Burwinkel, B, Bläker, H, Chang-Claude, J, Brenner, H, & Hoffmeister, M. (2019). A prognostic CpG score derived from epigenome-wide profiling of tumor tissue was independently associated with colorectal cancer survival. *Clin Epigenetics*, 11(1), 109. doi:10.1186/s13148-019-0703-4
121. *Juengel, E, Natsheh, I, Najafi, R, Rutz, J, Tsaur, I, Haferkamp, A, Chun, FK, & Blaheta, RA. (2019). Mechanisms behind Temsirolimus Resistance Causing Reactivated Growth and Invasive Behavior of Bladder Cancer Cells In Vitro. *Cancers (Basel)*, 11(6). doi:10.3390/cancers11060777
122. *Junginger, T, Goenner, U, Trinh, TT, Heintz, A, Lollert, A, Blettner, M, & Wollschlaeger, D. (2019). The Link Between Local Recurrence and Distant Metastases in Patients With Rectal Cancer. *Anticancer Res*, 39(6), 3079-3088. doi:10.21873/anticancer.13443
123. *Kaina, B, & Christmann, M. (2019). DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. *DNA Repair (Amst)*, 78, 128-141. doi:10.1016/j.dnarep.2019.04.007
124. Kappler, M, Pabst, U, Weinholdt, C, Taubert, H, Rot, S, Kaune, T, Kotrba, J, Porsch, M, Güttler, A, Bache, M, Krohn, K, Bull, F, Riemann, A, Wickenhauser, C, Seliger, B, Schubert, J, Al-Nawas, B, Thews, O, Grosse, I, Vordermark, D, & Eckert, AW. (2019). Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism. *Int J Mol Sci*, 20(19). doi:10.3390/ijms20194742

125. *Kauff, DW, Babic, B, Grimminger, PP, Kneist, W, & Lang, H. (2019). [Lymphadenectomy in oncological visceral surgery-Part 2 : Cancer of the upper and lower intestinal tract]. *Chirurg*, 90(6), 505-521. doi:10.1007/s00104-019-0963-8
126. Kehl, T, Schneider, L, Kattler, K, Stöckel, D, Wegert, J, Gerstner, N, Ludwig, N, Distler, U, Tenzer, S, Gessler, M, Walter, J, Keller, A, Graf, N, Meese, E, & Lenhof, HP. (2019). The role of TCF3 as potential master regulator in blastemal Wilms tumors. *Int J Cancer*, 144(6), 1432-1443. doi:10.1002/ijc.31834
127. Kelley, RK, Gane, E, Assenat, E, Siebler, J, Galle, PR, Merle, P, Hourmand, IO, Cleverly, A, Zhao, Y, Gueorguieva, I, Lahn, M, Faivre, S, Benhadji, KA, & Giannelli, G. (2019). A Phase 2 Study of Galunisertib (TGF- β 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. *Clin Transl Gastroenterol*, 10(7), e00056. doi:10.14309/ctg.0000000000000056
128. Klinghammer, K, Gauler, T, Dietz, A, Grünwald, V, Stöhlmacher, J, Knipping, S, Schroeder, M, Guntinas-Lichius, O, Frickhofen, N, Lindeman, HW, Fietkau, R, Haxel, B, Große-Thie, C, Maschmeyer, G, Zipfel, M, Martus, P, Knoedler, M, & Keilholz, U. (2019). Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). *Eur J Cancer*, 122, 53-60. doi:10.1016/j.ejca.2019.08.018
129. Knop, S, Engelhardt, M, Liebisch, P, Meisner, C, Holler, E, Metzner, B, Peest, D, Kaufmann, M, Bunjes, D, Straka, C, Fischer, T, Sezer, O, Hentrich, M, Ostermann, H, Bassermann, F, Hess, G, Hertenstein, B, Freund, M, Kropff, M, Schmidt, CA, Wolf, HH, Jung, W, Frickhofen, N, Mielke, S, Bargou, RC, Maschmeyer, G, Svaldi, M, Langer, CH, Gramatzki, M, Hebart, H, Kanz, L, & Einsele, H. (2019). Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. *Leukemia*, 33(11), 2710-2719. doi:10.1038/s41375-019-0537-2
130. Koizume, S, Takahashi, T, Yoshihara, M, Nakamura, Y, Ruf, W, Takenaka, K, Miyagi, E, & Miyagi, Y. (2019). Cholesterol Starvation and Hypoxia Activate the FVII Gene via the SREBP1-GILZ Pathway in Ovarian Cancer Cells to Produce Procoagulant Microvesicles. *Thromb Haemost*, 119(7), 1058-1071. doi:10.1055/s-0039-1687876
131. Koliarakis, V, Chalkidi, N, Henriques, A, Tzaferis, C, Polykratis, A, Waisman, A, Muller, W, Hackam, DJ, Pasparakis, M, & Kollias, G. (2019). Innate Sensing through Mesenchymal TLR4/MyD88 Signals Promotes Spontaneous Intestinal Tumorigenesis. *Cell Rep*, 26(3), 536-545.e534. doi:10.1016/j.celrep.2018.12.072
132. König, L, Lang, K, Heil, J, Golatta, M, Major, G, Krug, D, Hörner-Rieber, J, Häfner, MF, Koerber, SA, Harrabi, S, Bostel, T, Debus, J, & Uhl, M. (2019). Acute Toxicity and Early Oncological Outcomes After Intraoperative Electron Radiotherapy (IOERT) as Boost Followed by Whole Breast Irradiation in 157 Early Stage Breast Cancer Patients-First Clinical Results From a Single Center. *Front Oncol*, 9, 384. doi:10.3389/fonc.2019.00384
133. *König, TT, Goedeke, J, & Muensterer, OJ. (2019). Multiphoton microscopy in surgical oncology- a systematic review and guide for clinical translatability. *Surg Oncol*, 31, 119-131. doi:10.1016/j.suronc.2019.10.011
134. *Kraus, A, McKeague, M, Seiwert, N, Nagel, G, Geisen, SM, Ziegler, N, Trantakis, IA, Kaina, B, Thomas, AD, Sturla, SJ, & Fahrner, J. (2019). Immunological and mass spectrometry-based approaches to determine thresholds of the mutagenic DNA adduct O(6)-methylguanine in vivo. *Arch Toxicol*, 93(2), 559-572. doi:10.1007/s00204-018-2355-0
135. Krefting, F, Basara, N, Schütte, W, Späth-Schwalbe, E, Alt, J, Thiel, S, Kimmich, M, Fischer, JR, Kurz, S, Griesinger, F, & Christoph, DC. (2019). Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer. *Oncol Res Treat*, 42(5), 243-255. doi:10.1159/000499321
136. Kriegsmann, K, Baertsch, MA, Awwad, MHS, Merz, M, Hose, D, Seckinger, A, Jauch, A, Becker, N, Benner, A, Raab, MS, Hillengass, J, Bertsch, U, Dürig, J, Salwender, HJ, Hänel, M, Fenk, R, Munder, M, Weisel, K, Müller-Tidow, C, Goldschmidt, H, & Hundemer, M. (2019). Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients. *Blood Cancer J*, 9(2), 13. doi:10.1038/s41408-019-0174-z
137. Kröger, N, Eikema, DJ, Köster, L, Beelen, D, de Wreede, LC, Finke, J, Koenecke, C, Niederwieser, D, Bornhäuser, M, Schoenland, S, Potter, V, Wolschke, C, Maertens, J, Theobald, M, Kobbe, G, Itälä-Remes, M, Wulf, G, Kahls, P, Forcade, E, Greinix, H, Masszi, T, Yakoub-Agha, I, Chalandon, Y, & Robin, M. (2019). Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. *Br J Haematol*, 185(4), 725-732. doi:10.1111/bjh.15819

138. *Krüger, M, Metzger, C, Kämmerer, PW, & Brieger, J. (2019). The impact of cigarette smoke on activity of single nucleotide polymorphisms of the vascular endothelial growth factor-promoter gene in cells of the upper aerodigestive tract. *J Oral Pathol Med*, 48(9), 810-816. doi:10.1111/jop.12893
139. *Künzel, J, Gribko, A, Lu, Q, Stauber, RH, & Wünsch, D. (2019). Nanomedical detection and downstream analysis of circulating tumor cells in head and neck patients. *Biol Chem*, 400(11), 1465-1479. doi:10.1515/hsz-2019-0141
140. *Laible, M, Hartmann, K, Gürtler, C, Anzeneder, T, Wirtz, R, Weber, S, Keller, T, Sahin, U, Rees, M, & Ramaswamy, A. (2019). Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy. *BMC Cancer*, 19(1), 694. doi:10.1186/s12885-019-5890-z
141. *Lang, BM, Balermipas, P, Bauer, A, Blum, A, Brölsch, GF, Dirschka, T, Follmann, M, Frank, J, Frerich, B, Fritz, K, Hauschild, A, Heindl, LM, Howaldt, HP, Ihrler, S, Kakkassery, V, Klumpp, B, Krause-Bergmann, A, Löser, C, Meissner, M, Sachse, MM, Schlaak, M, Schön, MP, Tischendorf, L, Tronnier, M, Vordermark, D, Welzel, J, Weichenthal, M, Wiegand, S, Kaufmann, R, & Grabbe, S. (2019a). S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and Diagnosis. *J Dtsch Dermatol Ges*, 17(1), 94-103. doi:10.1111/ddg.13733
142. *Lang, BM, Balermipas, P, Bauer, A, Blum, A, Brölsch, GF, Dirschka, T, Follmann, M, Frank, J, Frerich, B, Fritz, K, Hauschild, A, Heindl, LM, Howaldt, HP, Ihrler, S, Kakkassery, V, Klumpp, B, Krause-Bergmann, A, Löser, C, Meissner, M, Sachse, MM, Schlaak, M, Schön, MP, Tischendorf, L, Tronnier, M, Vordermark, D, Welzel, J, Weichenthal, M, Wiegand, S, Kaufmann, R, & Grabbe, S. (2019b). S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-up. *J Dtsch Dermatol Ges*, 17(2), 214-230. doi:10.1111/ddg.13755
143. *Lang, H, Baumgart, J, Heinrich, S, Tripke, V, Passalacqua, M, Maderer, A, Galle, PR, Roth, W, Kloth, M, & Moehler, M. (2019). Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases. *Ann Surg*, 270(5), 799-805. doi:10.1097/sla.0000000000003527
144. *Lang, H, de Santibañes, E, Schlitt, HJ, Malagó, M, van Gulik, T, Machado, MA, Jovine, E, Heinrich, S, Ettorre, GM, Chan, A, Hernandez-Alejandro, R, Robles Campos, R, Sandström, P, Linecker, M, & Clavien, PA. (2019). 10th Anniversary of ALPPS-Lessons Learned and quo Vadis. *Ann Surg*, 269(1), 114-119. doi:10.1097/sla.0000000000002797
145. *Lautem, A, Simon, F, Hoppe-Lotichius, M, Mittler, J, Vollmar, J, Schad, A, Düber, C, Galle, PR, Otto, G, Zimmermann, T, & Lang, H. (2019). Expression and prognostic significance of insulin-like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization. *Oncol Rep*, 41(4), 2299-2310. doi:10.3892/or.2019.6995
146. Lebeau, A, Denkert, C, Sinn, P, Schmidt, M, & Wöckel, A. (2019). [Update of the German S3 breast cancer guideline : What is new for pathologists?]. *Pathologe*, 40(2), 185-198. doi:10.1007/s00292-019-0578-3
147. *Leber, N, Kaps, L, Yang, A, Aslam, M, Giardino, M, Klefenz, A, Choteschovsky, N, Rosigkeit, S, Mostafa, A, Nuhn, L, Schuppan, D, & Zentel, R. (2019). alpha-Mannosyl-Functionalized Cationic Nanohydrogel Particles for Targeted Gene Knockdown in Immunosuppressive Macrophages. *Macromol Biosci*, 19(7), e1900162. doi:10.1002/mabi.201900162
148. *Leinert, E, Schwentner, L, Blettner, M, Wöckel, A, Felberbaum, R, Flock, F, Kühn, T, Denking, MD, Janni, W, Kreienberg, R, & Singer, S. (2019). Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: Results from the prospective multicenter BRENDA II study. *Breast J*, 25(3), 386-392. doi:10.1111/tbj.13231
149. *Liebl, MC, & Hofmann, TG. (2019). Cell Fate Regulation upon DNA Damage: p53 Serine 46 Kinases Pave the Cell Death Road. *Bioessays*, 41(12), e1900127. doi:10.1002/bies.201900127
150. Linecker, M, Kuemmerli, C, Kambakamba, P, Schlegel, A, Muiesan, P, Capobianco, I, Nadalin, S, Torres, OJ, Mehrabi, A, Stavrou, GA, Oldhafer, KJ, Lurje, G, Balci, D, Lang, H, Robles-Campos, R, Hernandez-Alejandro, R, Malago, M, De Santibanes, E, Clavien, PA, & Petrowsky, H. (2019). Performance validation of the ALPPS risk model. *HPB (Oxford)*, 21(6), 711-721. doi:10.1016/j.hpb.2018.10.003
151. *Linnebacher, A, Mayer, P, Marnet, N, Bergmann, F, Herpel, E, Revia, S, Yin, L, Liu, L, Hackert, T, Giese, T, Herr, I, & Gaida, MM. (2019). Interleukin 21 Receptor/Ligand Interaction Is Linked to Disease Progression in Pancreatic Cancer. *Cells*, 8(9). doi:10.3390/cells8091104
152. Liu, D, Schilling, B, Liu, D, Sucker, A, Livingstone, E, Jerby-Amon, L, Zimmer, L, Gutzmer, R, Satzger, I, Loquai, C, Grabbe, S, Vokes, N, Margolis, CA, Conway, J, He, MX, Elmarakeby, H, Dietlein, F, Miao, D, Tracy, A, Gogas, H, Goldinger, SM,

- Utikal, J, Blank, CU, Rauschenberg, R, von Bubnoff, D, Krackhardt, A, Weide, B, Haferkamp, S, Kiecker, F, Izar, B, Garraway, L, Regev, A, Flaherty, K, Paschen, A, Van Allen, EM, & Schadendorf, D. (2019). Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. *Nat Med*, 25(12), 1916-1927. doi:10.1038/s41591-019-0654-5
153. *Lockhart, A, Pires, VB, Bento, F, Kellner, V, Luke-Glaser, S, Yakoub, G, Ulrich, HD, & Luke, B. (2019). RNase H1 and H2 Are Differentially Regulated to Process RNA-DNA Hybrids. *Cell Rep*, 29(9), 2890-2900.e2895. doi:10.1016/j.celrep.2019.10.108
 154. Longerich, T, Endris, V, Neumann, O, Rempel, E, Kirchner, M, Abadi, Z, Uhrig, S, Kriegsmann, M, Weiss, KH, Breuhahn, K, Mehrabi, A, Weber, TF, Wilkens, L, Straub, BK, Rosenwald, A, Schulze, F, Brors, B, Froehling, S, Pellegrino, R, Budczies, J, Schirmacher, P, & Stenzinger, A. (2019). RSPO2 gene rearrangement: a powerful driver of beta-catenin activation in liver tumours. *Gut*, 68(7), 1287-1296. doi:10.1136/gutjnl-2018-317632
 155. Luster, M, Aktolun, C, Amendoeira, I, Barczyński, M, Bible, KC, Duntas, LH, Elisei, R, Handkiewicz-Junak, D, Hoffmann, M, Jarzab, B, Leenhardt, L, Musholt, TJ, Newbold, K, Nixon, IJ, Smit, J, Sobrinho-Simões, M, Sosa, JA, Tuttle, RM, Verburg, FA, Wartofsky, L, & Führer, D. (2019). European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium. *Thyroid*, 29(1), 7-26. doi:10.1089/thy.2017.0129
 156. Lutz, MP, Zalberg, JR, Ducreux, M, Adenis, A, Allum, W, Aust, D, Carneiro, F, Grabsch, HI, Laurent-Puig, P, Lordick, F, Möhler, M, Mönig, S, Obermannova, R, Piessen, G, Riddell, A, Röcken, C, Roviello, F, Schneider, PM, Seewald, S, Smyth, E, van Cutsem, E, Verheij, M, Wagner, AD, & Otto, F. (2019). The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. *Eur J Cancer*, 112, 1-8. doi:10.1016/j.ejca.2019.01.106
 157. *Mager, R, Savko, O, Böhm, K, Thomas, A, Dotzauer, R, Borgmann, H, Jäger, W, Thomas, C, Haferkamp, A, Höfner, T, & Tsaur, I. (2019). Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. *Urol Oncol*, 37(12), 999-1005. doi:10.1016/j.urolonc.2019.07.005
 158. *Mähringer-Kunz, A, Steinle, V, Düber, C, Weinmann, A, Koch, S, Schmidtman, I, Schotten, S, Hinrichs, JB, Graafen, D, Pinto Dos Santos, D, Galle, PR, & Kloeckner, R. (2019). Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse? *Liver Int*, 39(2), 324-331. doi:10.1111/liv.13988
 159. Mai, EK, Hielscher, T, Bertsch, U, Schlenzka, J, Salwender, HJ, Munder, M, Gerecke, C, Dürsen, U, Brossart, P, Neben, K, Hillengass, J, Raab, MS, Merz, M, Baertsch, MA, Jauch, A, Hose, D, Martin, H, Lindemann, HW, Blau, IW, Scheid, C, Weisel, KC, & Goldschmidt, H. (2019). Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. *Leukemia*, 33(1), 258-261. doi:10.1038/s41375-018-0195-9
 160. Makarević, J, Rutz, J, Juengel, E, Maxeiner, S, Tsaur, I, Chun, FK, Bereiter-Hahn, J, & Blaheta, RA. (2019). Influence of the HDAC Inhibitor Valproic Acid on the Growth and Proliferation of Temsirolimus-Resistant Prostate Cancer Cells In Vitro. *Cancers (Basel)*, 11(4). doi:10.3390/cancers11040566
 161. *Malsy, M, Graf, B, & Almstedt, K. (2019). The active role of the transcription factor Sp1 in NFATc2-mediated gene regulation in pancreatic cancer. *BMC Biochem*, 20(1), 2. doi:10.1186/s12858-019-0105-4
 162. *Mann, C, Hadzijušević, E, Lang, H, & Grimminger, PP. (2019). Fully robotic Ivor-Lewis esophagectomy (RAMIE4) for esophageal cancer after emergency surgery and ligation of the gastroduodenal artery. *J Int Med Res*, 47(2), 1025-1029. doi:10.1177/0300060518814682
 163. *Marquardt, JU, & Edlich, F. (2019). Predisposition to Apoptosis in Hepatocellular Carcinoma: From Mechanistic Insights to Therapeutic Strategies. *Front Oncol*, 9, 1421. doi:10.3389/fonc.2019.01421
 164. *Marquardt, JU, Saborowski, A, Czauderna, C, & Vogel, A. (2019). The Changing Landscape of Systemic Treatment of Advanced Hepatocellular Carcinoma: New Targeted Agents and Immunotherapies. *Target Oncol*, 14(2), 115-123. doi:10.1007/s11523-019-00624-w
 165. *Martin, SZ, Wagner, DC, Hörner, N, Horst, D, Lang, H, Tagscherer, KE, & Roth, W. (2019). Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. *BMC Cancer*, 19(1), 1030. doi:10.1186/s12885-019-6270-4
 166. Mavratzas, A, Baek, S, Gerber, B, Schmidt, M, Moebus, V, Foerster, F, Grischke, EM, Fasching, P, Strumberg, D, Solomayer, E, Klare, P, Windemuth-Kieselbach, C, Hartmann, S, Schneeweiss, A, & Marmé, F. (2019). Sorafenib in

combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. *Breast*, 45, 22-28.
doi:10.1016/j.breast.2019.02.002

167. *Mayer, S, Iborra, S, Grimm, D, Steinsiek, L, Mahner, S, Bossart, M, Woelber, L, Voss, PJ, Gitsch, G, & Hasenburg, A. (2019). Sexual activity and quality of life in patients after treatment for breast and ovarian cancer. *Arch Gynecol Obstet*, 299(1), 191-201. doi:10.1007/s00404-018-4922-2
168. Mayland, CR, Gerlach, C, Sigurdardottir, K, Hansen, MIT, Leppert, W, Stachowiak, A, Krajewska, M, Garcia-Yanneo, E, Tripodoro, VA, Goldraij, G, Weber, M, Zambon, L, Passarini, JN, Saad, IB, Ellershaw, J, & Haugen, DF. (2019). Assessing quality of care for the dying from the bereaved relatives' perspective: Using pre-testing survey methods across seven countries to develop an international outcome measure. *Palliat Med*, 33(3), 357-368.
doi:10.1177/0269216318818299
169. *Michel, CS, Teschner, D, Schmidtman, I, Theobald, M, Hauptrock, B, Wagner-Drouet, EM, & Radsak, MP. (2019). Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization. *Sci Rep*, 9(1), 19911. doi:10.1038/s41598-019-56322-0
170. *Mikulić, S, Finke, J, Boukhallouk, F, Wüstenhagen, E, Sons, D, Homsy, Y, Reiss, K, Lang, T, & Florin, L. (2019). ADAM17-dependent signaling is required for oncogenic human papillomavirus entry platform assembly. *Elife*, 8.
doi:10.7554/eLife.44345
171. *Mikulić, S, & Florin, L. (2019). The endocytic trafficking pathway of oncogenic papillomaviruses. *Papillomavirus Res*, 7, 135-137. doi:10.1016/j.pvr.2019.03.004
172. *Moehler, M, Heo, J, Lee, HC, Tak, WY, Chao, Y, Paik, SW, Yim, HJ, Byun, KS, Baron, A, Ungerechts, G, Jonker, D, Ru, L, Cho, M, Kaubisch, A, Wege, H, Merle, P, Ebert, O, Habersetzer, F, Blanc, JF, Rosmorduc, O, Lencioni, R, Patt, R, Leen, AM, Foerster, F, Homerin, M, Stojkowitz, N, Lusky, M, Limacher, JM, Hennequi, M, Gaspar, N, McFadden, B, De Silva, N, Shen, D, Pelusio, A, Kirn, DH, Breitbach, CJ, & Burke, JM. (2019). Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). *Oncoimmunology*, 8(8), 1615817.
doi:10.1080/2162402x.2019.1615817
173. *Moehler, M, Maderer, A, Ehrlich, A, Foerster, F, Schad, A, Nickolay, T, Ruckes, C, Weinmann, A, Sivanathan, V, Marquardt, JU, Galle, PR, Woerns, M, & Thomaidis, T. (2019). Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naïve patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. *BMC Cancer*, 19(1), 55. doi:10.1186/s12885-018-5223-7
174. *Moehler, M, Ryu, MH, Dvorkin, M, Lee, KW, Coşkun, H, Wong, R, Chung, HC, Poltoratsky, A, Tsuji, A, Yen, CJ, Muntean, AS, Le Sourd, S, Vaccaro, GM, Overton, L, Boku, N, Wainberg, ZA, Patel, M, Sharma, M, Xiong, H, Conti, I, Taieb, J, & Bang, YJ. (2019). Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. *Future Oncol*, 15(6), 567-577. doi:10.2217/fon-2018-0668
175. *More, P, Goedtel-Armbrust, U, Shah, V, Mathaes, M, Kindler, T, Andrade-Navarro, MA, & Wojnowski, L. (2019). Drivers of topoisomerase II poisoning mimic and complement cytotoxicity in AML cells. *Oncotarget*, 10(51), 5298-5312. doi:10.18632/oncotarget.27112
176. Moreira, A, Loquai, C, Pföhler, C, Kähler, KC, Knauss, S, Heppt, MV, Gutzmer, R, Dimitriou, F, Meier, F, Mitzel-Rink, H, Schuler, G, Terheyden, P, Thoms, KM, Türk, M, Dummer, R, Zimmer, L, Schröder, R, & Heinzerling, L. (2019). Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. *Eur J Cancer*, 106, 12-23.
doi:10.1016/j.ejca.2018.09.033
177. Müller, S, Farag, I, Weickert, J, Braun, Y, Lollert, A, Dobberstein, J, Hötter, A, & Graf, N. (2019). Benchmarking Wilms' tumor in multisequence MRI data: why does current clinical practice fail? Which popular segmentation algorithms perform well? *J Med Imaging (Bellingham)*, 6(3), 034001. doi:10.1117/1.Jmi.6.3.034001
178. *Musholt, TJ, Staubitz, JI, Antonio Cámara, RJ, Musholt, PB, Humberg, D, Springer, E, & Schad, A. (2019). Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - A molecular and clinical analysis. *Eur J Surg Oncol*, 45(6), 1018-1024. doi:10.1016/j.ejso.2018.11.009
179. *Nabar, ND, Brandt, MP, Thomas, C, Tsaor, I, Bartsch, G, Jaeger, W, Haferkamp, A, & Höfner, T. (2019). Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice. *Minerva Urol Nefrol*, 71(3), 205-216. doi:10.23736/s0393-2249.18.03117-x

180. Nabieva, N, Häberle, L, Brucker, SY, Janni, W, Volz, B, Loehberg, CR, Hartkopf, AD, Walter, CB, Baake, G, Fridman, A, Malter, W, Wuerstlein, R, Harbeck, N, Hoffmann, O, Kuemmel, S, Martin, B, Thomssen, C, Graf, H, Wolf, C, Lux, MP, Bayer, CM, Rauh, C, Hack, CC, Almstedt, K, Gass, P, Heindl, F, Brodkorb, T, Lindner, C, Kolberg, HC, Krabisch, P, Weigel, M, Steinfeld-Birg, D, Kohls, A, Brucker, C, Schulz, V, Fischer, G, Pelzer, V, Rack, B, Beckmann, MW, Fehm, T, Rody, A, Maass, N, Hein, A, & Fasching, PA. (2019). Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. *Int J Cancer*, 145(8), 2114-2121. doi:10.1002/ijc.32294
181. *Neitzel, C, Seiwert, N, Göder, A, Diehl, E, Weber, C, Nagel, G, Stroh, S, Rasenberger, B, Christmann, M, & Fahrner, J. (2019). Lipoic Acid Synergizes with Antineoplastic Drugs in Colorectal Cancer by Targeting p53 for Proteasomal Degradation. *Cells*, 8(8). doi:10.3390/cells8080794
182. *Neumann, H, & Bisschops, R. (2019). Artificial intelligence and the future of endoscopy. *Dig Endosc*, 31(4), 389-390. doi:10.1111/den.13391
183. Neumeyer, S, Popanda, O, Butterbach, K, Edelmann, D, Bläker, H, Toth, C, Roth, W, Herpel, E, Jäkel, C, Schmezer, P, Benner, A, Burwinkel, B, Hoffmeister, M, Brenner, H, & Chang-Claude, J. (2019). DNA methylation profiling to explore colorectal tumor differences according to menopausal hormone therapy use in women. *Epigenomics*, 11(16), 1765-1778. doi:10.2217/epi-2019-0051
184. Neumeyer, S, Popanda, O, Edelmann, D, Butterbach, K, Toth, C, Roth, W, Bläker, H, Jiang, R, Herpel, E, Jäkel, C, Schmezer, P, Jansen, L, Alwers, E, Benner, A, Burwinkel, B, Hoffmeister, M, Brenner, H, & Chang-Claude, J. (2019). Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer. *Epigenetics*, 14(5), 477-493. doi:10.1080/15592294.2019.1595998
185. *Nezi-Cahn, S, Sicking, I, Almstedt, K, Battista, M, Heimes, AS, Krajnak, S, Steetskamp, J, Hasenburg, A, & Schmidt, M. (2019). Risk Factors for Chemotherapy-Associated Venous Thromboses in Gynaecological Oncology Patients. *Geburtshilfe Frauenheilkd*, 79(10), 1100-1109. doi:10.1055/a-0834-6468
186. *Orlandini von Niessen, AG, Poleganov, MA, Rechner, C, Plaschke, A, Kranz, LM, Fesser, S, Diken, M, Löwer, M, Vallazza, B, Beissert, T, Bukur, V, Kuhn, AN, Türeci, Ö, & Sahin, U. (2019). Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3' UTRs Identified by Cellular Library Screening. *Mol Ther*, 27(4), 824-836. doi:10.1016/j.ymthe.2018.12.011
187. *Panova-Noeva, M, Neu, MA, Eckerle, S, Spix, C, Schneider, A, Schmidtman, I, Spronk, HM, Pfeiffer, N, Beutel, M, Lackner, KJ, Münzel, T, Ten Cate, H, Merzenich, H, Faber, J, & Wild, PS. (2019). Cardiovascular risk factors are important determinants of platelet-dependent thrombin generation in adult survivors of childhood cancer. *Clin Res Cardiol*, 108(4), 438-447. doi:10.1007/s00392-018-1374-4
188. *Panova-Noeva, M, Wagner, B, Nagler, M, Arnold, N, Prochaska, JH, Eckerle, S, Spronk, HM, Merzenich, H, Wingerter, A, Schneider, A, Danckwardt, S, Ten Cate, H, Faber, J, & Wild, PS. (2019). Relation between platelet coagulant and vascular function, sex-specific analysis in adult survivors of childhood cancer compared to a population-based sample. *Sci Rep*, 9(1), 20090. doi:10.1038/s41598-019-56626-1
189. Papachristofilou, A, Hipp, MM, Klinkhardt, U, Früh, M, Sebastian, M, Weiss, C, Pless, M, Cathomas, R, Hilbe, W, Pall, G, Wehler, T, Alt, J, Bischoff, H, Geißler, M, Griesinger, F, Kallen, KJ, Fotin-Mleczek, M, Schröder, A, Scheel, B, Muth, A, Seibel, T, Stosnach, C, Doener, F, Hong, HS, Koch, SD, Gnad-Vogt, U, & Zippelius, A. (2019). Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. *J Immunother Cancer*, 7(1), 38. doi:10.1186/s40425-019-0520-5
190. Pfanzagl, B, Zevallos, VF, Schuppan, D, Pfragner, R, & Jensen-Jarolim, E. (2019). Histamine causes influx via T-type voltage-gated calcium channels in an enterochromaffin tumor cell line: potential therapeutic target in adverse food reactions. *Am J Physiol Gastrointest Liver Physiol*, 316(2), G291-g303. doi:10.1152/ajpgi.00261.2018
191. Ploussard, G, Borgmann, H, Briganti, A, de Visschere, P, Fütterer, JJ, Gandaglia, G, Heidegger, I, Kretschmer, A, Mathieu, R, Ost, P, Sooriakumaran, P, Surcel, C, Tilki, D, Tsaur, I, Valerio, M, & van den Bergh, R. (2019). Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies? *World J Urol*, 37(2), 243-251. doi:10.1007/s00345-018-2399-z
192. Ploussard, G, Gandaglia, G, Borgmann, H, de Visschere, P, Heidegger, I, Kretschmer, A, Mathieu, R, Surcel, C, Tilki, D, Tsaur, I, Valerio, M, van den Bergh, R, Ost, P, & Briganti, A. (2019). Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. *Eur Urol*, 76(4), 493-504. doi:10.1016/j.eururo.2018.10.041

193. Polifka, I, Agaimy, A, Herrmann, E, Spath, V, Trojan, L, Stöckle, M, Becker, F, Ströbel, P, Wülfing, C, Schrader, AJ, Barth, P, Staehler, M, Stief, C, Hohenfellner, M, Macher-Göppinger, S, Wullich, B, Noldus, J, Brenner, W, Roos, FC, Walter, B, Otto, W, Burger, M, Höfler, H, Haferkamp, A, Geppert, CI, Stöhr, C, & Hartmann, A. (2019). High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. *Hum Pathol*, 83, 212-223. doi:10.1016/j.humpath.2018.08.006
194. Polterauer, S, Schwameis, R, Grimm, C, Hillemanns, P, Jückstock, J, Hilpert, F, de Gregorio, N, Hasenburg, A, Sehouli, J, Fürst, ST, Strauß, HG, Baumann, K, Thiel, F, Mustea, A, Harter, P, Wimberger, P, Kölbl, H, Reinthaller, A, Woelber, L, & Mahner, S. (2019). Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study. *Gynecol Oncol*, 153(2), 286-291. doi:10.1016/j.ygyno.2019.02.007
195. Quaas, A, Heydt, C, Waldschmidt, D, Alakus, H, Zander, T, Goeser, T, Kasper, P, Bruns, C, Brunn, A, Roth, W, Hartmann, N, Bunck, A, Schmidt, M, Buettner, R, & Merkelbach-Bruse, S. (2019). Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma. *BMC Gastroenterol*, 19(1), 21. doi:10.1186/s12876-019-0942-z
196. *Radspieler, MM, Schindeldecker, M, Stenzel, P, Försch, S, Tagscherer, KE, Herpel, E, Hohenfellner, M, Hatiboglu, G, Roth, W, & Macher-Goeppinger, S. (2019). Lamin-B1 is a senescence-associated biomarker in clear-cell renal cell carcinoma. *Oncol Lett*, 18(3), 2654-2660. doi:10.3892/ol.2019.10593
197. Radtke, JP, Giganti, F, Wiesenfarth, M, Stabile, A, Marengo, J, Orczyk, C, Kasivisvanathan, V, Nyarangi-Dix, JN, Schütz, V, Dieffenbacher, S, Görtz, M, Stenzinger, A, Roth, W, Freeman, A, Punwani, S, Bonekamp, D, Schlemmer, HP, Hohenfellner, M, Emberton, M, & Moore, CM. (2019). Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS. *PLoS One*, 14(8), e0221350. doi:10.1371/journal.pone.0221350
198. Rajawat, GS, Belubbi, T, Nagarsenker, MS, Abrahamsson, B, Cristofaletti, R, Groot, DW, Langguth, P, Parr, A, Polli, JE, Mehta, M, Shah, VP, Tajiri, T, & Dressman, J. (2019). Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Ondansetron. *J Pharm Sci*, 108(10), 3157-3168. doi:10.1016/j.xphs.2019.05.033
199. Raven, PA, Lysakowski, S, Tan, Z, D'Costa, NM, Moskalev, I, Frees, S, Struss, W, Matsui, Y, Narita, S, Buttyan, R, Chavez-Munoz, C, & So, AI. (2019). Inhibition of GLI2 with antisense-oligonucleotides: A potential therapy for the treatment of bladder cancer. *J Cell Physiol*, 234(11), 20634-20647. doi:10.1002/jcp.28669
200. Renner, K, Bruss, C, Schnell, A, Koehl, G, Becker, HM, Fante, M, Menevse, AN, Kauer, N, Blazquez, R, Hacker, L, Decking, SM, Bohn, T, Faerber, S, Evert, K, Aigle, L, Amslinger, S, Landa, M, Krijgsman, O, Rozeman, EA, Brummer, C, Siska, PJ, Singer, K, Pektor, S, Miederer, M, Peter, K, Gottfried, E, Herr, W, Marchiq, I, Pouyssegur, J, Roush, WR, Ong, S, Warren, S, Pukrop, T, Beckhove, P, Lang, SA, Bopp, T, Blank, CU, Cleveland, JL, Oefner, PJ, Dettmer, K, Selby, M, & Kreutz, M. (2019). Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy. *Cell Rep*, 29(1), 135-150.e139. doi:10.1016/j.celrep.2019.08.068
201. *Renovanz, M, Soebianto, S, Tsakmaklis, H, Keric, N, Nadji-Ohl, M, Beutel, M, Ringel, F, Wollschläger, D, & Hickmann, AK. (2019). Evaluation of the psychological burden during the early disease trajectory in patients with intracranial tumors by the ultra-brief Patient Health Questionnaire for Depression and Anxiety (PHQ-4). *Support Care Cancer*, 27(12), 4469-4477. doi:10.1007/s00520-019-04718-z
202. *Ridder, DA, Duret, D, Wörns, MA, Schotten, S, Heinrich, S, Kloth, M, Springer, E, Roth, W, & Straub, BK. (2019). [Hepatocellular carcinoma in an inflammatory adenoma with β -catenin mutation in a patient with hepatocellular adenomatosis due to germline mutation in HNF1A]. *Z Gastroenterol*, 57(1), 46-51. doi:10.1055/a-0821-7154
203. *Ries, F, Alflen, A, Aranda Lopez, P, Beckert, H, Theobald, M, Schild, H, Teschner, D, & Radsak, MP. (2019). Antifungal Drugs Influence Neutrophil Effector Functions. *Antimicrob Agents Chemother*, 63(6). doi:10.1128/aac.02409-18
204. *Rohde, C, Yamaguchi, R, Mukhina, S, Sahin, U, Itoh, K, & Türeci, Ö. (2019). Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma. *Jpn J Clin Oncol*, 49(9), 870-876. doi:10.1093/jjco/hyz068
205. *Roick, J, Danker, H, Kersting, A, Dietrich, A, Dietz, A, Papsdorf, K, Meixensberger, J, Stolzenburg, JU, Wirtz, H, & Singer, S. (2019). The association of socioeconomic status with quality of life in cancer patients over a 6-month period using individual growth models. *Support Care Cancer*, 27(9), 3347-3355. doi:10.1007/s00520-018-4634-y

206. Rot, S, Kaune, T, Taubert, H, Greither, T, Kotrba, J, Güttler, A, Wichmann, H, Bilkenroth, U, Wienke, A, Al-Nawas, B, Bache, M, Vordermark, D, Wickenhauser, C, Bethmann, D, Eckert, AW, & Kappler, M. (2019). Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients. *BMC Cancer*, 19(1), 155. doi:10.1186/s12885-019-5327-8
207. Rücker, FG, Agrawal, M, Corbacioglu, A, Weber, D, Kapp-Schwoerer, S, Gaidzik, VI, Jahn, N, Schroeder, T, Wattad, M, Lübbert, M, Koller, E, Kindler, T, Götze, K, Ringhoffer, M, Westermann, J, Fiedler, W, Horst, HA, Greil, R, Schroers, R, Mayer, K, Heinicke, T, Krauter, J, Schlenk, RF, Thol, F, Heuser, M, Ganser, A, Bullinger, L, Paschka, P, Döhner, H, & Döhner, K. (2019). Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. *Blood*, 134(19), 1608-1618. doi:10.1182/blood.2019001425
208. *Russo, A, Paret, C, Alt, F, Burhenne, J, Fresnais, M, Wagner, W, Glaser, M, Bender, H, Huprich, S, Harter, PN, Filipski, K, Lehmann, N, Backes, N, Roth, L, Seidmann, L, Sommer, C, Brockmann, MA, Pietsch, T, Neu, MA, Wingerter, A, & Faber, J. (2019). Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. *Int J Mol Sci*, 20(17). doi:10.3390/ijms20174267
209. Saborowski, A, Wolff, K, Spielberg, S, Beer, B, Hartleben, B, Erlangga, Z, Becker, D, Dow, LE, Marhenke, S, Woller, N, Unger, K, Schirmacher, P, Manns, MP, Marquardt, JU, Vogel, A, & Saborowski, M. (2019). Murine Liver Organoids as a Genetically Flexible System to Study Liver Cancer In Vivo and In Vitro. *Hepatol Commun*, 3(3), 423-436. doi:10.1002/hep4.1312
210. Salem, J, Paffenholz, P, Bolenz, C, von Brandenstein, M, Cebulla, A, Haferkamp, A, Kuru, T, Lee, CT, Pfister, D, Tsaor, I, Borgmann, H, & Heidenreich, A. (2019). Websites on Bladder Cancer: an Appropriate Source of Patient Information? *J Cancer Educ*, 34(2), 381-387. doi:10.1007/s13187-017-1316-2
211. Salwender, H, Bertsch, U, Weisel, K, Duerig, J, Kunz, C, Benner, A, Blau, IW, Raab, MS, Hillengass, J, Hose, D, Huhn, S, Hundemer, M, Andrusis, M, Jauch, A, Seidel-Glaetzer, A, Lindemann, HW, Hensel, M, Fronhoffs, S, Martens, U, Hansen, T, Wattad, M, Graeven, U, Munder, M, Fenk, R, Haenel, M, Scheid, C, & Goldschmidt, H. (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. *BMC Cancer*, 19(1), 504. doi:10.1186/s12885-019-5600-x
212. *Sasca, D, Szybinski, J, Schüller, A, Shah, V, Heidelberger, J, Haehnel, PS, Dolnik, A, Kriege, O, Fehr, EM, Gebhardt, WH, Reid, G, Scholl, C, Theobald, M, Bullinger, L, Beli, P, & Kindler, T. (2019). NCAM1 (CD56) promotes leukemogenesis and confers drug resistance in AML. *Blood*, 133(21), 2305-2319. doi:10.1182/blood-2018-12-889725
213. *Sasca, D, Yun, H, Giotopoulos, G, Szybinski, J, Evan, T, Wilson, NK, Gerstung, M, Gallipoli, P, Green, AR, Hills, R, Russell, N, Osborne, CS, Papaemmanuil, E, Göttgens, B, Campbell, P, & Huntly, BJP. (2019). Cohesin-dependent regulation of gene expression during differentiation is lost in cohesin-mutated myeloid malignancies. *Blood*, 134(24), 2195-2208. doi:10.1182/blood.2019001553
214. Scheiner, B, Kirstein, MM, Hücke, F, Finkelmeier, F, Schulze, K, von Felden, J, Koch, S, Schwabl, P, Hinrichs, JB, Waneck, F, Waidmann, O, Reiberger, T, Müller, C, Sieghart, W, Trauner, M, Weinmann, A, Wege, H, Trojan, J, Peck-Radosavljevic, M, Vogel, A, & Pinter, M. (2019). Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. *Aliment Pharmacol Ther*, 49(10), 1323-1333. doi:10.1111/apt.15245
215. Schlenk, RF, Weber, D, Fiedler, W, Salih, HR, Wulf, G, Salwender, H, Schroeder, T, Kindler, T, Lübbert, M, Wolf, D, Westermann, J, Kraemer, D, Götze, KS, Horst, HA, Krauter, J, Girschikofsky, M, Ringhoffer, M, Südhoff, T, Held, G, Derigs, HG, Schroers, R, Greil, R, Grieshammer, M, Lange, E, Burchardt, A, Martens, U, Hertenstein, B, Marretta, L, Heuser, M, Thol, F, Gaidzik, VI, Herr, W, Krzykalla, J, Benner, A, Döhner, K, Ganser, A, Paschka, P, & Döhner, H. (2019). Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. *Blood*, 133(8), 840-851. doi:10.1182/blood-2018-08-869453
216. Schlenk, RF, Weber, D, Herr, W, Wulf, G, Salih, HR, Derigs, HG, Kuendgen, A, Ringhoffer, M, Hertenstein, B, Martens, UM, Grieshammer, M, Bernhard, H, Krauter, J, Girschikofsky, M, Wolf, D, Lange, E, Westermann, J, Koller, E, Kremers, S, Wattad, M, Heuser, M, Thol, F, Göhring, G, Haase, D, Teleanu, V, Gaidzik, V, Benner, A, Döhner, K, Ganser, A, Paschka, P, & Döhner, H. (2019). Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine. *Leukemia*, 33(8), 1923-1933. doi:10.1038/s41375-019-0395-y
217. Schnürch, HG, Ackermann, S, Alt-Radtke, CD, Angleitner, L, Barinoff, J, Beckmann, MW, Böing, C, Dannecker, C, Fehm, T, Gaase, R, Gass, P, Gebhardt, M, Giesekeing, F, Günthert, A, Hack, CC, Hantschmann, P, Horn, LC, Koch, MC, Letsch, A, Mallmann, P, Mangold, B, Marnitz, S, Mehlhorn, G, Paradies, K, Reinhardt, MJ, Tholen, R, Torsten, U, Weikel, W, Wölber, L, & Hampl, M. (2019). Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of

the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018). *Geburtshilfe Frauenheilkd*, 79(10), 1060-1078. doi:10.1055/a-0919-4959

218. Scholtes, C, Baust, K, Weinhold, L, Creutzig, U, Gnekow, A, Hinz, A, Kaatsch, P, Kreitz, K, Langer, T, Rutkowski, S, Singer, S, Spix, C, Teske, C, Schmid, M, Dilloo, D, & Calaminus, G. (2019). Health status, health-related quality of life, and socioeconomic outcome in childhood brain tumor survivors: a German cohort study. *Neuro Oncol*, 21(8), 1069-1081. doi:10.1093/neuonc/noz044
219. Schramm, F, Zimmermann, M, Jorch, N, Pekrun, A, Borkhardt, A, Imschweiler, T, Christiansen, H, Faber, J, Feuchtinger, T, Schmid, I, Beron, G, Horstmann, MA, & Escherich, G. (2019). Daunorubicin during delayed intensification decreases the incidence of infectious complications - a randomized comparison in trial CoALL 08-09. *Leuk Lymphoma*, 60(1), 60-68. doi:10.1080/10428194.2018.1473575
220. Schramm, F, Zur Stadt, U, Zimmermann, M, Jorch, N, Pekrun, A, Borkhardt, A, Imschweiler, T, Christiansen, H, Faber, J, Schmid, I, Feuchtinger, T, Beron, G, den Boer, ML, Pieters, R, Horstmann, MA, Janka-Schaub, GE, & Escherich, G. (2019). Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity. *Blood Adv*, 3(22), 3688-3699. doi:10.1182/bloodadvances.2019000576
221. Schröder, J, Schüller, V, May, A, Gerges, C, Anders, M, Becker, J, Hess, T, Kreuser, N, Thieme, R, Ludwig, KU, Noder, T, Venerito, M, Veits, L, Schmidt, T, Fuchs, C, Izbicki, JR, Hölscher, AH, Dakkak, D, Jansen-Winkel, B, Moulla, Y, Lyros, O, Niebisch, S, Mehdorn, M, Lang, H, Lorenz, D, Schumacher, B, Mayershofer, R, Vashist, Y, Ott, K, Vieth, M, Weismüller, J, Mangold, E, Nöthen, MM, Moebus, S, Knapp, M, Neuhaus, H, Rösch, T, Ell, C, Gockel, I, Schumacher, J, & Böhmer, AC. (2019). Identification of loci of functional relevance to Barrett's esophagus and esophageal adenocarcinoma: Cross-referencing of expression quantitative trait loci data from disease-relevant tissues with genetic association data. *PLoS One*, 14(12), e0227072. doi:10.1371/journal.pone.0227072
222. Schröder, W, Raptis, DA, Schmidt, HM, Gisbertz, SS, Moons, J, Asti, E, Luyer, MDP, Hölscher, AH, Schneider, PM, van Berge Henegouwen, MI, Nafteux, P, Nilsson, M, Räsänen, J, Palazzo, F, Mercer, S, Bonavina, L, Nieuwenhuijzen, GAP, Wijnhoven, BPL, Pattyn, P, Grimmering, PP, Bruns, CJ, & Gutschow, CA. (2019). Anastomotic Techniques and Associated Morbidity in Total Minimally Invasive Transthoracic Esophagectomy: Results From the EsoBenchmark Database. *Ann Surg*, 270(5), 820-826. doi:10.1097/sla.0000000000003538
223. Schulte, L, Scheiner, B, Voigtländer, T, Koch, S, Schweitzer, N, Marhenke, S, Ivanyi, P, Manns, MP, Rodt, T, Hinrichs, JB, Weinmann, A, Pinter, M, Vogel, A, & Kirstein, MM. (2019). Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma. *Liver Int*, 39(4), 714-726. doi:10.1111/liv.14048
224. *Schupp, J, Krebs, FK, Zimmer, N, Trzeciak, E, Schuppan, D, & Tuettenberg, A. (2019). Targeting myeloid cells in the tumor sustaining microenvironment. *Cell Immunol*, 343, 103713. doi:10.1016/j.cellimm.2017.10.013
225. *Sebastian, M, Schröder, A, Scheel, B, Hong, HS, Muth, A, von Boehmer, L, Zippelius, A, Mayer, F, Reck, M, Atanackovic, D, Thomas, M, Schneller, F, Stöhlmacher, J, Bernhard, H, Gröschel, A, Lander, T, Probst, J, Strack, T, Wiegand, V, Gnad-Vogt, U, Kallen, KJ, Hoerr, I, von der Muelbe, F, Fotin-Mleczek, M, Knuth, A, & Koch, SD. (2019). A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer. *Cancer Immunol Immunother*, 68(5), 799-812. doi:10.1007/s00262-019-02315-x
226. Shirin, H, Shpak, B, Epshtein, J, Karstensen, JG, Hoffman, A, de Ridder, R, Testoni, PA, Ishaq, S, Reddy, DN, Gross, SA, Neumann, H, Goetz, M, Abramowich, D, Moshkowitz, M, Mizrahi, M, Vilmann, P, Rey, JW, Sanduleanu-Dascalescu, S, Viale, E, Chaudhari, H, Pochapin, MB, Yair, M, Shnell, M, Yaari, S, Hendel, JW, Teubner, D, Bogie, RMM, Notaristefano, C, Simantov, R, Gluck, N, Israeli, E, Stigaard, T, Matalon, S, Vilkin, A, Benson, A, Sloth, S, Maliar, A, Waizbard, A, Jacob, H, Thielsen, P, Shachar, E, Rochberger, S, Hershcovici, T, Plougmann, JJ, Braverman, M, Tsvang, E, Abedi, AA, Brachman, Y, Siersema, PD, & Kiesslich, R. (2019). G-EYE colonoscopy is superior to standard colonoscopy for increasing adenoma detection rate: an international randomized controlled trial (with videos). *Gastrointest Endosc*, 89(3), 545-553. doi:10.1016/j.gie.2018.09.028
227. Shraibman, B, Barnea, E, Kadosh, DM, Haimovich, Y, Slobodin, G, Rosner, I, López-Larrea, C, Hilf, N, Kutruff, S, Song, C, Britten, C, Castle, J, Kreiter, S, Frenzel, K, Tatagiba, M, Tabatabai, G, Dietrich, PY, Dutoit, V, Wick, W, Platten, M, Winkler, F, von Deimling, A, Kroep, J, Sahuquillo, J, Martinez-Ricarte, F, Rodon, J, Lassen, U, Ottensmeier, C, van der Burg, SH, Thor Straten, P, Poulsen, HS, Ponsati, B, Okada, H, Rammensee, HG, Sahin, U, Singh, H, & Admon, A. (2019). Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. *Mol Cell Proteomics*, 18(6), 1255-1268. doi:10.1074/mcp.RA119.001524
228. *Siewert, C, Haas, H, Nawroth, T, Ziller, A, Nogueira, SS, Schroer, MA, Blanchet, CE, Svergun, DI, Radulescu, A, Bates, F, Huesemann, Y, Radsak, MP, Sahin, U, & Langguth, P. (2019). Investigation of charge ratio variation in mRNA - DEAE-dextran polyplex delivery systems. *Biomaterials*, 192, 612-620. doi:10.1016/j.biomaterials.2018.10.020

229. *Singer, S, Amdal, CD, Hammerlid, E, Tomaszewska, IM, Castro Silva, J, Mehanna, H, Santos, M, Inhestern, J, Brannan, C, Yarom, N, Fullerton, A, Pinto, M, Arraras, JI, Kiyota, N, Bonomo, P, Sherman, AC, Baumann, I, Galalae, R, Fernandez Gonzalez, L, Nicolatou-Galitis, O, Abdel-Hafeez, Z, Raber-Durlacher, J, Schmalz, C, Zotti, P, Boehm, A, Hofmeister, D, Krejovic Trivic, S, Loo, S, Chie, WC, Bjordal, K, Brokstad Herlofson, B, Grégoire, V, & Licitra, L. (2019). International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV. *Head Neck*, 41(6), 1725-1737. doi:10.1002/hed.25609
230. *Singer, S, Danker, H, Meixensberger, J, Briest, S, Dietz, A, Kortmann, RD, Stolzenburg, JU, Kersting, A, & Roick, J. (2019). Structured multi-disciplinary psychosocial care for cancer patients and the perceived quality of care from the patient perspective: a cluster-randomized trial. *J Cancer Res Clin Oncol*, 145(11), 2845-2854. doi:10.1007/s00432-019-03018-7
231. *Singer, S, Vogel, HJ, Guntinas-Lichius, O, Erdmann-Reusch, B, Fuchs, M, Taylor, K, Meyer, A, & Keszte, J. (2019). Multicenter prospective study on the use and outcome of rehabilitation after total laryngectomy in Germany. *Head Neck*, 41(4), 1070-1079. doi:10.1002/hed.25540
232. Singh, VK, Werner, S, Schwalm, S, Lennerz, V, Ruf, S, Stadler, S, Hackstein, H, Reiter, A, Wölfel, T, Damm-Welk, C, & Woessmann, W. (2019). NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma. *Oncoimmunology*, 8(9), e1625688. doi:10.1080/2162402x.2019.1625688
233. Smith, CP, Harmon, SA, Barrett, T, Bittencourt, LK, Law, YM, Shebel, H, An, JY, Czarniecki, M, Mehralivand, S, Coskun, M, Wood, BJ, Pinto, PA, Shih, JH, Choyke, PL, & Turkbey, B. (2019). Intra- and interreader reproducibility of PI-RADSv2: A multireader study. *J Magn Reson Imaging*, 49(6), 1694-1703. doi:10.1002/jmri.26555
234. *Smyth, EC, & Moehler, M. (2019). Late-line treatment in metastatic gastric cancer: today and tomorrow. *Ther Adv Med Oncol*, 11, 1758835919867522. doi:10.1177/1758835919867522
235. Splinter, M, Bostel, T, Sachpazidis, I, Fechter, T, Zamboglou, C, Jäkel, O, Huber, PE, Debus, J, Baltas, D, & Nicolay, NH. (2019). Dosimetric Impact of Interfractional Variations for Post-prostatectomy Radiotherapy to the Prostatic Fossa- Relevance for the Frequency of Position Verification Imaging and Treatment Adaptation. *Front Oncol*, 9, 1191. doi:10.3389/fonc.2019.01191
236. Sprave, T, Rosenberger, F, Verma, V, Förster, R, Bruckner, T, Schlampp, I, Bostel, T, Welzel, T, Akbaba, S, Rackwitz, T, Nicolay, NH, Grosu, AL, Wiskemann, J, Debus, J, & Rief, H. (2019). Paravertebral Muscle Training in Patients with Unstable Spinal Metastases Receiving Palliative Radiotherapy: An Exploratory Randomized Feasibility Trial. *Cancers (Basel)*, 11(11). doi:10.3390/cancers11111771
237. *Sprinzl, MF, Kirstein, MM, Koch, S, Seib, ML, Weinmann-Menke, J, Lang, H, Düber, C, Toenges, G, Zöller, D, Marquardt, JU, Wörns, MA, Galle, PR, Vogel, A, Pinter, M, & Weinmann, A. (2019). Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. *Liver Cancer*, 8(5), 387-402. doi:10.1159/000492628
238. *Staat, G, Daldrup-Link, HE, Herrmann, J, Hirsch, FW, Schäfer, JF, Seehofnerova, A, Sorantin, E, Theruvath, AJ, & Lollert, A. (2019). [From Xrays to PET/MR, and then? - Future imaging in pediatric radiology]. *Rofo*, 191(4), 357-366. doi:10.1055/a-0853-2744
239. *Staubitz, JI, Musholt, PB, & Musholt, TJ. (2019). The surgical dilemma of primary surgery for follicular thyroid neoplasms. *Best Pract Res Clin Endocrinol Metab*, 33(4), 101292. doi:10.1016/j.beem.2019.101292
240. *Staubitz, JI, & Musholt, TJ. (2019). [Individualization of the surgical procedure in response to overdiagnosis and overtreatment in differentiated thyroid carcinomas]. *Pathologe*, 40(Suppl 3), 342-346. doi:10.1007/s00292-019-00699-2
241. *Staubitz, JI, Musholt, TJ, Schad, A, Springer, E, Lang, H, Rajalingam, K, Roth, W, & Hartmann, N. (2019). ANKRD26-RET - A novel gene fusion involving RET in papillary thyroid carcinoma. *Cancer Genet*, 238, 10-17. doi:10.1016/j.cancergen.2019.07.002
242. *Staubitz, JI, Schad, A, Springer, E, Rajalingam, K, Lang, H, Roth, W, Hartmann, N, & Musholt, TJ. (2019). Novel rearrangements involving the RET gene in papillary thyroid carcinoma. *Cancer Genet*, 230, 13-20. doi:10.1016/j.cancergen.2018.11.002
243. Steckel, I, Singer, S, Keszte, J, Pabst, F, & Meyer, A. (2019). [Speech Intelligibility and Marital Quality in Couples after Total Laryngectomy - Partners' View]. *Psychother Psychosom Med Psychol*, 69(2), 63-71. doi:10.1055/s-0044-100359

244. *Stergiou, N, Gaidzik, N, Heimes, AS, Dietzen, S, Besenius, P, Jäkel, J, Brenner, W, Schmidt, M, Kunz, H, & Schmitt, E. (2019). Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid. *Cancer Immunol Res*, 7(1), 113-122. doi:10.1158/2326-6066.Cir-18-0256
245. *Stergiou, N, Nagel, J, Pektor, S, Heimes, AS, Jäkel, J, Brenner, W, Schmidt, M, Miederer, M, Kunz, H, Roesch, F, & Schmitt, E. (2019). Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer. *Int J Med Sci*, 16(9), 1188-1198. doi:10.7150/ijms.35452
246. Stintzing, S, Wirapati, P, Lenz, HJ, Neureiter, D, Fischer von Weikersthal, L, Decker, T, Kiani, A, Kaiser, F, Al-Batran, S, Heintges, T, Lerchenmüller, C, Kahl, C, Seipelt, G, Kullmann, F, Moehler, M, Scheithauer, W, Held, S, Modest, DP, Jung, A, Kirchner, T, Aderka, D, Tejpar, S, & Heinemann, V. (2019). Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial. *Ann Oncol*, 30(11), 1796-1803. doi:10.1093/annonc/mdz387
247. *Straub, BK, Witzel, HR, Pawella, LM, Renner, M, Eiteneuer, E, Hashani, M, Schirmacher, P, Roth, W, & Mechttersheimer, G. (2019). Perilipin 1 Expression Differentiates Liposarcoma from Other Types of Soft Tissue Sarcoma. *Am J Pathol*, 189(8), 1547-1558. doi:10.1016/j.ajpath.2019.04.017
248. Strieth, S, Ernst, BP, Both, I, Hirth, D, Pfisterer, LN, Künzel, J, & Eder, K. (2019). Randomized controlled single-blinded clinical trial of functional voice outcome after vascular targeting KTP laser microsurgery of early laryngeal cancer. *Head Neck*, 41(4), 899-907. doi:10.1002/hed.25474
249. *Tabujew, I, Willig, M, Leber, N, Freidel, C, Negwer, I, Koynov, K, Helm, M, Landfester, K, Zentel, R, Peneva, K, & Mailänder, V. (2019). Overcoming the barrier of CD8(+)T cells: Two types of nano-sized carriers for siRNA transport. *Acta Biomater*, 100, 338-351. doi:10.1016/j.actbio.2019.10.006
250. *Tang, Y, Reissig, S, Glasmacher, E, Regen, T, Wanke, F, Nikolaev, A, Gerlach, K, Popp, V, Karram, K, Fantini, MC, Schattenberg, JM, Galle, PR, Neurath, MF, Weigmann, B, Kurschus, FC, Hövelmeyer, N, & Waisman, A. (2019). Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFβ Signaling and Promote Colitis. *Gastroenterology*, 156(3), 692-707.e697. doi:10.1053/j.gastro.2018.10.023
251. *Tanyildizi, Y, Keweloh, S, Neu, MA, Russo, A, Wingerter, A, Weyer-Elberich, V, Stockinger, M, Schmidberger, H, Brockmann, MA, & Faber, J. (2019). Radiation-induced vascular changes in the intracranial irradiation field in medulloblastoma survivors: An MRI study. *Radiother Oncol*, 136, 50-55. doi:10.1016/j.radonc.2019.03.017
252. *Taylor, K, Singer, S, May, M, Durdu, G, & Petermann-Meyer, A. (2019). Outcome comparison of integrated psycho-oncological care versus unstructured care-Results of a non-randomised open-label two-arm trial. *Eur J Cancer Care (Engl)*, 28(5), e13127. doi:10.1111/ecc.13127
253. Thill, M, Jackisch, C, Janni, W, Müller, V, Albert, US, Bauerfeind, I, Blohmer, J, Budach, W, Dall, P, Diel, I, Fasching, PA, Fehm, T, Friedrich, M, Gerber, B, Hanf, V, Harbeck, N, Huober, J, Kolberg-Liedtke, C, Kreipe, HH, Krug, D, Kühn, T, Kümmel, S, Loibl, S, Lüftner, D, Lux, MP, Maass, N, Möbus, V, Müller-Schimpfle, M, Mundhenke, C, Nitz, U, Rhiem, K, Rody, A, Schmidt, M, Schneeweiss, A, Schütz, F, Sinn, HP, Solbach, C, Solomayer, EF, Stickeler, E, Thomssen, C, Untch, M, Wenz, F, Witzel, I, Wöckel, A, & Ditsch, N. (2019). AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. *Breast Care (Basel)*, 14(4), 247-255. doi:10.1159/000500999
254. *Tibubos, AN, Ernst, M, Brähler, E, Fischbeck, S, Hinz, A, Blettner, M, Zeissig, SR, Weyer, V, Imruck, BH, Binder, H, & Beutel, ME. (2019). Fatigue in survivors of malignant melanoma and its determinants: a register-based cohort study. *Support Care Cancer*, 27(8), 2809-2818. doi:10.1007/s00520-018-4587-1
255. *Tomicic, MT, Steigerwald, C, Rasenberger, B, Brozovic, A, & Christmann, M. (2019). Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6. *Arch Toxicol*, 93(8), 2265-2277. doi:10.1007/s00204-019-02513-7
256. Trautmann, M, Cheng, YY, Jensen, P, Azoitei, N, Brunner, I, Hüllein, J, Slabicki, M, Isfort, I, Cyra, M, Berthold, R, Wardelmann, E, Huss, S, Altwater, B, Rossig, C, Hafner, S, Simmet, T, Stählberg, A, Åman, P, Zenz, T, Lange, U, Kindler, T, Scholl, C, Hartmann, W, & Fröhling, S. (2019). Requirement for YAP1 signaling in myxoid liposarcoma. *EMBO Mol Med*, 11(5). doi:10.15252/emmm.201809889
257. *Tripke, V, Heinrich, S, Huber, T, Mittler, J, Hoppe-Lotichius, M, Straub, BK, & Lang, H. (2019). Surgical therapy of primary hepatic angiosarcoma. *BMC Surg*, 19(1), 5. doi:10.1186/s12893-018-0465-5

258. *Trippel, A, Halling, F, Heymann, P, Ayna, M, Al-Nawas, B, & Ziebart, T. (2019). The expression of melanoma-associated antigen A (MAGE-A) in oral squamous cell carcinoma: an evaluation of the significance for tumor prognosis. *Oral Maxillofac Surg*, 23(3), 343-352. doi:10.1007/s10006-019-00778-x
259. *Tsaour, I, Heidegger, I, Kretschmer, A, Borgmann, H, Gandaglia, G, Briganti, A, de Visschere, P, Mathieu, R, Valerio, M, van den Bergh, R, Ost, P, Mirvald, C, Tilki, D, Ploussard, G, & Surcel, C. (2019). Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now? *Cancer Treat Rev*, 75, 20-26. doi:10.1016/j.ctrv.2019.03.001
260. *Tsaour, I, Hüscher, T, Jüngel, E, Schneider, F, Schneider, M, Haferkamp, A, Thomas, C, Lieb, V, Wach, S, Taubert, H, Chun, FK, & Blaheta, RA. (2019). sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro. *Urol Oncol*, 37(6), 355.e351-355.e359. doi:10.1016/j.urolonc.2019.03.001
261. *Türeci, O, Sahin, U, Schulze-Bergkamen, H, Zvirbule, Z, Lordick, F, Koeberle, D, Thuss-Patience, P, Ettrich, T, Arnold, D, Bassermann, F, Al-Batran, SE, Wiechen, K, Dhaene, K, Maurus, D, Gold, M, Huber, C, Krivoschik, A, Arozullah, A, Park, JW, & Schuler, M. (2019). A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. *Ann Oncol*, 30(9), 1487-1495. doi:10.1093/annonc/mdz199
262. *Türeci, Ö, Mitnacht-Kraus, R, Wöll, S, Yamada, T, & Sahin, U. (2019). Characterization of zolbetuximab in pancreatic cancer models. *Oncoimmunology*, 8(1), e1523096. doi:10.1080/2162402x.2018.1523096
263. *Ugurel, S, Kortmann, RD, Mohr, P, Mentzel, T, Garbe, C, Breuninger, H, Bauer, S, & Grabbe, S. (2019). S1 guidelines for dermatofibrosarcoma protuberans (DFSP) - update 2018. *J Dtsch Dermatol Ges*, 17(6), 663-668. doi:10.1111/ddg.13849
264. van den Bergh, R, Gandaglia, G, Tilki, D, Borgmann, H, Ost, P, Surcel, C, Valerio, M, Sooriakumaran, P, Salomon, L, Briganti, A, Graefen, M, van der Poel, H, de la Taille, A, Montorsi, F, & Ploussard, G. (2019). Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. *Eur Urol Focus*, 5(2), 171-178. doi:10.1016/j.euf.2017.07.003
265. van Keulen, KE, Neumann, H, Schattenberg, JM, van Esch, AAJ, Kievit, W, Spaander, MCW, & Siersema, PD. (2019). A novel device for intracolonscopy cleansing of inadequately prepared colonoscopy patients: a feasibility study. *Endoscopy*, 51(1), 85-92. doi:10.1055/a-0632-1927
266. van Leerdam, ME, Roos, VH, van Hooft, JE, Balaguer, F, Dekker, E, Kaminski, MF, Latchford, A, Neumann, H, Ricciardiello, L, Rupińska, M, Saurin, JC, Tanis, PJ, Wagner, A, Jover, R, & Pellisé, M. (2019). Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy*, 51(11), 1082-1093. doi:10.1055/a-1016-4977
267. *Vascotto, F, Petschenka, J, Walzer, KC, Vormehr, M, Brkic, M, Strobl, S, Rösemann, R, Diken, M, Kreiter, S, Türeci, Ö, & Sahin, U. (2019). Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. *Oncoimmunology*, 8(7), 1601480. doi:10.1080/2162402x.2019.1601480
268. *Vaupel, P, Schmidberger, H, & Mayer, A. (2019). The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. *Int J Radiat Biol*, 95(7), 912-919. doi:10.1080/09553002.2019.1589653
269. *Verburg, FA, Wiessmann, M, Neuloh, G, Mottaghy, FM, & Brockmann, MA. (2019). Intraindividual comparison of selective intraarterial versus systemic intravenous 68Ga-DOTATATE PET/CT in patients with inoperable meningioma. *Nuklearmedizin*, 58(1), 23-27. doi:10.1055/a-0802-5039
270. *Vewinger, N, Huprich, S, Seidmann, L, Russo, A, Alt, F, Bender, H, Sommer, C, Samuel, D, Lehmann, N, Backes, N, Roth, L, Harter, PN, Filipinski, K, Faber, J, & Paret, C. (2019). IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients. *Int J Mol Sci*, 20(12). doi:10.3390/ijms20123027
271. Vollherbst, DF, Do, TD, Jugold, M, Eichwald, V, Macher-Göppinger, S, Pereira, PL, Bendszus, M, Möhlenbruch, MA, Richter, GM, Kauczor, HU, & Sommer, CM. (2019). The Novel X-Ray Visible Zein-Based Non-adhesive Precipitating Liquid Embolic HEI(E1_2017): An Exploratory Study. *Cardiovasc Intervent Radiol*, 42(6), 905-914. doi:10.1007/s00270-019-02179-9
272. *Vollmar, J, Kim, YO, Marquardt, JU, Becker, D, Galle, PR, Schuppan, D, & Zimmermann, T. (2019). Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFbeta. *Am J Physiol Gastrointest Liver Physiol*, 317(2), G195-g202. doi:10.1152/ajpgi.00088.2019
273. *Vormehr, M, Türeci, Ö, & Sahin, U. (2019). Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines. *Annu Rev Med*, 70, 395-407. doi:10.1146/annurev-med-042617-101816

274. Wagner, AD, Grabsch, HI, Mauer, M, Marreaud, S, Caballero, C, Thuss-Patience, P, Mueller, L, Elme, A, Moehler, MH, Martens, U, Kang, YK, Rha, SY, Cats, A, Tokunaga, M, & Lordick, F. (2019). EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. *BMC Cancer*, 19(1), 494. doi:10.1186/s12885-019-5675-4
275. Wagner, AD, Oertelt-Prigione, S, Adjei, A, Buclin, T, Cristina, V, Csajka, C, Coukos, G, Dafni, U, Dotto, GP, Ducreux, M, Fellay, J, Haanen, J, Hocquelet, A, Klinge, I, Lemmens, V, Letsch, A, Mauer, M, Moehler, M, Peters, S, & Özdemir, BC. (2019). Gender medicine and oncology: report and consensus of an ESMO workshop. *Ann Oncol*, 30(12), 1914-1924. doi:10.1093/annonc/mdz414
276. Warth, M, Koehler, F, Weber, M, Bardenheuer, HJ, Ditzen, B, & Kessler, J. (2019). "Song of Life (SOL)" study protocol: a multicenter, randomized trial on the emotional, spiritual, and psychobiological effects of music therapy in palliative care. *BMC Palliat Care*, 18(1), 14. doi:10.1186/s12904-019-0397-6
277. *Watermann, A, Gieringer, R, Bauer, AM, Kurch, S, Kiesslich, R, Tremel, W, Gosepath, J, & Brieger, J. (2019). Fluorescein- and EGFR-Antibody Conjugated Silica Nanoparticles for Enhancement of Real-time Tumor Border Definition Using Confocal Laser Endomicroscopy in Squamous Cell Carcinoma of the Head and Neck. *Nanomaterials (Basel)*, 9(10). doi:10.3390/nano9101378
278. Wei, T, Weiler, SME, Tóth, M, Sticht, C, Lutz, T, Thomann, S, De La Torre, C, Straub, B, Merker, S, Ruppert, T, Marquardt, J, Singer, S, Gretz, N, Schirmacher, P, & Breuhahn, K. (2019). YAP-dependent induction of UHMK1 supports nuclear enrichment of the oncogene MYBL2 and proliferation in liver cancer cells. *Oncogene*, 38(27), 5541-5550. doi:10.1038/s41388-019-0801-y
279. Weis, J, Wirtz, MA, Tomaszewski, KA, Hammerlid, E, Arraras, JI, Conroy, T, Lanceley, A, Schmidt, H, Singer, S, Pinto, M, Alm El-Din, M, Compter, I, Holzner, B, Hofmeister, D, Chie, WC, Harle, A, Flechtner, HH, & Bottomley, A. (2019). Sensitivity to change of the EORTC quality of life module measuring cancer-related fatigue (EORTC QLQ-Fa12): Results from the international psychometric validation. *Psychooncology*, 28(8), 1753-1761. doi:10.1002/pon.5151
280. *Werner, A, Pieh, D, Echchannaoui, H, Rupp, J, Rajalingam, K, Theobald, M, Closs, EI, & Munder, M. (2019). Cationic Amino Acid Transporter-1-Mediated Arginine Uptake Is Essential for Chronic Lymphocytic Leukemia Cell Proliferation and Viability. *Front Oncol*, 9, 1268. doi:10.3389/fonc.2019.01268
281. White, N, Oostendorp, L, Vickerstaff, V, Gerlach, C, Engels, Y, Maessen, M, Tomlinson, C, Wens, J, Leysen, B, Biasco, G, Zambrano, S, Eychmüller, S, Avgerinou, C, Chattat, R, Ottoboni, G, Veldhoven, C, & Stone, P. (2019). An online international comparison of thresholds for triggering a negative response to the "Surprise Question": a study protocol. *BMC Palliat Care*, 18(1), 36. doi:10.1186/s12904-019-0413-x
282. *Wiesmann, N, Gieringer, R, Grus, F, & Brieger, J. (2019). Phosphoproteome Profiling Reveals Multifunctional Protein NPM1 as part of the Irradiation Response of Tumor Cells. *Transl Oncol*, 12(2), 308-319. doi:10.1016/j.tranon.2018.10.015
283. *Wiesmann, N, Klunker, M, Demuth, P, Brenner, W, Tremel, W, & Brieger, J. (2019). Zinc overload mediated by zinc oxide nanoparticles as innovative anti-tumor agent. *J Trace Elem Med Biol*, 51, 226-234. doi:10.1016/j.jtemb.2018.08.002
284. *Willershausen, I, Schmidtman, I, Azaripour, A, Kledtke, J, Willershausen, B, & Hasenburg, A. (2019). Association between breast cancer chemotherapy, oral health and chronic dental infections: a pilot study. *Odontology*, 107(3), 401-408. doi:10.1007/s10266-019-00411-z
285. Wunderle, M, Pretschner, J, Brucker, SY, Volz, B, Hartmann, A, Fiessler, C, Hein, A, Häberle, L, Jud, SM, Lux, MP, Janni, W, Loehberg, CR, Hartkopf, AD, Walter, CB, Baake, G, Fridman, A, Malter, W, Wuerstlein, R, Harbeck, N, Hoffmann, O, Kümmel, S, Martin, B, Thomssen, C, Graf, H, Wolf, C, Bayer, CM, Hack, CC, Almstedt, K, Gass, P, Heindl, F, Brodkorb, TF, Nabieva, N, Lindner, C, Kolberg, HC, Krabisch, P, Weigel, M, Steinfeld-Birg, D, Kohls, A, Brucker, C, Schulz, V, Fischer, G, Pelzer, V, Wallwiener, D, Rack, B, Fehm, T, Rody, A, Maass, N, Beckmann, MW, Fasching, PA, & Rauh, C. (2019). Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. *Breast Cancer Res Treat*, 174(2), 453-461. doi:10.1007/s10549-018-05115-6
286. *Yan, G, Saeed, MEM, Foersch, S, Schneider, J, Roth, W, & Efferth, T. (2019). Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome. *Oncotarget*, 10(20), 1918-1931. doi:10.18632/oncotarget.26727

287. Yordanova, A, Ahrens, H, Feldmann, G, Brossart, P, Gaertner, FC, Fottner, C, Weber, MM, Ahmadzadehfar, H, Schreckenberger, M, Miederer, M, & Essler, M. (2019). Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors. *Clin Nucl Med*, 44(5), e329-e335. doi:10.1097/rlu.0000000000002532
288. Zhu, AX, Kang, YK, Yen, CJ, Finn, RS, Galle, PR, Llovet, JM, Assenat, E, Brandi, G, Pracht, M, Lim, HY, Rau, KM, Motomura, K, Ohno, I, Merle, P, Daniele, B, Shin, DB, Gerken, G, Borg, C, Hiriart, JB, Okusaka, T, Morimoto, M, Hsu, Y, Abada, PB, & Kudo, M. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*, 20(2), 282-296. doi:10.1016/s1470-2045(18)30937-9
289. *Zimmer, N, Kim, E, Sprang, B, Leukel, P, Khafaji, F, Ringel, F, Sommer, C, Tuettenberg, J, & Tuettenberg, A. (2019). GARP as an Immune Regulatory Molecule in the Tumor Microenvironment of Glioblastoma Multiforme. *Int J Mol Sci*, 20(15). doi:10.3390/ijms20153676

Publikationen UCT Mainz 2020

* Erst- und/oder Letztautor UCT Mainz

1. Agnelli, G, Becattini, C, Meyer, G, Muñoz, A, Huisman, MV, Connors, JM, Cohen, A, Bauersachs, R, Brenner, B, Torbicki, A, Sueiro, MR, Lambert, C, Gussoni, G, Campanini, M, Fontanella, A, Vescovo, G, & Verso, M. (2020). Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. *N Engl J Med*, 382(17), 1599-1607. doi:10.1056/NEJMoa1915103
2. *Ahmed, S, Kreft, A, Chowdhury, EH, Hossain, SM, Galle, PR, & Neumann, H. (2020). Molecular endoscopic imaging for the detection of Barrett's metaplasia using biodegradable inorganic nanoparticles: An ex-vivo pilot study on human tissue. *PLoS One*, 15(10), e0239814. doi:10.1371/journal.pone.0239814
3. *Akababa, S, Bostel, T, Lang, K, Bahadir, S, Lipman, D, Schmidberger, H, Matthias, C, Rotter, N, Knopf, A, Freudlsperger, C, Plinkert, P, Debus, J, & Adeberg, S. (2020). Large German Multicenter Experience on the Treatment Outcome of 207 Patients With Adenoid Cystic Carcinoma of the Major Salivary Glands. *Front Oncol*, 10, 593379. doi:10.3389/fonc.2020.593379
4. *Alberg, I, Kramer, S, Schinnerer, M, Hu, Q, Seidl, C, Leps, C, Drude, N, Möckel, D, Rijcken, C, Lammers, T, Diken, M, Maskos, M, Morsbach, S, Landfester, K, Tenzer, S, Barz, M, & Zentel, R. (2020). Polymeric Nanoparticles with Neglectable Protein Corona. *Small*, 16(18), e1907574. doi:10.1002/sml.201907574
5. *Allmann, S, Mayer, L, Olma, J, Kaina, B, Hofmann, TG, Tomicic, MT, & Christmann, M. (2020). Benzo[a]pyrene represses DNA repair through altered E2F1/E2F4 function marking an early event in DNA damage-induced cellular senescence. *Nucleic Acids Res*, 48(21), 12085-12101. doi:10.1093/nar/gkaa965
6. *Almstedt, K, Mendoza, S, Otto, M, Battista, MJ, Steetskamp, J, Heimes, AS, Krajnak, S, Poplawski, A, Gerhold-Ay, A, Hasenburger, A, Denkert, C, & Schmidt, M. (2020). EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer. *Breast Cancer Res Treat*, 182(1), 137-146. doi:10.1007/s10549-020-05688-1
7. Alwers, E, Jansen, L, Blaker, H, Kloor, M, Tagscherer, KE, Roth, W, Boakye, D, Herpel, E, Grulich, C, Chang-Claude, J, Brenner, H, & Hoffmeister, M. (2020). Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study. *Mol Oncol*, 14(2), 363-372. doi:10.1002/1878-0261.12611
8. Amaral, T, Kiecker, F, Schaefer, S, Stege, H, Kaehler, K, Terheyden, P, Gesierich, A, Gutzmer, R, Haferkamp, S, Uttikal, J, Berking, C, Rafei-Shamsabadi, D, Reinhardt, L, Meier, F, Karoglan, A, Posch, C, Gambichler, T, Pfoehler, C, Thoms, K, Tietze, J, Debus, D, Herbst, R, Emmert, S, Loquai, C, Hassel, JC, Meiss, F, Tueting, T, Heinrich, V, Eigentler, T, Garbe, C, & Zimmer, L. (2020). Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. *J Immunother Cancer*, 8(1). doi:10.1136/jitc-2019-000333
9. Amitay, EL, Carr, PR, Jansen, L, Alwers, E, Roth, W, Herpel, E, Kloor, M, Bläker, H, Chang-Claude, J, Brenner, H, & Hoffmeister, M. (2020). Postmenopausal hormone replacement therapy and colorectal cancer risk by molecular subtypes and pathways. *Int J Cancer*, 147(4), 1018-1026. doi:10.1002/ijc.32868
10. Amitay, EL, Carr, PR, Jansen, L, Roth, W, Alwers, E, Herpel, E, Kloor, M, Bläker, H, Chang-Claude, J, Brenner, H, & Hoffmeister, M. (2020). Smoking, alcohol consumption and colorectal cancer risk by molecular pathological subtypes and pathways. *Br J Cancer*, 122(11), 1604-1610. doi:10.1038/s41416-020-0803-0
11. *Anspach, L, Tsaryk, R, Seidmann, L, Unger, RE, Jayasinghe, C, Simiantonaki, N, Kirkpatrick, CJ, & Pröls, F. (2020). Function and mutual interaction of BiP-, PERK-, and IRE1α-dependent signalling pathways in vascular tumours. *J Pathol*, 251(2), 123-134. doi:10.1002/path.5423
12. Anstee, QM, Darlay, R, Cockell, S, Meroni, M, Govaere, O, Tiniakos, D, Burt, AD, Bedossa, P, Palmer, J, Liu, YL, Aithal, GP, Allison, M, Yki-Järvinen, H, Vacca, M, Dufour, JF, Invernizzi, P, Prati, D, Ekstedt, M, Kechagias, S, Francque, S, Petta, S, Bugianesi, E, Clement, K, Ratzu, V, Schattenberg, JM, Valenti, L, Day, CP, Cordell, HJ, & Daly, AK. (2020). Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort(☆). *J Hepatol*, 73(3), 505-515. doi:10.1016/j.jhep.2020.04.003
13. Aripov, T, Blettner, M, & Gorbunova, I. (2020). The impact of neighborhood to industrial areas on health in Uzbekistan: an ecological analysis of congenital diseases, infant mortality, and lung cancer. *Environ Sci Pollut Res Int*, 27(14), 17243-17249. doi:10.1007/s11356-020-08190-9

14. Ascierto, PA, Dummer, R, Gogas, HJ, Flaherty, KT, Arance, A, Mandala, M, Liskay, G, Garbe, C, Schadendorf, D, Krajsova, I, Gutzmer, R, de Groot, JWB, Loquai, C, Gollerkeri, A, Pickard, MD, & Robert, C. (2020). Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. *Eur J Cancer*, 126, 33-44. doi:10.1016/j.ejca.2019.11.016
15. Augustijns, P, Vertzoni, M, Reppas, C, Langguth, P, Lennernäs, H, Abrahamsson, B, Hasler, WL, Baker, JR, Vanuytsel, T, Tack, J, Corsetti, M, Bermejo, M, Paixão, P, Amidon, GL, & Hens, B. (2020). Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. *Eur J Pharm Sci*, 155, 105517. doi:10.1016/j.ejps.2020.105517
16. *Babic, B, Tagkalos, E, Gockel, I, Corvinus, F, Hadzijušufovic, E, Hoppe-Lotichius, M, Lang, H, van der Sluis, PC, & Grimmering, PP. (2020). C-reactive Protein Levels After Esophagectomy Are Associated With Increased Surgical Trauma and Complications. *Ann Thorac Surg*, 109(5), 1574-1583. doi:10.1016/j.athoracsur.2019.12.016
17. Balakrishnan, A, Lesurtel, M, Siriwardena, AK, Heinrich, S, Serrablo, A, Besselink, MGH, Erkan, M, Andersson, B, Polak, WG, Laurenzi, A, Olde Damink, SWM, Berrevoet, F, Frigerio, I, Ramia, JM, Gallagher, TK, Warner, S, Shrikhande, SV, Adam, R, Smith, MD, & Conlon, KC. (2020). Delivery of hepato-pancreato-biliary surgery during the COVID-19 pandemic: an European-African Hepato-Pancreato-Biliary Association (E-AHPBA) cross-sectional survey. *HPB (Oxford)*. doi:10.1016/j.hpb.2020.05.012
18. Barski, D, Gerullis, H, Ecke, T, Boros, M, Brune, J, Beutner, U, Tsaor, I, Ramon, A, & Otto, T. (2020). Application of Dried Human Amnion Graft to Improve Post-Prostatectomy Incontinence and Potency: A Randomized Exploration Study Protocol. *Adv Ther*, 37(1), 592-602. doi:10.1007/s12325-019-01158-3
19. *Bartsch, F, Baumgart, J, Hoppe-Lotichius, M, Straub, BK, Heinrich, S, & Lang, H. (2020). Intrahepatic cholangiocarcinoma - influence of resection margin and tumor distance to the liver capsule on survival. *BMC Surg*, 20(1), 61. doi:10.1186/s12893-020-00718-7
20. *Bartsch, F, Hahn, F, Müller, L, Baumgart, J, Hoppe-Lotichius, M, Kloeckner, R, & Lang, H. (2020). Relevance of suspicious lymph nodes in preoperative imaging for resectability, recurrence and survival of intrahepatic cholangiocarcinoma. *BMC Surg*, 20(1), 75. doi:10.1186/s12893-020-00730-x
21. *Bauer, KN, Simon, J, Mailänder, V, Landfester, K, & Wurm, FR. (2020). Polyphosphoester surfactants as general stealth coatings for polymeric nanocarriers. *Acta Biomater*, 116, 318-328. doi:10.1016/j.actbio.2020.09.016
22. *Beck, O, Paret, C, Russo, A, Burhenne, J, Fresnais, M, Steimel, K, Seidmann, L, Wagner, DC, Vewinger, N, Lehmann, N, Sprang, M, Backes, N, Roth, L, Neu, MA, Wingerter, A, Henninger, N, Malki, KE, Otto, H, Alt, F, Desuki, A, Kindler, T, & Faber, J. (2020). Safety and Activity of the Combination of Ceritinib and Dasatinib in Osteosarcoma. *Cancers (Basel)*, 12(4). doi:10.3390/cancers12040793
23. *Becker, C, Graf, N, Grabow, D, Creutzig, U, Reinhardt, D, Weyer-Elberich, V, Spix, C, & Kaatsch, P. (2020). Early deaths from childhood cancer in Germany 1980-2016. *Cancer Epidemiol*, 65, 101669. doi:10.1016/j.canep.2020.101669
24. *Bednarczyk, M, Stege, H, Grabbe, S, & Bros, M. (2020). beta2 Integrins-Multi-Functional Leukocyte Receptors in Health and Disease. *Int J Mol Sci*, 21(4). doi:10.3390/ijms21041402
25. Beelen, DW, Trenchel, R, Stelljes, M, Groth, C, Masszi, T, Remenyi, P, Wagner-Drouet, EM, Hauptrock, B, Dreger, P, Luft, T, Bethge, W, Vogel, W, Ciceri, F, Peccatori, J, Stolzel, F, Schetelig, J, Junghanss, C, Grosse-Thie, C, Michallet, M, Labussiere-Wallet, H, Schaefer-Eckart, K, Dressler, S, Grigoleit, GU, Mielke, S, Scheid, C, Holtick, U, Patriarca, F, Medeot, M, Rambaldi, A, Mico, MC, Niederwieser, D, Franke, GN, Hilgendorf, I, Winkelmann, NR, Russo, D, Socie, G, Peffault de Latour, R, Holler, E, Wolff, D, Glass, B, Casper, J, Wulf, G, Menzel, H, Basara, N, Bieniaszewska, M, Stuhler, G, Verbeek, M, Grass, S, Iori, AP, Finke, J, Benedetti, F, Pichlmeier, U, Hemmelmann, C, Tribanek, M, Klein, A, Mylius, HA, Baumgart, J, Dzierzak-Mietla, M, & Markiewicz, M. (2020). Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial. *Lancet Haematol*, 7(1), e28-e39. doi:10.1016/s2352-3026(19)30157-7
26. Begum, N, Maasberg, S, Pascher, A, Plöckinger, U, Gress, TM, Wurst, C, Weber, F, Raffel, A, Krausch, M, Holzer, K, Bartsch, DK, Musholt, TJ, Keck, T, Anlauf, M, Rinke, A, Pape, UF, & Goretzki, PE. (2020). Long-term outcome of surgical resection in patients with gastroenteropancreatic neuroendocrine neoplasia: results from a German nation-wide multi-centric registry. *Langenbecks Arch Surg*, 405(2), 145-154. doi:10.1007/s00423-020-01868-1

27. Bekes, I, Eichler, M, Singer, S, Friedl, TWP, Harbeck, N, Rack, B, Forstbauer, H, Dannecker, C, Huober, J, Kiechle, M, Lato, K, Janni, W, & Fink, V. (2020). Impact of Granulocyte Colony-Stimulating Factor (G-CSF) and Epoetin (EPO) on Hematologic Toxicities and Quality of Life in Patients During Adjuvant Chemotherapy in Early Breast Cancer: Results From the Multi-Center Randomized ADEBAR Trial. *Clin Breast Cancer*, 20(6), 439-447. doi:10.1016/j.clbc.2020.03.008
28. *Beltz, A, Zimmer, S, Michaelides, I, Evert, K, Psychogios, G, Bohr, C, & Künzel, J. (2020). Significance of Extranodal Extension in Surgically Treated HPV-Positive Oropharyngeal Carcinomas. *Front Oncol*, 10, 1394. doi:10.3389/fonc.2020.01394
29. *Bergholz, LM, Grimminger, P, Dikeoulia, E, Rossmann, H, Weinmann, A, Möhler, M, Zimmermann, T, Weber, MM, Galle, PR, Kaina, B, & Zimmermann, A. (2020). Pilot Study on Malnutrition and DNA Damage in Patients with Newly Diagnosed Gastrointestinal Tumors: Is DNA Damage Reversible by Early Individualized Nutritional Support? *J Gastrointest Liver Dis*, 29(4), 569-577. doi:10.15403/jgld-2589
30. *Berlth, F, Mann, C, Uzun, E, Tagkalos, E, Hadzijušufovic, E, Hillegersberg, R, Li, H, Egberts, JH, Lang, H, & Grimminger, PP. (2020). Technical details of the abdominal part during full robotic-assisted minimally invasive esophagectomy. *Dis Esophagus*, 33(Supplement_2). doi:10.1093/dote/daa084
31. Best, J, Bechmann, LP, Sowa, JP, Sydor, S, Dechene, A, Pflanz, K, Bedreli, S, Schotten, C, Geier, A, Berg, T, Fischer, J, Vogel, A, Bantel, H, Weinmann, A, Schattenberg, JM, Huber, Y, Wege, H, von Felden, J, Schulze, K, Bettinger, D, Thimme, R, Sinner, F, Schutte, K, Weiss, KH, Toyoda, H, Yasuda, S, Kumada, T, Berhane, S, Wichert, M, Heider, D, Gerken, G, Johnson, P, & Canbay, A. (2020). GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. *Clin Gastroenterol Hepatol*, 18(3), 728-735.e724. doi:10.1016/j.cgh.2019.11.012
32. Bette, S, Gradtke, CV, Cammardella, JH, Albertshauser, J, Wiestler, B, Barz, M, Meyer, B, Zimmer, C, Ryang, YM, Ringel, F, & Gempt, J. (2020). Perioperative neurocognitive functions in patients with neuroepithelial intracranial tumors. *J Neurooncol*, 147(1), 77-89. doi:10.1007/s11060-020-03398-8
33. Bläker, H, Haupt, S, Morak, M, Holinski-Feder, E, Arnold, A, Horst, D, Sieber-Frank, J, Seidler, F, von Winterfeld, M, Alwers, E, Chang-Claude, J, Brenner, H, Roth, W, Engel, C, Löffler, M, Möslin, G, Schackert, HK, Weitz, J, Perne, C, Aretz, S, Hüneburg, R, Schmiegell, W, Vangala, D, Rahner, N, Steinke-Lange, V, Heuveline, V, von Knebel Doeberitz, M, Ahadova, A, Hoffmeister, M, & Kloor, M. (2020). Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics. *Int J Cancer*, 147(10), 2801-2810. doi:10.1002/ijc.33273
34. *Bockamp, E, Rosigkeit, S, Siegl, D, & Schuppan, D. (2020). Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. *Cells*, 9(9). doi:10.3390/cells9092102
35. *Böckers, M, Paul, NW, & Efferth, T. (2020a). Bisphenolic compounds alter gene expression in MCF-7 cells through interaction with estrogen receptor α . *Toxicol Appl Pharmacol*, 399, 115030. doi:10.1016/j.taap.2020.115030
36. *Böckers, M, Paul, NW, & Efferth, T. (2020b). Indeno[1,2,3-cd]pyrene and picene mediate actions via estrogen receptor α signaling pathway in in vitro cell systems, altering gene expression. *Toxicol Appl Pharmacol*, 396, 114995. doi:10.1016/j.taap.2020.114995
37. *Böckers, M, Paul, NW, & Efferth, T. (2020c). Organophosphate ester tri-o-cresyl phosphate interacts with estrogen receptor α in MCF-7 breast cancer cells promoting cancer growth. *Toxicol Appl Pharmacol*, 395, 114977. doi:10.1016/j.taap.2020.114977
38. *Bogucka, K, Pompaiah, M, Marini, F, Binder, H, Harms, G, Kaulich, M, Klein, M, Michel, C, Radsak, MP, Rosigkeit, S, Grimminger, P, Schild, H, & Rajalingam, K. (2020). ERK3/MAPK6 controls IL-8 production and chemotaxis. *Elife*, 9. doi:10.7554/eLife.52511
39. Böhmer, AC, Hecker, J, Schröder, J, Gharahkhani, P, May, A, Gerges, C, Anders, M, Becker, J, Hess, T, Kreuser, N, Thieme, R, Noder, T, Venerito, M, Veits, L, Schmidt, T, Fuchs, C, Izbicki, JR, Hölscher, AH, Dietrich, A, Moulla, Y, Lyros, O, Lang, H, Lorenz, D, Schumacher, B, Mayershofer, R, Vashist, Y, Ott, K, Vieth, M, Weismüller, J, Moebus, S, Knapp, M, Neuhaus, H, Rösch, T, Ell, C, Nöthen, MM, Whiteman, DC, Tomlinson, I, Jankowski, J, Fitzgerald, RC, Palles, C, Vaughan, TL, Gockel, I, Thrift, AP, Fier, H, & Schumacher, J. (2020). Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. *Cancer Epidemiol Biomarkers Prev*, 29(2), 427-433. doi:10.1158/1055-9965.Epi-19-0374

40. Bong, SM, Bae, SH, Song, B, Gwak, H, Yang, SW, Kim, S, Nam, S, Rajalingam, K, Oh, SJ, Kim, TW, Park, S, Jang, H, & Lee, BI. (2020). Regulation of mRNA export through API5 and nuclear FGF2 interaction. *Nucleic Acids Res*, 48(11), 6340-6352. doi:10.1093/nar/gkaa335
41. Bonomo, P, Maruelli, A, Saieva, C, Taylor, K, Singer, S, Patelli, Z, Rogers, S, Mattavelli, D, Simon, C, Scotté, F, de Oliveira, TB, Murphy, B, Rhoten, BA, Tassini, U, Fallon, M, Gatidis, ON, Yarom, N, Bergamini, C, & Bossi, P. (2020). Assessing Preferences in Patients with Head and Neck Squamous Cell Carcinoma: Phase I and II of Questionnaire Development. *Cancers (Basel)*, 12(12). doi:10.3390/cancers12123577
42. *Bostel, T, Dreher, C, Wollschläger, D, Mayer, A, König, F, Bickelhaupt, S, Schlemmer, HP, Huber, PE, Sterzing, F, Bäumer, P, Debus, J, & Nicolay, NH. (2020). Exploring MR regression patterns in rectal cancer during neoadjuvant radiochemotherapy with daily T2- and diffusion-weighted MRI. *Radiat Oncol*, 15(1), 171. doi:10.1186/s13014-020-01613-4
43. *Bostel, T, Mattke, M, Nicolay, NH, Welzel, T, Wollschläger, D, Akbaba, S, Mayer, A, Sprave, T, Debus, J, & Uhl, M. (2020). High-dose carbon-ion based radiotherapy of primary and recurrent sacrococcygeal chordomas: long-term clinical results of a single particle therapy center. *Radiat Oncol*, 15(1), 206. doi:10.1186/s13014-020-01647-8
44. *Bostel, T, Rühle, A, Rackwitz, T, Mayer, A, Klodt, T, Oebel, L, Förster, R, Schlampp, I, Wollschläger, D, Rief, H, Sprave, T, Debus, J, Grosu, AL, Schmidberger, H, Akbaba, S, & Nicolay, NH. (2020). The Role of Palliative Radiotherapy in the Treatment of Spinal Bone Metastases from Head and Neck Tumors-A Multicenter Analysis of a Rare Event. *Cancers (Basel)*, 12(7). doi:10.3390/cancers12071950
45. Bouwman, BAM, Agostini, F, Garnerone, S, Petrosino, G, Gothe, HJ, Sayols, S, Moor, AE, Itzkovitz, S, Bienko, M, Roukos, V, & Crosetto, N. (2020). Genome-wide detection of DNA double-strand breaks by in-suspension BLISS. *Nat Protoc*, 15(12), 3894-3941. doi:10.1038/s41596-020-0397-2
46. Brackmann, LK, Poplawski, A, Grandt, CL, Schwarz, H, Hankeln, T, Rapp, S, Zahnreich, S, Galetzka, D, Schmitt, I, Grad, C, Eckhard, L, Mirsch, J, Blettner, M, Scholz-Kreisel, P, Hess, M, Binder, H, Schmidberger, H, & Marron, M. (2020). Comparison of time and dose dependent gene expression and affected pathways in primary human fibroblasts after exposure to ionizing radiation. *Mol Med*, 26(1), 85. doi:10.1186/s10020-020-00203-0
47. Brehaut, E, Neupane, D, Levis, B, Wu, Y, Sun, Y, Krishnan, A, He, C, Bhandari, PM, Negeri, Z, Riehm, KE, Rice, DB, Azar, M, Yan, XW, Imran, M, Chiovitti, MJ, Saadat, N, Cuijpers, P, Ioannidis, JPA, Markham, S, Patten, SB, Ziegelstein, RC, Henry, M, Ismail, Z, Loiselle, CG, Mitchell, ND, Tonelli, M, Boruff, JT, Kloda, LA, Beraldi, A, Braeken, A, Carter, G, Clover, K, Conroy, RM, Cukor, D, da Rocha, ESCE, De Souza, J, Downing, MG, Feinstein, A, Ferentinos, PP, Fischer, FH, Flint, AJ, Fujimori, M, Gallagher, P, Goebel, S, Jetté, N, Julião, M, Keller, M, Kjærgaard, M, Love, AW, Löwe, B, Martin-Santos, R, Michopoulos, I, Navines, R, O'Rourke, SJ, Öztürk, A, Pintor, L, Ponsford, JL, Rooney, AG, Sánchez-González, R, Schwarzbald, ML, Sharpe, M, Simard, S, Singer, S, Stone, J, Tung, KY, Turner, A, Walker, J, Walterfang, M, White, J, Benedetti, A, & Thoms, BD. (2020). Depression prevalence using the HADS-D compared to SCID major depression classification: An individual participant data meta-analysis. *J Psychosom Res*, 139, 110256. doi:10.1016/j.jpsychores.2020.110256
48. Breidenbach, C, Roth, R, Ansmann, L, Wesselmann, S, Dieng, S, Carl, EG, Feick, G, Oesterle, A, Bach, P, Beyer, B, Borowitz, R, Erdmann, J, Kunath, F, Oostdam, SJ, Tsaur, I, Zengerling, F, & Kowalski, C. (2020). Use of psycho-oncological services by prostate cancer patients: A multilevel analysis. *Cancer Med*, 9(11), 3680-3690. doi:10.1002/cam4.2999
49. Briggs, A, Daniele, B, Dick, K, Evans, TRJ, Galle, PR, Hubner, RA, Lopez, C, Siebert, U, & Tremblay, G. (2020). Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. *Br J Cancer*, 122(12), 1754-1759. doi:10.1038/s41416-020-0817-7
50. Buechner, P, Hinderer, M, Unberath, P, Metzger, P, Boeker, M, Acker, T, Haller, F, Mack, E, Nowak, D, Paret, C, Schanze, D, von Bubnoff, N, Wagner, S, Busch, H, Boerries, M, & Christoph, J. (2020). Requirements Analysis and Specification for a Molecular Tumor Board Platform Based on cBioPortal. *Diagnostics (Basel)*, 10(2). doi:10.3390/diagnostics10020093
51. Burchert, A, Bug, G, Fritz, LV, Finke, J, Stelljes, M, Röllig, C, Wollmer, E, Wäsch, R, Bornhäuser, M, Berg, T, Lang, F, Ehninger, G, Serve, H, Zeiser, R, Wagner, EM, Kröger, N, Wolschke, C, Schleuning, M, Götze, KS, Schmid, C, Crysandt, M, Eßeling, E, Wolf, D, Wang, Y, Böhm, A, Thiede, C, Haferlach, T, Michel, C, Bethge, W, Wündisch, T, Brandts, C, Harnisch, S, Wittenberg, M, Hoeffkes, HG, Rospleszcz, S, Burchardt, A, Neubauer, A, Brugger, M, Strauch, K, Schade-Brittinger, C, & Metzelder, SK. (2020). Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN). *J Clin Oncol*, 38(26), 2993-3002. doi:10.1200/jco.19.03345

52. Burgdorf, S, Porubsky, S, Marx, A, & Popovic, ZV. (2020). Cancer Acidity and Hypertonicity Contribute to Dysfunction of Tumor-Associated Dendritic Cells: Potential Impact on Antigen Cross-Presentation Machinery. *Cancers (Basel)*, 12(9). doi:10.3390/cancers12092403
53. *Büttner, M, Hinz, A, Singer, S, & Musholt, TJ. (2020). Quality of life of patients more than 1 year after surgery for thyroid cancer. *Hormones (Athens)*, 19(2), 233-243. doi:10.1007/s42000-020-00186-x
54. *Büttner, M, Locati, LD, Pinto, M, Araújo, C, Tomaszewska, IM, Kiyota, N, Vidhubala, E, Brannan, C, Hammerlid, E, Husson, O, Salem, D, Ioannidis, G, Gamper, E, Arraras, JI, Andry, G, Inhestern, J, Theurer, J, Taylor, K, & Singer, S. (2020). Quality of Life in Patients With Hypoparathyroidism After Treatment for Thyroid Cancer. *J Clin Endocrinol Metab*, 105(12). doi:10.1210/clinem/dgaa597
55. Buzdin, A, Sorokin, M, Garazha, A, Glusker, A, Aleshin, A, Poddubskaya, E, Sekacheva, M, Kim, E, Gaifullin, N, Giese, A, Seryakov, A, Rumiantsev, P, Moshkovskii, S, & Moiseev, A. (2020). RNA sequencing for research and diagnostics in clinical oncology. *Semin Cancer Biol*, 60, 311-323. doi:10.1016/j.semcancer.2019.07.010
56. *Cacicedo, ML, Medina-Montano, C, Kaps, L, Kappel, C, Gehring, S, & Bros, M. (2020). Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. *Cells*, 9(9). doi:10.3390/cells9091985
57. Calaminus, G, Schneider, DT, von Schweinitz, D, Jurgens, H, Infed, N, Schonberger, S, Olson, TA, Albers, P, Vokuhl, C, Stein, R, Looijenga, L, Sehouli, J, Metzelder, M, Claviez, A, Dworzak, M, Eggert, A, Frohlich, B, Gerber, NU, Kratz, CP, Faber, J, Klingebiel, T, Harms, D, & Gobel, U. (2020). Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. *Cancers (Basel)*, 12(3). doi:10.3390/cancers12030611
58. Canzler, U, Lück, HJ, Neuser, P, Sehouli, J, Burges, A, Harter, P, Schmalfeldt, B, Aminossadati, B, Mahner, S, Kommoss, S, Wimberger, P, Pfisterer, J, de Gregorio, N, Hasenburg, A, Gropp-Meier, M, El-Balat, A, Jackisch, C, du Bois, A, Meier, W, & Wagner, U. (2020). Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. *Arch Gynecol Obstet*, 301(5), 1267-1274. doi:10.1007/s00404-020-05529-y
59. Carr, PR, Amitay, EL, Jansen, L, Alwers, E, Roth, W, Herpel, E, Kloor, M, Schneider, M, Blaker, H, Chang-Claude, J, Brenner, H, & Hoffmeister, M. (2020). Association of BMI and major molecular pathological markers of colorectal cancer in men and women. *Am J Clin Nutr*, 111(3), 562-569. doi:10.1093/ajcn/nqz315
60. Charalampaki, P, Proskynitopoulos, PJ, Heimann, A, & Nakamura, M. (2020). 5-Aminolevulinic Acid Multispectral Imaging for the Fluorescence-Guided Resection of Brain Tumors: A Prospective Observational Study. *Front Oncol*, 10, 1069. doi:10.3389/fonc.2020.01069
61. Chibaudel, B, Henriques, J, Rakez, M, Brenner, B, Kim, TW, Martinez-Villacampa, M, Gallego-Plazas, J, Cervantes, A, Shim, K, Jonker, D, Guerin-Meyer, V, Mineur, L, Banzi, C, Dewdney, A, Dejthevaporn, T, Bloemendal, HJ, Roth, A, Moehler, M, Aranda, E, Van Cutsem, E, Tabernero, J, Schmoll, HJ, Hoff, PM, André, T, & de Gramont, A. (2020). Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial. *JAMA Netw Open*, 3(10), e2020425. doi:10.1001/jamanetworkopen.2020.20425
62. Chiu, PW, de Groot, EM, Yip, HC, Egberts, JH, Grimminger, P, Seto, Y, Uyama, I, van der Sluis, PC, Stein, H, Sallum, R, Ruurda, JP, & van Hillegersberg, R. (2020). Robot-assisted cervical esophagectomy: first clinical experiences and review of the literature. *Dis Esophagus*, 33(Supplement_2). doi:10.1093/dote/daaa052
63. Clemens, E, Broer, L, Langer, T, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Pluijm, SFM, Binder, H, Byrne, J, Broeder, EVD, Crocco, M, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Winther, JF, Rechnitzer, C, Hasle, H, Kepak, T, van der Kooi, AF, Kremer, LC, Kruseova, J, Kuehni, CE, van der Pal, H, Parfitt, R, Deuster, D, Matulat, P, Spix, C, Tillmanns, A, Tissing, WJE, Maier, L, Am Zehnhoff-Dinnesen, A, Zolk, O, & van den Heuvel-Eibrink, MM. (2020). Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. *Pharmacogenomics J*, 20(2), 294-305. doi:10.1038/s41397-019-0113-1
64. Cöktü, S, Spix, C, Kaiser, M, Beygo, J, Kleinle, S, Bachmann, N, Kohlschmidt, N, Prawitt, D, Beckmann, A, Klaes, R, Nevinny-Stickel-Hinzpeter, C, Döhnert, S, Kraus, C, Kadgien, G, Vater, I, Biskup, S, Kutsche, M, Kohlhasse, J, Eggermann, T, Zenker, M, & Kratz, CP. (2020). Cancer incidence and spectrum among children with genetically confirmed Beckwith-Wiedemann spectrum in Germany: a retrospective cohort study. *Br J Cancer*, 123(4), 619-623. doi:10.1038/s41416-020-0911-x

65. Crawford, LJ, Campbell, DC, Morgan, JJ, Lawson, MA, Down, JM, Chauhan, D, McAvera, RM, Morris, TC, Hamilton, C, Krishnan, A, Rajalingam, K, Chantry, AD, & Irvine, AE. (2020). The E3 ligase HUWE1 inhibition as a therapeutic strategy to target MYC in multiple myeloma. *Oncogene*, 39(27), 5001-5014. doi:10.1038/s41388-020-1345-x
66. *Czuderna, C, Stockinger, M, Ebersberger, A, Schmidberger, H, Muller, L, Kloeckner, R, Duber, C, Weinmann, A, Galle, PR, & Marquardt, JU. (2020). [Monocentric experiences of stereotactic body radiation therapy (SBRT) for advanced hepatocellular carcinomas (BCLC-C)]. *Z Gastroenterol*, 58(1), 39-47. doi:10.1055/a-1072-6683
67. Damasceno, LEA, Prado, DS, Veras, FP, Fonseca, MM, Toller-Kawahisa, JE, Rosa, MH, Públio, GA, Martins, TV, Ramalho, FS, Waisman, A, Cunha, FQ, Cunha, TM, & Alves-Filho, JC. (2020). PKM2 promotes Th17 cell differentiation and autoimmune inflammation by fine-tuning STAT3 activation. *J Exp Med*, 217(10). doi:10.1084/jem.20190613
68. *Danuta, G, Tobias, M, Marcus, D, Miriam, E, Nergiz, K, Olesja, S, Steffen, R, Tanja, Z, Christian, M, Thomas, H, Peter, SK, Heather, C, Johanna, M, Alicia, P, Heidi, R, Claudia, S, Thomas, H, Dirk, P, Manuela, M, & Heinz, S. (2020). Molecular karyotyping and gene expression analysis in childhood cancer patients. *J Mol Med (Berl)*, 98(8), 1107-1123. doi:10.1007/s00109-020-01937-4
69. de Groot, EM, Möller, T, Kingma, BF, Grimminger, PP, Becker, T, van Hillegersberg, R, Egberts, JH, & Ruurda, JP. (2020). Technical details of the hand-sewn and circular-stapled anastomosis in robot-assisted minimally invasive esophagectomy. *Dis Esophagus*, 33(Supplement_2). doi:10.1093/dote/daaa055
70. den Hollander, D, Fiore, M, Martin-Broto, J, Kasper, B, Casado Herraiz, A, Kulis, D, Nixon, I, Sodergren, SC, Eichler, M, van Houdt, WJ, Desar, IME, Ray-Coquard, I, Piccinin, C, Kosela-Paterczyk, H, Miah, A, Hentschel, L, Singer, S, Wilson, R, van der Graaf, WTA, & Husson, O. (2020). Incorporating the Patient Voice in Sarcoma Research: How Can We Assess Health-Related Quality of Life in This Heterogeneous Group of Patients? A Study Protocol. *Cancers (Basel)*, 13(1). doi:10.3390/cancers13010001
71. den Hollander, D, Van der Graaf, WTA, Fiore, M, Kasper, B, Singer, S, Desar, IME, & Husson, O. (2020). Unravelling the heterogeneity of soft tissue and bone sarcoma patients' health-related quality of life: a systematic literature review with focus on tumour location. *ESMO Open*, 5(5). doi:10.1136/esmoopen-2020-000914
72. Desch, AK, Hartung, K, Botzen, A, Brobeil, A, Rummel, M, Kurch, L, Georgi, T, Jox, T, Bielack, S, Burdach, S, Classen, CF, Claviez, A, Debatin, KM, Ebinger, M, Eggert, A, Faber, J, Flotho, C, Fruhwald, M, Graf, N, Jorch, N, Kontny, U, Kramm, C, Kulozik, A, Kuhr, J, Sykora, KW, Metzler, M, Muller, HL, Nathrath, M, Nusslein, T, Paulussen, M, Pekrun, A, Reinhardt, D, Reinhard, H, Rossig, C, Sauerbrey, A, Schlegel, PG, Schneider, DT, Scheurlen, W, Schweigerer, L, Simon, T, Suttrop, M, Vorwerk, P, Schmitz, R, Kluge, R, Mauz-Korholz, C, Korholz, D, Gattenlohner, S, & Brauninger, A. (2020). Genotyping circulating tumor DNA of pediatric Hodgkin lymphoma. *Leukemia*, 34(1), 151-166. doi:10.1038/s41375-019-0541-6
73. *Deuss, E, Gößwein, D, Gül, D, Zimmer, S, Foersch, S, Eger, CS, Limburg, I, Stauber, RH, & Künzel, J. (2020). Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer: Her1-4 and c-Met in Conjunction with the Clinical Features and Human Papillomavirus (p16) Status. *Cancers (Basel)*, 12(11). doi:10.3390/cancers12113358
74. Díaz-González, Á, Sanduzzi-Zamparelli, M, da Fonseca, LG, Di Costanzo, GG, Alves, R, Iavarone, M, Leal, C, Sacco, R, Matilla, AM, Hernández-Guerra, M, Aballay Soteras, G, Wörns, MA, Pinter, M, Varela, M, Ladekarl, M, Chagas, AL, Minguez, B, Arenas, JI, Granito, A, Sánchez-Torrijos, Y, Rojas, Á, Rodríguez de Lope, C, Alvares-da-Silva, MR, Pascual, S, Rimassa, L, Lledó, JL, Huertas, C, Sangro, B, Giannini, EG, Delgado, M, Vergara, M, Perelló, C, Lue, A, Sala, M, Gallego, A, Coll, S, Hernáez, T, Piñero, F, Pereira, G, França, A, Marín, J, Anders, M, Mello, V, Lozano, M, Nault, JC, Menéndez, J, García Juárez, I, Bruix, J, & Reig, M. (2020). International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. *Liver Int*, 40(6), 1467-1476. doi:10.1111/liv.14436
75. Dietzsch, S, Placzek, F, Pietschmann, K, von Bueren, AO, Matuschek, C, Glück, A, Guckenberger, M, Budach, V, Welzel, J, Pöttgen, C, Schmidberger, H, Heinzlmann, F, Paulsen, F, Escudero, MP, Schwarz, R, Hornung, D, Martini, C, Grosu, AL, Stueben, G, Jablonska, K, Dunst, J, Stranzl-Lawatsch, H, Dieckmann, K, Timmermann, B, Pietsch, T, Warmuth-Metz, M, Bison, B, Kwiecien, R, Benesch, M, Gerber, NU, Grotzer, MA, Pfister, SM, Clifford, SC, von Hoff, K, Klagges, S, Rutkowski, S, Kortmann, RD, & Mynarek, M. (2020). Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma - A Report From the HIT 2000 Trial. *Adv Radiat Oncol*, 5(6), 1158-1169. doi:10.1016/j.adro.2020.09.018
76. Dirven, L, Luerding, R, Beier, D, Bumès, E, Reinert, C, Seidel, C, Bonsanto, MM, Bremer, M, Rieken, S, Combs, SE, Herrlinger, U, Seliger, C, Kuntze, H, Mayer-Steinacker, R, Dieing, A, Bartels, C, Schnell, O, Weyerbrock, A, Seidel, S, Grauer, O, Nadji-Ohl, M, Paulsen, F, Weller, M, Wick, W, & Hau, P. (2020). Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study. *J Neurooncol*, 148(1), 117-130. doi:10.1007/s11060-020-03502-y

77. Ditsch, N, Untch, M, Kolberg-Liedtke, C, Jackisch, C, Krug, D, Friedrich, M, Janni, W, Müller, V, Albert, US, Banys-Paluchowski, M, Bauerfeind, I, Blohmer, JU, Budach, W, Dall, P, Diel, I, Fallenberg, EM, Fasching, PA, Fehm, T, Gerber, B, Gluz, O, Hanf, V, Harbeck, N, Heil, J, Huober, J, Kreipe, HH, Kühn, T, Kümmel, S, Loibl, S, Lüftner, D, Lux, M, Maass, N, Moebus, V, Mundhenke, C, Park-Simon, TW, Reimer, T, Rhiem, K, Rody, A, Schmidt, M, Schneeweiss, A, Solbach, C, Solomayer, EF, Stickeler, E, Thomssen, C, Witzel, I, Wöckel, A, & Thill, M. (2020). AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020. *Breast Care (Basel)*, 15(3), 294-309. doi:10.1159/000508736
78. *Dorweiler, B, El Beyrouti, H, Vahl, CF, Baqué, PE, & Ghazy, A. (2020). [The Future of Vascular Medicine - Role of 3D Printing]. *Zentralbl Chir*, 145(5), 448-455. doi:10.1055/a-1025-2066
79. Dreger, S, Wollschläger, D, Schafft, T, Hammer, GP, Blettner, M, & Zeeb, H. (2020). Cohort study of occupational cosmic radiation dose and cancer mortality in German aircrew, 1960-2014. *Occup Environ Med*, 77(5), 285-291. doi:10.1136/oemed-2019-106165
80. *Drenth, JPH, & Schattenberg, JM. (2020). The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success. *Expert Opin Investig Drugs*, 29(12), 1365-1375. doi:10.1080/13543784.2020.1839888
81. *Dzama, MM, Steiner, M, Rausch, J, Sasca, D, Schönfeld, J, Kunz, K, Taubert, MC, McGeehan, GM, Chen, CW, Mupo, A, Hähnel, P, Theobald, M, Kindler, T, Koche, RP, Vassiliou, GS, Armstrong, SA, & Kühn, MWM. (2020). Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. *Blood*, 136(21), 2442-2456. doi:10.1182/blood.2020005037
82. *Dzulko, M, Pons, M, Henke, A, Schneider, G, & Krämer, OH. (2020). The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation. *Biochim Biophys Acta Rev Cancer*, 1874(2), 188453. doi:10.1016/j.bbcan.2020.188453
83. *Eckrich, J, Kugler, P, Buhr, CR, Ernst, BP, Mendler, S, Baumgart, J, Brieger, J, & Wiesmann, N. (2020). Monitoring of tumor growth and vascularization with repetitive ultrasonography in the chicken chorioallantoic-membrane-assay. *Sci Rep*, 10(1), 18585. doi:10.1038/s41598-020-75660-y
84. *Efentakis, P, Doerschmann, H, Witzler, C, Siemer, S, Nikolaou, PE, Kastritis, E, Stauber, R, Dimopoulos, MA, Wenzel, P, Andreadou, I, & Terpos, E. (2020). Investigating the Vascular Toxicity Outcomes of the Irreversible Proteasome Inhibitor Carfilzomib. *Int J Mol Sci*, 21(15). doi:10.3390/ijms21155185
85. Eichler, M, Hentschel, L, Richter, S, Hohenberger, P, Kasper, B, Andreou, D, Pink, D, Jakob, J, Singer, S, Grützmann, R, Fung, S, Wardelmann, E, Arndt, K, Heidt, V, Hofbauer, C, Fried, M, Gaidzik, VI, Verpoort, K, Ahrens, M, Weitz, J, Schaser, KD, Bornhäuser, M, Schmitt, J, Schuler, MK, & The, PSG. (2020). The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany-Cross-Sectional Results of a Nationwide Observational Study (PROSa). *Cancers (Basel)*, 12(12). doi:10.3390/cancers12123590
86. Erb, HHH, Bodenbender, J, Handle, F, Diehl, T, Donix, L, Tsaar, I, Gleave, M, Haferkamp, A, Huber, J, Fuessel, S, Juengel, E, Culig, Z, & Thomas, C. (2020). Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer. *PLoS One*, 15(8), e0237248. doi:10.1371/journal.pone.0237248
87. *Erb, HHH, Sparwasser, P, Diehl, T, Hemmerlein-Thomas, M, Tsaar, I, Jungel, E, Sommer, U, Baretton, GB, Haferkamp, A, Neisius, A, & Thomas, C. (2020). AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC. *Urol Int*, 1-10. doi:10.1159/000504416
88. Erb, U, Hikel, J, Meyer, S, Ishikawa, H, Worst, TS, Nitschke, K, Nuhn, P, Porubsky, S, Weiss, C, Schroten, H, Adam, R, & Karremann, M. (2020). The Impact of Small Extracellular Vesicles on Lymphoblast Trafficking across the Blood-Cerebrospinal Fluid Barrier In Vitro. *Int J Mol Sci*, 21(15). doi:10.3390/ijms21155491
89. *Erdmann, F, Hvidtfeldt, UA, Sørensen, M, & Raaschou-Nielsen, O. (2020). Socioeconomic differences in the risk of childhood central nervous system tumors in Denmark: a nationwide register-based case-control study. *Cancer Causes Control*, 31(10), 915-929. doi:10.1007/s10552-020-01332-x
90. *Ernst, BP, Strieth, S, Katzer, F, Hodeib, M, Eckrich, J, Bahr, K, Rader, T, Kunzel, J, Froelich, MF, Matthias, C, Sommer, WH, & Becker, S. (2020). The use of structured reporting of head and neck ultrasound ensures time-efficiency and report quality during residency. *Eur Arch Otorhinolaryngol*, 277(1), 269-276. doi:10.1007/s00405-019-05679-z

91. *Ernst, BP, Wiesmann, N, Gieringer, R, Eckrich, J, & Brieger, J. (2020). HSP27 regulates viability and migration of cancer cell lines following irradiation. *J Proteomics*, 226, 103886. doi:10.1016/j.jprot.2020.103886
92. *Ernst, M, Brähler, E, Klein, EM, Jünger, C, Wild, PS, Faber, J, Schneider, A, & Beutel, ME. (2020). What's past is prologue: Recalled parenting styles are associated with childhood cancer survivors' mental health outcomes more than 25 years after diagnosis. *Soc Sci Med*, 252, 112916. doi:10.1016/j.socscimed.2020.112916
93. *Ernst, M, Brahler, E, Wild, PS, Faber, J, Merzenich, H, & Beutel, ME. (2020). The desire for children among adult survivors of childhood cancer: Psychometric evaluation of a cancer-specific questionnaire and relations with sociodemographic and psychological characteristics. *Psychooncology*, 29(3), 485-492. doi:10.1002/pon.5285
94. *Ernst, M, Brahler, E, Wild, PS, Junger, C, Faber, J, Schneider, A, & Beutel, ME. (2020). Risk factors for suicidal ideation in a large, registry-based sample of adult long-term childhood cancer survivors. *J Affect Disord*, 265, 351-356. doi:10.1016/j.jad.2020.01.080
95. Faehling, M, Schumann, C, Christopoulos, P, Hoffknecht, P, Alt, J, Horn, M, Eisenmann, S, Schlenska-Lange, A, Schütt, P, Steger, F, Brückl, WM, & Christoph, DC. (2020a). Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP. *Data Brief*, 34, 106556. doi:10.1016/j.dib.2020.106556
96. Faehling, M, Schumann, C, Christopoulos, P, Hoffknecht, P, Alt, J, Horn, M, Eisenmann, S, Schlenska-Lange, A, Schütt, P, Steger, F, Brückl, WM, & Christoph, DC. (2020b). Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). *Lung Cancer*, 150, 114-122. doi:10.1016/j.lungcan.2020.10.006
97. Finke, J, Hitschler, L, Boller, K, Florin, L, & Lang, T. (2020). HPV caught in the tetraspanin web? *Med Microbiol Immunol*, 209(4), 447-459. doi:10.1007/s00430-020-00683-1
98. Finke, J, Mikuličić, S, Loster, AL, Gawlitza, A, Florin, L, & Lang, T. (2020). Anatomy of a viral entry platform differentially functionalized by integrins $\alpha 3$ and $\alpha 6$. *Sci Rep*, 10(1), 5356. doi:10.1038/s41598-020-62202-9
99. Finn, RS, Boer, K, Bondarenko, I, Patel, R, Pinter, T, Schmidt, M, Shparyk, YV, Thummala, A, Voitko, N, Bananis, E, McRoy, L, Wilner, K, Huang, X, Kim, S, Slamon, DJ, & Ettl, J. (2020). Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1, TRIO-18). *Breast Cancer Res Treat*, 183(2), 419-428. doi:10.1007/s10549-020-05755-7
100. Finn, RS, Qin, S, Ikeda, M, Galle, PR, Ducreux, M, Kim, TY, Kudo, M, Breder, V, Merle, P, Kaseb, AO, Li, D, Verret, W, Xu, DZ, Hernandez, S, Liu, J, Huang, C, Mulla, S, Wang, Y, Lim, HY, Zhu, AX, & Cheng, AL. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. *N Engl J Med*, 382(20), 1894-1905. doi:10.1056/NEJMoa1915745
101. Firl, DJ, Sasaki, K, Agopian, VG, Gorgen, A, Kimura, S, Dumronggittigule, W, McVey, JC, Iesari, S, Mennini, G, Vitale, A, Finkenstedt, A, Onali, S, Hoppe-Lotichius, M, Vennarecci, G, Manzia, TM, Nicolini, D, Avolio, AW, Agnes, S, Vivarelli, M, Tisone, G, Ettorre, GM, Otto, G, Tsochatzis, E, Rossi, M, Viveiros, A, Cillo, U, Markmann, JF, Ikegami, T, Kaido, T, Lai, Q, Sapisochin, G, Lerut, J, & Aucejo, FN. (2020). Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients. *Hepatology*, 71(2), 569-582. doi:10.1002/hep.30838
102. Frank, AM, Braun, AH, Scheib, L, Agarwal, S, Schneider, IC, Fusil, F, Perian, S, Sahin, U, Thalheimer, FB, Verhoeven, E, & Buchholz, CJ. (2020). Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors. *Blood Adv*, 4(22), 5702-5715. doi:10.1182/bloodadvances.2020002229
103. *Frappart, PO, & Hofmann, TG. (2020). Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine. *Cancers (Basel)*, 12(10). doi:10.3390/cancers12102750
104. Friedrich, A, Assmann, AS, Schumacher, L, Stuijvenberg, JV, Kassack, MU, Schulz, WA, Roos, WP, Hansen, FK, Pflieger, M, Kurz, T, & Fritz, G. (2020). In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi). *Int J Mol Sci*, 21(13). doi:10.3390/ijms21134747
105. *Fuchs, N, Meta, M, Schuppan, D, Nuhn, L, & Schirmeister, T. (2020). Novel Opportunities for Cathepsin S Inhibitors in Cancer Immunotherapy by Nanocarrier-Mediated Delivery. *Cells*, 9(9). doi:10.3390/cells9092021

106. Funk, K, Czauderna, C, Klesse, R, Becker, D, Hajduk, J, Oelgeklaus, A, Reichenbach, F, Fimm-Todt, F, Lauterwasser, J, Galle, PR, Marquardt, JU, & Edlich, F. (2020). BAX Redistribution Induces Apoptosis Resistance and Selective Stress Sensitivity in Human HCC. *Cancers (Basel)*, 12(6). doi:10.3390/cancers12061437
107. *Gaida, MM. (2020). [The ambiguous role of the inflammatory micromilieu in solid tumors]. *Pathologie*, 41(Suppl 2), 118-123. doi:10.1007/s00292-020-00837-1
108. *Galetzka, D, Müller, T, Dittrich, M, Endres, M, Kartal, N, Sinizyn, O, Rapp, S, Zeller, T, Müller, C, Hankeln, T, Scholz-Kreisel, P, Chorzempa, H, Mirsch, J, Poplawski, A, Rossmann, H, Spix, C, Haaf, T, Prawitt, D, Marron, M, & Schmidberger, H. (2020). Molecular karyotyping and gene expression analysis in childhood cancer patients. *J Mol Med (Berl)*. doi:10.1007/s00109-020-01937-4
109. Gandaglia, G, Martini, A, Ploussard, G, Fossati, N, Stabile, A, De Visschere, P, Borgmann, H, Heidegger, I, Steinkohl, F, Kretschmer, A, Marra, G, Mathieu, R, Surcel, C, Tilki, D, Tsaur, I, Valerio, M, Van den Bergh, R, Ost, P, Gontero, P, Montorsi, F, & Briganti, A. (2020). External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. *Eur Urol*, 78(2), 138-142. doi:10.1016/j.eururo.2020.03.023
110. Gaonkar, KS, Marini, F, Rath, KS, Jain, P, Zhu, Y, Chimicles, NA, Brown, MA, Naqvi, AS, Zhang, B, Storm, PB, Maris, JM, Raman, P, Resnick, AC, Strauch, K, Taroni, JN, & Rokita, JL. (2020). annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions. *BMC Bioinformatics*, 21(1), 577. doi:10.1186/s12859-020-03922-7
111. Gebauer, J, Baust, K, Bardi, E, Grabow, D, Stein, A, van der Pal, HJ, Calaminus, G, & Langer, T. (2020). Guidelines for Long-Term Follow-Up after Childhood Cancer: Practical Implications for the Daily Work. *Oncol Res Treat*, 43(3), 61-69. doi:10.1159/000504200
112. *Gehrke, N, & Schattenberg, JM. (2020). Metabolic Inflammation-A Role for Hepatic Inflammatory Pathways as Drivers of Comorbidities in Nonalcoholic Fatty Liver Disease? *Gastroenterology*, 158(7), 1929-1947.e1926. doi:10.1053/j.gastro.2020.02.020
113. *Gerber, TS, Paschold, M, Lang, H, Roth, W, & Straub, BK. (2020). [Variation in morphology or two entities?]. *Pathologie*, 41(1), 70-72. doi:10.1007/s00292-019-00740-4
114. Gerke, JS, Orth, MF, Tolkach, Y, Romero-Perez, L, Wehweck, FS, Stein, S, Musa, J, Knott, MML, Holting, TLB, Li, J, Sannino, G, Marchetto, A, Ohmura, S, Cidre-Aranaz, F, Muller-Nurasyid, M, Strauch, K, Stief, C, Kristiansen, G, Kirchner, T, Buchner, A, & Grunewald, TGP. (2020). Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma. *Int J Cancer*, 146(7), 2036-2046. doi:10.1002/ijc.32792
115. *Gerlach, C, Taylor, K, Ferner, M, Munder, M, Weber, M, & Ramsenthaler, C. (2020). Challenges in the cultural adaptation of the German Myeloma Patient Outcome Scale (MyPOS): an outcome measure to support routine symptom assessment in myeloma care. *BMC Cancer*, 20(1), 245. doi:10.1186/s12885-020-06730-7
116. Gkika, E, Lenz, S, Schimek-Jasch, T, Waller, CF, Kremp, S, Schaefer-Schuler, A, Mix, M, Küsters, A, Tosch, M, Hehr, T, Eschmann, SM, Bultel, YP, Hass, P, Fleckenstein, J, Thieme, AH, Stockinger, M, Dieckmann, K, Miederer, M, Holl, G, Rischke, HC, Adebahr, S, König, J, Binder, H, Grosu, AL, & Nestle, U. (2020). Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer-A Secondary Analysis of the PET Plan Trial. *Cancers (Basel)*, 12(11). doi:10.3390/cancers12113359
117. Glass, O, Filozof, C, Nouredin, M, Berner-Hansen, M, Schabel, E, Omokaro, SO, Schattenberg, JM, Barradas, K, Miller, V, Francque, S, & Abdelmalek, MF. (2020). Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. *J Hepatol*, 73(3), 680-693. doi:10.1016/j.jhep.2020.04.030
118. Goebel, S, Knuth, C, Damm, M, Linden, D, Coburger, J, Ringel, F, Tabatabai, G, Mehdorn, M, & Renovanz, M. (2020). Towards the targeted assessment of relevant problems: Optimization of the distress Thermometer for adult neuro-oncological patients. *Psychooncology*, 29(12), 2057-2066. doi:10.1002/pon.5564
119. *Goetze, E, Kämmerer, PW, Al-Nawas, B, & Moergel, M. (2020). Integration of Perforator Vessels in CAD/CAM Free Fibula Graft Planning: A Clinical Feasibility Study. *J Maxillofac Oral Surg*, 19(1), 61-66. doi:10.1007/s12663-019-01215-y

120. *Goetze, E, Thiem, DGE, Gielisch, M, Al-Nawas, B, & Kämmerer, PW. (2020). [Digitalization and use of artificial intelligence in microvascular reconstructive facial surgery]. *Chirurg*, 91(3), 216-221. doi:10.1007/s00104-019-01103-8
121. Goldschmidt, H, Mai, EK, Dürig, J, Scheid, C, Weisel, KC, Kunz, C, Bertsch, U, Hielscher, T, Merz, M, Munder, M, Lindemann, HW, Hügler-Dörr, B, Tichy, D, Giesen, N, Hose, D, Seckinger, A, Huhn, S, Luntz, S, Jauch, A, Elmaagacli, A, Rabold, B, Fuhrmann, S, Brossart, P, Goerner, M, Bernhard, H, Hoffmann, M, Hillengass, J, Raab, MS, Blau, IW, Hänel, M, & Salwender, HJ. (2020). Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. *Leukemia*, 34(7), 1853-1865. doi:10.1038/s41375-020-0724-1
122. *Goldust, M, Giulini, M, Weidenthaler-Barth, B, Gupta, M, Grabbe, S, & Schepler, H. (2020). Increased risk of angiosarcoma secondary to cancer radiotherapy: Case series and review of the treatment options. *Dermatol Ther*, e13234. doi:10.1111/dth.13234
123. *Göllner, M, Ihrig-Biedert, I, Petermann, V, Saurin, S, Oelze, M, Kröller-Schön, S, Vujacic-Mirski, K, Kuntic, M, Pautz, A, Daiber, A, & Kleinert, H. (2020). NOX2ko Mice Show Largely Increased Expression of a Mutated NOX2 mRNA Encoding an Inactive NOX2 Protein. *Antioxidants (Basel)*, 9(11). doi:10.3390/antiox9111043
124. Gomes, AL, Matos-Rodrigues, GE, Frappart, PO, & Martins, RAP. (2020). RINT1 Loss Impairs Retinogenesis Through TRP53-Mediated Apoptosis. *Front Cell Dev Biol*, 8, 711. doi:10.3389/fcell.2020.00711
125. Govaere, O, Cockell, S, Tiniakos, D, Queen, R, Younes, R, Vacca, M, Alexander, L, Ravaioli, F, Palmer, J, Petta, S, Boursier, J, Rosso, C, Johnson, K, Wonders, K, Day, CP, Ekstedt, M, Orešič, M, Darlay, R, Cordell, HJ, Marra, F, Vidal-Puig, A, Bedossa, P, Schattenberg, JM, Clément, K, Allison, M, Bugianesi, E, Ratziu, V, Daly, AK, & Anstee, QM. (2020). Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. *Sci Transl Med*, 12(572). doi:10.1126/scitranslmed.aba4448
126. *Grimminger, PP, Hadzijušufovic, E, Babic, B, van der Sluis, PC, & Lang, H. (2020). Innovative fully robotic 4-arm Ivor Lewis esophagectomy for esophageal cancer (RAMIE4). *Dis Esophagus*, 33(3). doi:10.1093/dote/doz015
127. Gross, M, Poets, A, Steinfeldt, R, Urschitz, MS, Böckmann, K, Haase, B, & Poets, CF. (2020). Randomized Longitudinal Study Comparing Three Nasal Respiratory Support Modes to Prevent Intermittent Hypoxia in Very Preterm Infants. *Children (Basel)*, 7(10). doi:10.3390/children7100168
128. Grosser, B, Kohlruss, M, Slotta-Huspenina, J, Jesinghaus, M, Pfarr, N, Steiger, K, Novotny, A, Gaida, MM, Schmidt, T, Hapfelmeier, A, Ott, K, Weichert, W, & Keller, G. (2020). Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer. *Cancers (Basel)*, 12(6). doi:10.3390/cancers12061689
129. Grumme, J, Werncke, T, Meine, TC, Becker, LS, Kloeckner, R, Maschke, SK, Kirstein, MM, Vogel, A, Wacker, FK, Meyer, BC, Hinrichs, JB, & Rodt, T. (2020). Transarterial chemoembolization for hepatocellular carcinoma: quality of life, tumour response, safety and survival comparing two types of drug-eluting beads. *Abdom Radiol (NY)*. doi:10.1007/s00261-019-02349-w
130. *Gulati, S, Emmanuel, A, Patel, M, Williams, S, Haji, A, Hayee, B, & Neumann, H. (2020). Artificial intelligence in luminal endoscopy. *Ther Adv Gastrointest Endosc*, 13, 2631774520935220. doi:10.1177/2631774520935220
131. *Gulati, S, Patel, M, Emmanuel, A, Haji, A, Hayee, B, & Neumann, H. (2020). The future of endoscopy: Advances in endoscopic image innovations. *Dig Endosc*, 32(4), 512-522. doi:10.1111/den.13481
132. Hack, CC, Häberle, L, Brucker, SY, Janni, W, Volz, B, Loehberg, CR, Hartkopf, AD, Walter, CB, Baake, G, Fridman, A, Malter, W, Wuerstlein, R, Harbeck, N, Hoffmann, O, Kuemmel, S, Martin, B, Thomssen, C, Graf, H, Wolf, C, Lux, MP, Bayer, CM, Rauh, C, Almstedt, K, Gass, P, Heindl, F, Brodkorb, T, Willer, L, Lindner, C, Kolberg, HC, Krabisch, P, Weigel, M, Steinfeld-Birg, D, Kohls, A, Brucker, C, Schulz, V, Fischer, G, Pelzer, V, Rack, B, Beckmann, MW, Fehm, T, Rody, A, Maass, N, Hein, A, Fasching, PA, & Nabieva, N. (2020). Complementary and alternative medicine and musculoskeletal pain in the first year of adjuvant aromatase inhibitor treatment in early breast cancer patients. *Breast*, 50, 11-18. doi:10.1016/j.breast.2019.12.017
133. Hacker, UT, Hasenclever, D, Linder, N, Stocker, G, Chung, HC, Kang, YK, Moehler, M, Busse, H, & Lordick, F. (2020). Prognostic role of body composition parameters in gastric/gastroesophageal junction cancer patients from the EXPAND trial. *J Cachexia Sarcopenia Muscle*, 11(1), 135-144. doi:10.1002/jcsm.12484
134. *Hager, S, Fittler, FJ, Wagner, E, & Bros, M. (2020). Nucleic Acid-Based Approaches for Tumor Therapy. *Cells*, 9(9). doi:10.3390/cells9092061

135. *Hahn, F, Müller, L, Jungmann, F, Mähringer-Kunz, A, Tanyildizi, Y, Düber, C, Galle, PR, Weinmann, A, & Kloeckner, R. (2020). Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging. *J Cancer Res Clin Oncol*, 146(7), 1883-1890. doi:10.1007/s00432-020-03200-2
136. *Hahn, F, Muller, L, Mahringer-Kunz, A, Schotten, S, Duber, C, Hinrichs, JB, Maschke, SK, Galle, PR, Bartsch, F, Lang, H, Weinmann, A, & Kloeckner, R. (2020). Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system. *PLoS One*, 15(2), e0228501. doi:10.1371/journal.pone.0228501
137. *Hahn, F, Müller, L, Mähringer-Kunz, A, Tanyildizi, Y, Dos Santos, DP, Düber, C, Galle, PR, Weinmann, A, & Kloeckner, R. (2020). Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients. *J Oncol*, 2020, 7195373. doi:10.1155/2020/7195373
138. Hardy, T, Wonders, K, Younes, R, Aithal, GP, Aller, R, Allison, M, Bedossa, P, Betsou, F, Boursier, J, Brosnan, MJ, Burt, A, Cobbold, J, Cortez-Pinto, H, Day, CP, Dufour, JF, Ekstedt, M, Francque, S, Harrison, S, Miele, L, Nasr, P, Papatheodoridis, G, Petta, S, Tiniakos, D, Torstenson, R, Valenti, L, Holleboom, AG, Yki-Jarvinen, H, Geier, A, Romero-Gomez, M, Ratzu, V, Bugianesi, E, Schattenberg, JM, & Anstee, QM. (2020). The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. *Contemp Clin Trials*, 98, 106175. doi:10.1016/j.cct.2020.106175
139. *Hasenburg, A, Sehouli, J, Lampe, B, Reuss, A, Schmalfeld, B, Belau, AK, Bossart, M, Mahner, S, Hillemanns, P, Petry, U, du Bois, A, Herwig, U, Hilpert, F, Gropp-Meier, M, Hanf, V, Greimel, E, Wagner, U, & Harter, P. (2020). LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trial. *Int J Gynecol Cancer*, 30(10), 1548-1553. doi:10.1136/ijgc-2020-001551
140. *Heckel, M, Vogt, AR, Stiel, S, Radon, J, Kurkowski, S, Goebel, S, Ostgathe, C, & Weber, M. (2020). The quality of care of the dying in hospital-next-of-kin perspectives. *Support Care Cancer*, 28(9), 4527-4537. doi:10.1007/s00520-020-05465-2
141. *Heimes, AS, Härtner, F, Almstedt, K, Krajnak, S, Lebrecht, A, Battista, MJ, Edlund, K, Brenner, W, Hasenburg, A, Sahin, U, Gehrmann, M, Hengstler, JG, & Schmidt, M. (2020). Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes. *Int J Mol Sci*, 21(19). doi:10.3390/ijms21197178
142. *Heinrich, S, Castven, D, Galle, PR, & Marquardt, JU. (2020). Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. *Cancers (Basel)*, 12(9). doi:10.3390/cancers12092495
143. *Heinrich, S, Sprinzl, M, Schmidtmann, I, Heil, E, Koch, S, Czauderna, C, Heinrich, B, Philippe, PDL, Wörns, MA, Kloeckner, R, Galle, PR, Marquardt, JU, & Weinmann, A. (2020). Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. *United European Gastroenterol J*, 8(4), 444-452. doi:10.1177/2050640620904524
144. *Heinrich, S, Watzka, F, & Lang, H. (2020). Integrative Concepts for Liver Surgery. *Visc Med*, 36(5), 351-358. doi:10.1159/000511043
145. *Heller, M, Bauer, HK, Schwab, R, Blatt, S, Peters, K, Nezi-Cahn, S, Unger, RE, Hasenburg, A, & Brenner, W. (2020). The impact of intercellular communication for the generation of complex multicellular prevascularized tissue equivalents. *J Biomed Mater Res A*, 108(3), 734-748. doi:10.1002/jbm.a.36853
146. *Hess, G, Wagner, K, Keller, U, La Rosee, P, Atta, J, Hübel, K, Lerchenmueller, C, Schoendube, D, Witzens-Harig, M, Ruckes, C, Medler, C, van Oordt, C, Klapper, W, Theobald, M, & Dreyling, M. (2020). Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. *Hemasphere*, 4(3), e398. doi:10.1097/hs9.0000000000000398
147. *Higer, M, Cana, D, Podlech, J, Schadmand-Fischer, S, Schwarting, A, Teschner, D, Theobald, M, Wölfel, T, & Hess, G. (2020). Life-threatening disseminated enterovirus infection during combined rituximab and ibrutinib maintenance treatment for mantle cell lymphoma: a case report. *J Med Case Rep*, 14(1), 135. doi:10.1186/s13256-020-02457-y
148. Hirth, M, Gandla, J, Höper, C, Gaida, MM, Agarwal, N, Simonetti, M, Demir, A, Xie, Y, Weiss, C, Michalski, CW, Hackert, T, Ebert, MP, & Kuner, R. (2020). CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients. *Gastroenterology*, 159(2), 665-681.e613. doi:10.1053/j.gastro.2020.04.037

149. Hoegen, P, Lang, C, Akbaba, S, Häring, P, Splinter, M, Miltner, A, Bachmann, M, Stahl-Arnsberger, C, Brechter, T, El Shafie, RA, Weykamp, F, König, L, Debus, J, & Hörner-Rieber, J. (2020). Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung. *Front Oncol*, 10, 564857. doi:10.3389/fonc.2020.564857
150. *Hoffmann, MA, Buchholz, HG, Wieler, HJ, Miederer, M, Rosar, F, Fischer, N, Müller-Hübenthal, J, Trampert, L, Pektor, S, & Schreckenberger, M. (2020). PSA and PSA Kinetics Thresholds for the Presence of (68)Ga-PSMA-11 PET/CT-Detectable Lesions in Patients With Biochemical Recurrent Prostate Cancer. *Cancers (Basel)*, 12(2). doi:10.3390/cancers12020398
151. *Hoffmann, MA, Buchholz, HG, Wieler, HJ, Müller-Hübenthal, J, Trampert, L, Richardsen, I, & Schreckenberger, M. (2020). Diagnostic Performance of 68Ga-PSMA-11 Positron-emission-tomography/Computed-tomography in a Large Cohort of Patients with Biochemical Recurrence of Prostate Carcinoma. *Health Phys*, 119(1), 141-147. doi:10.1097/hp.0000000000001253
152. *Hoffmann, MA, Buchholz, HG, Wieler, HJ, Rosar, F, Miederer, M, Fischer, N, & Schreckenberger, M. (2020). Dual-Time Point [(68)Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer. *Cancers (Basel)*, 12(10). doi:10.3390/cancers12102788
153. Hoffmeister, M, Bläker, H, Jansen, L, Alwers, E, Amitay, EL, Carr, PR, Kloor, M, Herpel, E, Roth, W, Chang-Claude, J, & Brenner, H. (2020). Colonoscopy and Reduction of Colorectal Cancer Risk by Molecular Tumor Subtypes: A Population-Based Case-Control Study. *Am J Gastroenterol*, 115(12), 2007-2016. doi:10.14309/ajg.0000000000000819
154. *Hofmann, M, García, MA, Al-Gousous, J, Ruiz-Picazo, A, Thieringer, F, Nguyen, MA, Månsson, W, Galle, PR, & Langguth, P. (2020). In vitro prediction of in vivo absorption of ibuprofen from suspensions through rational choice of dissolution conditions. *Eur J Pharm Biopharm*, 149, 229-237. doi:10.1016/j.ejpb.2020.02.009
155. *Hofmann, S, Goedeke, J, König, TT, Poplawski, A, Muensterer, OJ, Faber, J, & Beck, O. (2020). Multivariate analysis on complications of central venous access devices in children with cancer and severe disease influenced by catheter tip position and vessel insertion site (A STROBE-compliant study). *Surg Oncol*, 34, 17-23. doi:10.1016/j.suronc.2020.02.009
156. Holch, JW, Held, S, Stintzing, S, Fischer von Weikersthal, L, Decker, T, Kiani, A, Kaiser, F, Heintges, T, Kahl, C, Kullmann, F, Scheithauer, W, Moehler, M, von Einem, JC, Michl, M, & Heinemann, V. (2020). Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306). *Ann Oncol*, 31(1), 72-78. doi:10.1016/j.annonc.2019.10.001
157. Hong, SM, Jung, D, Kiemen, A, Gaida, MM, Yoshizawa, T, Braxton, AM, Noë, M, Lionheart, G, Oshima, K, Thompson, ED, Burkhart, R, Wu, PH, Wirtz, D, Hruban, RH, & Wood, LD. (2020). Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion. *Mod Pathol*, 33(4), 639-647. doi:10.1038/s41379-019-0409-3
158. *Hötter, AM, Lollert, A, Mazaheri, Y, Müller, S, Schenk, JP, Mildener, PC, Akin, O, Graf, N, & Staatz, G. (2020). Diffusion-weighted MRI in the assessment of nephroblastoma: results of a multi-center trial. *Abdom Radiol (NY)*, 45(10), 3202-3212. doi:10.1007/s00261-020-02475-w
159. Huang, K, Madison, T, Wehler, B, Tiseo, M, Wilner, KD, & Mo, J. (2020). Effect of the patient information brochure in communicating the risks associated with crizotinib treatment to patients with non-small cell lung cancer (NSCLC) in Europe. *Pharmacol Res Perspect*, 8(2), e00570. doi:10.1002/prp2.570
160. Huang, W, Navarro-Serer, B, Jeong, YJ, Chianchiano, P, Xia, L, Luchini, C, Veronese, N, Dowiak, C, Ng, T, Trujillo, MA, Huang, B, Pflüger, MJ, Macgregor-Das, AM, Lionheart, G, Jones, D, Fujikura, K, Nguyen-Ngoc, KV, Neumann, NM, Groot, VP, Hasanain, A, van Oosten, AF, Fischer, SE, Gallinger, S, Singhi, AD, Zureikat, AH, Brand, RE, Gaida, MM, Heinrich, S, Burkhart, RA, He, J, Wolfgang, CL, Goggins, MG, Thompson, ED, Roberts, NJ, Ewald, AJ, & Wood, LD. (2020). Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome. *Cancer Res*, 80(13), 2804-2817. doi:10.1158/0008-5472.Can-19-1523
161. Huang, X, Schuppan, D, Rojas Tovar, LE, Zevallos, VF, Laponen, J, & Gänzle, M. (2020). Sourdough Fermentation Degrades Wheat Alpha-Amylase/Trypsin Inhibitor (ATI) and Reduces Pro-Inflammatory Activity. *Foods*, 9(7). doi:10.3390/foods9070943
162. *Huber, Y, Galle, PR, & Schattenberg, JM. (2020). [What is the (right) target for non-alcoholic fatty liver disease (NAFLD)?]. *Z Gastroenterol*, 58(1), 68-73. doi:10.1055/a-1068-3981

163. *Huber, Y, Labenz, C, Michel, M, Wörns, MA, Galle, PR, Kostev, K, & Schattenberg, JM. (2020). Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease. *Dtsch Arztebl Int*, 117(43), 719-724. doi:10.3238/arztebl.2020.0719
164. *Huettl, F, Lang, H, Paschold, M, Watzka, F, Wachter, N, Hensel, B, Kneist, W, & Huber, T. (2020). Rating of camera navigation skills in colorectal surgery. *Int J Colorectal Dis*, 35(6), 1111-1115. doi:10.1007/s00384-020-03543-9
165. Hvidtfeldt, UA, Erdmann, F, Urhoj, SK, Brandt, J, Geels, C, Ketzel, M, Frohn, LM, Christensen, JH, Sørensen, M, & Raaschou-Nielsen, O. (2020). Residential Exposure to PM(2.5) Components and Risk of Childhood Non-Hodgkin Lymphoma in Denmark: A Nationwide Register-Based Case-Control Study. *Int J Environ Res Public Health*, 17(23). doi:10.3390/ijerph17238949
166. Hvidtfeldt, UA, Erdmann, F, Urhøj, SK, Brandt, J, Geels, C, Ketzel, M, Frohn, LM, Christensen, JH, Sørensen, M, & Raaschou-Nielsen, O. (2020). Air pollution exposure at the residence and risk of childhood cancers in Denmark: A nationwide register-based case-control study. *EClinicalMedicine*, 28, 100569. doi:10.1016/j.eclim.2020.100569
167. Ignatavicius, P, Oberkofler, CE, Chapman, WC, DeMatteo, RP, Clary, BM, D'Angelica, MI, Tanabe, KK, Hong, JC, Aloia, TA, Pawlik, TM, Hernandez-Alejandro, R, Shah, SA, Vauthey, JN, Torzilli, G, Lang, H, Line, PD, Soubrane, O, Pinto-Marques, H, Robles-Campos, R, Boudjema, K, Lodge, P, Adam, R, Toso, C, Serrablo, A, Aldrighetti, L, DeOliveira, ML, Dutkowsky, P, Petrowsky, H, Linecker, M, Reiner, CS, Braun, J, Alihanov, R, Barauskas, G, Chan, ACY, Dong, J, Kokudo, N, Yamamoto, M, Kang, KJ, Fong, Y, Rela, M, De Aretxabala, X, De Santibañes, E, Mercado, M, Andriani, OC, Torres, OJM, Pinna, AD, & Clavien, PA. (2020). Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons: A Throw of the Dice? *Ann Surg*, 272(5), 715-722. doi:10.1097/sla.0000000000004331
168. *Ilysan, B, Thiramanas, R, Nazarova, N, Avlasevich, Y, Mailänder, V, Balushev, S, & Landfester, K. (2020). Temperature Sensing in Cells Using Polymeric Upconversion Nanocapsules. *Biomacromolecules*, 21(11), 4469-4478. doi:10.1021/acs.biomac.0c00377
169. Jackisch, C, Kreienberg, R, Blettner, M, Harbeck, N, Lück, HJ, Haidinger, R, Schmitt, DC, Schulte, H, Windemuth-Kieselbach, C, Zaun, S, & Hadji, P. (2020). Assessment of Quality of Life in Postmenopausal Women with Early Breast Cancer Participating in the PACT Trial: The Impact of Additional Patient Information Material Packages and Patient Compliance. *Breast Care (Basel)*, 15(3), 236-245. doi:10.1159/000500771
170. *Jiang, S, Xiao, M, Sun, W, Crespy, D, Mailänder, V, Peng, X, Fan, J, & Landfester, K. (2020). Synergistic Anticancer Therapy by Ovalbumin Encapsulation-Enabled Tandem Reactive Oxygen Species Generation. *Angew Chem Int Ed Engl*, 59(45), 20008-20016. doi:10.1002/anie.202006649
171. *Jo, SM, Wurm, FR, & Landfester, K. (2020). Oncolytic Nanoreactors Producing Hydrogen Peroxide for Oxidative Cancer Therapy. *Nano Lett*, 20(1), 526-533. doi:10.1021/acs.nanolett.9b04263
172. Justin, S, Rutz, J, Maxeiner, S, Chun, FK, Juengel, E, & Blaheta, RA. (2020). Chronic Sulforaphane Administration Inhibits Resistance to the mTOR-Inhibitor Everolimus in Bladder Cancer Cells. *Int J Mol Sci*, 21(11). doi:10.3390/ijms21114026
173. *Kadioglu, O, Saeed, M, Munder, M, Spuller, A, Greten, HJ, & Efferth, T. (2020a). Identification of Novel Rare ABCC1 Transporter Mutations in Tumor Biopsies of Cancer Patients. *Cells*, 9(2). doi:10.3390/cells9020299
174. *Kadioglu, O, Saeed, MEM, Munder, M, Spuller, A, Greten, HJ, & Efferth, T. (2020b). Effect of ABC transporter expression and mutational status on survival rates of cancer patients. *Biomed Pharmacother*, 131, 110718. doi:10.1016/j.biopha.2020.110718
175. *Kaina, B, Beltzig, L, Piee-Staffa, A, & Haas, B. (2020). Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells. *Int J Mol Sci*, 21(19). doi:10.3390/ijms21197006
176. *Kalasauskas, D, Keric, N, Abu Ajaj, S, von Cube, L, Ringel, F, & Renovanz, M. (2020). Psychological Burden in Meningioma Patients under a Wait-and-Watch Strategy and after Complete Resection Is High-Results of a Prospective Single Center Study. *Cancers (Basel)*, 12(12). doi:10.3390/cancers12123503
177. *Kalasauskas, D, Kronfeld, A, Renovanz, M, Kurz, E, Leukel, P, Krenzlin, H, Brockmann, MA, Sommer, CJ, Ringel, F, & Keric, N. (2020). Identification of High-Risk Atypical Meningiomas According to Semantic and Radiomic Features. *Cancers (Basel)*, 12(10). doi:10.3390/cancers12102942
178. *Kalasauskas, D, Sorokin, M, Sprang, B, Elmasri, A, Viehweg, S, Salinas, G, Opitz, L, Rave-Fraenk, M, Schulz-Schaeffer, W, Kantelhardt, SR, Giese, A, Buzdin, A, & Kim, EL. (2020). Diversity of Clinically Relevant Outcomes Resulting from

Hypofractionated Radiation in Human Glioma Stem Cells Mirrors Distinct Patterns of Transcriptomic Changes. *Cancers (Basel)*, 12(3). doi:10.3390/cancers12030570

179. Kapp-Schworer, S, Weber, D, Corbacioglu, A, Gaidzik, VI, Paschka, P, Krönke, J, Theis, F, Rücker, FG, Teleanu, MV, Panina, E, Jahn, N, Herzig, J, Kubanek, L, Schrade, A, Göhring, G, Fiedler, W, Kindler, T, Schroeder, T, Mayer, KT, Lübbert, M, Wattad, M, Götze, KS, Horst, HA, Koller, E, Wulf, G, Schleicher, J, Bentz, M, Krauter, J, Bullinger, L, Krzykalla, J, Benner, A, Schlenk, RF, Thol, F, Heuser, M, Ganser, A, Döhner, H, & Döhner, K. (2020). Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. *Blood*, 136(26), 3041-3050. doi:10.1182/blood.2020005998
180. *Kaps, L, Labenz, C, Galle, PR, Weinmann-Menke, J, Kostev, K, & Schattenberg, JM. (2020). Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. *United European Gastroenterol J*, 8(8), 942-948. doi:10.1177/2050640620944098
181. *Kaps, L, Leber, N, Klefenz, A, Choteschovsky, N, Zentel, R, Nuhn, L, & Schuppan, D. (2020). In Vivo siRNA Delivery to Immunosuppressive Liver Macrophages by α -Mannosyl-Functionalized Cationic Nanohydrogel Particles. *Cells*, 9(8). doi:10.3390/cells9081905
182. *Kaps, L, & Schuppan, D. (2020). Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. *Cells*, 9(9). doi:10.3390/cells9092027
183. *Kauff, DW, Roth, YDS, Bettzieche, RS, & Kneist, W. (2020). Fecal incontinence after total mesorectal excision for rectal cancer-impact of potential risk factors and pelvic intraoperative neuromonitoring. *World J Surg Oncol*, 18(1), 12. doi:10.1186/s12957-020-1782-6
184. *Keric, N, Kalasauskas, D, Freyschlag, CF, Gempt, J, Misch, M, Poplawski, A, Lange, N, Ayyad, A, Thome, C, Vajkoczy, P, Meyer, B, & Ringel, F. (2020). Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas. *J Neurooncol*, 146(2), 347-355. doi:10.1007/s11060-019-03382-x
185. *Kim, EL, Sorokin, M, Kantelhardt, SR, Kalasauskas, D, Sprang, B, Fauss, J, Ringel, F, Garazha, A, Albert, E, Gaifullin, N, Hartmann, C, Naumann, N, Bikar, SE, Giese, A, & Buzdin, A. (2020). Intratumoral Heterogeneity and Longitudinal Changes in Gene Expression Predict Differential Drug Sensitivity in Newly Diagnosed and Recurrent Glioblastoma. *Cancers (Basel)*, 12(2). doi:10.3390/cancers12020520
186. *Kingma, BF, Hadzijušufovic, E, Van der Sluis, PC, Bano, E, Lang, H, Ruurda, JP, Hillegersberg van, R, & Grimminger, PP. (2020). A structured training pathway to implement robot-assisted minimally invasive esophagectomy: the learning curve results from a high-volume center. *Dis Esophagus*, 33(Supplement_2). doi:10.1093/dote/daaa047
187. *Kiweler, N, Wunsch, D, Wirth, M, Mahendrarajah, N, Schneider, G, Stauber, RH, Brenner, W, Butter, F, & Kramer, OH. (2020). Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes. *J Cancer Res Clin Oncol*, 146(2), 343-356. doi:10.1007/s00432-019-03118-4
188. Klapdor, R, Hillemanns, P, Wölber, L, Jückstock, J, Hilpert, F, de Gregorio, N, Hasenburg, A, Sehouli, J, Fürst, S, Strauss, H, Baumann, K, Thiel, F, Mustea, A, Meier, W, Harter, P, Wimberger, P, Hanker, L, Schmalfeld, B, & Mahner, S. (2020). Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study. *Int J Gynecol Cancer*, 30(7), 920-926. doi:10.1136/ijgc-2019-001187
189. Klompenhouwer, AJ, Dwarkasing, RS, Doukas, M, Pellegrino, S, Vilgrain, V, Paradis, V, Soubrane, O, Beane, JD, Geller, DA, Nalesnik, MA, Tripke, V, Lang, H, Schmelzle, M, Pratschke, J, Schöning, W, Beal, E, Sun, S, Pawlik, TM, de Man, RA, & Ijzermans, JNM. (2020). Hepatic angiomyolipoma: an international multicenter analysis on diagnosis, management and outcome. *HPB (Oxford)*, 22(4), 622-629. doi:10.1016/j.hpb.2019.09.004
190. *Kneist, W, Stein, H, & Rheinwald, M. (2020). Da Vinci Single-Port robot-assisted transanal mesorectal excision: a promising preclinical experience. *Surg Endosc*, 34(7), 3232-3235. doi:10.1007/s00464-020-07444-4
191. Knipper, S, Sadat-Khonsari, M, Boehm, K, Mandel, P, Budäus, L, Steuber, T, Maurer, T, Heinzer, H, Schwarz, R, Sauter, G, Tilki, D, Huland, H, & Graefen, M. (2020). Impact of Adherence to Multidisciplinary Recommendations for Adjuvant Treatment in Radical Prostatectomy Patients With High Risk of Recurrence. *Clin Genitourin Cancer*, 18(2), e112-e121. doi:10.1016/j.clgc.2019.09.007
192. *Kögel, D, Linder, B, Brunschweiler, A, Chines, S, & Behl, C. (2020). At the Crossroads of Apoptosis and Autophagy: Multiple Roles of the Co-Chaperone BAG3 in Stress and Therapy Resistance of Cancer. *Cells*, 9(3). doi:10.3390/cells9030574

193. *Kohlmann, K, Janko, M, Ringel, F, & Renovanz, M. (2020). Self-efficacy for coping with cancer in glioma patients measured by the Cancer Behavior Inventory Brief Version. *Psychooncology*, 29(3), 582-585. doi:10.1002/pon.5292
194. Koller, M, Shamieh, O, Hjermstad, MJ, Hornslien, K, Young, T, Chalk, T, Ioannidis, G, Harle, A, Johnson, CD, Tomaszewski, KA, Serpentine, S, Pinto, M, van der Weijst, L, Janssens, A, Morag, O, Chie, WC, Arraras, JJ, Pompili, C, Jungraithmayr, W, Hechtner, M, Katsochi, D, Müller, K, Gräfenstein, L, Schulz, C, & Bottomley, A. (2020). Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study. *Lancet Oncol*, 21(5), 723-732. doi:10.1016/s1470-2045(20)30093-0
195. *Kosterhon, M, Neufurth, M, Neulen, A, Schafer, L, Conrad, J, Kantelhardt, SR, Muller, WEG, & Ringel, F. (2020). Multicolor 3D Printing of Complex Intracranial Tumors in Neurosurgery. *J Vis Exp*(155). doi:10.3791/60471
196. *Krajnak, S, Schnatz, C, Almstedt, K, Brenner, W, Haertner, F, Heimes, AS, Lebrecht, A, Makris, GM, Schwab, R, Hasenburger, A, Schmidt, M, & Battista, MJ. (2020). Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study. *Breast Cancer Res Treat*, 182(2), 389-399. doi:10.1007/s10549-020-05711-5
197. Kreis, ME, Ruppert, R, Kube, R, Strassburg, J, Lewin, A, Baral, J, Maurer, CA, Sauer, J, Winde, G, Thomasmeyer, R, Stelzner, S, Bambauer, C, Scheunemann, S, Faedrich, A, Junginger, T, Hermanek, P, & Merkel, S. (2020). MRI-Based Use of Neoadjuvant Chemoradiotherapy in Rectal Carcinoma: Surgical Quality and Histopathological Outcome of the OCUM Trial. *Ann Surg Oncol*, 27(2), 417-427. doi:10.1245/s10434-019-07696-y
198. *Krenzlin, H, Frenz, C, Schmitt, J, Masomi-Bornwasser, J, Wesp, D, Kalasauskas, D, Kerz, T, Lotz, J, Alessandri, B, Ringel, F, & Keric, N. (2020). High CSF thrombin concentration and activity is associated with an unfavorable outcome in patients with intracerebral hemorrhage. *PLoS One*, 15(11), e0241565. doi:10.1371/journal.pone.0241565
199. Kriegsmann, K, Hundemer, M, Hofmeister-Mielke, N, Reichert, P, Manta, CP, Awwad, MHS, Sauer, S, Bertsch, U, Besemer, B, Fenk, R, Hänel, M, Munder, M, Weisel, KC, Blau, IW, Neubauer, A, Müller-Tidow, C, Raab, MS, Goldschmidt, H, Huhn, S, & For The German-Speaking Myeloma Multicenter Group, G. (2020). Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. *Cancers (Basel)*, 12(8). doi:10.3390/cancers12082322
200. Kriegsmann, M, Casadonte, R, Maurer, N, Stoeck, C, Erlmeier, F, Moch, H, Junker, K, Zgorzelski, C, Weichert, W, Schwamborn, K, Deininger, SO, Gaida, M, Mechttersheimer, G, Stenzinger, A, Schirmacher, P, Hartmann, A, Kriegsmann, J, & Kriegsmann, K. (2020). Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy. *J Cancer*, 11(20), 6081-6089. doi:10.7150/jca.47698
201. *Krishnan, A, Berthelet, J, Renaud, E, Rosigkeit, S, Distler, U, Stawiski, E, Wang, J, Modrusan, Z, Fiedler, M, Bienz, M, Tenzer, S, Schad, A, Roth, W, Thiede, B, Seshagiri, S, Musholt, TJ, & Rajalingam, K. (2020). Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas. *Nat Commun*, 11(1), 2056. doi:10.1038/s41467-020-15955-w
202. *Kropp, KN, Schäufler, TJ, Fatho, M, Volkmar, M, Conradi, R, Theobald, M, Wölfel, T, & Wölfel, C. (2020). A bicistronic vector backbone for rapid seamless cloning and chimerization of αβT-cell receptor sequences. *PLoS One*, 15(9), e0238875. doi:10.1371/journal.pone.0238875
203. *Krüger, M, Metzger, C, Al-Nawas, B, Kämmerer, PW, & Brieger, J. (2020). Cigarette smoke modulates binding of the transcription factor MZF1 to the VEGF promoter and regulates VEGF expression in dependence of genetic variation SNP 405. *J Oral Pathol Med*. doi:10.1111/jop.13038
204. Kudo, M, Galle, PR, Brandi, G, Kang, YK, Yen, CJ, Finn, RS, Llovet, JM, Assenat, E, Merle, P, Chan, SL, Palmer, DH, Ikeda, M, Yamashita, T, Vogel, A, Huang, YH, Abada, PB, Yoshikawa, R, Shinozaki, K, Wang, C, Widau, RC, & Zhu, AX. (2020). Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. *JHEP Rep*, 3(2), 100215. doi:10.1016/j.jhepr.2020.100215
205. Kudo, M, Galle, PR, Llovet, JM, Finn, RS, Vogel, A, Motomura, K, Assenat, E, Merle, P, Brandi, G, Daniele, B, Okusaka, T, Tomášek, J, Borg, C, Dadduzio, V, Morimoto, M, Pracht, M, Jen, MH, Drove Ubreva, N, Widau, RC, Shinozaki, K, Yoshikawa, R, & Zhu, AX. (2020). Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. *Liver Int*. doi:10.1111/liv.14462
206. *Kulik, L, da Fonseca, LG, He, AR, Rimola, J, Wilson Woods, A, Zöllner, YF, & Galle, PR. (2020). Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion. *J Hepatocell Carcinoma*, 7, 423-433. doi:10.2147/jhc.S274930

207. Laakmann, E, Witzel, I, Neunhöffer, T, Weide, R, Schmidt, M, Park-Simon, TW, Möbus, V, Mundhenke, C, Polasik, A, Lübke, K, Hesse, T, Riecke, K, Thill, M, Fasching, PA, Denkert, C, Fehm, T, Nekljudova, V, Rey, J, Loibl, S, & Müller, V. (2020). Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. *Cancers (Basel)*, 12(10). doi:10.3390/cancers12102787
208. *Labenz, C, Toenges, G, Schattenberg, JM, Nagel, M, Huber, Y, Marquardt, JU, Labenz, J, Galle, PR, & Wörns, MA. (2020). Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies. *Clin Transl Gastroenterol*, 11(6), e00172. doi:10.14309/ctg.0000000000000172
209. Lai, Q, Vitale, A, Halazun, K, Iesari, S, Viveiros, A, Bhangui, P, Mennini, G, Wong, T, Uemoto, S, Lin, CC, Mittler, J, Ikegami, T, Zhe, Y, Zheng, SS, Soejima, Y, Hoppe-Lotichius, M, Chen, CL, Kaido, T, Lo, CM, Rossi, M, Soin, AS, Finkenstedt, A, Emond, JC, Cillo, U, & Lerut, J. (2020). Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort. *Cancers (Basel)*, 12(2). doi:10.3390/cancers12020452
210. *Lang, H. (2020). ALPPS - Beneficial or detrimental? *Surg Oncol*, 33, 249-253. doi:10.1016/j.suronc.2019.10.013
211. *Lang, H, Baumgart, J, & Mittler, J. (2020). Associated Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS) Registry: What Have We Learned? *Gut Liver*, 14(6), 699-706. doi:10.5009/gnl19233
212. Langer, T, Clemens, E, Broer, L, Maier, L, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Pluijm, SFM, Binder, H, Mayer, B, von dem Knesebeck, A, Byrne, J, van Dulmen-den Broeder, E, Crocco, M, Grabow, D, Kaatsch, P, Kaiser, M, Spix, C, Kenborg, L, Winther, JF, Rechnitzer, C, Hasle, H, Kepak, T, van der Kooi, AF, Kremer, LC, Kruseova, J, Bielack, S, Sorg, B, Hecker-Nolting, S, Kuehni, CE, Ansari, M, Kompis, M, van der Pal, H, Parfitt, R, Deuster, D, Matulat, P, Tillmanns, A, Tissing, WJE, Beck, JD, Elsner, S, Am Zehnhoff-Dinnesen, A, van den Heuvel-Eibrink, MM, & Zolk, O. (2020a). Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. *Eur J Cancer*, 138, 212-224. doi:10.1016/j.ejca.2020.07.019
213. Langer, T, Clemens, E, Broer, L, Maier, L, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Pluijm, SFM, Binder, H, Mayer, B, von dem Knesebeck, A, Byrne, J, van Dulmen-den Broeder, E, Crocco, M, Grabow, D, Kaatsch, P, Kaiser, M, Spix, C, Kenborg, L, Winther, JF, Rechnitzer, C, Hasle, H, Kepak, T, van der Kooi, AF, Kremer, LC, Kruseova, J, Bielack, S, Sorg, B, Hecker-Nolting, S, Kuehni, CE, Ansari, M, Kompis, M, van der Pal, HJ, Parfitt, R, Deuster, D, Matulat, P, Tillmanns, A, Tissing, WJE, Beck, JD, Elsner, S, Am Zehnhoff-Dinnesen, A, van den Heuvel-Eibrink, MM, & Zolk, O. (2020b). Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. *Data Brief*, 32, 106227. doi:10.1016/j.dib.2020.106227
214. Lankes, K, Hassan, Z, Doffo, MJ, Schneeweis, C, Lier, S, Öllinger, R, Rad, R, Krämer, OH, Keller, U, Saur, D, Reichert, M, Schneider, G, & Wirth, M. (2020). Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. *Mol Oncol*, 14(12), 3048-3064. doi:10.1002/1878-0261.12835
215. Lanvers-Kaminsky, C, Niemann, A, Eveslage, M, Beck, J, Kohnke, T, Martin, S, de Wit, M, Spriewald, B, Hauspurg, H, Hoelzer, D, Boos, J, & Gokbuget, N. (2020). Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. *Leuk Lymphoma*, 61(1), 138-145. doi:10.1080/10428194.2019.1658099
216. *Lehmann, N, Paret, C, El Malki, K, Russo, A, Neu, MA, Wingerter, A, Seidmann, L, Foersch, S, Ziegler, N, Roth, L, Backes, N, Sandhoff, R, & Faber, J. (2020). Tumor Lipids of Pediatric Papillary Renal Cell Carcinoma Stimulate Unconventional T Cells. *Front Immunol*, 11, 1819. doi:10.3389/fimmu.2020.01819
217. Leinert, E, Kreienberg, R, Wockel, A, Kuhn, T, Flock, F, Felberbaum, R, Janni, W, Taylor, K, Singer, S, & Schwentner, L. (2020). Survivors of primary breast cancer 5 years after surgery: follow-up care, long-term problems, and treatment regrets. Results of the prospective BRENDA II-study. *Arch Gynecol Obstet*, 301(3), 761-767. doi:10.1007/s00404-020-05437-1
218. Leiter, U, Loquai, C, Reinhardt, L, Rafei-Shamsabadi, D, Gutzmer, R, Kaehler, K, Heinzerling, L, Hassel, JC, Glutsch, V, Sirokay, J, Schlecht, N, Rübben, A, Gambichler, T, Schatton, K, Pfoehler, C, Franklin, C, Terheyden, P, Haferkamp, S, Mohr, P, Bischof, L, Livingstone, E, Zimmer, L, Weichenthal, M, Schadendorf, D, Meiwes, A, Keim, U, Garbe, C, Becker, JC, & Ugurel, S. (2020). Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients. *J Immunother Cancer*, 8(2). doi:10.1136/jitc-2020-000897

219. Leithner, D, Helbich, TH, Bernard-Davila, B, Marino, MA, Avendano, D, Martinez, DF, Jochelson, MS, Kapetas, P, Baltzer, PAT, Haug, A, Hacker, M, Tanyildizi, Y, Morris, EA, & Pinker, K. (2020). Multiparametric (18)F-FDG PET/MRI of the Breast: Are There Differences in Imaging Biomarkers of Contralateral Healthy Tissue Between Patients With and Without Breast Cancer? *J Nucl Med*, 61(1), 20-25. doi:10.2967/jnumed.119.230003
220. Levy, A, Wagner, AD, Chargari, C, Moehler, M, Verheij, M, Durand-Labrunie, J, Kissel, M, Chirat, E, Burtin, P, Ducreux, M, Boige, V, Nilsson, M, Boku, N, Chau, I, & Deutsch, E. (2020). Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. *Eur J Cancer*, 135, 103-112. doi:10.1016/j.ejca.2020.04.032
221. Li, J, Moustafa, M, Linecker, M, Lurje, G, Capobianco, I, Baumgart, J, Ratti, F, Rauchfuss, F, Balci, D, Fernandes, E, Montalti, R, Robles-Campos, R, Bjornsson, B, Topp, SA, Fronek, J, Liu, C, Wahba, R, Bruns, C, Brunner, SM, Schlitt, HJ, Heumann, A, Stüben, BO, Izbicki, JR, Bednarsch, J, Gringeri, E, Fasolo, E, Rolinger, J, Kristek, J, Hernandez-Alejandro, R, Schnitzbauer, A, Nuessler, N, Schön, MR, Voskanyan, S, Petrou, AS, Hahn, O, Soejima, Y, Vicente, E, Castro-Benitez, C, Adam, R, Tomassini, F, Troisi, RI, Kantas, A, Oldhafer, KJ, Ardiles, V, de Santibanes, E, Malago, M, Clavien, PA, Vivarelli, M, Settmacher, U, Aldrighetti, L, Neumann, U, Petrowsky, H, Cillo, U, Lang, H, & Nadalin, S. (2020). ALPPS for Locally Advanced Intrahepatic Cholangiocarcinoma: Did Aggressive Surgery Lead to the Oncological Benefit? An International Multi-center Study. *Ann Surg Oncol*, 27(5), 1372-1384. doi:10.1245/s10434-019-08192-z
222. *Lisch, W, & Vossmerbaeumer, U. (2020). Corneal opacity and copper levels of the Lewis syndrome after systemic chemotherapy. *Am J Ophthalmol Case Rep*, 20, 100926. doi:10.1016/j.ajoc.2020.100926
223. Locati, LD, Galbiati, D, Calareso, G, Alfieri, S, Singer, S, Cavalieri, S, Bergamini, C, Bossi, P, Orlandi, E, Resteghini, C, Platini, F, Granata, R, Quattrone, P, Mancinelli, M, Mariani, L, Lo Vullo, S, & Licitra, LF. (2020). Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. *Cancer*. doi:10.1002/cncr.32754
224. Lowe, DJ, Herzog, M, Mosler, T, Cohen, H, Felton, S, Beli, P, Raj, K, Galanty, Y, & Jackson, SP. (2020). Chronic irradiation of human cells reduces histone levels and deregulates gene expression. *Sci Rep*, 10(1), 2200. doi:10.1038/s41598-020-59163-4
225. *Lui, BG, Salomon, N, Wüstehube-Lausch, J, Daneschdar, M, Schmoltdt, HU, Türeci, Ö, & Sahin, U. (2020). Targeting the tumor vasculature with engineered cystine-knot miniproteins. *Nat Commun*, 11(1), 295. doi:10.1038/s41467-019-13948-y
226. Luiken, S, Fraas, A, Bieg, M, Sugiyanto, R, Goeppert, B, Singer, S, Ploeger, C, Warsow, G, Marquardt, JU, Sticht, C, De La Torre, C, Pusch, S, Mehrabi, A, Gretz, N, Schlesner, M, Eils, R, Schirmacher, P, Longerich, T, & Roessler, S. (2020). NOTCH target gene HES5 mediates oncogenic and tumor suppressive functions in hepatocarcinogenesis. *Oncogene*, 39(15), 3128-3144. doi:10.1038/s41388-020-1198-3
227. *Ma, J, Klemm, J, Gerardo-Ramírez, M, Frappart, L, Castven, D, Becker, D, Zoch, A, Parent, R, Bartosch, B, Minnich, K, Giovannini, M, Danckwardt, S, Hartmann, N, Morrison, H, Herrlich, P, Marquardt, JU, & Hartmann, M. (2020). Cluster of differentiation 44 promotes osteosarcoma progression in mice lacking the tumor suppressor Merlin. *Int J Cancer*, 147(9), 2564-2577. doi:10.1002/ijc.33144
228. Machairas, N, Lang, H, Jayant, K, Raptis, DA, & Sotiropoulos, GC. (2020). Intrahepatic cholangiocarcinoma: Limitations for resectability, current surgical concepts and future perspectives. *Eur J Surg Oncol*, 46(5), 740-746. doi:10.1016/j.ejso.2020.01.028
229. *Mähringer-Kunz, A, Wagner, F, Hahn, F, Weinmann, A, Brodehl, S, Schotten, S, Hinrichs, JB, Düber, C, Galle, PR, Pinto Dos Santos, D, & Kloeckner, R. (2020). Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. *Liver Int*, 40(3), 694-703. doi:10.1111/liv.14380
230. *Man, AWC, Zhou, Y, Xia, N, & Li, H. (2020). Involvement of Gut Microbiota, Microbial Metabolites and Interaction with Polyphenol in Host Immunometabolism. *Nutrients*, 12(10). doi:10.3390/nu12103054
231. *Mann, C, Berlth, F, Hadzijusufovic, E, Lang, H, & Grimminger, PP. (2020). Minimally invasive esophagectomy: clinical evidence and surgical techniques. *Langenbecks Arch Surg*. doi:10.1007/s00423-020-02003-w
232. *Markowitsch, SD, Schupp, P, Lauckner, J, Vakhrusheva, O, Slade, KS, Mager, R, Efferth, T, Haferkamp, A, & Juengel, E. (2020). Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis. *Cancers (Basel)*, 12(11). doi:10.3390/cancers12113150

233. Marquard, S, Thomann, S, Weiler, SME, Bissinger, M, Lutz, T, Sticht, C, Tóth, M, de la Torre, C, Gretz, N, Straub, BK, Marquardt, J, Schirmacher, P, & Breuhahn, K. (2020). Yes-associated protein (YAP) induces a secretome phenotype and transcriptionally regulates plasminogen activator Inhibitor-1 (PAI-1) expression in hepatocarcinogenesis. *Cell Commun Signal*, 18(1), 166. doi:10.1186/s12964-020-00634-6
234. Marra, G, Valerio, M, Heidegger, I, Tsaor, I, Mathieu, R, Ceci, F, Ploussard, G, van den Bergh, RCN, Kretschmer, A, Thibault, C, Ost, P, Tilki, D, Kasivisvanathan, V, Moschini, M, Sanchez-Salas, R, Gontero, P, Karnes, RJ, Montorsi, F, & Gandaglia, G. (2020). Management of Patients with Node-positive Prostate Cancer at Radical Prostatectomy and Pelvic Lymph Node Dissection: A Systematic Review. *Eur Urol Oncol*, 3(5), 565-581. doi:10.1016/j.euo.2020.08.005
235. Martin, D, Balcermpas, P, Gollrad, J, Weiß, C, Valentini, C, Stuschke, M, Schäfer, H, Henckenberens, C, Debus, J, Krug, D, Kuhnt, T, Brunner, T, Bostel, T, Engenhart-Cabillic, R, Nestle, U, Combs, S, Belka, C, Hautmann, M, Hildebrandt, G, Gani, C, Polat, B, Rödel, C, & Fokas, E. (2020). RADIANCE - Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial. *Clin Transl Radiat Oncol*, 23, 43-49. doi:10.1016/j.ctro.2020.04.010
236. Matos-Rodrigues, GE, Grigaravicius, P, Lopez, BS, Hofmann, TG, Frappart, PO, & Martins, RAP. (2020). ATRIP protects progenitor cells against DNA damage in vivo. *Cell Death Dis*, 11(10), 923. doi:10.1038/s41419-020-03090-9
237. *Mayer, A, Haist, M, Loquai, C, Grabbe, S, Rapp, M, Roth, W, Vaupel, P, & Schmidberger, H. (2020). Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study. *Cancers (Basel)*, 12(12). doi:10.3390/cancers12123753
238. *Mayer, P, Jiang, Y, Kuder, TA, Bergmann, F, Khristenko, E, Steinle, V, Kaiser, J, Hackert, T, Kauczor, HU, Klauß, M, & Gaida, MM. (2020). Diffusion Kurtosis Imaging-A Superior Approach to Assess Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. *Cancers (Basel)*, 12(6). doi:10.3390/cancers12061656
239. *Mayer, P, Kraft, A, Witzel, HR, Marnet, N, Hörner, N, Roth, W, Heinrich, S, Hackert, T, Bergmann, F, Kauczor, HU, Klaus, M, & Gaida, MM. (2020). Restricted Water Diffusion in Diffusion-Weighted Magnetic Resonance Imaging in Pancreatic Cancer is Associated with Tumor Hypoxia. *Cancers (Basel)*, 13(1). doi:10.3390/cancers13010089
240. *Mayer, P, Linnebacher, A, Glennemeier-Marke, H, Marnet, N, Bergmann, F, Hackert, T, Klaus, M, Poth, T, & Gaida, MM. (2020). The Microarchitecture of Pancreatic Cancer as Measured by Diffusion-Weighted Magnetic Resonance Imaging Is Altered by T Cells with a Tumor Promoting Th17 Phenotype. *Int J Mol Sci*, 21(1). doi:10.3390/ijms21010346
241. Mazzei-Abba, A, Folly, CL, Coste, A, Wakeford, R, Little, MP, Raaschou-Nielsen, O, Kendall, G, Hémon, D, Nikkilä, A, Spix, C, Auvinen, A, & Spycher, BD. (2020). Epidemiological studies of natural sources of radiation and childhood cancer: current challenges and future perspectives. *J Radiol Prot*, 40(1), R1-r23. doi:10.1088/1361-6498/ab5a38
242. McNamara, MG, Lopes, A, Wasan, H, Malka, D, Goldstein, D, Shannon, J, Okusaka, T, Knox, JJ, Wagner, AD, André, T, Cunningham, D, Moehler, M, Jensen, LH, Koeberle, D, Bekaii-Saab, T, Bridgewater, J, & Valle, JW. (2020). Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. *J Hepatol*, 73(5), 1109-1117. doi:10.1016/j.jhep.2020.05.014
243. *Mehralivand, S, Harmon, SA, Shih, JH, Smith, CP, Lay, N, Argun, B, Bednarova, S, Baroni, RH, Canda, AE, Ercan, K, Girometti, R, Karaarslan, E, Kural, AR, Purysko, AS, Rais-Bahrami, S, Tonso, VM, Magi-Galluzzi, C, Gordetsky, JB, Macarenco, R, Merino, MJ, Gumuskaya, B, Saglican, Y, Sioletic, S, Warren, AY, Barrett, T, Bittencourt, L, Coskun, M, Knauss, C, Law, YM, Malayeri, AA, Margolis, DJ, Marko, J, Yakar, D, Wood, BJ, Pinto, PA, Choyke, PL, Summers, RM, & Turkbey, B. (2020). Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. *AJR Am J Roentgenol*, 215(4), 903-912. doi:10.2214/ajr.19.22573
244. Meissl, K, Simonović, N, Amenitsch, L, Witalisz-Siepracka, A, Klein, K, Lassnig, C, Puga, A, Vogl, C, Poelzl, A, Bosmann, M, Dohnal, A, Sexl, V, Müller, M, & Strobl, B. (2020). STAT1 Isoforms Differentially Regulate NK Cell Maturation and Anti-tumor Activity. *Front Immunol*, 11, 2189. doi:10.3389/fimmu.2020.02189
245. Messerschmidt, C, Obermayer, B, Klinghammer, K, Ochsenreither, S, Treue, D, Stenzinger, A, Glimm, H, Fröhling, S, Kindler, T, Brandts, CH, Schulze-Osthoff, K, Weichert, W, Tinhofer, I, Klauschen, F, Keilholz, U, Beule, D, & Rieke, DT. (2020). Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. *Int J Cancer*, 147(8), 2293-2302. doi:10.1002/ijc.33123

246. *Michel, M, Kalliga, E, Labenz, C, Straub, BK, Worns, MA, Galle, PR, & Schattenberg, JM. (2020). A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. *Z Gastroenterol*, 58(1), 57-62. doi:10.1055/a-1062-8788
247. *Michel, M, & Schattenberg, JM. (2020). [Liver-specific diagnostic for non-alcoholic fatty liver disease (NAFLD) - time to replace liver biopsy?]. *Z Gastroenterol*, 58(12), 1233-1240. doi:10.1055/a-1291-8483
248. *Mikulić, S, Fritzen, A, Scheffer, K, Strunk, J, Cabañas, C, Sperrhacke, M, Reiss, K, & Florin, L. (2020). Tetraspanin CD9 affects HPV16 infection by modulating ADAM17 activity and the ERK signalling pathway. *Med Microbiol Immunol*, 209(4), 461-471. doi:10.1007/s00430-020-00671-5
249. Modest, DP, Heinemann, V, Folprecht, G, Denecke, T, Pratschke, J, Lang, H, Bemelmans, M, Becker, T, Rentsch, M, Seehofer, D, Bruns, CJ, Gebauer, B, Held, S, Stahler, A, Heinrich, K, von Einem, JC, Stintzing, S, Neumann, UP, & Ricard, I. (2020). Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3- AIOCRK0306. *Ann Surg Oncol*, 27(7), 2389-2401. doi:10.1245/s10434-020-08219-w
250. *Moehler, M, Maderer, A, Thuss-Patience, PC, Brenner, B, Meiler, J, Ettrich, TJ, Hofheinz, RD, Al-Batran, SE, Vogel, A, Mueller, L, Lutz, MP, Lordick, F, Alsina, M, Borchert, K, Greil, R, Eisterer, W, Schad, A, Slotta-Huspenina, J, Van Cutsem, E, & Lorenzen, S. (2020). Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic oesophageal squamous cell cancer: a prospective, open-label, randomised phase III AIO/EORTC trial (POWER). *Ann Oncol*, 31(2), 228-235. doi:10.1016/j.annonc.2019.10.018
251. Monig, S, Ott, K, Gockel, I, Lorenz, D, Ludwig, K, Messmann, H, Moehler, M, Piso, P, Weimann, A, & Meyer, HJ. (2020). [S3 guidelines on gastric cancer-diagnosis and treatment of adenocarcinoma of the stomach and esophagogastric junction : Version 2.0-August 2019. AWMF register number: 032/009OL]. *Chirurg*, 91(1), 37-40. doi:10.1007/s00104-020-01112-y
252. Moore, A, Hikri, E, Goshen-Lago, T, Barkan, T, Morgenstern, S, Brook, E, Maderer, A, Roth, W, Gordon, N, Kashtan, H, Brenner, B, Moehler, M, & Aharon, IB. (2020). Young-onset gastric cancer and Epstein-Barr Virus (EBV) - a major player in the pathogenesis? *BMC Cancer*, 20(1), 34. doi:10.1186/s12885-020-6517-0
253. Moreno, P, de la Quintana Basarrate, A, Musholt, TJ, Paunovic, I, Puccini, M, Vidal, O, Ortega, J, & Kraimps, JL. (2020). Laparoscopy versus open adrenalectomy in patients with solid tumor metastases: results of a multicenter European study. *Gland Surg*, 9(Suppl 2), S159-S165. doi:10.21037/gs.2019.10.15
254. *Müller, L, Mähringer-Kunz, A, Jungmann, F, Tanyildizi, Y, Bartsch, F, Czauderna, C, Düber, C, Galle, PR, Weinmann, A, Kloeckner, R, & Hahn, F. (2020). Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score. *J Oncol*, 2020, 6180613. doi:10.1155/2020/6180613
255. *Musholt, TJ. (2020). [Resection strategy for locally advanced thyroid carcinoma]. *Chirurg*, 91(12), 1030-1037. doi:10.1007/s00104-020-01262-z
256. Musoro, JZ, Coens, C, Singer, S, Tribius, S, Oosting, SF, Groenvold, M, Simon, C, Machiels, JP, Grégoire, V, Velikova, G, Cocks, K, Sprangers, MAG, King, MT, & Bottomley, A. (2020). Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 scores in patients with head and neck cancer. *Head Neck*, 42(11), 3141-3152. doi:10.1002/hed.26363
257. Mynarek, M, von Hoff, K, Pietsch, T, Ottensmeier, H, Warmuth-Metz, M, Bison, B, Pfister, S, Korshunov, A, Sharma, T, Jaeger, N, Ryzhova, M, Zheludkova, O, Golanov, A, Rushing, EJ, Hasselblatt, M, Koch, A, Schüller, U, von Deimling, A, Sahm, F, Sill, M, Riemenschneider, MJ, Dohmen, H, Monoranu, CM, Sommer, C, Staszewski, O, Mawrin, C, Schittenhelm, J, Brück, W, Filipiński, K, Hartmann, C, Meinhardt, M, Pietschmann, K, Haberler, C, Slavc, I, Gerber, NU, Grotzer, M, Benesch, M, Schlegel, PG, Deinlein, F, von Bueren, AO, Friedrich, C, Juhnke, BO, Obrecht, D, Fleischhack, G, Kwiecien, R, Faldum, A, Kortmann, RD, Kool, M, & Rutkowski, S. (2020). Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. *J Clin Oncol*, 38(18), 2028-2040. doi:10.1200/jco.19.03057
258. Nabavizadeh, R, Petrinc, B, Necchi, A, Tsaur, I, Albersen, M, & Master, V. (2020). Utility of Minimally Invasive Technology for Inguinal Lymph Node Dissection in Penile Cancer. *J Clin Med*, 9(8). doi:10.3390/jcm9082501
259. *Nagel, M, Labenz, C, Wörns, MA, Marquardt, JU, Galle, PR, Schattenberg, JM, & Nguyen-Tat, M. (2020). Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives. *Health Qual Life Outcomes*, 18(1), 10. doi:10.1186/s12955-019-1268-9

260. Nestle, U, Adebahr, S, Kaier, K, Gkika, E, Schimek-Jasch, T, Hechtner, M, Momm, F, Gaertner, J, Becker, G, & Grosu, AL. (2020). Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial. *Radiother Oncol*, 148, 82-88. doi:10.1016/j.radonc.2020.03.018
261. Nestle, U, Schimek-Jasch, T, Kremp, S, Schaefer-Schuler, A, Mix, M, Kusters, A, Tosch, M, Hehr, T, Eschmann, SM, Bultel, YP, Hass, P, Fleckenstein, J, Thieme, A, Stockinger, M, Dieckmann, K, Miederer, M, Holl, G, Rischke, HC, Gkika, E, Adebahr, S, König, J, & Grosu, AL. (2020). Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. *Lancet Oncol*. doi:10.1016/s1470-2045(20)30013-9
262. Noordhoek, I, Blok, EJ, Meershoek-Klein Kranenbarg, E, Putter, H, Duijm-de Carpentier, M, Rutgers, EJT, Seynaeve, C, Bartlett, JMS, Vannetzel, JM, Rea, DW, Hasenburg, A, Paridaens, R, Markopoulos, CJ, Hozumi, Y, Portielje, JEA, Kroep, JR, van de Velde, CJH, & Liefers, GJ. (2020). Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials. *J Clin Oncol*, 38(28), 3273-3281. doi:10.1200/jco.19.02427
263. *Nourse, J, Spada, S, & Danckwardt, S. (2020). Emerging Roles of RNA 3'-end Cleavage and Polyadenylation in Pathogenesis, Diagnosis and Therapy of Human Disorders. *Biomolecules*, 10(6). doi:10.3390/biom10060915
264. Nwosu, ZC, Piorońska, W, Battello, N, Zimmer, AD, Dewidar, B, Han, M, Pereira, S, Blagojevic, B, Castven, D, Charlestin, V, Holenya, P, Lohead, J, De La Torre, C, Gretz, N, Sajjakulnukit, P, Zhang, L, Ward, MH, Marquardt, JU, di Magliano, MP, Lyssiotis, CA, Sleeman, J, Wölfl, S, Ebert, MP, Meyer, C, Hofmann, U, & Dooley, S. (2020). Severe metabolic alterations in liver cancer lead to ERK pathway activation and drug resistance. *EBioMedicine*, 54, 102699. doi:10.1016/j.ebiom.2020.102699
265. Olthof, PB, Aldrighetti, L, Alihanov, R, Cescon, M, Groot Koerkamp, B, Jarnagin, WR, Nadalin, S, Pratschke, J, Schmelze, M, Sparrelid, E, Lang, H, Guglielmi, A, & van Gulik, TM. (2020). Portal Vein Embolization is Associated with Reduced Liver Failure and Mortality in High-Risk Resections for Perihilar Cholangiocarcinoma. *Ann Surg Oncol*, 27(7), 2311-2318. doi:10.1245/s10434-020-08258-3
266. Pala, A, Nadji-Ohl, M, Faust, K, Rückriegel, S, Roder, C, von der Brelie, C, Forster, MT, Löbel, F, Schommer, S, Löhr, M, Renovanz, M, Gröbel, N, Rothenbacher, D, König, R, Engelke, J, Schmitz, B, Wirtz, CR, Ringel, F, Senft, C, Rohde, V, Tatagiba, M, Ernestus, RI, Vajkoczy, P, Ganslandt, O, Nagel, G, & Coburger, J. (2020). Multicentric Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients with Low-Grade Gliomas: The LoG-Glio Project. *J Neurol Surg A Cent Eur Neurosurg*, 81(1), 48-57. doi:10.1055/s-0039-1693650
267. *Paßlick, D, Reinholz, J, Simon, J, Piradashvili, K, Jiang, S, Li, M, Landfester, K, & Mailänder, V. (2020). Nanovaccine impact on dendritic cells: transcriptome analysis enables new insights into antigen and adjuvant effects. *Nanomedicine (Lond)*, 15(21), 2053-2069. doi:10.2217/nnm-2019-0460
268. *Pektor, S, Schloder, J, Klasen, B, Bausbacher, N, Wagner, DC, Schreckenberger, M, Grabbe, S, Jonuleit, H, & Miederer, M. (2020). Using immuno-PET imaging to monitor kinetics of T cell-mediated inflammation and treatment efficiency in a humanized mouse model for GvHD. *Eur J Nucl Med Mol Imaging*, 47(5), 1314-1325. doi:10.1007/s00259-019-04507-0
269. Persigehl, T, Baumhauer, M, Baeßler, B, Beyer, LP, Bludau, M, Bruns, C, Bunck, AC, Germer, CT, Grenacher, L, Hackländer, T, Haneder, S, Heinrich, S, Heusch, P, Hoffmann, M, Juchems, MS, Kröger, JR, Kotter, E, Layer, G, Maintz, D, Menke, J, Palmowski, M, Pantelis, D, Pinto Dos Santos, D, Popp, FC, Schäfer, N, Schlemmer, HP, Schreyer, AG, Siedek, F, Stippel, D, Völker, M, Waldschmidt, DT, Weber, TF, von Winterfeld, M, Wybranski, C, Zander, T, & Wessling, J. (2020). Structured Reporting of Solid and Cystic Pancreatic Lesions in CT and MRI: Consensus-Based Structured Report Templates of the German Society of Radiology (DRG). *Rofo*, 192(7), 641-656. doi:10.1055/a-1150-8217
270. *Pielenhofer, J, Sohl, J, Windbergs, M, Langguth, P, & Radsak, MP. (2020). Current Progress in Particle-Based Systems for Transdermal Vaccine Delivery. *Front Immunol*, 11, 266. doi:10.3389/fimmu.2020.00266
271. *Pollul, G, Bostel, T, Grossmann, S, Akbaba, S, Karle, H, Stockinger, M, & Schmidberger, H. (2020). Pediatric craniospinal irradiation with a short partial-arc VMAT technique for medulloblastoma tumors in dosimetric comparison. *Radiat Oncol*, 15(1), 256. doi:10.1186/s13014-020-01690-5
272. *Portaluri, M, Tramacere, F, Portaluri, T, & Gianicolo, EAL. (2020). Southern Italy: How the Availability of Radiation Therapy, Patient Outcomes, and Risk to Health Care Providers Have Changed During the Coronavirus Disease 2019 Pandemic. *Adv Radiat Oncol*, 5(4), 597-600. doi:10.1016/j.adro.2020.03.016

273. *Rades, D, Bartscht, T, Hunold, P, Schmidberger, H, König, L, Debus, J, Belka, C, Homann, N, Spillner, P, Petersen, C, Kuhnt, T, Fietkau, R, Ridwelski, K, Karcher-Kilian, K, Kranich, A, Männikkö, S, Schild, SE, Maderer, A, & Moehler, M. (2020). Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2). *Strahlenther Onkol*, 196(9), 795-804. doi:10.1007/s00066-020-01646-4
274. *Raker, VK, Becker, C, Landfester, K, & Steinbrink, K. (2020). Targeted Activation of T Cells with IL-2-Coupled Nanoparticles. *Cells*, 9(9). doi:10.3390/cells9092063
275. Ray-Coquard, I, Cibula, D, Mirza, MR, Reuss, A, Ricci, C, Colombo, N, Koch, H, Goffin, F, Gonzalez-Martin, A, Ottevanger, PB, Baumann, K, Bjorge, L, Lesoin, A, Burges, A, Rosenberg, P, Gropp-Meier, M, Harrela, M, Harter, P, Frenel, JS, Minarik, T, Pisano, C, Hasenburg, A, Merger, M, & du Bois, A. (2020). Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. *Int J Cancer*, 146(2), 439-448. doi:10.1002/ijc.32606
276. *Reinhard, K, Rengstl, B, Oehm, P, Michel, K, Billmeier, A, Hayduk, N, Klein, O, Kuna, K, Ouchan, Y, Woll, S, Christ, E, Weber, D, Suchan, M, Bukur, T, Birtel, M, Jahndel, V, Mroz, K, Hobohm, K, Kranz, L, Diken, M, Kuhlcke, K, Tureci, O, & Sahin, U. (2020). An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. *Science*, 367(6476), 446-453. doi:10.1126/science.aay5967
277. *Renovanz, M, Hickmann, AK, Nadji-Ohl, M, Keric, N, Weimann, E, Wirtz, CR, Singer, S, Ringel, F, & Coburger, J. (2020). Health-related quality of life and distress in elderly vs. younger patients with high-grade glioma-results of a multicenter study. *Support Care Cancer*, 28(11), 5165-5175. doi:10.1007/s00520-020-05354-8
278. *Renovanz, M, Hippler, M, Voss, M, Wehinger, J, Keßler, AF, Gempt, J, Nadji-Ohl, M, Weiß Lucas, C, Rapp, M, Misch, M, Coburger, J, Mehlitz, M, Meixensberger, J, Keric, N, Tabatabai, G, Blettner, M, Schranz, M, & Singer, S. (2020). Glioma patients in outpatient care-optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial. *Trials*, 21(1), 434. doi:10.1186/s13063-020-04321-2
279. *Riegel, K, & Rajalingam, K. (2020). The non-linearity of RAF-MEK signaling in dendritic cells. *Cell Cycle*, 19(18), 2249-2259. doi:10.1080/15384101.2020.1795990
280. *Riegel, K, Schloder, J, Sobczak, M, Jonuleit, H, Thiede, B, Schild, H, & Rajalingam, K. (2020). RAF kinases are stabilized and required for dendritic cell differentiation and function. *Cell Death Differ*, 27(4), 1300-1315. doi:10.1038/s41418-019-0416-4
281. *Rimassa, L, & Wörns, MA. (2020). Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. *Liver Int*. doi:10.1111/liv.14533
282. Rinaldetti, S, Worst, TS, Rempel, E, Kriegmair, MC, Hartmann, A, Porubsky, S, Bolenz, C, & Erben, P. (2020). Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer. *Sci Rep*, 10(1), 20472. doi:10.1038/s41598-020-77252-2
283. *Rodriguez-Alvarez, M, Kim, D, & Khobta, A. (2020). EGFP Reporters for Direct and Sensitive Detection of Mutagenic Bypass of DNA Lesions. *Biomolecules*, 10(6). doi:10.3390/biom10060902
284. Roick, J, Berner, R, Bernig, T, Erdlenbruch, B, Escherich, G, Faber, J, Klein, C, Bochennek, K, Kratz, C, Kuhr, J, Langler, A, Lode, HN, Metzler, M, Muller, H, Reinhardt, D, Sauerbrey, A, Schepper, F, Scheurlen, W, Schneider, D, Schwabe, GC, & Richter, M. (2020). Social inequalities in the participation and activity of children and adolescents with leukemia, brain tumors, and sarcomas (SUPATEEN): a protocol for a multicenter longitudinal prospective observational study. *BMC Pediatr*, 20(1), 48. doi:10.1186/s12887-020-1943-3
285. *Roick, J, Danker, H, Dietz, A, Papsdorf, K, & Singer, S. (2020). Predictors of changes in quality of life in head and neck cancer patients: a prospective study over a 6-month period. *Eur Arch Otorhinolaryngol*, 277(2), 559-567. doi:10.1007/s00405-019-05695-z
286. *Roldán, DB, Grimmmler, M, Hartmann, C, Hubich-Rau, S, Beißert, T, Paret, C, Cagna, G, Rohde, C, Wöll, S, Koslowski, M, Türeci, Ö, & Sahin, U. (2020). PLAC1 is essential for FGF7/FGFR11b-induced Akt-mediated cancer cell proliferation. *Oncotarget*, 11(20), 1862-1875. doi:10.18632/oncotarget.27582
287. Rosar, F, Pauly, P, Ries, M, Schaefer-Schuler, A, Maus, S, Schreckenberger, M, Khreish, F, & Ezziddin, S. (2020). Determination of split renal function by PSMA imaging: comparison of (68)Ga-PSMA-11 PET with (99m)Tc-MAG3 scintigraphy. *Am J Nucl Med Mol Imaging*, 10(5), 249-256.

288. Rosar, F, Ribbat, K, Ries, M, Linxweiler, J, Bartholomä, M, Maus, S, Schreckenberger, M, Ezziddin, S, & Khreish, F. (2020). Neuron-specific enolase has potential value as a biomarker for [(18)F]FDG/[(68)Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients. *EJNMMI Res*, 10(1), 52. doi:10.1186/s13550-020-00640-2
289. Rosenzweig, B, Bex, A, Dotan, ZA, Frydenberg, M, Klotz, L, Lotan, Y, Schulman, CC, Tsaur, I, & Ramon, J. (2020). Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists. *Urol Oncol*, 38(12), 929.e921-929.e910. doi:10.1016/j.urolonc.2020.09.015
290. Roth, S, Zamzow, K, Gaida, MM, Heikenwälder, M, Tjaden, C, Hinz, U, Bose, P, Michalski, CW, & Hackert, T. (2020). Evolution of the immune landscape during progression of pancreatic intraductal papillary mucinous neoplasms to invasive cancer. *EBioMedicine*, 54, 102714. doi:10.1016/j.ebiom.2020.102714
291. *Ruf, W, & Graf, C. (2020). Coagulation signaling and cancer immunotherapy. *Thromb Res*, 191 Suppl 1, S106-s111. doi:10.1016/s0049-3848(20)30406-0
292. Ruhnke, M, Cornely, OA, Schmidt-Hieber, M, Alakel, N, Boell, B, Buchheidt, D, Christopeit, M, Hasenkamp, J, Heinz, WJ, Hentrich, M, Karthaus, M, Koldehoff, M, Maschmeyer, G, Panse, J, Penack, O, Schleicher, J, Teschner, D, Ullmann, AJ, Vehreschild, M, von Lilienfeld-Toal, M, Weissinger, F, & Schwartz, S. (2020). Treatment of invasive fungal diseases in cancer patients-Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). *Mycoses*, 63(7), 653-682. doi:10.1111/myc.13082
293. *Sahin, U, Oehm, P, Derhovanessian, E, Jabulowsky, RA, Vormehr, M, Gold, M, Maurus, D, Schwarck-Kokarakis, D, Kuhn, AN, Omokoko, T, Kranz, LM, Diken, M, Kreiter, S, Haas, H, Attig, S, Rae, R, Cuk, K, Kemmer-Brück, A, Breitzkreuz, A, Tolliver, C, Caspar, J, Quinkhardt, J, Hebich, L, Stein, M, Hohberger, A, Vogler, I, Liebig, I, Renken, S, Sikorski, J, Leierer, M, Müller, V, Mitzel-Rink, H, Miederer, M, Huber, C, Grabbe, S, Utikal, J, Pinter, A, Kaufmann, R, Hassel, JC, Loquai, C, & Türeci, Ö. (2020). An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. *Nature*, 585(7823), 107-112. doi:10.1038/s41586-020-2537-9
294. *Salazar, Y, Zheng, X, Brunn, D, Raifer, H, Picard, F, Zhang, Y, Winter, H, Guenther, S, Weigert, A, Weigmann, B, Dumoutier, L, Renauld, JC, Waisman, A, Schmall, A, Tufman, A, Fink, L, Brüne, B, Bopp, T, Grimminger, F, Seeger, W, Pullamsetti, SS, Huber, M, & Savai, R. (2020). Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. *J Clin Invest*, 130(7), 3560-3575. doi:10.1172/jci124037
295. Salzmann, M, Leiter, U, Loquai, C, Zimmer, L, Ugurel, S, Gutzmer, R, Thoms, KM, Enk, AH, & Hassel, JC. (2020). Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. *Eur J Cancer*, 138, 125-132. doi:10.1016/j.ejca.2020.07.029
296. *Sangro, B, Chan, SL, Meyer, T, Reig, M, El-Khoueiry, A, & Galle, PR. (2020). Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. *J Hepatol*, 72(2), 320-341. doi:10.1016/j.jhep.2019.10.021
297. *Schattenberg, JM. (2020). Emerging Pharmacological Treatment in Nonalcoholic Steatohepatitis. *Visc Med*, 36(5), 411-416. doi:10.1159/000507231
298. *Schaupp, L, Muth, S, Rogell, L, Kofoed-Branzk, M, Melchior, F, Lienenklaus, S, Ganai-Vonarburg, SC, Klein, M, Guendel, F, Hain, T, Schütze, K, Grundmann, U, Schmitt, V, Dorsch, M, Spanier, J, Larsen, PK, Schwanz, T, Jäckel, S, Reinhardt, C, Bopp, T, Danckwardt, S, Mahnke, K, Heinz, GA, Mashregi, MF, Durek, P, Kalinke, U, Kretz, O, Huber, TB, Weiss, S, Wilhelm, C, Macpherson, AJ, Schild, H, Diefenbach, A, & Probst, HC. (2020). Microbiota-Induced Type I Interferons Instruct a Poised Basal State of Dendritic Cells. *Cell*, 181(5), 1080-1096.e1019. doi:10.1016/j.cell.2020.04.022
299. *Scherger, M, Bolli, E, Antunes, ARP, Arnouk, S, Stickdorn, J, Van Driessche, A, Schild, H, Grabbe, S, De Geest, BG, Van Ginderachter, JA, & Nuhn, L. (2020). Transient Multivalent Nanobody Targeting to CD206-Expressing Cells via PH-Degradable Nanogels. *Cells*, 9(10). doi:10.3390/cells9102222
300. *Schimanski, CC, Kasper, S, Hegewisch-Becker, S, Schröder, J, Overkamp, F, Kullmann, F, Bechstein, WO, Vöhringer, M, Öllinger, R, Lordick, F, Heinemann, V, Geißler, M, Schulz-Abelius, A, Bernhard, H, Schön, MR, Greil, R, Galle, P, Lang, H, Schmidtman, I, & Moehler, M. (2020). Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). *Oncoimmunology*, 9(1), 1806680. doi:10.1080/2162402x.2020.1806680
301. Schleicher, S, Grote, S, Malenke, E, Chan, KC, Schaller, M, Fehrenbacher, B, Riester, R, Kluba, T, Frauenfeld, L, Boesmueller, H, Göhring, G, Schlegelberger, B, Handgretinger, R, Kopp, HG, Traub, F, & Boehme, KA. (2020).

Establishment and Characterization of a Sclerosing Spindle Cell Rhabdomyosarcoma Cell Line with a Complex Genomic Profile. *Cells*, 9(12). doi:10.3390/cells9122668

302. Schlenk, RF, Paschka, P, Krzykalla, J, Weber, D, Kapp-Schwoerer, S, Gaidzik, VI, Leis, C, Fiedler, W, Kindler, T, Schroeder, T, Mayer, K, Lubbert, M, Wattad, M, Gotze, K, Horst, HA, Koller, E, Wulf, G, Schleicher, J, Bentz, M, Greil, R, Hertenstein, B, Krauter, J, Martens, U, Nachbaur, D, Abu Samra, M, Girschikofsky, M, Basara, N, Benner, A, Thol, F, Heuser, M, Ganser, A, Dohner, K, & Dohner, H. (2020). Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. *J Clin Oncol*, 38(6), 623-632. doi:10.1200/jco.19.01406
303. *Schmidt, M. (2020). Prognostic and predictive markers for adjuvant therapy. *Curr Opin Obstet Gynecol*, 32(1), 100-105. doi:10.1097/gco.0000000000000594
304. Schnitzbauer, AA, Eberhard, J, Bartsch, F, Brunner, SM, Ceyhan, GO, Walter, D, Fries, H, Hannes, S, Hecker, A, Li, J, Oldhafer, K, Rahbari, N, Rauchfuss, F, Schlitt, HJ, Settmacher, U, Stavrou, G, Weitz, J, Lang, H, Bechstein, WO, & Rückert, F. (2020). The MEGNA Score and Preoperative Anemia are Major Prognostic Factors After Resection in the German Intrahepatic Cholangiocarcinoma Cohort. *Ann Surg Oncol*, 27(4), 1147-1155. doi:10.1245/s10434-019-07968-7
305. Schöpf, B, Weissensteiner, H, Schäfer, G, Fazzini, F, Charoentong, P, Naschberger, A, Rupp, B, Fendt, L, Bukur, V, Giese, I, Sorn, P, Sant'Anna-Silva, AC, Iglesias-Gonzalez, J, Sahin, U, Kronenberg, F, Gnaiger, E, & Klocker, H. (2020). OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation. *Nat Commun*, 11(1), 1487. doi:10.1038/s41467-020-15237-5
306. *Schrörs, B, Boegel, S, Albrecht, C, Bukur, T, Bukur, V, Holtsträter, C, Ritzel, C, Manninen, K, Tadmor, AD, Vormehr, M, Sahin, U, & Löwer, M. (2020). Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model. *Front Oncol*, 10, 1195. doi:10.3389/fonc.2020.01195
307. Schulz, C, Heinemann, V, Heinrich, K, Haas, M, Holch, JW, Fraccaroli, A, Held, S, von Einem, JC, Modest, DP, Fischer von Weikersthal, L, Kullmann, F, Moehler, M, Scheithauer, W, Jung, A, & Stintzing, S. (2020). Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. *Anticancer Drugs*, 31(8), 856-865. doi:10.1097/cad.0000000000000965
308. Schündeln, MM, Lange, T, Knoll, M, Spix, C, Brenner, H, Bozorgmehr, K, & Stock, C. (2020). Methods of spatial cluster detection in rare childhood cancers: Benchmarking data and results from a simulation study on nephroblastoma. *Data Brief*, 34, 106683. doi:10.1016/j.dib.2020.106683
309. *Seibold, P, Auvinen, A, Auerbeck, D, Bourguignon, M, Hartikainen, JM, Hoeschen, C, Laurent, O, Noël, G, Sabatier, L, Salomaa, S, & Blettner, M. (2020). Clinical and epidemiological observations on individual radiation sensitivity and susceptibility. *Int J Radiat Biol*, 96(3), 324-339. doi:10.1080/09553002.2019.1665209
310. *Seiwert, N, Heylmann, D, Hasselwander, S, & Fahrner, J. (2020). Mechanism of colorectal carcinogenesis triggered by heme iron from red meat. *Biochim Biophys Acta Rev Cancer*, 1873(1), 188334. doi:10.1016/j.bbcan.2019.188334
311. *Seiwert, N, Wecklein, S, Demuth, P, Hasselwander, S, Kemper, TA, Schwerdtle, T, Brunner, T, & Fahrner, J. (2020). Heme oxygenase 1 protects human colonocytes against ROS formation, oxidative DNA damage and cytotoxicity induced by heme iron, but not inorganic iron. *Cell Death Dis*, 11(9), 787. doi:10.1038/s41419-020-02950-8
312. Sellmer, A, Pils, B, Beyer, M, Pongratz, H, Wirth, L, Elz, S, Dove, S, Henninger, SJ, Spiekermann, K, Polzer, H, Klaeger, S, Kuster, B, Böhmer, FD, Fiebig, HH, Krämer, OH, & Mahboobi, S. (2020). A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia. *Eur J Med Chem*, 193, 112232. doi:10.1016/j.ejmech.2020.112232
313. *Sethi, R, Becker, J, Graaf, J, Löwer, M, Suchan, M, Sahin, U, & Weber, D. (2020). Integrative analysis of structural variations using short-reads and linked-reads yields highly specific and sensitive predictions. *PLoS Comput Biol*, 16(11), e1008397. doi:10.1371/journal.pcbi.1008397
314. Shiban, E, Joerger, AK, Janssen, I, Issa, M, Lange, N, Wagner, A, Feihl, S, Ringel, F, & Meyer, B. (2020). Low-Grade Infection and Implant Failure Following Spinal Instrumentation: A Prospective Comparative Study. *Neurosurgery*, 87(5), 964-970. doi:10.1093/neuros/nyaa133

315. Siedek, F, Muehe, AM, Theruvath, AJ, Avedian, R, Pribnow, A, Spunt, SL, Liang, T, Farrell, C, & Daldrup-Link, HE. (2020). Comparison of ferumoxytol- and gadolinium chelate-enhanced MRI for assessment of sarcomas in children and adolescents. *Eur Radiol*, 30(3), 1790-1803. doi:10.1007/s00330-019-06569-y
316. *Siemer, S, Wunsch, D, Khamis, A, Lu, Q, Scherberich, A, Filippi, M, Krafft, MP, Hagemann, J, Weiss, C, Ding, GB, Stauber, RH, & Gribko, A. (2020). Nano Meets Micro-Translational Nanotechnology in Medicine: Nano-Based Applications for Early Tumor Detection and Therapy. *Nanomaterials (Basel)*, 10(2). doi:10.3390/nano10020383
317. *Siewert, CD, Haas, H, Cornet, V, Nogueira, SS, Nawroth, T, Uebbing, L, Ziller, A, Al-Gousous, J, Radulescu, A, Schroer, MA, Blanchet, CE, Svergun, DI, Radsak, MP, Sahin, U, & Langguth, P. (2020). Hybrid Biopolymer and Lipid Nanoparticles with Improved Transfection Efficacy for mRNA. *Cells*, 9(9). doi:10.3390/cells9092034
318. Smyth, E, Knodler, M, Giraut, A, Mauer, M, Nilsson, M, Van Grieken, N, Wagner, AD, Moehler, M, & Lordick, F. (2020). VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. *Front Oncol*, 9, 1320. doi:10.3389/fonc.2019.01320
319. Sommer, U, Eckstein, M, Ammann, J, Braunschweig, T, Macher-Göppinger, S, Schwamborn, K, Hieke-Schulz, S, Harlow, G, Flores, M, Wullich, B, Wirth, M, Roth, W, Knüchel, R, Weichert, W, Baretton, G, & Hartmann, A. (2020). Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma. *Clin Genitourin Cancer*, 18(5), e629-e642. doi:10.1016/j.clgc.2020.02.009
320. *Sorn, P, Holtstrater, C, Lower, M, Sahin, U, & Weber, D. (2020). ArtiFuse-computational validation of fusion gene detection tools without relying on simulated reads. *Bioinformatics*, 36(2), 373-379. doi:10.1093/bioinformatics/btz613
321. *Sprang, M, Paret, C, & Faber, J. (2020). CpG-Islands as Markers for Liquid Biopsies of Cancer Patients. *Cells*, 9(8). doi:10.3390/cells9081820
322. Staartjes, VE, Broggi, M, Zattra, CM, Vasella, F, Velz, J, Schiavolin, S, Serra, C, Bartek, J, Fletcher-Sandersjö, A, Förander, P, Kalasauskas, D, Renovanz, M, Ringel, F, Brawanski, KR, Kerschbaumer, J, Freyschlag, CF, Jakola, AS, Sjøvik, K, Solheim, O, Schatlo, B, Sachkova, A, Bock, HC, Hussein, A, Rohde, V, Broekman, MLD, Nogarede, CO, Lemmens, CMC, Kernbach, JM, Neuloh, G, Bozinov, O, Krayenbühl, N, Sarnthein, J, Ferroli, P, Regli, L, & Stienen, MN. (2020). Development and external validation of a clinical prediction model for functional impairment after intracranial tumor surgery. *J Neurosurg*, 134(6), 1743-1750. doi:10.3171/2020.4.Jns20643
323. Stahler, A, Stintzing, S, Modest, DP, Ricard, I, Giessen-Jung, C, Kapaun, C, Ivanova, B, Kaiser, F, Fischer von Weikersthal, L, Moosmann, N, Schalhorn, A, Stauch, M, Kiani, A, Held, S, Decker, T, Moehler, M, Neumann, J, Kirchner, T, Jung, A, & Heinemann, V. (2020). Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials. *Clin Cancer Res*, 26(24), 6559-6567. doi:10.1158/1078-0432.Ccr-20-2748
324. Stahler, A, Stintzing, S, von Einem, JC, Westphalen, CB, Heinrich, K, Krämer, N, Michl, M, Modest, DP, von Weikersthal, LF, Decker, T, Kiani, A, Heintges, T, Kahl, C, Kullmann, F, Scheithauer, W, Moehler, M, Kaiser, F, Kirchner, T, Jung, A, & Heinemann, V. (2020). Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial. *Eur J Cancer*, 137, 250-259. doi:10.1016/j.ejca.2020.07.003
325. *Staubitz, JI, Bode, J, Poplawski, A, Watzka, F, Pohlenz, J, Lang, H, & Musholt, TJ. (2020). Thyroid surgery in children and young adults: potential overtreatment and complications. *Langenbecks Arch Surg*, 405(4), 451-460. doi:10.1007/s00423-020-01896-x
326. *Stenzel, PJ, Schindeldecker, M, Tagscherer, KE, Foersch, S, Herpel, E, Hohenfellner, M, Hatiboglu, G, Alt, J, Thomas, C, Haferkamp, A, Roth, W, & Macher-Goeppinger, S. (2020). Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma. *Transl Oncol*, 13(2), 336-345. doi:10.1016/j.tranon.2019.11.002
327. Stern, H, Seidenbusch, M, Hapfelmeier, A, Meierhofer, C, Naumann, S, Schmid, I, Spix, C, & Ewert, P. (2020). Increased Cancer Incidence Following up to 15 Years after Cardiac Catheterization in Infants under One Year between 1980 and 1998-A Single Center Observational Study. *J Clin Med*, 9(2). doi:10.3390/jcm9020315
328. Stickel, F, Lutz, P, Buch, S, Nischalke, HD, Silva, I, Rausch, V, Fischer, J, Weiss, KH, Gotthardt, D, Rosendahl, J, Marot, A, Elamly, M, Krawczyk, M, Casper, M, Lammert, F, Buckley, TWM, McQuillin, A, Spengler, U, Eyer, F, Vogel, A,

- Marhenke, S, von Felden, J, Wege, H, Sharma, R, Atkinson, S, Franke, A, Nehring, S, Moser, V, Schafmayer, C, Spahr, L, Lackner, C, Stauber, RE, Canbay, A, Link, A, Valenti, L, Grove, JI, Aithal, GP, Marquardt, JU, Fateen, W, Zopf, S, Dufour, JF, Trebicka, J, Datz, C, Deltenre, P, Mueller, S, Berg, T, Hampe, J, & Morgan, MY. (2020). Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers. *Hepatology*, 72(1), 88-102. doi:10.1002/hep.30996
329. *Stössel, S, Neu, MA, Wingerter, A, Bloch, W, Zimmer, P, Paret, C, Malki, KE, Baumann, FT, Russo, A, Henninger, N, Lehmann, N, Otto, H, & Faber, J. (2020). Benefits of Exercise Training for Children and Adolescents Undergoing Cancer Treatment: Results From the Randomized Controlled MUCKI Trial. *Front Pediatr*, 8, 243. doi:10.3389/fped.2020.00243
330. *Tagkalos, E, Goense, L, Hoppe-Lotichius, M, Ruurda, JP, Babic, B, Hadzijusufovic, E, Kneist, W, van der Sluis, PC, Lang, H, van Hillegersberg, R, & Grimmering, PP. (2020). Robot-assisted minimally invasive esophagectomy (RAMIE) compared to conventional minimally invasive esophagectomy (MIE) for esophageal cancer: a propensity-matched analysis. *Dis Esophagus*. doi:10.1093/dote/doz060
331. Taylor, RS, Taylor, RJ, Bayliss, S, Hagström, H, Nasr, P, Schattenberg, JM, Ishigami, M, Toyoda, H, Wai-Sun Wong, V, Peleg, N, Shlomai, A, Sebastiani, G, Seko, Y, Bhala, N, Younossi, ZM, Anstee, QM, McPherson, S, & Newsome, PN. (2020). Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Gastroenterology*, 158(6), 1611-1625.e1612. doi:10.1053/j.gastro.2020.01.043
332. *Theruvath, AJ, Siedek, F, Muehe, AM, Garcia-Diaz, J, Kirchner, J, Martin, O, Link, MP, Spunt, S, Pribnow, A, Rosenberg, J, Herrmann, K, Gatidis, S, Schäfer, JF, Moseley, M, Umutlu, L, & Daldrup-Link, HE. (2020). Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI. *Radiology*, 296(1), 143-151. doi:10.1148/radiol.2020192508
333. *Thiramanas, R, Jiang, S, Simon, J, Landfester, K, & Mailänder, V. (2020). Silica Nanocapsules with Different Sizes and Physicochemical Properties as Suitable Nanocarriers for Uptake in T-Cells. *Int J Nanomedicine*, 15, 6069-6084. doi:10.2147/ijn.S246322
334. *Thiramanas, R, Li, M, Jiang, S, Landfester, K, & Mailänder, V. (2020). Cellular Uptake of siRNA-Loaded Nanocarriers to Knockdown PD-L1: Strategies to Improve T-cell Functions. *Cells*, 9(9). doi:10.3390/cells9092043
335. *Thomaidis, T, Kallimanis, G, May, G, Zhou, P, Sivanathan, V, Mosko, J, Triantafyllidis, JK, Teshima, C, & Moehler, M. (2020). Advances in the endoscopic management of malignant biliary obstruction. *Ann Gastroenterol*, 33(4), 338-347. doi:10.20524/aog.2020.0497
336. *Thomas, A, Vanthoor, J, Vos, G, Tsaar, I, & Albersen, M. (2020). Risk factors and molecular characterization of penile cancer: impact on prognosis and potential targets for systemic therapy. *Curr Opin Urol*, 30(2), 202-207. doi:10.1097/mou.0000000000000712
337. *Uebbing, L, Ziller, A, Siewert, C, Schroer, MA, Blanchet, CE, Svergun, DI, Ramishetti, S, Peer, D, Sahin, U, Haas, H, & Langguth, P. (2020). Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. *Langmuir*, 36(44), 13331-13341. doi:10.1021/acs.langmuir.0c02446
338. Unsoeld, M, Lamprecht, U, Traub, F, Hermes, B, Scharpf, M, Potkrajic, V, Zips, D, Paulsen, F, & Eckert, F. (2020). MR Thermometry Data Correlate with Pathological Response for Soft Tissue Sarcoma of the Lower Extremity in a Single Center Analysis of Prospectively Registered Patients. *Cancers (Basel)*, 12(4). doi:10.3390/cancers12040959
339. Valentin, ML, Barco, S, Studer, G, Clemens, R, Kreuzpointner, R, Sebastian, T, Thalhammer, C, & Kucher, N. (2020). Prevalence of carotid plaque stenosis after head and neck radiotherapy - an observational study of 156 survivors. *Vasa*, 49(6), 467-473. doi:10.1024/0301-1526/a000896
340. Vanthoor, J, Thomas, A, Tsaar, I, & Albersen, M. (2020). Making surgery safer by centralization of care: impact of case load in penile cancer. *World J Urol*, 38(6), 1385-1390. doi:10.1007/s00345-019-02866-9
341. *Vermehren, MF, Wiesmann, N, Deschner, J, Brieger, J, Al-Nawas, B, & Kämmerer, PW. (2020). Comparative analysis of the impact of e-cigarette vapor and cigarette smoke on human gingival fibroblasts. *Toxicol In Vitro*, 69, 105005. doi:10.1016/j.tiv.2020.105005
342. *Vogt, A, Stiel, S, Heckel, M, Goebel, S, Mai, SS, Seifert, A, Gerlach, C, Ostgathe, C, & Weber, M. (2020). Assessment of the quality of end-of-life care: translation and validation of the German version of the "Care of the Dying Evaluation" (CODE-GER) - a questionnaire for bereaved relatives. *Health Qual Life Outcomes*, 18(1), 311. doi:10.1186/s12955-020-01473-2

343. Volcic, M, Sparrer, KMJ, Koepke, L, Hotter, D, Sauter, D, Stürzel, CM, Scherer, M, Stamminger, T, Hofmann, TG, Arhel, NJ, Wiesmüller, L, & Kirchhoff, F. (2020). Vpu modulates DNA repair to suppress innate sensing and hyper-integration of HIV-1. *Nat Microbiol*, 5(10), 1247-1261. doi:10.1038/s41564-020-0753-6
344. *Vormehr, M, Diken, M, Tureci, O, Sahin, U, & Kreiter, S. (2020). Personalized Neo-Epitope Vaccines for Cancer Treatment. *Recent Results Cancer Res*, 214, 153-167. doi:10.1007/978-3-030-23765-3_5
345. *Wagner, AD, Lordick, F, Grabsch, HI, Terashima, M, Terada, M, Yoshikawa, T, Boku, N, Kataoka, K, Smyth, EC, Mauer, M, Haustermans, K, & Moehler, MH. (2020). Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. *Eur J Cancer*, 124, 67-76. doi:10.1016/j.ejca.2019.09.006
346. *Waldmann, CM, Kopka, K, & Wagner, S. (2020). (18)F-Labeled Small-Molecule and Low-Molecular-Weight PET Tracers for the Noninvasive Detection of Cancer. *Recent Results Cancer Res*, 216, 283-318. doi:10.1007/978-3-030-42618-7_8
347. Wang, D, Tabti, R, Elderwish, S, Abou-Hamdan, H, Djehal, A, Yu, P, Yurugi, H, Rajalingam, K, Nebigil, CG, & Désaubry, L. (2020). Prohibitin ligands: a growing armamentarium to tackle cancers, osteoporosis, inflammatory, cardiac and neurological diseases. *Cell Mol Life Sci*, 77(18), 3525-3546. doi:10.1007/s00018-020-03475-1
348. Wei, G, An, P, Vaid, KA, Nasser, I, Huang, P, Tan, L, Zhao, S, Schuppan, D, & Popov, YV. (2020). Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer. *Am J Physiol Gastrointest Liver Physiol*, 318(1), G174-g188. doi:10.1152/ajpgi.00041.2019
349. Weiland, T, Eckert, A, Tomazic, PV, Wolf, A, Pondorfer, P, Vasicek, S, Graupp, M, Holzmeister, C, Moser, U, Andrianakis, A, Kangler, G, Kiss, P, Brcic, L, Kappler, M, Wickenhauser, C, Haak, A, Krüger, M, Al-Nawas, B, Blatt, S, Brockmeyer, N, Skaletz-Rorowski, A, Potthoff, A, French, LE, Charnowski, S, Reinholz, M, Kaufmann, AM, Thies, S, Lambrecht, HG, Seliger, B, Wild, DC, & Thurnher, D. (2020). DRH1 - a novel blood-based HPV tumour marker. *EBioMedicine*, 56, 102804. doi:10.1016/j.ebiom.2020.102804
350. *Weinmann, A, & Galle, PR. (2020). Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. *Curr Oncol*, 27(Suppl 3), S152-s164. doi:10.3747/co.27.7315
351. Weise, F, Vieth, M, Reinhold, D, Haybaeck, J, Goni, E, Lippert, H, Ridwelski, K, Lingohr, P, Schildberg, C, Vassos, N, Kruschewski, M, Krasniuk, I, Grimminger, PP, Waidmann, O, Peitz, U, Veits, L, Kreuser, N, Lang, H, Bruns, C, Moehler, M, Lordick, F, Gockel, I, Schumacher, J, Malfertheiner, P, & Venerito, M. (2020). Gastric cancer in autoimmune gastritis: A case-control study from the German centers of the staR project on gastric cancer research. *United European Gastroenterol J*, 8(2), 175-184. doi:10.1177/2050640619891580
352. Weisel, K, Spencer, A, Lentzsch, S, Avet-Loiseau, H, Mark, TM, Spicka, I, Masszi, T, Lauri, B, Levin, MD, Bosi, A, Hungria, V, Cavo, M, Lee, JJ, Nooka, A, Quach, H, Munder, M, Lee, C, Barreto, W, Corradini, P, Min, CK, Chanan-Khan, AA, Horvath, N, Capra, M, Beksac, M, Ovilla, R, Jo, JC, Shin, HJ, Sonneveld, P, Casneuf, T, DeAngelis, N, Amin, H, Ukropec, J, Kobos, R, & Mateos, MV. (2020). Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk. *J Hematol Oncol*, 13(1), 115. doi:10.1186/s13045-020-00948-5
353. Westphalen, BC, Bokemeyer, C, Büttner, R, Fröhling, S, Gaidzik, VI, Glimm, H, Hacker, UT, Heinemann, V, Illert, AL, Keilholz, U, Kindler, T, Kirschner, M, Schilling, B, Siveke, JT, Schroeder, T, Tischler, V, Wagner, S, Weichert, W, Zips, D, & Loges, S. (2020). Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group 'Molecular Diagnostics and Therapy'. *Eur J Cancer*, 135, 1-7. doi:10.1016/j.ejca.2020.04.019
354. Wiechmann, S, Maisonneuve, P, Grebbin, BM, Hoffmeister, M, Kaulich, M, Clevers, H, Rajalingam, K, Kurinov, I, Farin, HF, Sicheri, F, & Ernst, A. (2020). Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids. *J Biol Chem*. doi:10.1074/jbc.RA119.011025
355. *Wiesmann, N, Tremel, W, & Brieger, J. (2020). Zinc oxide nanoparticles for therapeutic purposes in cancer medicine. *J Mater Chem B*, 8(23), 4973-4989. doi:10.1039/d0tb00739k
356. *Woelfinger, P, Epp, K, Schaefer, L, Kriege, D, Theobald, M, Bopp, T, & Wagner-Drouet, EM. (2020). CD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimen. *Br J Haematol*, 191(2), 253-262. doi:10.1111/bjh.16706

357. *Woerl, AC, Eckstein, M, Geiger, J, Wagner, DC, Daher, T, Stenzel, P, Fernandez, A, Hartmann, A, Wand, M, Roth, W, & Foersch, S. (2020). Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides. *Eur Urol*, 78(2), 256-264. doi:10.1016/j.eururo.2020.04.023
358. Wörmann, B, Bokemeyer, C, Burmeister, T, Köhne, CH, Schwab, M, Arnold, D, Blohmer, JU, Borner, M, Brucker, S, Cascorbi, I, Decker, T, de Wit, M, Dietz, A, Einsele, H, Eisterer, W, Folprecht, G, Hilbe, W, Hoffmann, J, Knauf, W, Kunzmann, V, Largiadèr, CR, Lorenzen, S, Lüftner, D, Moehler, M, Nöthen, MM, Pox, C, Reinacher-Schick, A, Scharl, A, Schlegelberger, B, Seufferlein, T, Sinn, M, Stroth, M, Tamm, I, Trümper, L, Wilhelm, M, Wöll, E, & Hofheinz, RD. (2020). Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper. *Oncol Res Treat*, 43(11), 628-636. doi:10.1159/000510258
359. Xu, X, Honda, K, Miura, N, Hori, S, Le Blanc, S, Bergmann, F, Gaida, MM, Volkmar, M, Schimmack, S, Hackert, T, Strobel, O, & Felix, K. (2020). Actinin-4 splice variant - a complementary diagnostic and prognostic marker of pancreatic neuroendocrine neoplasms. *J Cancer*, 11(8), 2318-2328. doi:10.7150/jca.37503
360. *Yamamoto, S, Sano, Y, Mottacki, N, & Neumann, H. (2020). Axis-keeping shortening technique for colonic intubation. *VideoGIE*, 5(12), 630-633. doi:10.1016/j.vgie.2020.08.005
361. *Yan, G, Dawood, M, Böckers, M, Klauck, SM, Fottner, C, Weber, MM, & Efferth, T. (2020). Multiple modes of cell death in neuroendocrine tumors induced by artesunate. *Phytomedicine*, 79, 153332. doi:10.1016/j.phymed.2020.153332
362. *Yurugi, H, Zhuang, Y, Siddiqui, FA, Liang, H, Rosigkeit, S, Zeng, Y, Abou-Hamdan, H, Bockamp, E, Zhou, Y, Abankwa, D, Zhao, W, Désaubry, L, & Rajalingam, K. (2020). A subset of flavaglines inhibits KRAS nanoclustering and activation. *J Cell Sci*, 133(12). doi:10.1242/jcs.244111
363. *Zahnreich, S, Poplawski, A, Hartel, C, Eckhard, LS, Galetzka, D, Hankeln, T, Löbrich, M, Marron, M, Mirsch, J, Ritter, S, Scholz-Kreisel, P, Spix, C, & Schmidberger, H. (2020). Spontaneous and Radiation-Induced Chromosome Aberrations in Primary Fibroblasts of Patients With Pediatric First and Second Neoplasms. *Front Oncol*, 10, 1338. doi:10.3389/fonc.2020.01338
364. *Zahnreich, S, Rösler, HP, Schwanbeck, C, Karle, H, & Schmidberger, H. (2020). Radiation-induced DNA double-strand breaks in peripheral leukocytes and therapeutic response of heel spur patients treated by orthovoltage X-rays or a linear accelerator. *Strahlenther Onkol*, 196(12), 1116-1127. doi:10.1007/s00066-020-01662-4
365. *Zahnreich, S, Weber, B, Rösch, G, Schindler, D, & Schmidberger, H. (2020). Compromised repair of radiation-induced DNA double-strand breaks in Fanconi anemia fibroblasts in G2. *DNA Repair (Amst)*, 96, 102992. doi:10.1016/j.dnarep.2020.102992
366. Zastrow, S, Krabbe, LM, Wolff, I, Capitanio, U, Klatte, T, Ecke, T, Huck, N, Borgmann, H, Scavuzzo, A, Cindolo, L, Schips, L, Surcel, C, Mirvald, C, Cabo, AV, Musquera, M, Hutterer, G, Prochazkova, K, Stief, C, Wirth, M, May, M, & Brookman-May, S. (2020). External validation of a postoperative nomogram for the prediction of disease-specific survival in patients with papillary renal cell carcinoma using a large multicenter database. *Int J Clin Oncol*, 25(1), 145-150. doi:10.1007/s10147-019-01530-x
367. Zebralla, V, Müller, J, Wald, T, Boehm, A, Wichmann, G, Berger, T, Birnbaum, K, Heuermann, K, Oeltze-Jafra, S, Neumuth, T, Singer, S, Büttner, M, Dietz, A, & Wiegand, S. (2020). Obtaining Patient-Reported Outcomes Electronically With "OncoFunction" in Head and Neck Cancer Patients During Aftercare. *Front Oncol*, 10, 549915. doi:10.3389/fonc.2020.549915
368. Zeiser, R, von Bubnoff, N, Butler, J, Mohty, M, Niederwieser, D, Or, R, Szer, J, Wagner, EM, Zuckerman, T, Mahuzier, B, Xu, J, Wilke, C, Gandhi, KK, & Socié, G. (2020). Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. *N Engl J Med*, 382(19), 1800-1810. doi:10.1056/NEJMoa1917635
369. *Zhao, F, Vakhrusheva, O, Markowitsch, SD, Slade, KS, Tsaur, I, Cinatl, J, Jr., Michaelis, M, Efferth, T, Haferkamp, A, & Juengel, E. (2020). Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction. *Cells*, 9(12). doi:10.3390/cells9122643
370. Zhu, AX, Nipp, RD, Finn, RS, Galle, PR, Llovet, JM, Blanc, JF, Okusaka, T, Chau, I, Cella, D, Girvan, A, Gable, J, Bowman, L, Wang, C, Hsu, Y, Abada, PB, & Kudo, M. (2020). Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. *ESMO Open*, 5(4). doi:10.1136/esmoopen-2020-000797

371. Ziegler, V, Deußen, M, Schumacher, L, Roos, WP, & Fritz, G. (2020). Anticancer drug and ionizing radiation-induced DNA damage differently influences transcription activity and DDR-related stress responses of an endothelial monolayer. *Biochim Biophys Acta Mol Cell Res*, 1867(6), 118678. doi:10.1016/j.bbamcr.2020.118678
372. Zimmer, L, Livingstone, E, Hassel, JC, Fluck, M, Eigentler, T, Loquai, C, Haferkamp, S, Gutzmer, R, Meier, F, Mohr, P, Hauschild, A, Schilling, B, Menzer, C, Kieker, F, Dippel, E, Rösch, A, Simon, JC, Conrad, B, Körner, S, Windemuth-Kieselbach, C, Schwarz, L, Garbe, C, Becker, JC, & Schadendorf, D. (2020). Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet*, 395(10236), 1558-1568. doi:10.1016/s0140-6736(20)30417-7
373. *Zimmer, N, Krebs, FK, Zimmer, S, Mitzel-Rink, H, Kumm, EJ, Jurk, K, Grabbe, S, Loquai, C, & Tuettenberg, A. (2020). Platelet-Derived GARP Induces Peripheral Regulatory T Cells-Potential Impact on T Cell Suppression in Patients with Melanoma-Associated Thrombocytosis. *Cancers (Basel)*, 12(12). doi:10.3390/cancers12123653
374. Zolotovskaia, MA, Sorokin, MI, Petrov, IV, Poddubskaya, EV, Moiseev, AA, Sekacheva, MI, Borisov, NM, Tkachev, VS, Garazha, AV, Kaprin, AD, Shegay, PV, Giese, A, Kim, E, Roumiantsev, SA, & Buzdin, AA. (2020). Disparity between Inter-Patient Molecular Heterogeneity and Repertoires of Target Drugs Used for Different Types of Cancer in Clinical Oncology. *Int J Mol Sci*, 21(5). doi:10.3390/ijms21051580

Publikationen UCT Mainz 2021

* Erst- und/oder Letztautor UCT Mainz

1. Abboud, T, Asendorf, T, Heinrich, J, Faust, K, Krieg, SM, Seidel, K, Mielke, D, Matthies, C, Ringel, F, Rohde, V, & Szelényi, A. (2021). Transcranial versus Direct Cortical Stimulation for Motor-Evoked Potentials during Resection of Supratentorial Tumors under General Anesthesia (The TRANSEKT-Trial): Study Protocol for a Randomized Controlled Trial. *Biomedicines*, 9(10). doi:10.3390/biomedicines9101490
2. *Akbaba, S, Rühle, A, Rothhaar, S, Zamboglou, C, Gkika, E, Foerster, R, Oebel, L, Klodt, T, Schmidberger, H, Grosu, AL, Debus, J, Bostel, T, & Nicolay, NH. (2021). Treatment outcomes of elderly salivary gland cancer patients undergoing radiotherapy - Results from a large multicenter analysis. *Radiother Oncol*, 156, 266-274. doi:10.1016/j.radonc.2020.12.024
3. Al-Batran, SE, Hofheinz, RD, Reichart, A, Pauligk, C, Schönherr, C, Schlag, R, Siegler, G, Dörfel, S, Koenigsmann, M, Zahn, MO, Schubert, J, Aldaoud, A, Höffkes, HG, Schulz, H, Hahn, L, Uhlig, J, Blau, W, Stauch, M, Weniger, J, Wolf, M, Jacobasch, L, Bildat, S, Wehmeyer, J, Homann, N, Trojan, J, Waidmann, O, Fietz, T, Feustel, HP, Groschek, M, Wierecky, J, Waibel, K, Mahlmann, S, Schwindel, U, Peters, U, Schuch, G, Pink, D, Eschenburg, H, Wörns, MA, Harich, HD, von Weikersthal, LF, Däßler, KU, Behringer, DM, Messmann, H, Kretzschmar, A, Gallmeier, E, Forstbauer, H, Kunzmann, V, Papke, J, Büchner-Steudel, P, Vehling-Kaiser, U, Springfeld, C, Vogel, A, Ettrich, TJ, Schaaf, M, Hausen, GZ, & Götze, TO. (2021). Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry. *Int J Cancer*, 148(6), 1478-1488. doi:10.1002/ijc.33336
4. Alankus, B, Ecker, V, Vahl, N, Braun, M, Weichert, W, Macher-Göppinger, S, Gehring, T, Neumayer, T, Zenz, T, Buchner, M, & Ruland, J. (2021). Pathological RANK signaling in B cells drives autoimmunity and chronic lymphocytic leukemia. *J Exp Med*, 218(2). doi:10.1084/jem.20200517
5. *Alberg, I, Kramer, S, Leps, C, Tenzer, S, & Zentel, R. (2021). Effect of Core-Crosslinking on Protein Corona Formation on Polymeric Micelles. *Macromol Biosci*, 21(4), e2000414. doi:10.1002/mabi.202000414
6. Albers, P, Wiegel, T, Schmidberger, H, Bussar-Maatz, R, Härter, M, Kristiansen, G, Martus, P, Meisner, C, Wellek, S, Grozinger, K, Renner, P, Burmester, M, Schneider, F, & Stöckle, M. (2021). Termination rates and histological reclassification of active surveillance patients with low- and early intermediate-risk prostate cancer: results of the PREFERE trial. *World J Urol*, 39(1), 65-72. doi:10.1007/s00345-020-03154-7
7. *Alexa, M, Hasenburg, A, & Battista, MJ. (2021). The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions. *Cancers (Basel)*, 13(6). doi:10.3390/cancers13061478
8. Ali, N, Bolenz, C, Todenhöfer, T, Stenzel, A, Deetmar, P, Kriegmair, M, Knoll, T, Porubsky, S, Hartmann, A, Popp, J, Kriegmair, MC, & Bocklitz, T. (2021). Deep learning-based classification of blue light cystoscopy imaging during transurethral resection of bladder tumors. *Sci Rep*, 11(1), 11629. doi:10.1038/s41598-021-91081-x
9. *Alishah, K, Birtel, M, Masoumi, E, Jafarzadeh, L, Mirzaee, HR, Hadjati, J, Voss, RH, Diken, M, & Asad, S. (2021). CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. *J Transl Med*, 19(1), 482. doi:10.1186/s12967-021-03146-0
10. *Almansour, H, Afat, S, Fritz, V, Schick, F, Nachbar, M, Thorwarth, D, Zips, D, Müller, AC, Nikolaou, K, Othman, AE, & Wegener, D. (2021). Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Comparison to a Standard 3 T MRI. *Cancers (Basel)*, 13(7). doi:10.3390/cancers13071533
11. *Alqahtani, SA, & Schattenberg, JM. (2021). Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. *Expert Rev Mol Diagn*, 21(10), 1065-1078. doi:10.1080/14737159.2021.1964958
12. Alwers, E, Jansen, L, Kather, J, Amitay, E, Bläker, H, Kloor, M, Tagscherer, KE, Roth, W, Herpel, E, Chang-Claude, J, Brenner, H, & Hoffmeister, M. (2021). Response to neoadjuvant treatment among rectal cancer patients in a population-based cohort. *Int J Colorectal Dis*, 36(1), 177-185. doi:10.1007/s00384-020-03744-2
13. Arnold, F, Gout, J, Wiese, H, Weissinger, SE, Roger, E, Perkhofer, L, Walter, K, Scheible, J, Prelli Bozzo, C, Lechel, A, Ettrich, TJ, Azoitei, N, Hao, L, Fürstberger, A, Kaminska, EK, Sparrer, KMJ, Rasche, V, Wiese, S, Kestler, HA, Möller, P,

- Seufferlein, T, Frappart, PO, & Kleger, A. (2021). RINT1 Regulates SUMOylation and the DNA Damage Response to Preserve Cellular Homeostasis in Pancreatic Cancer. *Cancer Res*, 81(7), 1758-1774. doi:10.1158/0008-5472.Can-20-2633
14. *Arnold, N, Merzenich, H, Wingerter, A, Schulz, A, Schneider, A, Prochaska, JH, Göbel, S, Neu, MA, Henninger, N, Panova-Noeva, M, Eckerle, S, Spix, C, Schmidtman, I, Lackner, KJ, Beutel, ME, Pfeiffer, N, Münzel, T, Faber, J, & Wild, PS. (2021). Promotion of Arterial Stiffness by Childhood Cancer and Its Characteristics in Adult Long-Term Survivors. *J Am Heart Assoc*, 10(5), e015609. doi:10.1161/jaha.119.015609
 15. Assarzadegan, N, Thompson, E, Salimian, K, Gaida, MM, Brosens, LAA, Wood, L, Ali, SZ, & Hruban, RH. (2021). Pathology of intraductal papillary mucinous neoplasms. *Langenbecks Arch Surg*, 406(8), 2643-2655. doi:10.1007/s00423-021-02201-0
 16. Awwad, MHS, Mahmoud, A, Bruns, H, Echchannaoui, H, Kriegsmann, K, Lutz, R, Raab, MS, Bertsch, U, Munder, M, Jauch, A, Weisel, K, Maier, B, Weinhold, N, Salwender, HJ, Eckstein, V, Hänel, M, Fenk, R, Dürig, J, Brors, B, Benner, A, Müller-Tidow, C, Goldschmidt, H, & Hundemer, M. (2021). Selective elimination of immunosuppressive T cells in patients with multiple myeloma. *Leukemia*, 35(9), 2602-2615. doi:10.1038/s41375-021-01172-x
 17. Bachmann, F, Schreder, M, Engelhardt, M, Langer, C, Wolleschak, D, Mügge, LO, Dürk, H, Schäfer-Eckart, K, Blau, IW, Gramatzki, M, Liebisch, P, Grube, M, I, VM, Bassermann, F, Metzner, B, Röhl, C, Hertenstein, B, Khandanpour, C, Dechow, T, Hebart, H, Jung, W, Theurich, S, Maschmeyer, G, Salwender, H, Hess, G, Bittrich, M, Rasche, L, Brioli, A, Eckardt, KU, Straka, C, Held, S, Einsele, H, & Knop, S. (2021). Kinetics of Renal Function during Induction in Newly Diagnosed Multiple Myeloma: Results of Two Prospective Studies by the German Myeloma Study Group DSM. *Cancers (Basel)*, 13(6). doi:10.3390/cancers13061322
 18. Baertsch, MA, Mai, EK, Hielscher, T, Bertsch, U, Salwender, HJ, Munder, M, Fuhrmann, S, Dürsen, U, Brossart, P, Neben, K, Schlenzka, J, Kunz, C, Raab, MS, Hillengaß, J, Jauch, A, Seckinger, A, Hose, D, Lutz, S, Sonneveld, P, Lokhorst, H, Martin, H, Goerner, M, Hoffmann, M, Lindemann, HW, Bernhard, H, Blau, IW, Scheid, C, Besemer, B, Weisel, KC, Hänel, M, Dürig, J, & Goldschmidt, H. (2021). Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. *Blood Cancer J*, 11(1), 1. doi:10.1038/s41408-020-00390-3
 19. Bartlett, JMS, Bayani, J, Kornaga, E, Xu, K, Pond, GR, Piper, T, Mallon, E, Yao, CQ, Boutros, PC, Hasenburger, A, Dunn, JA, Markopoulos, C, Dirix, L, Seynaeve, C, van de Velde, CJH, Stein, RC, & Rea, D. (2021). Comparative survival analysis of multiparametric tests-when molecular tests disagree-A TEAM Pathology study. *NPJ Breast Cancer*, 7(1), 90. doi:10.1038/s41523-021-00297-7
 20. *Bartsch, F, Eberhard, J, Rückert, F, Schmelzle, M, Lehwald-Tywuschik, N, Fichtner-Feigl, S, Gaedcke, J, Oldhafer, KJ, Oldhafer, F, Diener, M, Mehrabi, A, Settmacher, U, Becker, T, Keck, T, Friess, H, Strücker, B, Opitz, S, Lemke, J, Schnitzbauer, A, & Lang, H. (2021). Repeated resection for recurrent intrahepatic cholangiocarcinoma: A retrospective German multicentre study. *Liver Int*, 41(1), 180-191. doi:10.1111/liv.14682
 21. *Bartsch, F, Hahn, F, Müller, L, Baumgart, J, Hoppe-Lotichius, M, Kloeckner, R, & Lang, H. (2021). Intrahepatic cholangiocarcinoma: Introducing the preoperative prediction score based on preoperative imaging. *Hepatobiliary Pancreat Dis Int*, 20(3), 262-270. doi:10.1016/j.hbpd.2020.08.002
 22. *Bartsch, F, Heuft, LK, Baumgart, J, Hoppe-Lotichius, M, Margies, R, Gerber, TS, Foerster, F, Weinmann, A, Straub, BK, Mittler, J, Heinrich, S, & Lang, H. (2021). Influence of Lymphangio (L), Vascular (V), and Perineural (Pn) Invasion on Recurrence and Survival of Resected Intrahepatic Cholangiocarcinoma. *J Clin Med*, 10(11). doi:10.3390/jcm10112426
 23. Bazarbachi, AH, Labopin, M, Kröger, N, Brecht, A, Blaise, D, Clausen, J, Fanin, R, Einsele, H, Cavanna, L, Itälä-Remes, M, Bulabois, CE, Kündgen, L, Martin, H, Schmid, C, Wagner-Drouet, EM, Alakel, N, Bazarbachi, A, Savani, B, Nagler, A, & Mohty, M. (2021). Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia. *Clin Lymphoma Myeloma Leuk*, 21(12), 831-840. doi:10.1016/j.clml.2021.07.010
 24. *Beck, JD, Reidenbach, D, Salomon, N, Sahin, U, Türeci, Ö, Vormehr, M, & Kranz, LM. (2021). mRNA therapeutics in cancer immunotherapy. *Mol Cancer*, 20(1), 69. doi:10.1186/s12943-021-01348-0
 25. Becker, LS, Gutberlet, M, Maschke, SK, Werncke, T, Dewald, CLA, von Falck, C, Vogel, A, Kloeckner, R, Meyer, BC, Wacker, F, & Hinrichs, JB. (2021). Evaluation of a Motion Correction Algorithm for C-Arm Computed Tomography Acquired During Transarterial Chemoembolization. *Cardiovasc Intervent Radiol*, 44(4), 610-618. doi:10.1007/s00270-020-02729-6

26. *Becker, P, Pabst, A, Bjelopavlovic, M, Müller, D, & Kämmerer, PW. (2021). Treatment Modalities of Recurrent Oral Mucosal Melanoma In Situ. *Medicina (Kaunas)*, 57(9). doi:10.3390/medicina57090965
27. Beckmann, L, Rolling, CC, Voigtländer, M, Mäder, J, Klingler, F, Schlenker, A, Lehr, C, Bokemeyer, C, Ruf, W, & Langer, F. (2021). Bacitracin and Rutin Regulate Tissue Factor Production in Inflammatory Monocytes and Acute Myeloid Leukemia Blasts. *Cancers (Basel)*, 13(16). doi:10.3390/cancers13163941
28. *Bednarczyk, M, Medina-Montano, C, Fittler, FJ, Stege, H, Roskamp, M, Kuske, M, Langer, C, Vahldieck, M, Montermann, E, Tubbe, I, Röhrig, N, Dzionek, A, Grabbe, S, & Bros, M. (2021). Complement-Opsonized Nano-Carriers Are Bound by Dendritic Cells (DC) via Complement Receptor (CR)3, and by B Cell Subpopulations via CR-1/2, and Affect the Activation of DC and B-1 Cells. *Int J Mol Sci*, 22(6). doi:10.3390/ijms22062869
29. *Beltzig, L, Frumkina, A, Schwarzenbach, C, & Kaina, B. (2021). Cytotoxic, Genotoxic and Senolytic Potential of Native and Micellar Curcumin. *Nutrients*, 13(7). doi:10.3390/nu13072385
30. *Beltzig, L, Stratenwerth, B, & Kaina, B. (2021). Accumulation of Temozolomide-Induced Apoptosis, Senescence and DNA Damage by Metronomic Dose Schedule: A Proof-of-Principle Study with Glioblastoma Cells. *Cancers (Basel)*, 13(24). doi:10.3390/cancers13246287
31. *Berlth, F, Knospe, L, Jansen-Winkel, B, Hadzijušević, E, Tagkalos, E, Niebisch, S, Moulla, Y, Chalopin, C, Köhler, H, Maktabi, M, Lang, H, Grimminger, P, & Gockel, I. (2021). [Status of minimally invasive gastrectomy : Current advancements: robotic surgery and intraoperative imaging for gastric cancer]. *Chirurg*, 92(6), 528-534. doi:10.1007/s00104-021-01391-z
32. *Berte, N, Eich, M, Heylmann, D, Koks, C, Van Gool, SW, & Kaina, B. (2021). Impaired DNA repair in mouse monocytes compared to macrophages and precursors. *DNA Repair (Amst)*, 98, 103037. doi:10.1016/j.dnarep.2020.103037
33. Berthold, F, Spix, C, Erttmann, R, Hero, B, Michaelis, J, Treuner, J, Ernst, A, & Schilling, FH. (2021). Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial. *JNCI Cancer Spectr*, 5(4), pkab041. doi:10.1093/jncics/pkab041
34. Bette, S, Ruhland, JM, Wiestler, B, Barz, M, Meyer, B, Zimmer, C, Ryang, YM, Ringel, F, & Gempt, J. (2021). Postoperative cognitive functions in patients with benign intracranial lesions. *Sci Rep*, 11(1), 8757. doi:10.1038/s41598-021-88061-6
35. Birrer, DL, Golcher, H, Casadei, R, Haile, SR, Fritsch, R, Hussung, S, Brunner, TB, Fietkau, R, Meyer, T, Grützmann, R, Merkel, S, Ricci, C, Ingaldi, C, Di Marco, M, Guido, A, Serra, C, Minni, F, Pestalozzi, B, Petrowsky, H, DeOliveira, M, Bechstein, WO, Bruns, CJ, Oberkofler, CE, Puhon, M, Lesurtel, M, Heinrich, S, & Clavien, PA. (2021). Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled Trials. *Ann Surg*, 274(5), 713-720. doi:10.1097/sla.00000000000005126
36. *Bitar, L, Schumann, U, König, R, Zipp, F, & Schmidt, MHH. (2021). Targeting Immune Modulators in Glioma While Avoiding Autoimmune Conditions. *Cancers (Basel)*, 13(14). doi:10.3390/cancers13143524
37. *Blatt, S, Pabst, A, Zimmer, S, Walter, C, Al-Nawas, B, & Krüger, M. (2021). Clinical efficacy of an antibody-based detection system for human papilloma virus infection in oral squamous cell carcinoma. *Clin Oral Investig*, 25(5), 2837-2843. doi:10.1007/s00784-020-03601-0
38. *Blatt, S, Thiem, DGE, Kyak, S, Pabst, A, Al-Nawas, B, & Kämmerer, PW. (2021). Possible Implications for Improved Osteogenesis? The Combination of Platelet-Rich Fibrin With Different Bone Substitute Materials. *Front Bioeng Biotechnol*, 9, 640053. doi:10.3389/fbioe.2021.640053
39. *Blatt, S, Thiem, DGE, Pabst, A, Al-Nawas, B, & Kämmerer, PW. (2021). Does Platelet-Rich Fibrin Enhance the Early Angiogenic Potential of Different Bone Substitute Materials? An In Vitro and In Vivo Analysis. *Biomedicines*, 9(1). doi:10.3390/biomedicines9010061
40. *Blümler, P, Friedrich, RP, Pereira, J, Baun, O, Alexiou, C, & Mailänder, V. (2021). Contactless Nanoparticle-Based Guiding of Cells by Controllable Magnetic Fields. *Nanotechnol Sci Appl*, 14, 91-100. doi:10.2147/nsa.S298003
41. Bockhorst, C, Dietrich, J, Vogt, TJ, Stauber, RH, Strieth, S, Bootz, F, Dietrich, D, & Vos, L. (2021). The DNA methylation landscape of PD-1 (PDCD1) and adjacent lncRNA AC131097.3 in head and neck squamous cell carcinoma. *Epigenomics*, 13(2), 113-127. doi:10.2217/epi-2020-0208

42. *Boedecker, C, Huettl, F, Saalfeld, P, Paschold, M, Kneist, W, Baumgart, J, Preim, B, Hansen, C, Lang, H, & Huber, T. (2021). Using virtual 3D-models in surgical planning: workflow of an immersive virtual reality application in liver surgery. *Langenbecks Arch Surg*, 406(3), 911-915. doi:10.1007/s00423-021-02127-7
43. *Boehm, K, Borgmann, H, Ebert, T, Höfner, T, Khaljani, E, Schmid, M, Schulze-Seemann, W, Weib, P, & Herden, J. (2021). Stage and Grade Migration in Prostate Cancer Treated With Radical Prostatectomy in a Large German Multicenter Cohort. *Clin Genitourin Cancer*, 19(2), 162-166.e161. doi:10.1016/j.clgc.2020.12.004
44. *Bogucka, K, Marini, F, Rosigkeit, S, Schloeder, J, Jonuleit, H, David, K, Schlackow, M, & Rajalingam, K. (2021). ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis. *Cancer Gene Ther*, 28(5), 359-374. doi:10.1038/s41417-020-00245-w
45. *Bostel, T, Akbaba, S, Wollschläger, D, Klodt, T, Oebel, L, Mayer, A, Drabke, S, Sprave, T, Debus, J, Förster, R, Rief, H, Rühle, A, Grosu, AL, Schmidberger, H, & Nicolay, NH. (2021). Comparative Analyses of Two Established Scores to Assess the Stability of Spinal Bone Metastases Before and After Palliative Radiotherapy. *Front Oncol*, 11, 753768. doi:10.3389/fonc.2021.753768
46. Boulos, JC, Saeed, MEM, Chatterjee, M, Bülbül, Y, Crudo, F, Marko, D, Munder, M, Klauck, SM, & Efferth, T. (2021). Repurposing of the ALK Inhibitor Crizotinib for Acute Leukemia and Multiple Myeloma Cells. *Pharmaceuticals (Basel)*, 14(11). doi:10.3390/ph14111126
47. Brandis, JEP, Kihn, KC, Taraban, MB, Schnorr, J, Confer, AM, Batelu, S, Sun, D, Rodriguez, JD, Jiang, W, Goldberg, DP, Langguth, P, Stemmler, TL, Yu, YB, Kane, MA, Polli, JE, & Michel, SLJ. (2021). Evaluation of the Physicochemical Properties of the Iron Nanoparticle Drug Products: Brand and Generic Sodium Ferric Gluconate. *Mol Pharm*, 18(4), 1544-1557. doi:10.1021/acs.molpharmaceut.0c00922
48. Brändle, SM, Cerina, M, Weber, S, Held, K, Menke, AF, Alcalá, C, Gebert, D, Herrmann, AM, Pellkofer, H, Gerdes, LA, Bittner, S, Leyboldt, F, Teegen, B, Komorowski, L, Kümpfel, T, Hohlfeld, R, Meuth, SG, Casanova, B, Melzer, N, Beltrán, E, & Dornmair, K. (2021). Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA(A) receptor encephalitis. *Proc Natl Acad Sci U S A*, 118(9). doi:10.1073/pnas.1916337118
49. *Brandstetter, G, Blatt, S, Goldschmitt, J, Taylor, L, Heymann, P, Al-Nawas, B, & Ziebart, T. (2021). Targeted sensitization of tumor cells for radiation through monocarboxylate transporters 1 and 4 inhibition in vitro. *Clin Oral Investig*, 25(1), 295-310. doi:10.1007/s00784-020-03364-8
50. *Brendlin, AS, Peisen, F, Almansour, H, Afat, S, Eigentler, T, Amaral, T, Faby, S, Calvarons, AF, Nikolaou, K, & Othman, AE. (2021). A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. *J Immunother Cancer*, 9(11). doi:10.1136/jitc-2021-003261
51. *Bresadola, L, Weber, D, Ritzel, C, Löwer, M, Bukur, V, Akilli-Öztürk, Ö, Becker, J, Mehanna, H, Schrörs, B, Vascotto, F, Sahin, U, & Kong, A. (2021). Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient. *Int J Mol Sci*, 22(14). doi:10.3390/ijms22147583
52. *Bröder, S, Jäger, W, Thüroff, JW, & Stein, R. (2021). Orthotopic MAINZ pouch bladder substitution - long-term follow-up. *Cent European J Urol*, 74(2), 235-240. doi:10.5173/ceju.2021.0275.R2
53. *Brückner, M, Simon, J, Landfester, K, & Mailänder, V. (2021). The conjugation strategy affects antibody orientation and targeting properties of nanocarriers. *Nanoscale*, 13(21), 9816-9824. doi:10.1039/d0nr08191d
54. Bruix, J, Chan, SL, Galle, PR, Rimassa, L, & Sangro, B. (2021). Systemic treatment of hepatocellular carcinoma: An EASL position paper. *J Hepatol*, 75(4), 960-974. doi:10.1016/j.jhep.2021.07.004
55. *Buhr, CR, Eckrich, J, Klunker, M, Bruns, K, Wiesmann, N, Tremel, W, & Brieger, J. (2021). Determination of the LD(50) with the chick embryo chorioallantoic membrane (CAM) assay as a promising alternative in nanotoxicological evaluation. *Nanotoxicology*, 15(5), 690-705. doi:10.1080/17435390.2021.1916635
56. Burbano De Lara, S, Tran, DDH, Allister, AB, Polenkowski, M, Nashan, B, Koch, M, & Tamura, T. (2021). C20orf204, a hepatocellular carcinoma-specific protein interacts with nucleolin and promotes cell proliferation. *Oncogenesis*, 10(3), 31. doi:10.1038/s41389-021-00320-3
57. *Buse, S, Alexandrov, A, Mazzone, E, Mottrie, A, & Haferkamp, A. (2021). Surgical benchmarks, mid-term oncological outcomes, and impact of surgical team composition on simultaneous enbloc robot-assisted radical cystectomy and nephroureterectomy. *BMC Urol*, 21(1), 73. doi:10.1186/s12894-021-00839-y

58. *Butsch, CS, Heider, J, Brockmann, MA, Pfeiffer, N, Ringel, FA, Schwandt, E, & Ponto, KA. (2021). [Pulsatile tumor of the orbit]. *Ophthalmologie*, 118(1), 60-64. doi:10.1007/s00347-020-01060-2
59. *Büttner-Herold, M, Sticht, C, Wiech, T, & Porubsky, S. (2021). Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms. *Histopathology*, 78(5), 738-748. doi:10.1111/his.14282
60. *Büttner, M, Rimmel, H, Bartès, B, Singer, S, & Luster, M. (2021). Management of thyroid cancer: results from a German and French patient survey. *Hormones (Athens)*, 20(2), 323-332. doi:10.1007/s42000-020-00260-4
61. Cadoni, S, Ishaq, S, Hassan, C, Falt, P, Fuccio, L, Siau, K, Leung, JW, Anderson, J, Binmoeller, KF, Radaelli, F, Rutter, MD, Sugimoto, S, Muhammad, H, Bhandari, P, Draganov, PV, de Groen, P, Wang, AY, Yen, AW, Hamerski, C, Thorlacius, H, Neumann, H, Ramirez, F, Mulder, CJJ, Albéniz, E, Amato, A, Arai, M, Bak, A, Barret, M, Bayupurnama, P, Cheung, R, Ching, HL, Cohen, H, Dolwani, S, Friedland, S, Harada, H, Hsieh, YH, Hayee, B, Kuwai, T, Lorenzo-Zúñiga, V, Liggi, M, Mizukami, T, Mura, D, Nylander, D, Olafsson, S, Paggi, S, Pan, Y, Parra-Blanco, A, Ransford, R, Rodriguez-Sanchez, J, Senturk, H, Suzuki, N, Tseng, CW, Uchima, H, Uedo, N, & Leung, FW. (2021). Water-assisted colonoscopy: an international modified Delphi review on definitions and practice recommendations. *Gastrointest Endosc*, 93(6), 1411-1420.e1418. doi:10.1016/j.gie.2020.10.011
62. Calaminus, G, Baust, K, Berger, C, Byrne, J, Binder, H, Casagrande, L, Grabow, D, Grootenhuys, M, Kaatsch, P, Kaiser, M, Kepak, T, Kepáková, K, Kremer, LCM, Kruseova, J, Luks, A, Spix, C, van den Berg, M, van den Heuvel-Eibrink, MMM, van Dulmen-den Broeder, E, Kuonen, R, Sommer, G, & Kuehni, C. (2021). Health-Related Quality of Life in European Childhood Cancer Survivors: Protocol for a Study Within PanCareLIFE. *JMIR Res Protoc*, 10(1), e21851. doi:10.2196/21851
63. Cano-Linares, MI, Yáñez-Vilches, A, García-Rodríguez, N, Barrientos-Moreno, M, González-Prieto, R, San-Segundo, P, Ulrich, HD, & Prado, F. (2021). Non-recombinogenic roles for Rad52 in translesion synthesis during DNA damage tolerance. *EMBO Rep*, 22(1), e50410. doi:10.15252/embr.202050410
64. Catenacci, DV, Rosales, M, Chung, HC, H, HY, Shen, L, Moehler, M, & Kang, YK. (2021). MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. *Future Oncol*, 17(10), 1155-1164. doi:10.2217/fon-2020-1007
65. *Champanhac, C, Haas, H, Landfester, K, & Mailänder, V. (2021). Heparin modulates the cellular uptake of nanomedicines. *Biomater Sci*, 9(4), 1227-1231. doi:10.1039/d0bm01946a
66. Chari, A, Munder, M, Weisel, K, Jenner, M, Bygrave, C, Petrucci, MT, Boccadoro, M, Cavo, M, van de Donk, N, Turgut, M, Demirkan, F, Karadogan, I, Libby, E, Kleiman, R, Kuppens, S, Bandekar, R, Neff, T, Heuck, C, Qi, M, Clemens, PL, & Goldschmidt, H. (2021). Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. *Adv Ther*, 38(2), 1328-1341. doi:10.1007/s12325-020-01601-w
67. *Cieslikowski, WA, Haber, T, Krajnak, S, Anic, K, Hasenburger, A, Mager, R, Thüroff, JW, & Brenner, W. (2021). Co-administration of tyrosine kinase inhibitors with rottlerin in metastatic prostate cancer cells. *Excli j*, 20, 1585-1596. doi:10.17179/excli2021-3980
68. Coombes, RC, Tovey, H, Kilburn, L, Mansi, J, Palmieri, C, Bartlett, J, Hicks, J, Makris, A, Evans, A, Loibl, S, Denkert, C, Murray, E, Grieve, R, Coleman, R, Borley, A, Schmidt, M, Rautenberg, B, Kunze, CA, Rhein, U, Mehta, K, Mousa, K, Dibble, T, Lu, XL, von Minckwitz, G, & Bliss, JM. (2021). Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial. *JAMA Oncol*, 7(9), 1291-1301. doi:10.1001/jamaoncol.2021.2193
69. Cossarizza, A, Chang, HD, Radbruch, A, Abrignani, S, Addo, R, Akdis, M, Andrä, I, Andreato, F, Annunziato, F, Arranz, E, Bacher, P, Bari, S, Barnaba, V, Barros-Martins, J, Baumjohann, D, Beccaria, CG, Bernardo, D, Boardman, DA, Borger, J, Böttcher, C, Brockmann, L, Burns, M, Busch, DH, Cameron, G, Cammarata, I, Cassotta, A, Chang, Y, Chirido, FG, Christakou, E, Čičin-Šain, L, Cook, L, Corbett, AJ, Cornelis, R, Cosmi, L, Davey, MS, De Biasi, S, De Simone, G, Del Zotto, G, Delacher, M, Di Rosa, F, Santo, JD, Diefenbach, A, Dong, J, Dörner, T, Dress, RJ, Dutertre, CA, Eckle, SBG, Eede, P, Evrard, M, Falk, CS, Feuerer, M, Fillatreau, S, Fiz-Lopez, A, Follo, M, Foulds, GA, Fröbel, J, Gagliani, N, Galletti, G, Gangae, A, Garbi, N, Garrote, JA, Geginat, J, Gherardin, NA, Gibellini, L, Ginhoux, F, Godfrey, DI, Gruarin, P, Haftmann, C, Hansmann, L, Harpur, CM, Hayday, AC, Heine, G, Hernández, DC, Herrmann, M, Hoelsken, O, Huang, Q, Huber, S, Huber, JE, Huehn, J, Hundemer, M, Hwang, WYK, Iannaccone, M, Ivison, SM, Jäck, HM, Jani, PK, Keller, B, Kessler, N, Ketelaars, S, Knop, L, Knopf, J, Koay, HF, Kobow, K, Kriegsmann, K, Kristyanto, H, Krueger, A, Kuehne, JF, Kunze-Schumacher, H, Kvistborg, P, Kwok, I, Latorre, D, Lenz, D, Levings, MK, Lino, AC, Liotta, F, Long, HM, Lugli, E, MacDonald, KN, Maggi, L, Maini, MK, Mair, F, Manta, C, Manz, RA, Mashregi, MF, Mazzoni, A, McCluskey, J, Mei, HE,

- Melchers, F, Melzer, S, Mielenz, D, Monin, L, Moretta, L, Multhoff, G, Muñoz, LE, Muñoz-Ruiz, M, Muscate, F, Natalini, A, Neumann, K, Ng, LG, Niedobitek, A, Niemz, J, Almeida, LN, Notarbartolo, S, Ostendorf, L, Pallett, LJ, Patel, AA, Percin, GI, Peruzzi, G, Pinti, M, Pockley, AG, Pracht, K, Prinz, I, Pujol-Autonell, I, Pulvirenti, N, Quatrini, L, Quinn, KM, Radbruch, H, Rhys, H, Rodrigo, MB, Romagnani, C, Saggau, C, Sakaguchi, S, Sallusto, F, Sanderink, L, Sandroock, I, Schauer, C, Scheffold, A, Scherer, HU, Schiemann, M, Schildberg, FA, Schober, K, Schoen, J, Schuh, W, Schüler, T, Schulz, AR, Schulz, S, Schulze, J, Simonetti, S, Singh, J, Sitnik, KM, Stark, R, Starossom, S, Stehle, C, Szelinski, F, Tan, L, Tarnok, A, Tornack, J, Tree, TIM, van Beek, JJP, van de Veen, W, van Gisbergen, K, Vasco, C, Verheyden, NA, von Borstel, A, Ward-Hartstonge, KA, Warnatz, K, Waskow, C, Wiedemann, A, Wilharm, A, Wing, J, Wirz, O, Wittner, J, Yang, JHM, & Yang, J. (2021). Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). *Eur J Immunol*, 51(12), 2708-3145. doi:10.1002/eji.202170126
70. Cotarelo, CL, Zschöck-Manus, A, Schmidt, M, Schad, A, Brochhausen, C, Kirkpatrick, CJ, & Thaler, S. (2021). Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer. *Clin Exp Metastasis*, 38(1), 61-72. doi:10.1007/s10585-020-10065-9
 71. Crouchet, E, Bandiera, S, Fujiwara, N, Li, S, El Saghire, H, Fernández-Vaquero, M, Riedl, T, Sun, X, Hirschfield, H, Jühling, F, Zhu, S, Roehlen, N, Ponsolles, C, Heydmann, L, Saviano, A, Qian, T, Venkatesh, A, Lupberger, J, Verrier, ER, Sojoodi, M, Oudot, MA, Duong, FHT, Masia, R, Wei, L, Thumann, C, Durand, SC, González-Motos, V, Heide, D, Hetzer, J, Nakagawa, S, Ono, A, Song, WM, Higashi, T, Sanchez, R, Kim, RS, Bian, CB, Kiani, K, Croonenborghs, T, Subramanian, A, Chung, RT, Straub, BK, Schuppan, D, Ankavay, M, Cocquerel, L, Schaeffer, E, Goossens, N, Koh, AP, Mahajan, M, Nair, VD, Gunasekaran, G, Schwartz, ME, Bardeesy, N, Shalek, AK, Rozenblatt-Rosen, O, Reggev, A, Felli, E, Pessaux, P, Tanabe, KK, Heikenwälder, M, Schuster, C, Pochet, N, Zeisel, MB, Fuchs, BC, Hoshida, Y, & Baumert, TF. (2021). A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. *Nat Commun*, 12(1), 5525. doi:10.1038/s41467-021-25468-9
 72. *Czuderna, C, Poplawski, A, O'Rourke, CJ, Castven, D, Pérez-Aguilar, B, Becker, D, Heilmann-Heimbach, S, Odenthal, M, Amer, W, Schmiel, M, Drebber, U, Binder, H, Ridder, DA, Schindeldecker, M, Straub, BK, Galle, PR, Andersen, JB, Thorgeirsson, SS, Park, YN, & Marquardt, JU. (2021). Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis. *JCI Insight*, 6(17). doi:10.1172/jci.insight.146196
 73. *Das, K, Cockerell, CJ, Patil, A, Pietkiewicz, P, Giulini, M, Grabbe, S, & Goldust, M. (2021). Machine Learning and Its Application in Skin Cancer. *Int J Environ Res Public Health*, 18(24). doi:10.3390/ijerph182413409
 74. *Delacher, M, Simon, M, Sanderink, L, Hotz-Wagenblatt, A, Wuttke, M, Schambeck, K, Schmidleithner, L, Bittner, S, Pant, A, Ritter, U, Hehlhans, T, Riegel, D, Schneider, V, Groeber-Becker, FK, Eigenberger, A, Gebhard, C, Strieder, N, Fischer, A, Rehli, M, Hoffmann, P, Edinger, M, Strowig, T, Huehn, J, Schmidl, C, Werner, JM, Prantl, L, Brors, B, Imbusch, CD, & Feuerer, M. (2021). Single-cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. *Immunity*, 54(4), 702-720.e717. doi:10.1016/j.immuni.2021.03.007
 75. Denkert, C, Seither, F, Schneeweiss, A, Link, T, Blohmer, JU, Just, M, Wimberger, P, Forberger, A, Tesch, H, Jackisch, C, Schmatloch, S, Reinisch, M, Solomayer, EF, Schmitt, WD, Hanusch, C, Fasching, PA, Lübke, K, Solbach, C, Huober, J, Rhiem, K, Marmé, F, Reimer, T, Schmidt, M, Sinn, BV, Janni, W, Stickeler, E, Michel, L, Stötzer, O, Hahnen, E, Furlanetto, J, Seiler, S, Nekljudova, V, Untch, M, & Loibl, S. (2021). Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. *Lancet Oncol*, 22(8), 1151-1161. doi:10.1016/s1470-2045(21)00301-6
 76. Deutschbein, T, Jaurisch-Hancke, C, Knappe, UJ, Saeger, W, Flitsch, J, Bojunga, J, Buchfelder, M, Ditzen, B, Gerlach, R, Gertzen, E, Honegger, J, Horstmann, GA, Koch, A, Kreitschmann-Andermahr, I, Kunz, M, Lagrèze, WA, Nicolay, NH, Paulus, W, Reincke, M, Schmidt, MA, Weber, MM, Wilhelm, H, & Fassnacht, M. (2021). First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors. *Exp Clin Endocrinol Diabetes*, 129(3), 250-264. doi:10.1055/a-1373-4087
 77. *Dietrich, C, & Hofmann, TG. (2021). Ferroptosis Meets Cell-Cell Contacts. *Cells*, 10(9). doi:10.3390/cells10092462
 78. Dighe, SG, Chen, J, Yan, L, He, Q, Gharahkhani, P, Onstad, L, Levine, DM, Palles, C, Ye, W, Gammon, MD, Iyer, PG, Anderson, LA, Liu, G, Wu, AH, Dai, JY, Chow, WH, Risch, HA, Lagergren, J, Shaheen, NJ, Bernstein, L, Corley, DA, Prenen, H, deCaestecker, J, MacDonald, D, Moayyedi, P, Barr, H, Love, SB, Chegwidan, L, Attwood, S, Watson, P, Harrison, R, Ott, K, Moebus, S, Venerito, M, Lang, H, Mayershofer, R, Knapp, M, Veits, L, Gerges, C, Weismüller, J, Gockel, I, Vashist, Y, Nöthen, MM, Izbicki, JR, Manner, H, Neuhaus, H, Rösch, T, Böhmer, AC, Hölscher, AH, Anders, M, Pech, O, Schumacher, B, Schmidt, C, Schmidt, T, Noder, T, Lorenz, D, Vieth, M, May, A, Hess, T, Kreuser, N, Becker, J, Ell, C, Ambrosone, CB, Moysich, KB, MacGregor, S, Tomlinson, I, Whiteman, DC, Jankowski, J, Schumacher, J, Vaughan, TL, Madeleine, MM, Hardie, LJ, & Buas, MF. (2021). Germline variation in the insulin-like growth factor pathway and

risk of Barrett's esophagus and esophageal adenocarcinoma. *Carcinogenesis*, 42(3), 369-377.
doi:10.1093/carcin/bgaa132

79. *Docherty, M, Regnier, SA, Capkun, G, Balp, MM, Ye, Q, Janssens, N, Tietz, A, Löffler, J, Cai, J, Pedrosa, MC, & Schattenberg, JM. (2021). Development of a novel machine learning model to predict presence of nonalcoholic steatohepatitis. *J Am Med Inform Assoc*, 28(6), 1235-1241. doi:10.1093/jamia/ocab003
80. *Dölen, Y, Gileadi, U, Chen, JL, Valente, M, Creemers, JHA, Van Dinther, EAW, van Riessen, NK, Jäger, E, Hruby, M, Cerundolo, V, Diken, M, Figdor, CG, & de Vries, IJM. (2021). PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses. *Front Immunol*, 12, 641703. doi:10.3389/fimmu.2021.641703
81. *Dotzauer, R, Böhm, K, Brandt, MP, Sparwasser, P, Haack, M, Frees, SK, Kamal, MM, Mager, R, Jäger, W, Höfner, T, Tsaur, I, Haferkamp, A, & Borgmann, H. (2021). Global change of surgical and oncological clinical practice in urology during early COVID-19 pandemic. *World J Urol*, 39(9), 3139-3145. doi:10.1007/s00345-020-03333-6
82. *Dotzauer, R, La Torre, A, Thomas, A, Brandt, MP, Böhm, K, Mager, R, Borgmann, H, Jäger, W, Kurosch, M, Höfner, T, Ruckes, C, Haferkamp, A, & Tsaur, I. (2021). Robot-assisted simple prostatectomy versus open simple prostatectomy: a single-center comparison. *World J Urol*, 39(1), 149-156. doi:10.1007/s00345-020-03168-1
83. Dressler, FF, Dogan, S, Hennig, M, Frank, T, Struck, J, Cebulla, A, Salem, J, Borgmann, H, Klatte, T, Kramer, MW, & Hofbauer, S. (2021). [Current practice patterns of perioperative cystectomy management in Germany: a questionnaire survey]. *Aktuelle Urol*, 52(1), 82-87. doi:10.1055/a-1025-2523
84. *Dudda, M, Mann, C, Heinz, J, Schmidgen, I, Weid, F, Kühn, M, Saloga, J, Grabbe, S, & Loquai, C. (2021). Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature. *Melanoma Res*, 31(1), 81-84. doi:10.1097/cmr.0000000000000703
85. *Dupont, CA, Riegel, K, Pempaiah, M, Juhl, H, & Rajalingam, K. (2021). Druggable genome and precision medicine in cancer: current challenges. *FEBS J*, 288(21), 6142-6158. doi:10.1111/febs.15788
86. Edlund, K, Madjar, K, Lebrecht, A, Aktas, B, Pilch, H, Hoffmann, G, Hofmann, M, Kolberg, HC, Boehm, D, Battista, M, Seehase, M, Stewen, K, Gebhard, S, Cadenas, C, Marchan, R, Brenner, W, Hasenburg, A, Koelbl, H, Solbach, C, Gehrmann, M, Tanner, B, Weber, KE, Loibl, S, Sachinidis, A, Rahnenführer, J, Schmidt, M, & Hengstler, JG. (2021). Gene Expression-Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial. *Clin Cancer Res*, 27(8), 2148-2158. doi:10.1158/1078-0432.Ccr-20-2662
87. Eichinger, S, Morange, PE, Cattaneo, M, Fretigny, M, Rauch, A, van Hylckama Vlieg, A, Trégouët, DA, Ruf, W, Levi, M, Páramo, JA, van der Poll, T, Kyrle, PA, Garagiola, I, & Peyvandi, F. (2021). The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. *Hemasphere*, 5(10), e643. doi:10.1097/hs9.0000000000000643
88. Eichler, M, Pink, D, Menge, F, Jakob, J, Hentschel, L, Richter, S, Hohenberger, P, Kasper, B, Andreou, D, Singer, S, Grützmann, R, Dmytrow, DI, Arndt, K, Tuchscherer, A, Reichardt, P, Ahrens, M, Kunitz, A, Mohm, J, Bornhäuser, M, Schmitt, J, & Schuler, MK. (2021). Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa). *Eur J Cancer Care (Engl)*, 30(6), e13484. doi:10.1111/ecc.13484
89. Endres, T, Solvie, D, Heidelberger, JB, Andrioletti, V, Baluapuri, A, Ade, CP, Muhar, M, Eilers, U, Vos, SM, Cramer, P, Zuber, J, Beli, P, Popov, N, Wolf, E, Gallant, P, & Eilers, M. (2021). Ubiquitylation of MYC couples transcription elongation with double-strand break repair at active promoters. *Mol Cell*, 81(4), 830-844.e813. doi:10.1016/j.molcel.2020.12.035
90. Erben, P, Becker, C, Tsaur, I, Stope, MB, & Todenhöfer, T. (2021). [Molecular subtypes of urothelial carcinoma of the bladder-background and clinical relevance]. *Urologe A*, 60(1), 81-88. doi:10.1007/s00120-020-01396-2
91. *Erdmann, F, Frederiksen, LE, Bonaventure, A, Mader, L, Hasle, H, Robison, LL, & Winther, JF. (2021). Childhood cancer: Survival, treatment modalities, late effects and improvements over time. *Cancer Epidemiol*, 71(Pt B), 101733. doi:10.1016/j.canep.2020.101733
92. *Erdmann, F, Frederiksen, LE, Mogensen, H, Pedersen, C, Mader, L, Talbäck, M, Bautz, A, Hirvonen, E, Kyrölahti, A, Korhonen, LM, Hasle, H, Malila, N, Madanat-Harjuoja, LM, Feychting, M, & Winther, JF. (2021). Cohort Profile: The

93. *Erdmann, F, Hvidtfeldt, UA, Dalton, SO, Sørensen, M, & Raaschou-Nielsen, O. (2021). Individual and neighbourhood socioeconomic measures and the risk of non-central nervous system solid tumours in children: A nationwide register-based case-control study in Denmark. *Cancer Epidemiol*, 73, 101947. doi:10.1016/j.canep.2021.101947
94. *Erdmann, F, Hvidtfeldt, UA, Feychting, M, Sørensen, M, & Raaschou-Nielsen, O. (2021). Is the risk of childhood leukaemia associated with socioeconomic measures in Denmark? A nationwide register-based case-control study. *Int J Cancer*, 148(9), 2227-2240. doi:10.1002/ijc.33402
95. *Erdmann, F, Wellbrock, M, Trübenbach, C, Spix, C, Schrappe, M, Schüz, J, Grabow, D, & Eichinger, M. (2021). Impact of the COVID-19 pandemic on incidence, time of diagnosis and delivery of healthcare among paediatric oncology patients in Germany in 2020: Evidence from the German Childhood Cancer Registry and a qualitative survey. *Lancet Reg Health Eur*, 9, 100188. doi:10.1016/j.lanepe.2021.100188
96. Erlmeier, F, Steffens, S, Stöhr, C, Herrmann, E, Polifka, I, Agaimy, A, Trojan, L, Ströbel, P, Becker, F, Wülfing, C, Barth, P, Stöckle, M, Staehler, M, Stief, C, Haferkamp, A, Hohenfellner, M, Macher-Göppinger, S, Wullich, B, Noldus, J, Brenner, W, Roos, FC, Walter, B, Otto, W, Burger, M, Schrader, AJ, Hartmann, A, & Ivanyi, P. (2021). Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. *Clin Genitourin Cancer*, 19(1), 53-59.e51. doi:10.1016/j.clgc.2020.07.002
97. *Ernst, M, Brähler, E, Wild, PS, Faber, J, Merzenich, H, & Beutel, ME. (2021). Loneliness predicts suicidal ideation and anxiety symptoms in long-term childhood cancer survivors. *Int J Clin Health Psychol*, 21(1), 100201. doi:10.1016/j.ijchp.2020.10.001
98. Espinet, E, Gu, Z, Imbusch, CD, Giese, NA, Büscher, M, Safavi, M, Weisenburger, S, Klein, C, Vogel, V, Falcone, M, Insua-Rodríguez, J, Reitberger, M, Thiel, V, Kossi, SO, Muckenhuber, A, Sarai, K, Lee, AYL, Backx, E, Zarei, S, Gaida, MM, Rodríguez-Paredes, M, Donato, E, Yen, HY, Eils, R, Schlesner, M, Pfarr, N, Hackert, T, Plass, C, Brors, B, Steiger, K, Weichenhan, D, Arda, HE, Rومان, I, Kopp, JL, Strobel, O, Weichert, W, Sprick, MR, & Trumpp, A. (2021). Aggressive PDACs Show Hypomethylation of Repetitive Elements and the Execution of an Intrinsic IFN Program Linked to a Ductal Cell of Origin. *Cancer Discov*, 11(3), 638-659. doi:10.1158/2159-8290.Cd-20-1202
99. *Esposito, I, Häberle, L, Yavas, A, Kraft, A, & Gaida, MM. (2021). [Intraductal neoplasms of the pancreas]. *Pathologe*, 42(5), 472-483. doi:10.1007/s00292-021-00966-1
100. *Farooq Baba, PU, Rasool, Z, Younas Khan, I, Cockerell, CJ, Wang, R, Kassir, M, Stege, H, Grabbe, S, & Goldust, M. (2021). Merkel Cell Carcinoma: From Pathobiology to Clinical Management. *Biology (Basel)*, 10(12). doi:10.3390/biology10121293
101. Feijen, EAM, van Dalen, EC, van der Pal, HJH, Reulen, RC, Winter, DL, Keuhni, CE, Morsellino, V, Alessi, D, Allodji, RS, Byrne, J, Bardi, E, Jakab, Z, Grabow, D, Garwicz, S, Haddy, N, Jankovic, M, Kaatsch, P, Levitt, GA, Ronckers, CM, Schindera, C, Skinner, R, Zalatel, L, Hjorth, L, Tissing, WJE, De Vathaire, F, Hawkins, MM, & Kremer, LCM. (2021). Increased risk of cardiac ischaemia in a pan-European cohort of 36 205 childhood cancer survivors: a PanCareSurFup study. *Heart*, 107(1), 33-40. doi:10.1136/heartjnl-2020-316655
102. Feil, C, Staib, F, Berger, MR, Stein, T, Schmidtman, I, Forster, A, & Schimanski, CC. (2021). Sniffer dogs can identify lung cancer patients from breath and urine samples. *BMC Cancer*, 21(1), 917. doi:10.1186/s12885-021-08651-5
103. *Feiner, M, Keszte, J, Meyer, A, Kulnik, ST, Maasz, M, Lothaller, H, Fuchs, M, Hormes, K, Oeken, J, Vogel, HJ, Koscielny, S, Papst, F, & Singer, S. (2021). Effects of Finding the Speech-Language Pathologist Likeable on Postlaryngectomy Speech Intelligibility Outcomes. *Folia Phoniatr Logop*, 73(6), 577-585. doi:10.1159/000513928
104. Finkelmeier, F, Scheiner, B, Leyh, C, Best, J, Fründt, TW, Czauderna, C, Beutel, A, Bettinger, D, Weiß, J, Meischl, T, Kütting, F, Waldschmidt, DT, Radu, P, Schultheiß, M, Peiffer, KH, Ettrich, TJ, Weinmann, A, Wege, H, Venerito, M, Dufour, JF, Lange, CM, Pinter, M, & Waidmann, O. (2021). Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. *Liver Cancer*, 10(4), 360-369. doi:10.1159/000515490
105. *Foersch, S, Eckstein, M, Wagner, DC, Gach, F, Woerl, AC, Geiger, J, Glasner, C, Schelbert, S, Schulz, S, Porubsky, S, Kreft, A, Hartmann, A, Agaimy, A, & Roth, W. (2021). Deep learning for diagnosis and survival prediction in soft tissue sarcoma. *Ann Oncol*, 32(9), 1178-1187. doi:10.1016/j.annonc.2021.06.007

106. *Foerster, F, & Galle, PR. (2021). The Current Landscape of Clinical Trials for Systemic Treatment of HCC. *Cancers (Basel)*, 13(8). doi:10.3390/cancers13081962
107. Foerster, R, Zwahlen, DR, Buchali, A, Tang, H, Schroeder, C, Windisch, P, Vu, E, Akbaba, S, Bostel, T, Sprave, T, Zamboglou, C, Zilli, T, Stelmes, JJ, Telkhade, T, & Murthy, V. (2021). Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review. *Cancers (Basel)*, 13(4). doi:10.3390/cancers13040759
108. Fontana, E, Meyers, J, Sobrero, A, Iveson, T, Shields, AF, Taieb, J, Yoshino, T, Souglakos, I, Smyth, EC, Lordick, F, Moehler, M, Giraut, A, Harkin, A, Labianca, R, Meyerhardt, J, André, T, Boukovinas, I, Lonardi, S, Saunders, M, Vernerey, D, Oki, E, Georgoulas, V, Ben-Aharon, I, & Shi, Q. (2021). Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. *J Clin Oncol*, 39(36), 4009-4019. doi:10.1200/jco.21.02008
109. Forschner, A, Loquai, C, Meiss, F, Huening, S, Pawlowski, J, Bradfisch, F, Lehr, S, & Nashan, D. (2021). Is there an overtreatment of melanoma patients at the end of their life? Results of a multicenter study on 193 melanoma patients. *J Dtsch Dermatol Ges*, 19(9), 1297-1305. doi:10.1111/ddg.14501
110. Fotopoulou, C, Planchamp, F, Aytulu, T, Chiva, L, Cina, A, Ergönül, Ö, Fagotti, A, Haidopoulos, D, Hasenburg, A, Hughes, C, Knapp, P, Morice, P, Schneider, S, Sehoul, J, Stamatakis, E, Suria, S, Taskiran, C, Trappe, RU, & Campbell, J. (2021). European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. *Int J Gynecol Cancer*, 31(9), 1199-1206. doi:10.1136/ijgc-2021-002951
111. Franck, C, Zimmermann, N, Goni, E, Lippert, H, Ridwelski, K, Kruschewski, M, Kreuser, N, Lingohr, P, Schildberg, C, Vassos, N, Waidmann, O, Peitz, U, Lang, H, Grmminger, PP, Bruns, C, Veits, L, Vieth, M, Moehler, M, Lordick, F, Gockel, I, Schumacher, J, Malfertheiner, P, & Venerito, M. (2021). Different Prevalence of Alarm, Dyspeptic and Reflux Symptoms in Patients with Cardia and Non-cardia Gastric Cancer. *J Gastrointestin Liver Dis*, 30(4), 431-437. doi:10.15403/jgld-3795
112. Fransen, LFC, Berkelmans, GHK, Asti, E, Henegouwen, M, Berth, F, Bonavina, L, Brown, A, Bruns, C, van Daele, E, Gisbertz, SS, Grmminger, PP, Gutschow, CA, Hannink, G, Hölscher, AH, Kauppi, J, Lagarde, SM, Mercer, S, Moons, J, Nafteux, P, Nilsson, M, Palazzo, F, Pattyn, P, Raptis, DA, Räsänen, J, Rosato, EL, Rouvelas, I, Schmidt, HM, Schneider, PM, Schröder, W, van der Sluis, PC, Wijnhoven, BPL, Nieuwenhuijzen, GAP, & Luyer, MDP. (2021). The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival: An International Multicenter Cohort Study. *Ann Surg*, 274(6), e1129-e1137. doi:10.1097/sla.0000000000003772
113. Franzese, O, Torino, F, Giannetti, E, Cioccoloni, G, Aquino, A, Faraoni, I, Fuggetta, MP, De Vecchis, L, Giuliani, A, Kaina, B, & Bonmassar, E. (2021). Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment? *Int J Mol Sci*, 22(19). doi:10.3390/ijms221910672
114. Frederiksen, LE, Pedersen, C, Mogensen, H, Mader, L, Bautz, A, Talbäck, M, Hirvonen, E, Norsker, FN, Hasle, H, Malila, N, Madanat-Harjuoja, L, Feychting, M, Erdmann, F, & Winther, JF. (2022). Employment status and occupational positions of childhood cancer survivors from Denmark, Finland and Sweden: A Nordic register-based cohort study from the SALICCS research programme. *Lancet Reg Health Eur*, 12, 100258. doi:10.1016/j.lanepe.2021.100258
115. Freise, C, Lee, H, Chronowski, C, Chan, D, Cziomer, J, Rühl, M, Dagdelen, T, Lösekann, M, Erben, U, Catic, A, Tegge, W, Schuppan, D, Somasundaram, R, & Sahin, E. (2021). Alpha-single chains of collagen type VI inhibit the fibrogenic effects of triple helical collagen VI in hepatic stellate cells. *PLoS One*, 16(9), e0254557. doi:10.1371/journal.pone.0254557
116. *Freitag, K, Hamdan, S, Reddehase, MJ, & Holtappels, R. (2021). Immunodominant Cytomegalovirus Epitopes Suppress Subdominant Epitopes in the Generation of High-Avidity CD8 T Cells. *Pathogens*, 10(8). doi:10.3390/pathogens10080956
117. *Freudenberger, F, Ohler, A, Theobald, M, & Hess, G. (2021). Cure rate in the elderly patients with diffuse large B cell lymphoma deteriorates after the age of 80-results from a single-center survey. *Ann Hematol*, 100(4), 1013-1021. doi:10.1007/s00277-021-04461-8
118. Friedrich, M, Kühn, T, Janni, W, Müller, V, Banys-Pachulowski, M, Kolberg-Liedtke, C, Jackisch, C, Krug, D, Albert, US, Bauerfeind, I, Blohmer, J, Budach, W, Dall, P, Fallenberg, EM, Fasching, PA, Fehm, T, Gerber, B, Gluz, O, Hanf, V, Harbeck, N, Heil, J, Huober, J, Kreipe, HH, Kümmel, S, Loibl, S, Lüftner, D, Lux, MP, Maass, N, Möbus, V, Mundhenke, C, Nitz, U, Park-Simon, TW, Reimer, T, Rhiem, K, Rody, A, Schmidt, M, Schneeweiss, A, Schütz, F, Sinn, HP, Solbach, C, Solomayer, EF, Stickeler, E, Thomssen, C, Untch, M, Witzel, I, Wöckel, A, Thill, M, & Ditsch, N. (2021). AGO

119. Frost, N, Christopoulos, P, Kauffmann-Guerrero, D, Stratmann, J, Riedel, R, Schaefer, M, Alt, J, Gütz, S, Christoph, DC, Laack, E, Faehling, M, Fischer, R, Fenchel, K, Haen, S, Heukamp, L, Schulz, C, & Griesinger, F. (2021). Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. *Ther Adv Med Oncol*, 13, 1758835920980558. doi:10.1177/1758835920980558
120. *Gairing, SJ, Thol, F, Müller, L, Hahn, F, Thomaidis, T, Czauderna, C, Bartsch, F, Pitton, MB, Marquardt, JU, Wörns, MA, Galle, PR, Moehler, M, Weinmann, A, Kloeckner, R, & Foerster, F. (2021). The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. *J Clin Med*, 10(12). doi:10.3390/jcm10122732
121. *Galata, C, Karampinis, I, Roessner, ED, & Stamenovic, D. (2021). Risk factors for surgical complications after anatomic lung resections in the era of VATS and ERAS. *Thorac Cancer*, 12(23), 3255-3262. doi:10.1111/1759-7714.14197
122. *Galle, PR, Dufour, JF, Peck-Radosavljevic, M, Trojan, J, & Vogel, A. (2021). Systemic therapy of advanced hepatocellular carcinoma. *Future Oncol*, 17(10), 1237-1251. doi:10.2217/fon-2020-0758
123. *Galle, PR, Finn, RS, Qin, S, Ikeda, M, Zhu, AX, Kim, TY, Kudo, M, Breder, V, Merle, P, Kaseb, A, Li, D, Mulla, S, Verret, W, Xu, DZ, Hernandez, S, Ding, B, Liu, J, Huang, C, Lim, HY, Cheng, AL, & Ducreux, M. (2021). Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. *Lancet Oncol*, 22(7), 991-1001. doi:10.1016/s1473-2045(21)00151-0
124. *Galle, PR, Kudo, M, Llovet, JM, Finn, RS, Karwal, M, Pezet, D, Kim, TY, Yang, TS, Lonardi, S, Tomasek, J, Phelip, JM, Toucheffu, Y, Koh, SJ, Stirnimann, G, Liang, K, Ogburn, KD, Wang, C, Abada, P, Widau, RC, & Zhu, AX. (2021). Ramucicromab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. *Liver Int*, 41(11), 2759-2767. doi:10.1111/liv.14994
125. *García, MA, Cristofolletti, R, Abrahamsson, B, Groot, DW, Parr, A, Polli, JE, Mehta, M, Shah, VP, Tomakazu, T, Dressman, JB, & Langguth, P. (2021). Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine. *J Pharm Sci*, 110(5), 1935-1947. doi:10.1016/j.xphs.2021.02.019
126. *Gassenmaier, S, Afat, S, Nickel, D, Mostapha, M, Herrmann, J, & Othman, AE. (2021). Deep learning-accelerated T2-weighted imaging of the prostate: Reduction of acquisition time and improvement of image quality. *Eur J Radiol*, 137, 109600. doi:10.1016/j.ejrad.2021.109600
127. *Gassenmaier, S, Afat, S, Nickel, MD, Mostapha, M, Herrmann, J, Almansour, H, Nikolaou, K, & Othman, AE. (2021). Accelerated T2-Weighted TSE Imaging of the Prostate Using Deep Learning Image Reconstruction: A Prospective Comparison with Standard T2-Weighted TSE Imaging. *Cancers (Basel)*, 13(14). doi:10.3390/cancers13143593
128. *Gassenmaier, S, Küstner, T, Nickel, D, Herrmann, J, Hoffmann, R, Almansour, H, Afat, S, Nikolaou, K, & Othman, AE. (2021). Deep Learning Applications in Magnetic Resonance Imaging: Has the Future Become Present? *Diagnostics (Basel)*, 11(12). doi:10.3390/diagnostics11122181
129. *Geiß, C, Witzler, C, Poschet, G, Ruf, W, & Régnier-Vigouroux, A. (2021). Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells. *Eur J Immunol*, 51(5), 1246-1261. doi:10.1002/eji.202048957
130. *Gerber, TS, Agaimy, A, Hartmann, A, Habekost, M, Roth, W, Stenzinger, A, Schirmacher, P, & Straub, BK. (2021). SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report. *Diagn Pathol*, 16(1), 52. doi:10.1186/s13000-021-01112-4
131. *Gerber, TS, Bartsch, F, Wagner, DC, Schindeldecker, M, Heuft, LK, Roth, W, Lang, H, & Straub, BK. (2021). Clinicopathological Significance of Syndecan-1 in Cholangiocarcinoma: A Study Based on Immunohistochemistry and Public Sequencing Data. *J Clin Med*, 10(13). doi:10.3390/jcm10132745
132. *Gergely, KM, Podlech, J, Becker, S, Freitag, K, Krauter, S, Büscher, N, Holtappels, R, Plachter, B, Reddehase, MJ, & Lemmermann, NAW. (2021). Therapeutic Vaccination of Hematopoietic Cell Transplantation Recipients Improves Protective CD8 T-Cell Immunotherapy of Cytomegalovirus Infection. *Front Immunol*, 12, 694588. doi:10.3389/fimmu.2021.694588

133. *Gerges, C, Neumann, H, Sr., Ishaq, S, Sivanathan, V, Galle, PR, Neuhaus, H, & Neumann, H. (2021). Evaluation of a novel colonoscope offering flexibility adjuster - a retrospective observational study. *Therap Adv Gastroenterol*, 14, 17562848211013494. doi:10.1177/17562848211013494
134. Giebel, S, Labopin, M, Socié, G, Beauvais, D, Klein, S, Wagner-Drouet, EM, Blaise, D, Nguyen-Quoc, S, Bourhis, JH, Thiebaut, A, Labussière-Wallet, H, Charbonnier, A, Berceanu, A, Diez-Martin, JL, Fegueux, N, Esteve, J, Nagler, A, & Mohty, M. (2021). Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant*, 56(5), 1047-1055. doi:10.1038/s41409-020-01139-z
135. *Giustozzi, M, Valerio, L, Agnelli, G, Becattini, C, Fronk, EM, Klok, FA, Konstantinides, SV, Vedovati, MC, Cohen, AT, & Barco, S. (2021). Sex-specific differences in the presentation, clinical course, and quality of life of patients with acute venous thromboembolism according to baseline risk factors. Insights from the PREFER in VTE. *Eur J Intern Med*, 88, 43-51. doi:10.1016/j.ejim.2021.03.014
136. Gkika, E, Schimek-Jasch, T, Kremp, S, Lenz, S, Stockinger, M, Schaefer-Schuler, A, Mix, M, Küsters, A, Tosch, M, Hehr, T, Eschmann, SM, Bultel, YP, Hass, P, Fleckenstein, J, Thieme, AH, Dieckmann, K, Miederer, M, Holl, G, Rischke, HC, Adebahr, S, König, J, Binder, H, Grosu, AL, & Nestle, U. (2021). Impact of radiotherapy protocol adherence in NSCLC patients treated with concurrent chemoradiation: RTQA results of the PET-Plan trial. *Radiother Oncol*, 163, 32-38. doi:10.1016/j.radonc.2021.07.017
137. *Gnekow, AK, Kandels, D, Pietsch, T, Bison, B, Warmuth-Metz, M, Thomale, UW, Kortmann, RD, Timmermann, B, Driever, PH, Witt, O, Schmidt, R, & Spix, C. (2021). Doubling Recruitment of Pediatric Low-grade Glioma within Two Decades does not change Outcome - Report from the German LGG Studies. *Klin Padiatr*, 233(3), 107-122. doi:10.1055/a-1471-5897
138. *Göder, A, Ginter, T, Heinzl, T, Stroh, S, Fahrner, J, Henke, A, & Krämer, OH. (2021). STAT1 N-terminal domain discriminatively controls type I and type II IFN signaling. *Cytokine*, 144, 155552. doi:10.1016/j.cyto.2021.155552
139. Gogas, H, Dummer, R, Ascierto, PA, Arance, A, Mandalà, M, Liszkay, G, Garbe, C, Schadendorf, D, Krajsová, I, Gutzmer, R, Sileni, VC, Dutriaux, C, Yamazaki, N, Loquai, C, Queirolo, P, Jan de Willem, G, Sellier, AT, Suissa, J, Murris, J, Gollerkeri, A, Robert, C, & Flaherty, KT. (2021). Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). *Eur J Cancer*, 152, 116-128. doi:10.1016/j.ejca.2021.04.028
140. Goldraij, G, Tripodoro, VA, Aloisio, M, Castro, SA, Gerlach, C, Mayland, CR, & Haugen, DF. (2021). One chance to get it right: improving clinical handovers for better symptom control at the end of life. *BMJ Open Qual*, 10(3). doi:10.1136/bmjopen-2021-001436
141. González-Prieto, R, Eifler-Olivi, K, Claessens, LA, Willemstein, E, Xiao, Z, Talavera Ormeno, CMP, Ovaa, H, Ulrich, HD, & Vertegaal, ACO. (2021). Global non-covalent SUMO interaction networks reveal SUMO-dependent stabilization of the non-homologous end joining complex. *Cell Rep*, 34(4), 108691. doi:10.1016/j.celrep.2021.108691
142. González García, LE, Ninan, N, Simon, J, Madathiparambil Visalakshan, R, Bright, R, Wahono, SK, Ostrikov, K, Mailänder, V, Landfester, K, Goswami, N, & Vasilev, K. (2021). Ultra-small gold nanoclusters assembled on plasma polymer-modified zeolites: a multifunctional nanohybrid with anti-haemorrhagic and anti-inflammatory properties. *Nanoscale*, 13(47), 19936-19945. doi:10.1039/d1nr06591b
143. Goranci-Buzhala, G, Mariappan, A, Ricci-Vitiani, L, Josipovic, N, Pacioni, S, Gottardo, M, Ptok, J, Schaal, H, Callaini, G, Rajalingam, K, Dynlacht, B, Hadian, K, Papantonis, A, Pallini, R, & Gopalakrishnan, J. (2021). Cilium induction triggers differentiation of glioma stem cells. *Cell Rep*, 36(10), 109656. doi:10.1016/j.celrep.2021.109656
144. Gout, J, Perkhofer, L, Morawe, M, Arnold, F, Ihle, M, Biber, S, Lange, S, Roger, E, Kraus, JM, Stifter, K, Hahn, SA, Zamperone, A, Engleitner, T, Müller, M, Walter, K, Rodriguez-Aznar, E, Sainz, B, Jr., Hermann, PC, Hessmann, E, Müller, S, Azoitei, N, Lechel, A, Liebau, S, Wagner, M, Simeone, DM, Kestler, HA, Seufferlein, T, Wiesmüller, L, Rad, R, Frappart, PO, & Kleger, A. (2021). Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer. *Gut*, 70(4), 743-760. doi:10.1136/gutjnl-2019-319970
145. Greten, TF, Abou-Alfa, GK, Cheng, AL, Duffy, AG, El-Khoueiry, AB, Finn, RS, Galle, PR, Goyal, L, He, AR, Kaseb, AO, Kelley, RK, Lencioni, R, Lujambio, A, Mabry Hrones, D, Pinato, DJ, Sangro, B, Troisi, RI, Wilson Woods, A, Yau, T, Zhu, AX, & Melero, I. (2021). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. *J Immunother Cancer*, 9(9). doi:10.1136/jitc-2021-002794

146. *Gribko, A, Stiefel, J, Liebetanz, L, Nagel, SM, Künzel, J, Wandrey, M, Hagemann, J, Stauber, RH, Freese, C, & Gül, D. (2021). IsoMAG-An Automated System for the Immunomagnetic Isolation of Squamous Cell Carcinoma-Derived Circulating Tumor Cells. *Diagnostics (Basel)*, 11(11). doi:10.3390/diagnostics11112040
147. Grimmelmann, I, Momma, M, Zimmer, L, Hassel, JC, Heinzerling, L, Pföhler, C, Loquai, C, Ruini, C, Utikal, J, Thoms, KM, Kähler, KC, Eigentler, T, Herbst, RA, Meier, F, Debus, D, Berking, C, Kochanek, C, Ugurel, S, & Gutzmer, R. (2021). Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatocology Group. *Eur J Cancer*, 149, 1-10. doi:10.1016/j.ejca.2021.02.017
148. *Grimminger, PP, Staubitz, JI, Perez, D, Ghadban, T, Reeh, M, Scognamiglio, P, Izbicki, JR, Biebl, M, Fuchs, H, Bruns, CJ, Lang, H, Becker, T, & Egberts, JH. (2021). Multicenter Experience in Robot-Assisted Minimally Invasive Esophagectomy - a Comparison of Hybrid and Totally Robot-Assisted Techniques. *J Gastrointest Surg*, 25(10), 2463-2469. doi:10.1007/s11605-021-05044-8
149. Grote, S, Traub, F, Mittelstaet, J, Seitz, C, Kaiser, A, Handgretinger, R, & Schleicher, S. (2021). Adapter Chimeric Antigen Receptor (AdCAR)-Engineered NK-92 Cells for the Multiplex Targeting of Bone Metastases. *Cancers (Basel)*, 13(5). doi:10.3390/cancers13051124
150. Guhlich, M, Hubert, L, Mergler, CPN, Rave-Fraenk, M, Dröge, LH, Leu, M, Schmidberger, H, Rieken, S, Hille, A, & Schirmer, MA. (2021). Identification of Risk Loci for Radiotoxicity in Prostate Cancer by Comprehensive Genotyping of TGFBI and TGFBR1. *Cancers (Basel)*, 13(21). doi:10.3390/cancers13215585
151. Gutzmer, R, Loquai, C, Robert, C, Dréno, B, Guminski, A, Lewis, K, Arntz, R, Martelli, S, Squitieri, N, & Kheterpal, M. (2021). Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis. *Dermatol Ther (Heidelb)*, 11(5), 1839-1849. doi:10.1007/s13555-021-00588-8
152. Gutzmer, R, Robert, C, Loquai, C, Schadendorf, D, Squitieri, N, Arntz, R, Martelli, S, & Dummer, R. (2021). Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis. *BMC Cancer*, 21(1), 1244. doi:10.1186/s12885-021-08968-1
153. *Haas, B, Ciftcioglu, J, Jermar, S, Weickhardt, S, Eckstein, N, & Kaina, B. (2021). Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent. *J Cancer Res Clin Oncol*, 147(3), 779-792. doi:10.1007/s00432-020-03485-3
154. *Haist, M, Stege, H, Grabbe, S, & Bros, M. (2021). The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment. *Cancers (Basel)*, 13(2). doi:10.3390/cancers13020210
155. *Haist, M, Stege, H, Pémmler, S, Heinz, J, Fleischer, MI, Graf, C, Ruf, W, Loquai, C, & Grabbe, S. (2021). Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors-A Retrospective, Real-World Cohort Study. *Cancers (Basel)*, 13(20). doi:10.3390/cancers13205103
156. Hajda, J, Leuchs, B, Angelova, AL, Frehtman, V, Rommelaere, J, Mertens, M, Pilz, M, Kieser, M, Krebs, O, Dahm, M, Huber, B, Engeland, CE, Mavratzas, A, Hohmann, N, Schreiber, J, Jäger, D, Halama, N, Sedlaczek, O, Gaida, MM, Daniel, V, Springfield, C, & Ungerechts, G. (2021). Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. *Clin Cancer Res*, 27(20), 5546-5556. doi:10.1158/1078-0432.Ccr-21-1020
157. Halazun, KJ, Rosenblatt, RE, Mehta, N, Lai, Q, Hajifathalian, K, Gorgen, A, Brar, G, Sasaki, K, Doyle, MBM, Tabrizian, P, Agopian, VG, Najjar, M, Ivanics, T, Samstein, B, Brown, RS, Jr., Emond, JC, Yao, F, Lerut, J, Rossi, M, Mennini, G, Iesari, S, Finkenstedt, A, Schaefer, B, Mittler, J, Hoppe-Lotichius, M, Quintini, C, Aucejo, F, Chapman, W, & Sapisochin, G. (2021). Dynamic α -Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. *JAMA Surg*, 156(6), 559-567. doi:10.1001/jamasurg.2021.0954
158. Harter, P, Sehouli, J, Vergote, I, Ferron, G, Reuss, A, Meier, W, Greggi, S, Mosgard, BJ, Selle, F, Guyon, F, Pomel, C, Lécure, F, Zang, R, Avall-Lundqvist, E, Kim, JW, Ponce, J, Raspagliesi, F, Kristensen, G, Classe, JM, Hillemanns, P, Jensen, P, Hasenburg, A, Ghaem-Maghani, S, Mirza, MR, Lund, B, Reinthaller, A, Santaballa, A, Olaitan, A, Hilpert, F, & du Bois, A. (2021). Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer. *N Engl J Med*, 385(23), 2123-2131. doi:10.1056/NEJMoa2103294

159. *Hasenburg, A, Eichkorn, D, Vossnagen, F, Obermayr, E, Geroldinger, A, Zeillinger, R, & Bossart, M. (2021). Biomarker-based early detection of epithelial ovarian cancer based on a five-protein signature in patient's plasma - a prospective trial. *BMC Cancer*, 21(1), 1037. doi:10.1186/s12885-021-08682-y
160. *Hasenburg, A, Plett, H, Krämer, B, Braicu, E, Czogalla, B, Bossart, M, Singer, S, Mayr, D, Staebler, A, du Bois, A, Kommoss, S, Link, T, Burges, A, Heitz, F, Keul, J, Trillsch, F, Harter, P, Wimberger, P, Buderath, P, & Klar, M. (2021). The effect of fertility-sparing surgery on sexuality and global quality of life in women with malignant ovarian germ cell and sex cord stromal tumors: an analysis of the CORSETT database of the AGO study group. *Arch Gynecol Obstet*, 304(6), 1541-1549. doi:10.1007/s00404-021-06019-5
161. Hassan, Z, Schneeweis, C, Wirth, M, Müller, S, Geismann, C, Neuß, T, Steiger, K, Krämer, OH, Schmid, RM, Rad, R, Arlt, A, Reichert, M, Saur, D, & Schneider, G. (2021). Important role of Nfkb2 in the Kras(G12D)-driven carcinogenesis in the pancreas. *Pancreatology*, 21(5), 912-919. doi:10.1016/j.pan.2021.03.012
162. Haugen, DF, Hufthammer, KO, Gerlach, C, Sigurdardottir, K, Hansen, MIT, Ting, G, Tripodoro, VA, Goldraij, G, Yanneo, EG, Leppert, W, Wolszczak, K, Zambon, L, Passarini, JN, Saad, IAB, Weber, M, Ellershaw, J, & Mayland, CR. (2021). Good Quality Care for Cancer Patients Dying in Hospitals, but Information Needs Unmet: Bereaved Relatives' Survey within Seven Countries. *Oncologist*, 26(7), e1273-e1284. doi:10.1002/onco.13837
163. *Haupts, A, Vogel, A, Foersch, S, Hartmann, M, Maderer, A, Wachter, N, Huber, T, Kneist, W, Roth, W, Lang, H, Moehler, M, & Hartmann, N. (2021). Comparative analysis of nuclear and mitochondrial DNA from tissue and liquid biopsies of colorectal cancer patients. *Sci Rep*, 11(1), 16745. doi:10.1038/s41598-021-95006-6
164. Heidegger, I, Necchi, A, Pircher, A, Tsaur, I, Marra, G, Kasivisvanathan, V, Kretschmer, A, Mathieu, R, Ceci, F, van den Bergh, RCN, Thibault, C, Tilki, D, Valerio, M, Surcel, C, & Gandaglia, G. (2021). A Systematic Review of the Emerging Role of Immune Checkpoint Inhibitors in Metastatic Castration-resistant Prostate Cancer: Will Combination Strategies Improve Efficacy? *Eur Urol Oncol*, 4(5), 745-754. doi:10.1016/j.euo.2020.10.010
165. Heilig, CE, Horak, P, Kreutzfeldt, S, Teleanu, V, Mock, A, Renner, M, Bhatti, IA, Hutter, B, Hüllein, J, Fröhlich, M, Uhrig, S, Süße, H, Heiligenthal, L, Ochsenreither, S, Illert, AL, Vogel, A, Desuki, A, Heinemann, V, Heidegger, S, Bitzer, M, Scheytt, M, Brors, B, Hübschmann, D, Baretton, G, Stenzinger, A, Steindorf, K, Benner, A, Jäger, D, Heining, C, Glimm, H, Fröhling, S, & Schlenk, RF. (2021). Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial. *ESMO Open*, 6(6), 100310. doi:10.1016/j.esmoop.2021.100310
166. *Heimes, AS, Krämer, H, Härtner, F, Almstedt, K, Krajnak, S, Battista, MJ, Brenner, W, Hasenburg, A, & Schmidt, M. (2021). Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy. *Breast Care (Basel)*, 16(5), 444-451. doi:10.1159/000511992
167. *Heimes, D, Müller, LK, Schellin, A, Naujokat, H, Graetz, C, Schwendicke, F, Goedecke, M, Beck-Broichsitter, B, & Kämmerer, PW. (2021). Consequences of the COVID-19 Pandemic and Governmental Containment Policies on the Detection and Therapy of Oral Malignant Lesions-A Retrospective, Multicenter Cohort Study from Germany. *Cancers (Basel)*, 13(12). doi:10.3390/cancers13122892
168. Heinemann, V, von Weikersthal, LF, Decker, T, Kiani, A, Kaiser, F, Al-Batran, SE, Heintges, T, Lerchenmüller, C, Kahl, C, Seipelt, G, Kullmann, F, Moehler, M, Scheithauer, W, Held, S, Miller-Phillips, L, Modest, DP, Jung, A, Kirchner, T, & Stintzing, S. (2021). FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. *Br J Cancer*, 124(3), 587-594. doi:10.1038/s41416-020-01140-9
169. Heinicke, T, Labopin, M, Polge, E, Stelljes, M, Ganser, A, Tischer, J, Brecht, A, Kröger, N, Beelen, DW, Scheid, C, Bethge, W, Dreger, P, Bunjes, D, Wagner, E, Platzbecker, U, Savani, BN, Nagler, A, & Mohty, M. (2021). Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT. *Leuk Lymphoma*, 62(2), 399-409. doi:10.1080/10428194.2020.1827248
170. Heinrich, B, Brown, ZJ, Diggs, LP, Vormehr, M, Ma, C, Subramanyam, V, Rosato, U, Ruf, B, Walz, JS, McVey, JC, Wabitsch, S, Fu, Q, Yu, SJ, Zhang, Q, Lai, CW, Sahin, U, & Greten, TF. (2021). Steatohepatitis Impairs T-cell-Directed Immunotherapies Against Liver Tumors in Mice. *Gastroenterology*, 160(1), 331-345.e336. doi:10.1053/j.gastro.2020.09.031
171. *Heinrich, S, & Lang, H. (2021). [Evidence of minimally invasive oncological surgery of the liver]. *Chirurg*, 92(4), 316-325. doi:10.1007/s00104-020-01338-w

172. *Heinrich, S, Seehofer, D, Corvinus, F, Tripke, V, Huber, T, Hüttl, F, Penzkofer, L, Mittler, J, Abu Hilal, M, & Lang, H. (2021). [Advantages and future perspectives of laparoscopic liver surgery]. *Chirurg*, 92(6), 542-549. doi:10.1007/s00104-020-01288-3
173. Hempler, I, Heidt, V, Riccetti, N, Singer, S, & Hermes-Moll, K. (2021). ["We knew it was going to be tough, but we didn't expect this!" Experiences with the inclusion of cancer patients with a migrant background and their relatives in the field of psycho-oncology]. *Z Evid Fortbild Qual Gesundheitswes*, 166, 55-59. doi:10.1016/j.zefq.2021.08.002
174. *Hempler, I, Riccetti, N, Hermes-Moll, K, Heidt, V, & Singer, S. (2021). [Psycho-Oncological Care for People with a Migration Background and their Relatives - Results of Semi-Structured Interviews with Physicians]. *Psychother Psychosom Med Psychol*, 71(8), 335-342. doi:10.1055/a-1390-4061
175. *Herbert, SL, Wöckel, A, Kreienberg, R, Kühn, T, Flock, F, Felberbaum, R, Janni, W, Curtaz, C, Kiesel, M, Stüber, T, Diessner, J, Salmen, J, Schwentner, L, Fink, V, Bekes, I, Leinert, E, Lato, K, Polasik, A, Schochter, F, & Singer, S. (2021). To which extent do breast cancer survivors feel well informed about disease and treatment 5 years after diagnosis? *Breast Cancer Res Treat*, 185(3), 677-684. doi:10.1007/s10549-020-05974-y
176. *Herold, S, Klodt, T, Toelle, D, Dennebaum, M, Lippe, E, Walz, C, Kaes, J, Kreft, A, Siegel, E, Munder, M, & Teschner, D. (2021). Lethal systemic and brain infection caused by *Prototheca zopfii* algae in a patient with acute myeloid leukemia. *Med Mycol Case Rep*, 32, 17-20. doi:10.1016/j.mmcr.2021.01.004
177. *Herrmann, J, Afat, S, Brendlin, A, Chaika, M, Lingg, A, & Othman, AE. (2021). Clinical Evaluation of an Abbreviated Contrast-Enhanced Whole-Body MRI for Oncologic Follow-Up Imaging. *Diagnostics (Basel)*, 11(12). doi:10.3390/diagnostics11122368
178. Hettmer, S, Dachy, G, Seitz, G, Agaimy, A, Duncan, C, Jongmans, M, Hirsch, S, Kventzel, I, Kordes, U, de Krijger, RR, Metzler, M, Michaeli, O, Nemes, K, Poluha, A, Ripperger, T, Russo, A, Smetsers, S, Sparber-Sauer, M, Stutz, E, Bourdeaut, F, Kratz, CP, & Demoulin, JB. (2021). Genetic testing and surveillance in infantile myofibromatosis: a report from the SIOPE Host Genome Working Group. *Fam Cancer*, 20(4), 327-336. doi:10.1007/s10689-020-00204-2
179. *Heylmann, D, Ponath, V, Kindler, T, & Kaina, B. (2021). Comparison of DNA repair and radiosensitivity of different blood cell populations. *Sci Rep*, 11(1), 2478. doi:10.1038/s41598-021-81058-1
180. Hilgendorf, I, Bergelt, C, Bokemeyer, C, Kaatsch, P, Seifart, U, Stein, A, & Langer, T. (2021). Long-Term Follow-Up of Children, Adolescents, and Young Adult Cancer Survivors. *Oncol Res Treat*, 44(4), 184-189. doi:10.1159/000514381
181. Hölig, K, Schmidt, H, Hütter, G, Kramer, M, Teipel, R, Heidrich, K, Zimmer, K, Heidenreich, F, Blechschmidt, M, Torosian, T, Ordemann, R, Kroschinsky, F, Rücker-Braun, E, Gopsca, L, Wagner-Drouet, EM, Oelschlaegel, U, Schmidt, AH, Bornhäuser, M, Ehninger, G, & Schetelig, J. (2021). Salvage treatment with plerixafor in poor mobilizing allogeneic stem cell donors: results of a prospective phase II-trial. *Bone Marrow Transplant*, 56(3), 635-645. doi:10.1038/s41409-020-01053-4
182. Horak, P, Heining, C, Kreutzfeldt, S, Hutter, B, Mock, A, Hüllelin, J, Fröhlich, M, Uhrig, S, Jahn, A, Rump, A, Geldon, L, Möhrmann, L, Hanf, D, Teleanu, V, Heilig, CE, Lipka, DB, Allgäuer, M, Ruhnke, L, Laßmann, A, Endris, V, Neumann, O, Penzel, R, Beck, K, Richter, D, Winter, U, Wolf, S, Pfütze, K, Georg, C, Meißburger, B, Buchhalter, I, Augustin, M, Aulitzky, WE, Hohenberger, P, Kroiss, M, Schirmacher, P, Schlenk, RF, Keilholz, U, Klauschen, F, Folprecht, G, Bauer, S, Siveke, JT, Brandts, CH, Kindler, T, Boerries, M, Illert, AL, von Bubnoff, N, Jost, PJ, Spiekermann, K, Bitzer, M, Schulze-Osthoff, K, von Kalle, C, Klink, B, Brors, B, Stenzinger, A, Schröck, E, Hübschmann, D, Weichert, W, Glimm, H, & Fröhling, S. (2021). Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. *Cancer Discov*, 11(11), 2780-2795. doi:10.1158/2159-8290.Cd-21-0126
183. Hötter, AM, Mazaheri, Y, Lollert, A, Schenk, JP, Zheng, J, Capanu, M, Akin, O, Graf, N, & Staatz, G. (2021). Diffusion-weighted MRI and histogram analysis: assessment of response to neoadjuvant chemotherapy in nephroblastoma. *Abdom Radiol (NY)*, 46(7), 3317-3325. doi:10.1007/s00261-021-03032-9
184. *Hotz, C, Wagenaar, TR, Gieseke, F, Bangari, DS, Callahan, M, Cao, H, Diekmann, J, Diken, M, Grunwitz, C, Hebert, A, Hsu, K, Bernardo, M, Karikó, K, Kreiter, S, Kuhn, AN, Levit, M, Malkova, N, Masciari, S, Pollard, J, Qu, H, Ryan, S, Selmi, A, Schlereth, J, Singh, K, Sun, F, Tillmann, B, Tolstykh, T, Weber, W, Wicke, L, Witzel, S, Yu, Q, Zhang, YA, Zheng, G, Lager, J, Nabel, GJ, Sahin, U, & Wiederschain, D. (2021). Local delivery of mRNA-encoding cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. *Sci Transl Med*, 13(610), eabc7804. doi:10.1126/scitranslmed.abc7804

185. Hrgovic, I, Kleemann, J, Doll, M, Loquai, C, Weid, F, Louwen, F, Zoeller, N, Kippenberger, S, Kaufmann, R, & Meissner, M. (2021). Evaluation of 2-methoxyestradiol serum levels as a potential prognostic marker in malignant melanoma. *Mol Clin Oncol*, 15(1), 141. doi:10.3892/mco.2021.2303
186. *Huber, T, Huettl, F, Tripke, V, Baumgart, J, & Lang, H. (2021). Experiences With Three-dimensional Printing in Complex Liver Surgery. *Ann Surg*, 273(1), e26-e27. doi:10.1097/sla.0000000000004348
187. *Huettl, F, Saalfeld, P, Hansen, C, Preim, B, Poplawski, A, Kneist, W, Lang, H, & Huber, T. (2021). Virtual reality and 3D printing improve preoperative visualization of 3D liver reconstructions-results from a preclinical comparison of presentation modalities and user's preference. *Ann Transl Med*, 9(13), 1074. doi:10.21037/atm-21-512
188. Hungria, V, Beksac, M, Weisel, KC, Nooka, AK, Masszi, T, Spicka, I, Munder, M, Mateos, MV, Mark, TM, Qi, M, Qin, X, Fastenau, J, Spencer, A, Sonneveld, P, Garvin, W, Renaud, T, & Gries, KS. (2021). Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial. *Br J Haematol*, 193(3), 561-569. doi:10.1111/bjh.17321
189. Huppertsberg, A, Kaps, L, Zhong, Z, Schmitt, S, Stickdorn, J, Deswarte, K, Combes, F, Czysch, C, De Vrieze, J, Kasmi, S, Choteschovsky, N, Klefenz, A, Medina-Montano, C, Winterwerber, P, Chen, C, Bros, M, Lienenklaus, S, Sanders, NN, Koynov, K, Schuppan, D, Lambrecht, BN, David, SA, De Geest, BG, & Nuhn, L. (2021). Squaric Ester-Based, pH-Degradable Nanogels: Modular Nanocarriers for Safe, Systemic Administration of Toll-like Receptor 7/8 Agonistic Immune Modulators. *J Am Chem Soc*, 143(26), 9872-9883. doi:10.1021/jacs.1c03772
190. *Huppertz, T, Horstmann, V, Scharnow, C, Ruckes, C, Bahr, K, Matthias, C, & Gouveris, H. (2021). OSA in patients with head and neck cancer is associated with cancer size and oncologic outcome. *Eur Arch Otorhinolaryngol*, 278(7), 2485-2491. doi:10.1007/s00405-020-06355-3
191. Hussain, T, Gellrich, D, Siemer, S, Reichel, CA, Eckrich, J, Dietrich, D, Knauer, SK, Stauber, RH, & Strieth, S. (2021). TNF- α -Inhibition Improves the Biocompatibility of Porous Polyethylene Implants In Vivo. *Tissue Eng Regen Med*, 18(2), 297-303. doi:10.1007/s13770-020-00325-w
192. Iavarone, M, Invernizzi, F, Ivanics, T, Mazza, S, Zavaglia, C, Sanduzzi-Zamparelli, M, Fraile-López, M, Czauderna, C, Di Costanzo, G, Bhooi, S, Pinter, M, Manini, MA, Amadeo, G, Yunquera, AF, Piñero, F, Blanco Rodríguez, MJ, Anders, M, Aballay Soteras, G, Villadsen, GE, Yoon, PD, Cesarini, L, Díaz-González, Á, González-Diéguez, ML, Tortora, R, Weinmann, A, Mazzaferro, V, Romero Cristóbal, M, Crespo, G, Regnault, H, De Giorgio, M, Varela, M, Prince, R, Scudeller, L, Donato, MF, Wörns, MA, Bruix, J, Sapisochin, G, Lampertico, P, & Reig, M. (2021). Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. *Liver Transpl*, 27(12), 1767-1778. doi:10.1002/lt.26264
193. Ibrahim, HS, Abdelsalam, M, Zeyn, Y, Zessin, M, Mustafa, AM, Fischer, MA, Zeyen, P, Sun, P, Bülbül, EF, Vecchio, A, Erdmann, F, Schmidt, M, Robaa, D, Barinka, C, Romier, C, Schutkowski, M, Krämer, OH, & Sippl, W. (2021). Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity. *Int J Mol Sci*, 23(1). doi:10.3390/ijms23010369
194. *Jacobs, B, Gebel, V, Heger, L, Grèze, V, Schild, H, Dudziak, D, & Ullrich, E. (2021). Characterization and Manipulation of the Crosstalk Between Dendritic and Natural Killer Cells Within the Tumor Microenvironment. *Front Immunol*, 12, 670540. doi:10.3389/fimmu.2021.670540
195. Jain, D, Guleria, P, Singh, V, Parshad, R, Kumar, S, Gaiser, T, Kurz, KS, Ott, G, Porubsky, S, Preissler, G, Sauer, CG, Schölch, S, Ströbel, P, Hielscher, T, Marx, A, & Popovic, ZV. (2021). GTF2I Mutation in Thymomas: Independence From Racial-Ethnic Backgrounds. An Indian/German Comparative Study. *Pathol Oncol Res*, 27, 1609858. doi:10.3389/pore.2021.1609858
196. Janjigian, YY, Shitara, K, Moehler, M, Garrido, M, Salman, P, Shen, L, Wyrwicz, L, Yamaguchi, K, Skoczylas, T, Campos Bragagnoli, A, Liu, T, Schenker, M, Yanez, P, Tehfe, M, Kowalyszyn, R, Karamouzis, MV, Bruges, R, Zander, T, Pazo-Cid, R, Hitre, E, Feeney, K, Cleary, JM, Poulart, V, Cullen, D, Lei, M, Xiao, H, Kondo, K, Li, M, & Ajani, JA. (2021). First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet*, 398(10294), 27-40. doi:10.1016/s0140-6736(21)00797-2
197. Jansson, H, Olthof, PB, Bergquist, A, Ligthart, MAP, Nadalin, S, Troisi, RI, Groot Koerkamp, B, Alikhanov, R, Lang, H, Guglielmi, A, Cescon, M, Jarnagin, WR, Aldrighetti, L, van Gulik, TM, & Sparrelid, E. (2021). Outcome after resection for

perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study. *HPB (Oxford)*, 23(11), 1751-1758. doi:10.1016/j.hpb.2021.04.011

198. *Jartarkar, SR, Patil, A, Wollina, U, Gold, MH, Stege, H, Grabbe, S, & Goldust, M. (2021). New diagnostic and imaging technologies in dermatology. *J Cosmet Dermatol*, 20(12), 3782-3787. doi:10.1111/jocd.14499
199. Jesinghaus, M, Schmitt, M, Lang, C, Reiser, M, Scheiter, A, Konukiewicz, B, Steiger, K, Silva, M, Tschurtschenthaler, M, Lange, S, Foersch, S, Becker, KF, Saur, D, Friess, H, Halfter, K, Engel, J, Boxberg, M, Pfarr, N, Wilhelm, D, & Weichert, W. (2021). Morphology Matters: A Critical Reappraisal of the Clinical Relevance of Morphologic Criteria From the 2019 WHO Classification in a Large Colorectal Cancer Cohort Comprising 1004 Cases. *Am J Surg Pathol*, 45(7), 969-978. doi:10.1097/pas.0000000000001692
200. Jing, Y, Ren, Y, Witzel, HR, & Dobрева, G. (2021). A BMP4-p38 MAPK signaling axis controls ISL1 protein stability and activity during cardiogenesis. *Stem Cell Reports*, 16(8), 1894-1905. doi:10.1016/j.stemcr.2021.06.017
201. Jiso, A, Demuth, P, Bachowsky, M, Haas, M, Seiwert, N, Heylmann, D, Rasenberger, B, Christmann, M, Dietrich, L, Brunner, T, Riyanti, Schäberle, TF, Plubrukarn, A, & Fahrer, J. (2021). Natural Merosesquiterpenes Activate the DNA Damage Response via DNA Strand Break Formation and Trigger Apoptotic Cell Death in p53-Wild-type and Mutant Colorectal Cancer. *Cancers (Basel)*, 13(13). doi:10.3390/cancers13133282
202. *Johann, K, Bohn, T, Shahneh, F, Luther, N, Birke, A, Jaurich, H, Helm, M, Klein, M, Raker, VK, Bopp, T, Barz, M, & Becker, C. (2021). Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression. *Nat Commun*, 12(1), 5981. doi:10.1038/s41467-021-26269-w
203. Jonas, RA, Rokohl, AC, Kakkassery, V, Ponto, KA, Lohneis, P, & Heindl, LM. (2021). [Diagnostics of benign and malignant tumors of the orbit]. *Ophthalmologe*, 118(10), 987-994. doi:10.1007/s00347-021-01429-x
204. *Juengel, E, Schnalke, P, Rutz, J, Maxeiner, S, Chun, FK, & Blaheta, RA. (2021). Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells-A View towards Second Line Renal Cell Carcinoma Treatment. *Biomedicines*, 9(11). doi:10.3390/biomedicines9111630
205. *Jung, T, Haist, M, Kuske, M, Grabbe, S, & Bros, M. (2021). Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond. *Int J Mol Sci*, 22(18). doi:10.3390/ijms22189890
206. Kaatsch, HL, Becker, BV, Schüle, S, Ostheim, P, Nestler, K, Jakobi, J, Schäfer, B, Hantke, T, Brockmann, MA, Abend, M, Waldeck, S, Port, M, Scherthan, H, & Ullmann, R. (2021). Gene expression changes and DNA damage after ex vivo exposure of peripheral blood cells to various CT photon spectra. *Sci Rep*, 11(1), 12060. doi:10.1038/s41598-021-91023-7
207. *Kaatsch, P, Byrne, J, Grabow, D, & On Behalf Of The PanCare, LC. (2021). Managing a Pan-European Consortium on Late Effects among Long-Term Survivors of Childhood and Adolescent Cancer-The PanCareLIFE Project. *Int J Environ Res Public Health*, 18(8). doi:10.3390/ijerph18083918
208. Kähler, KC, Gutzmer, R, Meier, F, Zimmer, L, Heppt, M, Gesierich, A, Thoms, KM, Utikal, J, Hassel, JC, Loquai, C, Pföhler, C, Heinzerling, L, Kaatz, M, Göppner, D, Pflugfelder, A, Böhne, AS, Satzger, I, Reinhardt, L, Placke, JM, Schadendorf, D, & Ugurel, S. (2021). Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study. *Front Oncol*, 11, 672172. doi:10.3389/fonc.2021.672172
209. Kaiser, J, Hinz, U, Mayer, P, Hank, T, Niesen, W, Hackert, T, Gaida, MM, Büchler, MW, & Strobel, O. (2021). Clinical presentation and prognosis of adenosquamous carcinoma of the pancreas - Matched-pair analysis with pancreatic ductal adenocarcinoma. *Eur J Surg Oncol*, 47(7), 1734-1741. doi:10.1016/j.ejso.2021.02.011
210. Kaiser, JC, Blettner, M, & Stathopoulos, GT. (2021). Biologically based models of cancer risk in radiation research. *Int J Radiat Biol*, 97(1), 2-11. doi:10.1080/09553002.2020.1784490
211. *Kalasauskas, D, Keric, N, Abu Ajaj, S, von Cube, L, Ringel, F, & Renovanz, M. (2021). Distress and quality of life do not change over time in patients with operated and conservatively managed intracranial meningioma. *Acta Neurochir (Wien)*, 163(12), 3417-3424. doi:10.1007/s00701-021-05004-w
212. *Kalasauskas, D, Tanyildizi, Y, Renovanz, M, Brockmann, MA, Sommer, CJ, Ringel, F, & Keric, N. (2021). Evaluation of Resection Margin after Image-Guided Dural Tail Resection in Convexity Meningiomas. *J Clin Med*, 10(6). doi:10.3390/jcm10061177

213. *Kappel, C, Seidl, C, Medina-Montano, C, Schinnerer, M, Alberg, I, Leps, C, Sohl, J, Hartmann, AK, Fichter, M, Kuske, M, Schunke, J, Kuhn, G, Tubbe, I, Paßlick, D, Hobernik, D, Bent, R, Haas, K, Montermann, E, Walzer, K, Diken, M, Schmidt, M, Zentel, R, Nuhn, L, Schild, H, Tenzer, S, Mailänder, V, Barz, M, Bros, M, & Grabbe, S. (2021). Density of Conjugated Antibody Determines the Extent of Fc Receptor Dependent Capture of Nanoparticles by Liver Sinusoidal Endothelial Cells. *ACS Nano*, 15(9), 15191-15209. doi:10.1021/acsnano.1c05713
214. *Karampinis, I, Galata, C, Arani, A, Grilli, M, Hetjens, S, Shackcloth, M, Buder, S, Stamenovic, D, & Roessner, ED. (2021). Autologous blood pleurodesis for the treatment of postoperative air leaks. A systematic review and meta-analysis. *Thorac Cancer*, 12(20), 2648-2654. doi:10.1111/1759-7714.14138
215. *Karampinis, I, Rathmann, N, Kostrzewa, M, Diehl, SJ, Schoenberg, SO, Hohenberger, P, & Roessner, ED. (2021). Computer tomography guided thoracoscopic resection of small pulmonary nodules in the hybrid theatre. *PLoS One*, 16(11), e0258896. doi:10.1371/journal.pone.0258896
216. *Kaufmann, J, Biscio, CAN, Bankhead, P, Zimmer, S, Schmidberger, H, Rubak, E, & Mayer, A. (2021). Using the R Package Spatstat to Assess Inhibitory Effects of Microregional Hypoxia on the Infiltration of Cancers of the Head and Neck Region by Cytotoxic T Lymphocytes. *Cancers (Basel)*, 13(8). doi:10.3390/cancers13081924
217. *Kaya, S, Wiesmann, N, Goldschmitt, J, Krüger, M, Al-Nawas, B, & Heider, J. (2021). Differences in the expression of caveolin-1 isoforms in cancer-associated and normal fibroblasts of patients with oral squamous cell carcinoma. *Clin Oral Investig*, 25(10), 5823-5831. doi:10.1007/s00784-021-03887-8
218. Kazdal, D, Rempel, E, Oliveira, C, Allgäuer, M, Harms, A, Singer, K, Kohlwe, E, Ormanns, S, Fink, L, Kriegsmann, J, Leichsenring, M, Kriegsmann, K, Stögbauer, F, Tavernar, L, Leichsenring, J, Volckmar, AL, Longuespée, R, Winter, H, Eichhorn, M, Heußel, CP, Herth, F, Christopoulos, P, Reck, M, Muley, T, Weichert, W, Budczies, J, Thomas, M, Peters, S, Warth, A, Schirmacher, P, Stenzinger, A, & Kriegsmann, M. (2021). Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma. *Transl Lung Cancer Res*, 10(4), 1666-1678. doi:10.21037/tlcr-20-1168
219. *Kelly, RJ, Ajani, JA, Kuzdzal, J, Zander, T, Van Cutsem, E, Piessen, G, Mendez, G, Feliciano, J, Motoyama, S, Lièvre, A, Uronis, H, Elimova, E, Grootscholten, C, Geboes, K, Zafar, S, Snow, S, Ko, AH, Feeney, K, Schenker, M, Kocon, P, Zhang, J, Zhu, L, Lei, M, Singh, P, Kondo, K, Cleary, JM, & Moehler, M. (2021). Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *N Engl J Med*, 384(13), 1191-1203. doi:10.1056/NEJMoa2032125
220. Kendre, G, Marhenke, S, Lorz, G, Becker, D, Reineke-Plaaß, T, Poth, T, Murugesan, K, Kühnel, F, Woller, N, Wirtz, RM, Pich, A, Marquardt, JU, Saborowski, M, Vogel, A, & Saborowski, A. (2021). The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma. *Hepatology*, 74(3), 1357-1370. doi:10.1002/hep.31799
221. Kesch, C, Heidegger, I, Kasivisvanathan, V, Kretschmer, A, Marra, G, Preisser, F, Tilki, D, Tsaor, I, Valerio, M, van den Bergh, RCN, Fankhauser, CD, Zattoni, F, & Gandaglia, G. (2021). Radical Prostatectomy: Sequelae in the Course of Time. *Front Surg*, 8, 684088. doi:10.3389/fsurg.2021.684088
222. *Khreish, F, Ribbat, K, Bartholomä, M, Maus, S, Stemler, T, Hierlmeier, I, Linxweiler, J, Schreckenberger, M, Ezziddin, S, & Rosar, F. (2021). Value of Combined PET Imaging with [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [(177)Lu]Lu-PSMA-617 RLT. *Cancers (Basel)*, 13(16). doi:10.3390/cancers13164134
223. Klein, EM, Tichy, D, Salwender, HJ, Mai, EK, Duerig, J, Weisel, KC, Benner, A, Bertsch, U, Akhavanpoor, M, Besemer, B, Munder, M, Lindemann, HW, Hose, D, Seckinger, A, Luntz, S, Jauch, A, Elmaagacli, A, Fuhrmann, S, Brossart, P, Goerner, M, Bernhard, H, Raab, MS, Blau, IW, Haenel, M, Scheid, C, Goldschmidt, H, & On Behalf Of The German-Speaking Myeloma Multicenter Group, G. (2021). Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. *Cancers (Basel)*, 13(19). doi:10.3390/cancers13194856
224. Kliesch, S, Schmidt, S, Wilborn, D, Aigner, C, Albrecht, W, Bedke, J, Beintker, M, Beyersdorff, D, Bokemeyer, C, Busch, J, Classen, J, de Wit, M, Dieckmann, KP, Diemer, T, Dieing, A, Gockel, M, Göckel-Beining, B, Hakenberg, OW, Heidenreich, A, Heinzelbecker, J, Herkommer, K, Hermanns, T, Kaufmann, S, Kornmann, M, Kotzerke, J, Krege, S, Kristiansen, G, Lorch, A, Müller, AC, Oechsle, K, Ohloff, T, Oing, C, Otto, U, Pfister, D, Pichler, R, Recken, H, Rick, O, Rudolph, Y, Ruf, C, Schirren, J, Schmelz, H, Schmidberger, H, Schrader, M, Schwyer, S, Seeling, S, Souchon, R, Winter, C, Wittekind, C, Zengerling, F, Zermann, DH, Zillmann, R, & Albers, P. (2021a). Management of Germ Cell Tumours of the Testes in Adult Patients: German Clinical Practice Guideline, PART II - Recommendations for the Treatment of Advanced, Recurrent, and Refractory Disease and Extragonadal and Sex Cord/Stromal Tumours and for the Management of Follow-Up, Toxicity, Quality of Life, Palliative Care, and Supportive Therapy. *Urol Int*, 105(3-4), 181-191. doi:10.1159/000511245

225. Kliesch, S, Schmidt, S, Wilborn, D, Aigner, C, Albrecht, W, Bedke, J, Beintker, M, Beyersdorff, D, Bokemeyer, C, Busch, J, Classen, J, de Wit, M, Dieckmann, KP, Diemer, T, Dieing, A, Gockel, M, Göckel-Beining, B, Hakenberg, OW, Heidenreich, A, Heinzlbecker, J, Herkommer, K, Hermanns, T, Kaufmann, S, Kornmann, M, Kotzerke, J, Krega, S, Kristiansen, G, Lorch, A, Müller, AC, Oechsle, K, Ohloff, T, Oing, C, Otto, U, Pfister, D, Pichler, R, Recken, H, Rick, O, Rudolph, Y, Ruf, C, Schirren, J, Schmelz, H, Schmidberger, H, Schrader, M, Schweyer, S, Seeling, S, Souchon, R, Winter, C, Wittekind, C, Zengerling, F, Zermann, DH, Zillmann, R, & Albers, P. (2021b). Management of Germ Cell Tumours of the Testis in Adult Patients. German Clinical Practice Guideline Part I: Epidemiology, Classification, Diagnosis, Prognosis, Fertility Preservation, and Treatment Recommendations for Localized Stages. *Urol Int*, 105(3-4), 169-180. doi:10.1159/000510407
226. Klionsky, DJ, Abdel-Aziz, AK, Abdelfatah, S, Abdellatif, M, Abdoli, A, Abel, S, Abeliovich, H, Abildgaard, MH, Abudu, YP, Acevedo-Arozena, A, Adamopoulos, IE, Adeli, K, Adolph, TE, Adornetto, A, Aflaki, E, Agam, G, Agarwal, A, Aggarwal, BB, Agnello, M, Agostinis, P, Agrewala, JN, Agrotis, A, Aguilar, PV, Ahmad, ST, Ahmed, ZM, Ahumada-Castro, U, Aits, S, Aizawa, S, Akkoc, Y, Akoumianaki, T, Akpınar, HA, Al-Abd, AM, Al-Akra, L, Al-Gharaibeh, A, Alaoui-Jamali, MA, Alberti, S, Alcocer-Gómez, E, Alessandri, C, Ali, M, Alim Al-Bari, MA, Aliwaini, S, Alizadeh, J, Almacellas, E, Almasan, A, Alonso, A, Alonso, GD, Altan-Bonnet, N, Altieri, DC, Álvarez É, MC, Alves, S, Alves da Costa, C, Alzaharna, MM, Amadio, M, Amantini, C, Amaral, C, Ambrosio, S, Amer, AO, Ammanathan, V, An, Z, Andersen, SU, Andrabi, SA, Andrade-Silva, M, Andres, AM, Angelini, S, Ann, D, Anozie, UC, Ansari, MY, Antas, P, Antebi, A, Antón, Z, Anwar, T, Apetoh, L, Apostolova, N, Araki, T, Araki, Y, Arasaki, K, Araújo, WL, Araya, J, Arden, C, Arévalo, MA, Arguelles, S, Arias, E, Arikath, J, Arimoto, H, Ariosa, AR, Armstrong-James, D, Arnauné-Pelloquin, L, Aroca, A, Arroyo, DS, Arsov, I, Artero, R, Asaro, DML, Aschner, M, Ashrafizadeh, M, Ashur-Fabian, O, Atanasov, AG, Au, AK, Auberger, P, Auner, HW, Aurelian, L, Autelli, R, Avagliano, L, Ávalos, Y, Aveic, S, Aveleira, CA, Avin-Wittenberg, T, Aydin, Y, Ayton, S, Ayyadevara, S, Azzopardi, M, Baba, M, Backer, JM, Backues, SK, Bae, DH, Bae, ON, Bae, SH, Baehrecke, EH, Baek, A, Baek, SH, Baek, SH, Bagetta, G, Bagniewska-Zadworna, A, Bai, H, Bai, J, Bai, X, Bai, Y, Bairagi, N, Baksi, S, Balbi, T, Baldari, CT, Balduini, W, Ballabio, A, Ballester, M, Balazadeh, S, Balzan, R, Bandopadhyay, R, Banerjee, S, Banerjee, S, Bánréti, Á, Bao, Y, Baptista, MS, Baracca, A, Barbat, C, Bargiela, A, Barilà, D, Barlow, PG, Barmada, SJ, Barreiro, E, Barreto, GE, Bartek, J, Bartel, B, Bartolome, A, Barve, GR, Basagoudanavar, SH, Bassham, DC, Bast, RC, Jr., Basu, A, Batoko, H, Batten, I, Baulieu, EE, Baumgarner, BL, Bayry, J, Beale, R, Beau, I, Beaumatin, F, Bechara, LRG, Beck, GR, Jr., Beers, MF, Begun, J, Behrends, C, Behrens, GMN, Bei, R, Bejarano, E, Bel, S, Behl, C, Belaid, A, Belgareh-Touzé, N, Bellarosa, C, Belleudi, F, Belló Pérez, M, Bello-Morales, R, Beltran, JSO, Beltran, S, Benbrook, DM, Bendorius, M, Benitez, BA, Benito-Cuesta, I, Bensalem, J, Berchtold, MW, Berezowska, S, Bergamaschi, D, Bergami, M, Bergmann, A, Berliocchi, L, Berlioz-Torrent, C, Bernard, A, Berthou, L, Besirli, CG, Besteiro, S, Betin, VM, Beyaert, R, Bezbradica, JS, Bhaskar, K, Bhatia-Kissova, I, Bhattacharya, R, Bhattacharya, S, Bhattacharyya, S, Bhuiyan, MS, Bhutia, SK, Bi, L, Bi, X, Biden, TJ, Bijian, K, Billes, VA, Binart, N, Bincoletto, C, Birgisdottir, AB, Bjorkoy, G, Blanco, G, Blas-Garcia, A, Blasiak, J, Blomgran, R, Blomgren, K, Blum, JS, Boada-Romero, E, Boban, M, Boesze-Battaglia, K, Boeuf, P, Boland, B, Bomont, P, Bonaldo, P, Bonam, SR, Bonfili, L, Bonifacio, JS, Boone, BA, Bootman, MD, Bordi, M, Borner, C, Bornhauser, BC, Borthakur, G, Bosch, J, Bose, S, Botana, LM, Botas, J, Boulanger, CM, Boulton, ME, Bourdenx, M, Bourgeois, B, Bourke, NM, Bousquet, G, Boya, P, Bozhkov, PV, Bozi, LHM, Bozkurt, TO, Brackney, DE, Brandts, CH, Braun, RJ, Braus, GH, Bravo-Sagua, R, Bravo-San Pedro, JM, Brest, P, Bringer, MA, Briones-Herrera, A, Broadus, VC, Brodersen, P, Brodsky, JL, Brody, SL, Bronson, PG, Bronstein, JM, Brown, CN, Brown, RE, Brum, PC, Brumell, JH, Brunetti-Pierri, N, Bruno, D, Bryson-Richardson, RJ, Bucci, C, Buchrieser, C, Bueno, M, Buitrago-Molina, LE, Buraschi, S, Buch, S, Buchan, JR, Buckingham, EM, Budak, H, Budini, M, Bultynck, G, Burada, F, Burgoyne, JR, Burón, MI, Bustos, V, Büttner, S, Butturini, E, Byrd, A, Cabas, I, Cabrera-Benitez, S, Cadwell, K, Cai, J, Cai, L, Cai, Q, Cairó, M, Calbet, JA, Caldwell, GA, Caldwell, KA, Call, JA, Calvani, R, Calvo, AC, Calvo-Rubio Barrera, M, Camara, NO, Camonis, JH, Camougrand, N, Campanella, M, Campbell, EM, Campbell-Valois, FX, Campello, S, Campesi, I, Campos, JC, Camuzard, O, Cancino, J, Candido de Almeida, D, Canesi, L, Caniggia, I, Canonico, B, Cantí, C, Cao, B, Caraglia, M, Caramés, B, Carchman, EH, Cardenal-Muñoz, E, Cardenas, C, Cardenas, L, Cardoso, SM, Carew, JS, Carle, GF, Carleton, G, Carloni, S, Carmona-Gutierrez, D, Carneiro, LA, Carnevali, O, Carosi, JM, Carra, S, Carrier, A, Carrier, L, Carroll, B, Carter, AB, Carvalho, AN, Casanova, M, Casas, C, Casas, J, Cassioli, C, Castillo, EF, Castillo, K, Castillo-Lluva, S, Castoldi, F, Castori, M, Castro, AF, Castro-Caldas, M, Castro-Hernandez, J, Castro-Obregon, S, Catz, SD, Cavadas, C, Cavaliere, F, Cavallini, G, Cavinato, M, Cayuela, ML, Cebollada Rica, P, Cecarini, V, Cecconi, F, Cechowska-Pasko, M, Cenci, S, Ceperuelo-Mallafré, V, Cerqueira, JJ, Cerutti, JM, Cervia, D, Cetintas, VB, Cetrullo, S, Chae, HJ, Chagin, AS, Chai, CY, Chakrabarti, G, Chakrabarti, O, Chakraborty, T, Chakraborty, T, Chami, M, Chamilos, G, Chan, DW, Chan, EYW, Chan, ED, Chan, HYE, Chan, HH, Chan, H, Chan, MTV, Chan, YS, Chandra, PK, Chang, CP, Chang, C, Chang, HC, Chang, K, Chao, J, Chapman, T, Charlet-Berguerand, N, Chatterjee, S, Chaube, SK, Chaudhary, A, Chauhan, S, Chaum, E, Checler, F, Cheetham, ME, Chen, CS, Chen, GC, Chen, JF, Chen, LL, Chen, L, Chen, L, Chen, M, Chen, MK, Chen, N, Chen, Q, Chen, RH, Chen, S, Chen, W, Chen, W, Chen, XM, Chen, XW, Chen, X, Chen, Y, Chen, YG, Chen, Y, Chen, Y, Chen, YJ, Chen, YQ, Chen, ZS, Chen, Z, Chen, ZH, Chen, ZJ, Chen, Z, Cheng, H, Cheng, J, Cheng, SY, Cheng, W, Cheng, X, Cheng, XT, Cheng, Y, Cheng, Z, Chen, Z, Cheong, H, Cheong, JK, Chernyak, BV, Cherry, S, Cheung, CFR, Cheung, CHA, Cheung, KH, Chevet, E, Chi, RJ, Chiang, AKS, Chiaradonna, F, Chiarelli, R, Chiariello, M, Chica, N, Chiozza, S, Chiong, M, Chiou, SH, Chiramel, AI, Chiurchiù, V, Cho, DH, Choe, SK, Choi, AMK, Choi, ME, Choudhury, KR, Chow, NS, Chu, CT, Chua, JP, Chua, JJE, Chung, H, Chung, KP, Chung, S, Chung, SH, Chung, YL, Cianfanelli, V, Ciechomska, IA, Cifuentes, M, Cinque, L, Cirak, S, Cirone, M, Clague, MJ, Clarke, R, Clementi, E, Coccia, EM, Codogno, P, Cohen, E, Cohen, MM, Colasanti, T, Colasuonno, F, Colbert, RA, Colell, A, Čolić, M, Coll, NS, Collins, MO, Colombo, MI, Colón-Ramos, DA, Combaret, L, Comincini, S, Cominetti, MR, Consiglio, A, Conte, A, Conti,

F, Contu, VR, Cookson, MR, Coombs, KM, Coppens, I, Corasaniti, MT, Corkery, DP, Cordes, N, Cortese, K, Costa, MDC, Costantino, S, Costelli, P, Coto-Montes, A, Crack, PJ, Crespo, JL, Criollo, A, Crippa, V, Cristofani, R, Csizmadia, T, Cuadrado, A, Cui, B, Cui, J, Cui, Y, Cui, Y, Culetto, E, Cumino, AC, Cybulsky, AV, Czaja, MJ, Czuczwar, SJ, D'Adamo, S, D'Amelio, M, D'Arcangelo, D, D'Lugos, AC, D'Orazi, G, da Silva, JA, Dafsari, HS, Dagda, RK, Dagdas, Y, Daglia, M, Dai, X, Dai, Y, Dai, Y, Dal Col, J, Dalhaimer, P, Dalla Valle, L, Dallenga, T, Dalmasso, G, Damme, M, Dando, I, Dantuma, NP, Darling, AL, Das, H, Dasarathy, S, Dasari, SK, Dash, S, Daumke, O, Dauphinee, AN, Davies, JS, Dávila, VA, Davis, RJ, Davis, T, Dayalan Naidu, S, De Amicis, F, De Bosscher, K, De Felice, F, De Franceschi, L, De Leonibus, C, de Mattos Barbosa, MG, De Meyer, GRY, De Milito, A, De Nunzio, C, De Palma, C, De Santi, M, De Virgilio, C, De Zio, D, Debnath, J, DeBosch, BJ, Decuyper, JP, Deehan, MA, Deflorian, G, DeGregori, J, Dehay, B, Del Rio, G, Delaney, JR, Delbridge, LMD, Delorme-Axford, E, Delpino, MV, Demarchi, F, Dembitz, V, Demers, ND, Deng, H, Deng, Z, Dengjel, J, Dent, P, Denton, D, DePamphilis, ML, Der, CJ, Deretic, V, Descoteaux, A, Devis, L, Devkota, S, Devuyst, O, Dewson, G, Dharmasivam, M, Dhiman, R, di Bernardo, D, Di Cristina, M, Di Domenico, F, Di Fazio, P, Di Fonzo, A, Di Guardo, G, Di Guglielmo, GM, Di Leo, L, Di Malta, C, Di Nardo, A, Di Rienzo, M, Di Sano, F, Diallynas, G, Diao, J, Diaz-Araya, G, Diaz-Laviada, I, Dickinson, JM, Diederich, M, Dieudé, M, Dikic, I, Ding, S, Ding, WX, Dini, L, Dinić, J, Dinic, M, Dinkova-Kostova, AT, Dionne, MS, Distler, JHW, Diwan, A, Dixon, IMC, Djavaheri-Mergny, M, Dobrinski, I, Dobrovinskaya, O, Dobrowolski, R, Dobson, RCJ, Đokić, J, Dokmeci Emre, S, Donadelli, M, Dong, B, Dong, X, Dong, Z, Dorn li, GW, Dotsch, V, Dou, H, Dou, J, Dowaidar, M, Dridi, S, Drucker, L, Du, A, Du, C, Du, G, Du, HN, Du, LL, du Toit, A, Duan, SB, Duan, X, Duarte, SP, Dubrovskaya, A, Dunlop, EA, Dupont, N, Durán, RV, Dwarakanath, BS, Dyshlovoy, SA, Ebrahimi-Fakhari, D, Eckhart, L, Edelstein, CL, Efferth, T, Eftekharpour, E, Eichinger, R, Eid, N, Eisenberg, T, Eissa, NT, Eissa, S, Ejarque, M, El Andaloussi, A, El-Hage, N, El-Naggar, S, Eleuteri, AM, El-Shafey, ES, Elgendy, M, Eliopoulos, AG, Elizalde, MM, Elks, PM, Elsassner, HP, Elsherbiny, ES, Emerling, BM, Emre, NCT, Eng, CH, Engedal, N, Engelbrecht, AM, Engelsen, AST, Enserink, JM, Escalante, R, Esclatine, A, Escobar-Henriques, M, Eskelinen, EL, Espert, L, Eusebio, MO, Fabrias, G, Fabrizi, C, Facchiano, A, Facchiano, F, Fadeel, B, Fader, C, Faesen, AC, Fairlie, WD, Falcó, A, Falkenburger, BH, Fan, D, Fan, J, Fan, Y, Fang, EF, Fang, Y, Fang, Y, Fanto, M, Farfel-Becker, T, Faure, M, Fazeli, G, Fedele, AO, Feldman, AM, Feng, D, Feng, J, Feng, L, Feng, Y, Feng, Y, Feng, W, Fenz Araujo, T, Ferguson, TA, Fernández Á, F, Fernandez-Checa, JC, Fernández-Veledo, S, Fernie, AR, Ferrante, AW, Jr., Ferraresi, A, Ferrari, MF, Ferreira, JCB, Ferro-Novick, S, Figueras, A, Filadi, R, Filigheddu, N, Filippi-Chiela, E, Filomeni, G, Fimia, GM, Fineschi, V, Finetti, F, Finkbeiner, S, Fisher, EA, Fisher, PB, Flamigni, F, Fliesler, SJ, Flo, TH, Florance, I, Florey, O, Florio, T, Fodor, E, Follo, C, Fon, EA, Forlino, A, Fornai, F, Fortini, P, Fracassi, A, Fraldi, A, Franco, B, Franco, R, Franconi, F, Frankel, LB, Friedman, SL, Fröhlich, LF, Frühbeck, G, Fuentes, JM, Fujiki, Y, Fujita, N, Fujiwara, Y, Fukuda, M, Fulda, S, Furic, L, Furuya, N, Fusco, C, Gack, MU, Gaffke, L, Galadari, S, Galasso, A, Galindo, MF, Gallolu Kankanamalage, S, Galluzzi, L, Galy, V, Gammoh, N, Gan, B, Ganley, IG, Gao, F, Gao, H, Gao, M, Gao, P, Gao, SJ, Gao, W, Gao, X, Garcera, A, Garcia, MN, Garcia, VE, García-Del Portillo, F, Garcia-Escudero, V, Garcia-Garcia, A, Garcia-Macia, M, García-Moreno, D, Garcia-Ruiz, C, García-Sanz, P, Garg, AD, Gargini, R, Garofalo, T, Garry, RF, Gassen, NC, Gatica, D, Ge, L, Ge, W, Geiss-Friedlander, R, Gelfi, C, Genschik, P, Gentle, IE, Gerbino, V, Gerhardt, C, Germain, K, Germain, M, Gewirtz, DA, Ghasemipour Afshar, E, Ghavami, S, Ghigo, A, Ghosh, M, Giamas, G, Giampietri, C, Giatromanolaki, A, Gibson, GE, Gibson, SB, Ginet, V, Giniger, E, Giorgi, C, Girao, H, Girardin, SE, Giridharan, M, Giuliano, S, Giulivi, C, Giuriato, S, Giustiniani, J, Glusko, A, Goder, V, Goginashvili, A, Golab, J, Goldstone, DC, Golebiewska, A, Gomes, LR, Gomez, R, Gómez-Sánchez, R, Gomez-Puerto, MC, Gomez-Sintes, R, Gong, Q, Goni, FM, González-Gallego, J, Gonzalez-Hernandez, T, Gonzalez-Polo, RA, Gonzalez-Reyes, JA, González-Rodríguez, P, Goping, IS, Gorbatyuk, MS, Gorbunov, NV, Görgülü, K, Gorjod, RM, Gorski, SM, Goruppi, S, Gotor, C, Gottlieb, RA, Gozes, I, Gozuacik, D, Graef, M, Gräler, MH, Granatiero, V, Grasso, D, Gray, JP, Green, DR, Greenhough, A, Gregory, SL, Griffin, EF, Grinstaff, MW, Gros, F, Grose, C, Gross, AS, Gruber, F, Grumati, P, Grune, T, Gu, X, Guan, JL, Guardia, CM, Guda, K, Guerra, F, Guerri, C, Guha, P, Guillén, C, Gujar, S, Gukovskaya, A, Gukovsky, I, Gunst, J, Günther, A, Guntur, AR, Guo, C, Guo, C, Guo, H, Guo, LW, Guo, M, Gupta, P, Gupta, SK, Gupta, S, Gupta, VB, Gupta, V, Gustafsson, AB, Guterman, DD, H, BR, Haapasalo, A, Haber, JE, Hać, A, Hadano, S, Hafrén, AJ, Haidar, M, Hall, BS, Halldén, G, Hamacher-Brady, A, Hamann, A, Hamasaki, M, Han, W, Hansen, M, Hanson, PI, Hao, Z, Harada, M, Harhaji-Trajkovic, L, Hariharan, N, Haroon, N, Harris, J, Hasegawa, T, Hasima Nagoor, N, Haspel, JA, Haucke, V, Hawkins, WD, Hay, BA, Haynes, CM, Hayrabydyan, SB, Hays, TS, He, C, He, Q, He, RR, He, YW, He, YY, Heakal, Y, Heberle, AM, Hejtmancik, JF, Helgason, GV, Henkel, V, Herb, M, Hergovich, A, Herman-Antosiewicz, A, Hernández, A, Hernandez, C, Hernandez-Diaz, S, Hernandez-Gea, V, Herpin, A, Herreros, J, Hervás, JH, Hesselton, D, Hetz, C, Heussler, VT, Higuchi, Y, Hilfiker, S, Hill, JA, Hlavacek, WS, Ho, EA, Ho, IHT, Ho, PW, Ho, SL, Ho, WY, Hobbs, GA, Hochstrasser, M, Hoet, PHM, Hofius, D, Hofman, P, Höhn, A, Holmberg, CI, Hombrebueno, JR, Yi-Ren Hong, CH, Hooper, LV, Hoppe, T, Horos, R, Hoshida, Y, Hsin, IL, Hsu, HY, Hu, B, Hu, D, Hu, LF, Hu, MC, Hu, R, Hu, W, Hu, YC, Hu, ZW, Hua, F, Hua, J, Hua, Y, Huan, C, Huang, C, Huang, C, Huang, C, Huang, H, Huang, K, Huang, MLH, Huang, R, Huang, S, Huang, T, Huang, X, Huang, YJ, Huber, TB, Hubert, V, Hubner, CA, Hughes, SM, Hughes, WE, Humbert, M, Hummer, G, Hurley, JH, Hussain, S, Hussain, S, Hussey, PJ, Hutabarat, M, Hwang, HY, Hwang, S, Ieni, A, Ikeda, F, Imagawa, Y, Imai, Y, Imbriano, C, Imoto, M, Inman, DM, Inoki, K, Iovanna, J, Iozzo, RV, Ippolito, G, Irazoqui, JE, Iribarren, P, Ishaq, M, Ishikawa, M, Ishimwe, N, Isidoro, C, Ismail, N, Issazadeh-Navikas, S, Itakura, E, Ito, D, Ivankovic, D, Ivanova, S, Iyer, AKV, Izquierdo, JM, Izumi, M, Jäättelä, M, Jabir, MS, Jackson, WT, Jacobo-Herrera, N, Jacomin, AC, Jacquin, E, Jadiya, P, Jaeschke, H, Jagannath, C, Jakobi, AJ, Jakobsson, J, Janji, B, Jansen-Dürr, P, Jansson, PJ, Jantsch, J, Januszewski, S, Jassey, A, Jean, S, Jeltsch-David, H, Jendelova, P, Jenny, A, Jensen, TE, Jessen, N, Jewell, JL, Ji, J, Jia, L, Jia, R, Jiang, L, Jiang, Q, Jiang, R, Jiang, T, Jiang, X, Jiang, Y, Jimenez-Sanchez, M, Jin, EJ, Jin, F, Jin, H, Jin, L, Jin, L, Jin, M, Jin, S, Jo, EK, Joffre, C, Johansen, T, Johnson, GVW, Johnston, SA, Jokitalo, E, Jolly, MK, Joosten, LAB, Jordan, J, Joseph, B, Ju, D, Ju, JS, Ju, J, Juárez, E, Judith, D, Juhász, G, Jun, Y, Jung, CH, Jung, SC, Jung, YK, Jungbluth, H, Jungverdorben, J, Just, S, Kaarniranta, K, Kaasik, A, Kabuta, T, Kaganovich, D, Kahana, A, Kain, R, Kajimura, S, Kalamvoki, M, Kalia, M, Kalinowski, DS, Kaludercic, N, Kalvari, I,

Kaminska, J, Kaminsky, VO, Kanamori, H, Kanasaki, K, Kang, C, Kang, R, Kang, SS, Kaniyappan, S, Kanki, T, Kanneganti, TD, Kanthasamy, AG, Kanthasamy, A, Kantorow, M, Kapuy, O, Karamouzis, MV, Karim, MR, Karmakar, P, Katare, RG, Kato, M, Kaufmann, SHE, Kauppinen, A, Kaushal, GP, Kaushik, S, Kawasaki, K, Kazan, K, Ke, PY, Keating, DJ, Keber, U, Kehrl, JH, Keller, KE, Keller, CW, Kemper, JK, Kenific, CM, Kepp, O, Kermorgant, S, Kern, A, Ketteler, R, Keulers, TG, Khalfin, B, Khalil, H, Khambu, B, Khan, SY, Khandelwal, VKM, Khandia, R, Kho, W, Khobreakar, NV, Khuansuwan, S, Khundadze, M, Killackey, SA, Kim, D, Kim, DR, Kim, DH, Kim, DE, Kim, EY, Kim, EK, Kim, HR, Kim, HS, Hyung-Ryong, K, Kim, JH, Kim, JK, Kim, JH, Kim, J, Kim, JH, Kim, KI, Kim, PK, Kim, SJ, Kimball, SR, Kimchi, A, Kimmelman, AC, Kimura, T, King, MA, Kinghorn, KJ, Kinsey, CG, Kirkin, V, Kirshenbaum, LA, Kiselev, SL, Kishi, S, Kitamoto, K, Kitaoka, Y, Kitazato, K, Kitsis, RN, Kittler, JT, Kjaerulff, O, Klein, PS, Klopstock, T, Klucken, J, Knævelsrud, H, Knorr, RL, Ko, BCB, Ko, F, Ko, JL, Kobayashi, H, Kobayashi, S, Koch, I, Koch, JC, Koenig, U, Kögel, D, Koh, YH, Koike, M, Kohlwein, SD, Kocaturk, NM, Komatsu, M, König, J, Kono, T, Kopp, BT, Korcsmaros, T, Korkmaz, G, Korolchuk, VI, Korsnes, MS, Koskela, A, Kota, J, Kotake, Y, Kotler, ML, Kou, Y, Koukourakis, MI, Koustas, E, Kovacs, AL, Kovács, T, Koya, D, Kozako, T, Kraft, C, Krainc, D, Krämer, H, Krasnodembskaya, AD, Kretz-Remy, C, Kroemer, G, Ktistakis, NT, Kuchitsu, K, Kuenen, S, Kuerschner, L, Kukar, T, Kumar, A, Kumar, A, Kumar, D, Kumar, D, Kumar, S, Kume, S, Kumsta, C, Kundu, CN, Kundu, M, Kunnumakkara, AB, Kurgan, L, Kutateladze, TG, Kutlu, O, Kwak, S, Kwon, HJ, Kwon, TK, Kwon, YT, Kyrnizi, I, La Spada, A, Labonté, P, Ladoire, S, Laface, I, Lafont, F, Lagace, DC, Lahiri, V, Lai, Z, Laird, AS, Lakkaraju, A, Lamark, T, Lan, SH, Landajuela, A, Lane, DJR, Lane, JD, Lang, CH, Lange, C, Langel, Ü, Langer, R, Lapaquette, P, Laporte, J, LaRusso, NF, Lastres-Becker, I, Lau, WCY, Laurie, GW, Lavandero, S, Law, BYK, Law, HK, Layfield, R, Le, W, Le Stunff, H, Leary, AY, Lebrun, JJ, Leck, LYW, Leduc-Gaudet, JP, Lee, C, Lee, CP, Lee, DH, Lee, EB, Lee, EF, Lee, GM, Lee, HJ, Lee, HK, Lee, JM, Lee, JS, Lee, JA, Lee, JY, Lee, JH, Lee, M, Lee, MG, Lee, MJ, Lee, MS, Lee, SY, Lee, SJ, Lee, SY, Lee, SB, Lee, WH, Lee, YR, Lee, YH, Lee, Y, Lefebvre, C, Legouis, R, Lei, YL, Lei, Y, Leikin, S, Leitinger, G, Lemus, L, Leng, S, Lenoir, O, Lenz, G, Lenz, HJ, Lenzi, P, León, Y, Leopoldino, AM, Leszczyc, C, Leskelä, S, Letellier, E, Leung, CT, Leung, PS, Leventhal, JS, Levine, B, Lewis, PA, Ley, K, Li, B, Li, DQ, Li, J, Li, J, Li, J, Li, K, Li, L, Li, M, Li, M, Li, M, Li, M, Li, PL, Li, MQ, Li, Q, Li, S, Li, T, Li, W, Li, W, Li, X, Li, YP, Li, Y, Li, Z, Li, Z, Li, Z, Lian, J, Liang, C, Liang, Q, Liang, W, Liang, Y, Liang, Y, Liao, G, Liao, L, Liao, M, Liao, YF, Librizzi, M, Lie, PPY, Lilly, MA, Lim, HJ, Lima, TRR, Limana, F, Lin, C, Lin, CW, Lin, DS, Lin, FC, Lin, JD, Lin, KM, Lin, KH, Lin, LT, Lin, PH, Lin, Q, Lin, S, Lin, SJ, Lin, W, Lin, X, Lin, YX, Lin, YS, Linden, R, Lindner, P, Ling, SC, Lingor, P, Linnemann, AK, Liou, YC, Lipinski, MM, Lipovšek, S, Lira, VA, Lisiak, N, Liton, PB, Liu, C, Liu, CH, Liu, CF, Liu, CH, Liu, F, Liu, H, Liu, HS, Liu, HF, Liu, H, Liu, J, Liu, J, Liu, L, Liu, L, Liu, M, Liu, Q, Liu, W, Liu, W, Liu, XH, Liu, X, Liu, X, Liu, X, Liu, X, Liu, Y, Liu, Y, Liu, Y, Liu, Y, Liu, Y, Livingston, JA, Lizard, G, Lizcano, JM, Ljubojevic-Holzer, S, ME, LL, Llobet-Navás, D, Llorente, A, Lo, CH, Lobato-Márquez, D, Long, Q, Long, YC, Loos, B, Loos, JA, López, MG, López-Doménech, G, López-Guerrero, JA, López-Jiménez, AT, López-Pérez, Ó, López-Valero, I, Lorenowicz, MJ, Lorente, M, Lorincz, P, Lossi, L, Lotersztajn, S, Lovat, PE, Lovell, JF, Lovy, A, Löw, P, Lu, G, Lu, H, Lu, JH, Lu, JJ, Lu, M, Lu, S, Luciani, A, Lucocq, JM, Ludovico, P, Luftig, MA, Luhr, M, Luis-Ravelo, D, Lum, JJ, Luna-Dulcey, L, Lund, AH, Lund, VK, Lünemann, JD, Lüningschrör, P, Luo, H, Luo, R, Luo, S, Luo, Z, Luparello, C, Lüscher, B, Luu, L, Lyakhovich, A, Lyamzaev, KG, Lystad, AH, Lytvynchuk, L, Ma, AC, Ma, C, Ma, M, Ma, NF, Ma, QH, Ma, X, Ma, Y, Ma, Z, MacDougald, OA, Macian, F, MacIntosh, GC, MacKeigan, JP, Macleod, KF, Maday, S, Madeo, F, Madesh, M, Madl, T, Madrigal-Matute, J, Maeda, A, Maejima, Y, Magarinos, M, Mahavadi, P, Maiani, E, Maiese, K, Maiti, P, Maiuri, MC, Majello, B, Major, MB, Makareeva, E, Malik, F, Mallilankaraman, K, Malorni, W, Maloyan, A, Mammadova, N, Man, GCW, Manai, F, Mancias, JD, Mandelkow, EM, Mandell, MA, Manfredi, AA, Manjili, MH, Manjithaya, R, Manque, P, Manshian, BB, Manzano, R, Manzoni, C, Mao, K, Marchese, C, Marchetti, S, Marconi, AM, Marcucci, F, Mardente, S, Mareninova, OA, Margeta, M, Mari, M, Marinelli, S, Marinelli, O, Mariño, G, Mariotto, S, Marshall, RS, Marten, MR, Martens, S, Martin, APJ, Martin, KR, Martin, S, Martin, S, Martín-Segura, A, Martín-Acebes, MA, Martín-Burriel, I, Martín-Rincon, M, Martín-Sanz, P, Martina, JA, Martinet, W, Martinez, A, Martinez, J, Martinez Velazquez, M, Martinez-Lopez, N, Martinez-Vicente, M, Martins, DO, Martins, JO, Martins, WK, Martins-Marques, T, Marzetti, E, Masaldan, S, Masclaux-Daubresse, C, Mashek, DG, Massa, V, Massieu, L, Masson, GR, Masuelli, L, Masyuk, AI, Masyuk, TV, Matarrese, P, Matheu, A, Matoba, S, Matsuzaki, S, Mattar, P, Matte, A, Mattoscio, D, Mauriz, JL, Mauthe, M, Mauvezin, C, Maverakis, E, Maycotte, P, Mayer, J, Mazzocchi, G, Mazzoni, C, Mazzulli, JR, McCarty, N, McDonald, C, McGill, MR, McKenna, SL, McLaughlin, B, McLoughlin, F, McNiven, MA, McWilliams, TG, Mehta-Grigoriou, F, Medeiros, TC, Medina, DL, Megeney, LA, Megyeri, K, Mehrpour, M, Mehta, JL, Meijer, AJ, Meijer, AH, Mejlvang, J, Meléndez, A, Melk, A, Memisoglu, G, Mendes, AF, Meng, D, Meng, F, Meng, T, Menna-Barreto, R, Menon, MB, Mercer, C, Mercier, AE, Mergny, JL, Merighi, A, Merkley, SD, Merla, G, Meske, V, Mestre, AC, Metur, SP, Meyer, C, Meyer, H, Mi, W, Miallet-Perez, J, Miao, J, Micale, L, Miki, Y, Milan, E, Milczarek, M, Miller, DL, Miller, SI, Miller, S, Millward, SW, Milosevic, I, Minina, EA, Mirzaei, H, Mirzaei, HR, Mirzaei, M, Mishra, A, Mishra, N, Mishra, PK, Misirkic Marjanovic, M, Misasi, R, Misra, A, Misso, G, Mitchell, C, Mitou, G, Miura, T, Miyamoto, S, Miyazaki, M, Miyazaki, M, Miyazaki, T, Miyazawa, K, Mizushima, N, Mogensen, TH, Mograbi, B, Mohammadinejad, R, Mohamud, Y, Mohanty, A, Mohapatra, S, Möhlmann, T, Mohammed, A, Moles, A, Moley, KH, Molinari, M, Mollace, V, Möller, AB, Mollereau, B, Mollinedo, F, Montagna, C, Monteiro, MJ, Montella, A, Montes, LR, Montico, B, Mony, VK, Monzio Compagnoni, G, Moore, MN, Moosavi, MA, Mora, AL, Mora, M, Morales-Alamo, D, Moratalla, R, Moreira, PI, Morelli, E, Moreno, S, Moreno-Blas, D, Moresi, V, Morga, B, Morgan, AH, Morin, F, Morishita, H, Moritz, OL, Moriyama, M, Moriyasu, Y, Morleo, M, Morselli, E, Moruno-Manchon, JF, Moscat, J, Mostowy, S, Motori, E, Moura, AF, Moustaid-Moussa, N, Mrakovcic, M, Muciño-Hernández, G, Mukherjee, A, Mukhopadhyay, S, Mulcahy Levy, JM, Mulero, V, Muller, S, Münch, C, Munjal, A, Munoz-Canoves, P, Muñoz-Galdeano, T, Münz, C, Murakawa, T, Muratori, C, Murphy, BM, Murphy, JP, Murthy, A, Myöhänen, TT, Mysorekar, IU, Mytych, J, Nabavi, SM, Nabissi, M, Nagy, P, Nah, J, Nahimana, A, Nakagawa, I, Nakamura, K, Nakatogawa, H, Nandi, SS, Nanjundan, M, Nanni, M, Napolitano, G, Nardacci, R, Narita, M, Nassif, M, Nathan, I, Natsumeda, M, Naude, RJ, Naumann, C, Naveiras, O, Navid, F, Nawrocki, ST, Nazarko, TY, Nazio, F, Negoita, F, Neill, T,

Neisch, AL, Neri, LM, Netea, MG, Neubert, P, Neufeld, TP, Neumann, D, Neutzner, A, Newton, PT, Ney, PA, Nezis, IP, Ng, CCW, Ng, TB, Nguyen, HTT, Nguyen, LT, Ni, HM, C, NC, Ni, Z, Nicolao, MC, Nicoli, F, Nieto-Diaz, M, Nilsson, P, Ning, S, Niranjana, R, Nishimune, H, Niso-Santano, M, Nixon, RA, Nobili, A, Nobrega, C, Noda, T, Nogueira-Recalde, U, Nolan, TM, Nombela, I, Novak, I, Novoa, B, Nozawa, T, Nukina, N, Nussbaum-Krammer, C, Nylandsted, J, O'Donovan, TR, O'Leary, SM, O'Rourke, EJ, O'Sullivan, MP, O'Sullivan, TE, Oddo, S, Oehme, I, Ogawa, M, Ogier-Denis, E, Ogmundsdottir, MH, Ogretmen, B, Oh, GT, Oh, SH, Oh, YJ, Ohama, T, Ohashi, Y, Ohmuraya, M, Oikonomou, V, Ojha, R, Okamoto, K, Okazawa, H, Oku, M, Oliván, S, Oliveira, JMA, Ollmann, M, Olzmann, JA, Omari, S, Omary, MB, Önal, G, Ondrej, M, Ong, SB, Ong, SG, Onnis, A, Orellana, JA, Orellana-Muñoz, S, Ortega-Villaizan, MDM, Ortiz-Gonzalez, XR, Ortona, E, Osiewacz, HD, Osman, AK, Osta, R, Otegui, MS, Otsu, K, Ott, C, Ottobri, L, Ou, JJ, Outeiro, TF, Oynebraten, I, Ozturk, M, Pagès, G, Pahari, S, Pajares, M, Pajvani, UB, Pal, R, Paladino, S, Pallet, N, Palmieri, M, Palmisano, G, Palumbo, C, Pampaloni, F, Pan, L, Pan, Q, Pan, W, Pan, X, Panasyuk, G, Pandey, R, Pandey, UB, Pandya, V, Paneni, F, Pang, SY, Panzarini, E, Papademetrio, DL, Papaleo, E, Papinski, D, Papp, D, Park, EC, Park, HT, Park, JM, Park, JI, Park, JT, Park, J, Park, SC, Park, SY, Parola, AH, Parys, JB, Pasquier, A, Pasquier, B, Passos, JF, Pastore, N, Patel, HH, Patschan, D, Pattingre, S, Pedraza-Alva, G, Pedraza-Chaverri, J, Pedrozo, Z, Pei, G, Pei, J, Peled-Zehavi, H, Pellegrini, JM, Pelletier, J, Peñalva, MA, Peng, D, Peng, Y, Penna, F, Pennuto, M, Pentimalli, F, Pereira, CM, Pereira, GJS, Pereira, LC, Pereira de Almeida, L, Perera, ND, Pérez-Lara, Á, Perez-Oliva, AB, Pérez-Pérez, ME, Periyasamy, P, Perl, A, Perrotta, C, Perrotta, I, Pestell, RG, Petersen, M, Petrache, I, Petrovski, G, Pfirrmann, T, Pfister, AS, Philips, JA, Pi, H, Picca, A, Pickrell, AM, Picot, S, Pierantoni, GM, Pierdominici, M, Pierre, P, Pierrefite-Carle, V, Pierzynowska, K, Pietrocila, F, Pietruczuk, M, Pignata, C, Pimentel-Muñoz, FX, Pinar, M, Pinheiro, RO, Pinkas-Kramarski, R, Pinton, P, Pirce, K, Piya, S, Pizzo, P, Plantinga, TS, Platta, HW, Plaza-Zabala, A, Plomann, M, Plotnikov, EY, Plun-Favreau, H, Pluta, R, Pocock, R, Pöggeler, S, Pohl, C, Poirot, M, Poletti, A, Ponpuak, M, Popelka, H, Popova, B, Porta, H, Porte Alcon, S, Portilla-Fernandez, E, Post, M, Potts, MB, Poulton, J, Powers, T, Prahlad, V, Prajsnar, TK, Praticò, D, Prencipe, R, Priault, M, Proikas-Cezanne, T, Promponas, VJ, Proud, CG, Puertollano, R, Puglielli, L, Pulini, T, Puri, D, Puri, R, Puyal, J, Qi, X, Qi, Y, Qian, W, Qiang, L, Qiu, Y, Quadrilatero, J, Quarleri, J, Raben, N, Rabinowich, H, Ragana, D, Ragusa, MJ, Rahimi, N, Rahmati, M, Raia, V, Raimundo, N, Rajasekaran, NS, Ramachandra Rao, S, Rami, A, Ramírez-Pardo, I, Ramsden, DB, Randow, F, Rangarajan, PN, Ranieri, D, Rao, H, Rao, L, Rao, R, Rathore, S, Ratnayaka, JA, Ratovitski, EA, Ravanani, P, Ravagnani, G, Ray, SK, Razani, B, Rebecca, V, Reggiori, F, Régner-Vigouroux, A, Reichert, AS, Reigada, D, Reiling, JH, Rein, T, Reipert, S, Rekha, RS, Ren, H, Ren, J, Ren, W, Renault, T, Renga, G, Reue, K, Rewitz, K, Ribeiro de Andrade Ramos, B, Riazuddin, SA, Ribeiro-Rodrigues, TM, Ricci, JE, Ricci, R, Riccio, V, Richardson, DR, Rikihisa, Y, Risbud, MV, Risueño, RM, Ritis, K, Rizza, S, Rizzuto, R, Roberts, HC, Roberts, LD, Robinson, KJ, Roccheri, MC, Rocchi, S, Rodney, GG, Rodrigues, T, Rodrigues Silva, VR, Rodriguez, A, Rodriguez-Barrueco, R, Rodriguez-Henche, N, Rodriguez-Rocha, H, Roelofs, J, Rogers, RS, Rogov, VV, Rojo, AI, Rolka, K, Romanello, V, Romani, L, Romano, A, Romano, PS, Romeo-Guitart, D, Romero, LC, Romero, M, Roney, JC, Rongo, C, Roperto, S, Rosenfeldt, MT, Rosenstiel, P, Rosenwald, AG, Roth, KA, Roth, L, Roth, S, Rouschop, KMA, Roussel, BD, Roux, S, Rovere-Querini, P, Roy, A, Rozieres, A, Ruano, D, Rubinsztein, DC, Rubtsova, MP, Ruckdeschel, K, Ruckenstein, C, Rudolf, E, Rudolf, R, Ruggieri, A, Ruparel, AA, Rusmini, P, Russell, RR, Russo, GL, Russo, M, Russo, R, Ryabaya, OO, Ryan, KM, Ryu, KY, Sabater-Arcis, M, Sachdev, U, Sacher, M, Sachse, C, Sadhu, A, Sadoshima, J, Safren, N, Saftig, P, Sagana, AP, Sahay, G, Sahebkar, A, Sahin, M, Sahin, O, Sahni, S, Saito, N, Saito, S, Saito, T, Sakai, R, Sakai, Y, Sakamaki, JI, Saksela, K, Salazar, G, Salazar-Degracia, A, Salekdeh, GH, Saluja, AK, Sampaio-Marques, B, Sanchez, MC, Sanchez-Alcazar, JA, Sanchez-Vera, V, Sancho-Shimizu, V, Sanderson, JT, Sandri, M, Santaguida, S, Santambrogio, L, Santana, MM, Santoni, G, Sanz, A, Sanz, P, Saran, S, Sardiello, M, Sargeant, TJ, Sarin, A, Sarkar, C, Sarkar, S, Sarrias, MR, Sarkar, S, Sarmah, DE, Sarparanta, J, Sathyanarayan, A, Sathyanarayanan, R, Scaglione, KM, Scatozza, F, Schaefer, L, Schaefer, ZT, Schable, UE, Schapira, AHV, Scharl, M, Schatzl, HM, Schein, CH, Scheper, W, Scheuring, D, Schiaffino, MV, Schiappacassi, M, Schindl, R, Schlattner, U, Schmidt, O, Schmitt, R, Schmidt, SD, Schmitz, I, Schmukler, E, Schneider, A, Schneider, BE, Schober, R, Schoijet, AC, Schott, MB, Schramm, M, Schröder, B, Schuh, K, Schüller, C, Schulze, RJ, Schürmanns, L, Schwamborn, JC, Schwarten, M, Scialo, F, Sciarretta, S, Scott, MJ, Scotto, KW, Scovassi, AI, Scrima, A, Scivo, A, Sebastian, D, Sebt, S, Sedej, S, Segatori, L, Segev, N, Seglen, PO, Seiliez, I, Seki, E, Selleck, SB, Sellke, FW, Selsby, JT, Sendtner, M, Senturk, S, Seranova, E, Sergi, C, Serra-Moreno, R, Sesaki, H, Settembre, C, Setty, SRG, Sgarbi, G, Sha, O, Shacka, JJ, Shah, JA, Shang, D, Shao, C, Shao, F, Sharbati, S, Sharkey, LM, Sharma, D, Sharma, G, Sharma, K, Sharma, P, Sharma, S, Shen, HM, Shen, H, Shen, J, Shen, M, Shen, W, Shen, Z, Sheng, R, Sheng, Z, Sheng, ZH, Shi, J, Shi, X, Shi, YH, Shiba-Fukushima, K, Shieh, JJ, Shimada, Y, Shimizu, S, Shimozaawa, M, Shintani, T, Shoemaker, CJ, Shojai, I, Shrivage, BV, Shridhar, V, Shu, CW, Shu, HB, Shui, K, Shukla, AK, Shutt, TE, Sica, V, Siddiqui, A, Sierra, A, Sierra-Torre, V, Signorelli, S, Sil, P, Silva, BJA, Silva, JD, Silva-Pavez, E, Silvente-Poirot, S, Simmonds, RE, Simon, AK, Simon, HU, Simons, M, Singh, A, Singh, LP, Singh, R, Singh, SV, Singh, SK, Singh, SB, Singh, S, Singh, SP, Sinha, D, Sinha, RA, Sinha, S, Sirkko, A, Sirote, K, Sivridis, EL, Skendros, P, Skirycz, A, Slaninová, I, Smaili, SS, Smertenko, A, Smith, MD, Soenen, SJ, Sohn, EJ, Sok, SPM, Solaini, G, Soldati, T, Soleimanpour, SA, Soler, RM, Solovchenko, A, Somarelli, JA, Sonawane, A, Song, F, Song, HK, Song, JX, Song, K, Song, Z, Soria, LR, Sorice, M, Soukas, AA, Soukup, SF, Sousa, D, Sousa, N, Spagnuolo, PA, Spector, SA, Srinivas Bharath, MM, St Clair, D, Stagni, V, Staiano, L, Stalneck, CA, Stankov, MV, Stathopoulos, PB, Stefan, K, Stefan, SM, Stefanis, L, Steffan, JS, Steinkasserer, A, Stenmark, H, Sterneckert, J, Stevens, C, Stoka, V, Storch, S, Stork, B, Strappazon, F, Strohecker, AM, Stupack, DG, Su, H, Su, LY, Su, L, Suarez-Fontes, AM, Subauste, CS, Subbian, S, Subirada, PV, Sudhandiran, G, Sue, CM, Sui, X, Summers, C, Sun, G, Sun, J, Sun, K, Sun, MX, Sun, Q, Sun, Y, Sun, Z, Sunahara, KKS, Sundberg, E, Susztak, K, Sutovsky, P, Suzuki, H, Sweeney, G, Symons, JD, Sze, SCW, Szewczyk, NJ, Tabęcka-Łonczynska, A, Tabolacci, C, Tacke, F, Taegtmeyer, H, Tafani, M, Tagaya, M, Tai, H, Tait, SWG, Takahashi, Y, Takats, S, Talwar, P, Tam, C, Tam, SY, Tampellini, D, Tamura, A, Tan, CT, Tan, EK, Tan, YQ, Tanaka, M, Tanaka, M, Tang, D, Tang, J, Tang, TS, Tanida, I, Tao, Z, Taouis, M, Tatenhorst, L, Tavernarakis, N, Taylor, A, Taylor, GA, Taylor, JM, Tchetina, E, Tee, AR, Tegeder, I, Teis, D, Teixeira, N,

Teixeira-Clerc, F, Tekirdag, KA, Tencomnao, T, Tenreiro, S, Tepikin, AV, Testillano, PS, Tettamanti, G, Tharaux, PL, Thedieck, K, Thekkinghat, AA, Thellung, S, Thinwa, JW, Thirumalaikumar, VP, Thomas, SM, Thomes, PG, Thorburn, A, Thukral, L, Thum, T, Thumm, M, Tian, L, Tichy, A, Till, A, Timmerman, V, Titorenko, VI, Todi, SV, Todorova, K, Toivonen, JM, Tomaipitina, L, Tomar, D, Tomas-Zapico, C, Tomić, S, Tong, BC, Tong, C, Tong, X, Tooze, SA, Torgersen, ML, Torii, S, Torres-López, L, Torriglia, A, Towers, CG, Towns, R, Toyokuni, S, Trajkovic, V, Tramontano, D, Tran, QG, Travassos, LH, Trelford, CB, Tremel, S, Trougakos, IP, Tsao, BP, Tschan, MP, Tse, HF, Tse, TF, Tsugawa, H, Tsvetkov, AS, Tumbarello, DA, Tumtas, Y, Tuñón, MJ, Turcotte, S, Turk, B, Turk, V, Turner, BJ, Tuxworth, RI, Tyler, JK, Tyutereva, EV, Uchiyama, Y, Ugun-Klusek, A, Uhlig, HH, Ułamek-Kozioł, M, Ulasov, IV, Umekawa, M, Ungermann, C, Unno, R, Urbe, S, Uribe-Carretero, E, Üstün, S, Uversky, VN, Vaccari, T, Vaccaro, MI, Vahsen, BF, Vakifahmetoglu-Norberg, H, Valdor, R, Valente, MJ, Valko, A, Vallee, RB, Valverde, AM, Van den Berghe, G, van der Veen, S, Van Kaer, L, van Loosdregt, J, van Wijk, SJL, Vandenbergh, W, Vanhorebeek, I, Vannier-Santos, MA, Vannini, N, Vanrell, MC, Vantaggiato, C, Varano, G, Varela-Nieto, I, Varga, M, Vasconcelos, MH, Vats, S, Vavvas, DG, Vega-Naredo, I, Vega-Rubin-de-Celis, S, Velasco, G, Velázquez, AP, Vellai, T, Vellenga, E, Velotti, F, Verdier, M, Verginis, P, Vergne, I, Verkade, P, Verma, M, Verstrecken, P, Vervliet, T, Vervoorts, J, Vessoni, AT, Victor, VM, Vidal, M, Vidoni, C, Vieira, OV, Vierstra, RD, Viganó, S, Vihinen, H, Vijayan, V, Vila, M, Vilar, M, Villalba, JM, Villalobo, A, Villarejo-Zori, B, Villarroja, F, Villarroja, J, Vincent, O, Vindis, C, Viret, C, Viscomi, MT, Visnjic, D, Vitale, I, Vocablo, DJ, Voitsekhovskaja, OV, Volonté, C, Volta, M, Vomero, M, Von Haefen, C, Vooijs, MA, Voos, W, Vucicevic, L, Wade-Martins, R, Waguri, S, Waite, KA, Wakatsuki, S, Walker, DW, Walker, MJ, Walker, SA, Walter, J, Wandosell, FG, Wang, B, Wang, CY, Wang, C, Wang, C, Wang, C, Wang, CY, Wang, D, Wang, F, Wang, F, Wang, F, Wang, F, Wang, H, Wang, H, Wang, H, Wang, H, Wang, H, Wang, HG, Wang, J, Wang, J, Wang, J, Wang, J, Wang, K, Wang, L, Wang, L, Wang, MH, Wang, M, Wang, N, Wang, N, Wang, P, Wang, P, Wang, P, Wang, P, Wang, QJ, Wang, Q, Wang, QK, Wang, QA, Wang, WT, Wang, W, Wang, X, Wang, X, Wang, Y, Wang, Y, Wang, Y, Wang, YY, Wang, Y, Wang, Y, Wang, Y, Wang, Y, Wang, Z, Wang, Z, Wang, Z, Warnes, G, Warnsmann, V, Watada, H, Watanabe, E, Watchon, M, Wawrzyńska, A, Weaver, TE, Wegrzyn, G, Wehman, AM, Wei, H, Wei, L, Wei, T, Wei, Y, Weiergräber, OH, Wehl, CC, Weindl, G, Weiskirchen, R, Wells, A, Wen, RH, Wen, X, Werner, A, Weykopf, B, Wheatley, SP, Whitton, JL, Whitworth, AJ, Wiktorska, K, Wildenberg, ME, Wileman, T, Wilkinson, S, Willbold, D, Williams, B, Williams, RSB, Williams, RL, Williamson, PR, Wilson, RA, Winner, B, Winsor, NJ, Witkin, SS, Wodrich, H, Woehlbier, U, Wollert, T, Wong, E, Wong, JH, Wong, RW, Wong, VKW, Wong, WW, Wu, AG, Wu, C, Wu, J, Wu, J, Wu, J, Wu, KK, Wu, M, Wu, SY, Wu, S, Wu, SY, Wu, S, Wu, WKK, Wu, X, Wu, X, Wu, YW, Wu, Y, Xavier, RJ, Xia, H, Xia, L, Xia, Z, Xiang, G, Xiang, J, Xiang, M, Xiang, W, Xiao, B, Xiao, G, Xiao, H, Xiao, HT, Xiao, J, Xiao, L, Xiao, S, Xiao, Y, Xie, B, Xie, CM, Xie, M, Xie, Y, Xie, Z, Xie, Z, Xilouri, M, Xu, C, Xu, E, Xu, H, Xu, J, Xu, J, Xu, L, Xu, WW, Xu, X, Xue, Y, Yakhine-Diop, SMS, Yamaguchi, M, Yamaguchi, O, Yamamoto, A, Yamashina, S, Yan, S, Yan, SJ, Yan, Z, Yanagi, Y, Yang, C, Yang, DS, Yang, H, Yang, HT, Yang, H, Yang, JM, Yang, J, Yang, J, Yang, L, Yang, L, Yang, M, Yang, PM, Yang, Q, Yang, S, Yang, S, Yang, SF, Yang, W, Yang, WY, Yang, X, Yang, X, Yang, Y, Yang, Y, Yao, H, Yao, S, Yao, X, Yao, YG, Yao, YM, Yasui, T, Yazdankhah, M, Yen, PM, Yi, C, Yin, XM, Yin, Y, Yin, Z, Yin, Z, Ying, M, Ying, Z, Yip, CK, Yiu, SPT, Yoo, YH, Yoshida, K, Yoshii, SR, Yoshimori, T, Yousefi, B, Yu, B, Yu, H, Yu, J, Yu, J, Yu, L, Yu, ML, Yu, SW, Yu, VC, Yu, WH, Yu, Z, Yu, Z, Yuan, J, Yuan, LQ, Yuan, S, Yuan, SF, Yuan, Y, Yuan, Z, Yue, J, Yue, Z, Yun, J, Yung, RL, Zacks, DN, Zaffagnini, G, Zambelli, VO, Zanella, I, Zang, QS, Zanivan, S, Zappavigna, S, Zaragoza, P, Zarbalis, KS, Zarebkohan, A, Zarrouk, A, Zeitlin, SO, Zeng, J, Zeng, JD, Žerovnik, E, Zhan, L, Zhang, B, Zhang, DD, Zhang, H, Zhang, H, Zhang, H, Zhang, H, Zhang, H, Zhang, H, Zhang, H, Zhang, HL, Zhang, J, Zhang, J, Zhang, JP, Zhang, KYB, Zhang, LW, Zhang, L, Zhang, L, Zhang, L, Zhang, L, Zhang, M, Zhang, P, Zhang, S, Zhang, W, Zhang, X, Zhang, XW, Zhang, X, Zhang, X, Zhang, X, Zhang, X, Zhang, XD, Zhang, Y, Zhang, Y, Zhang, Y, Zhang, YD, Zhang, Y, Zhang, YY, Zhang, Y, Zhang, Z, Zhang, Z, Zhang, Z, Zhang, Z, Zhang, Z, Zhao, H, Zhao, L, Zhao, S, Zhao, T, Zhao, XF, Zhao, Y, Zhao, Y, Zhao, Y, Zhao, Y, Zheng, G, Zheng, K, Zheng, L, Zheng, S, Zheng, XL, Zheng, Y, Zheng, ZG, Zhivotovsky, B, Zhong, Q, Zhou, A, Zhou, B, Zhou, C, Zhou, G, Zhou, H, Zhou, H, Zhou, H, Zhou, J, Zhou, J, Zhou, J, Zhou, K, Zhou, R, Zhou, XJ, Zhou, Y, Zhou, Y, Zhou, Y, Zhou, ZY, Zhou, Z, Zhu, B, Zhu, C, Zhu, GQ, Zhu, H, Zhu, H, Zhu, H, Zhu, WG, Zhu, Y, Zhu, Y, Zhuang, H, Zhuang, X, Zientara-Rytter, K, Zimmermann, CM, Ziviani, E, Zoladek, T, Zong, WX, Zorov, DB, Zorzano, A, Zou, W, Zou, Z, Zou, Z, Zuryn, S, Zwierschke, W, Brand-Saberi, B, Dong, XC, Kenchappa, CS, Li, Z, Lin, Y, Oshima, S, Rong, Y, Sluimer, JC, Stallings, CL, & Tong, CK. (2021). Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)(1). *Autophagy*, 17(1), 1-382. doi:10.1080/15548627.2020.1797280

227. *Kloeckner, R, Galle, PR, & Bruix, J. (2021). Local and Regional Therapies for Hepatocellular Carcinoma. *Hepatology*, 73 Suppl 1, 137-149. doi:10.1002/hep.31424
228. Knispel, S, Gassenmaier, M, Menzies, AM, Loquai, C, Johnson, DB, Franklin, C, Gutzmer, R, Hassel, JC, Weishaupt, C, Eigentler, T, Schilling, B, Schummer, P, Sirokay, J, Kiecker, F, Owen, CN, Fleischer, MI, Cann, C, Kähler, KC, Mohr, P, Bluhm, L, Niebel, D, Thoms, KM, Goldinger, SM, Reinhardt, L, Meier, F, Berking, C, Reinhard, R, Susok, L, Ascierto, PA, Drexler, K, Pföhler, C, Tietze, J, Heinzerling, L, Livingstone, E, Ugurel, S, Long, GV, Stang, A, Schadendorf, D, & Zimmer, L. (2021). Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. *Eur J Cancer*, 148, 61-75. doi:10.1016/j.ejca.2021.01.034
229. Kobayashi, S, Koizume, S, Takahashi, T, Ueno, M, Oishi, R, Nagashima, S, Sano, Y, Fukushima, T, Tezuka, S, Morimoto, M, Nakamura, S, Narimatsu, H, Ruf, W, & Miyagi, Y. (2021). Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. *Cancer Sci*, 112(11), 4679-4691. doi:10.1111/cas.15106

230. Koch, EAT, Petzold, A, Wessely, A, Dippel, E, Gesierich, A, Gutzmer, R, Hassel, JC, Haferkamp, S, Hohberger, B, Kähler, KC, Knorr, H, Kreuzberg, N, Leiter, U, Loquai, C, Meier, F, Meissner, M, Mohr, P, Pföhler, C, Rahimi, F, Schadendorf, D, Schell, B, Schlaak, M, Terheyden, P, Thoms, KM, Schuler-Thurner, B, Ugurel, S, Ulrich, J, Utikal, J, Weichenthal, M, Ziller, F, Berking, C, Heppt, MV, & On Behalf Of The German Dermatologic Cooperative Oncology Group De, COGCOM. (2021). Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis. *Cancers (Basel)*, 13(13). doi:10.3390/cancers13133359
231. *Koessler, T, Alsina, M, Arnold, D, Ben-Aharon, I, Lutz, MP, Obermannova, R, Peeters, M, Sclafani, F, Smyth, E, Valle, JW, Wagner, AD, Wyrwicz, L, Fontana, E, & Moehler, M. (2021). Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. *Br J Cancer*, 125(7), 911-919. doi:10.1038/s41416-021-01474-y
232. Kohlhaas, V, Blakemore, SJ, Al-Maarri, M, Nickel, N, Pal, M, Roth, A, Hövelmeyer, N, Schäfer, SC, Knittel, G, Lohneis, P, Nikolic, M, Wiederstein, JL, Franitza, M, Georgomonolis, T, Reinart, N, Herling, M, Herling, C, Hartmann, EM, Rosenwald, A, Klapper, W, Büttner, R, Moia, R, Rossi, D, Boldorini, R, Gaidano, G, Frenzel, LP, Reinhardt, HC, Brüning, JC, Hallek, M, Krüger, M, Peifer, M, Pallasch, CP, & Wunderlich, FT. (2021). Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. *Blood*, 137(5), 646-660. doi:10.1182/blood.202005734
233. Kohlruss, M, Krenauer, M, Grosser, B, Pfarr, N, Jesinghaus, M, Slotta-Huspenina, J, Novotny, A, Hapfelmeier, A, Schmidt, T, Steiger, K, Gaida, MM, Reiche, M, Bauer, L, Ott, K, Weichert, W, & Keller, G. (2021). Diverse 'just-right' levels of chromosomal instability and their clinical implications in neoadjuvant treated gastric cancer. *Br J Cancer*, 125(12), 1621-1631. doi:10.1038/s41416-021-01587-4
234. Kohlruss, M, Ott, K, Grosser, B, Jesinghaus, M, Slotta-Huspenina, J, Novotny, A, Hapfelmeier, A, Schmidt, T, Gaida, MM, Weichert, W, & Keller, G. (2021). Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. *Cancers (Basel)*, 13(5). doi:10.3390/cancers13051048
235. Konukiewicz, B, Kasajima, A, Schmitt, M, Schwamborn, K, Groll, T, Schick Tanz, F, Delbridge, C, Schütze, LM, Wilhelm, D, Lang, C, Lange, S, Foersch, S, Jank, P, Steiger, K, Werder, AV, Denkert, C, Weichert, W, Klöppel, G, & Jesinghaus, M. (2021). Neuroendocrine Differentiation in Conventional Colorectal Adenocarcinomas: Incidental Finding or Prognostic Biomarker? *Cancers (Basel)*, 13(20). doi:10.3390/cancers13205111
236. Konukiewicz, B, Schmitt, M, Silva, M, Pohl, J, Lang, C, Steiger, K, Halfter, K, Engel, J, Schlitter, AM, Boxberg, M, Pfarr, N, Wilhelm, D, Foersch, S, Tschurtschenthaler, M, Weichert, W, & Jesinghaus, M. (2021). Loss of CDX2 in colorectal cancer is associated with histopathologic subtypes and microsatellite instability but is prognostically inferior to hematoxylin-eosin-based morphologic parameters from the WHO classification. *Br J Cancer*, 125(12), 1632-1646. doi:10.1038/s41416-021-01553-0
237. Kostka, T, Empl, MT, Seiwert, N, Geisen, SM, Hoffmann, P, Adam, J, Seeger, B, Shay, JW, Christmann, M, Sturla, SJ, Fahrner, J, & Steinberg, P. (2021). Repair of O6-carboxymethylguanine adducts by O6-methylguanine-DNA methyltransferase in human colon epithelial cells. *Carcinogenesis*, 42(8), 1110-1118. doi:10.1093/carcin/bgab049
238. *Kowalzik, F, Schreiner, D, Jensen, C, Teschner, D, Gehring, S, & Zepp, F. (2021). mRNA-Based Vaccines. *Vaccines (Basel)*, 9(4). doi:10.3390/vaccines9040390
239. *Krajnak, S, Decker, T, Schollenberger, L, Rosé, C, Ruckes, C, Fehm, T, Thomssen, C, Harbeck, N, & Schmidt, M. (2021). Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy: VINO-METRO-AGO-B-046. *J Cancer Res Clin Oncol*, 147(11), 3391-3400. doi:10.1007/s00432-021-03599-2
240. *Krajnak, S, Loewe, A, Battista, MJ, Hasenburger, A, Heimes, AS, Schmidt, M, Schwab, R, & Brenner, W. (2021). The Impact of Insulin on Low-dose Metronomic Vinorelbine and Mafosfamide in Breast Cancer Cells. *Anticancer Res*, 41(3), 1243-1250. doi:10.21873/anticancerres.14881
241. Krakauer, EL, Kane, K, Kwete, X, Afshan, G, Bazzett-Matabele, L, Ruthnie Bien-Aimé, DD, Borges, LF, Byrne-Martelli, S, Connor, S, Correa, R, Devi, CRB, Diop, M, Elmore, SN, Gafer, N, Goodman, A, Grover, S, Hasenburger, A, Irwin, K, Kamdar, M, Kumar, S, Truong, QXN, Randall, T, Rassouli, M, Sessa, C, Spence, D, Trimble, T, Varghese, C, & Fidarova, E. (2021). Essential Package of Palliative Care for Women With Cervical Cancer: Responding to the Suffering of a Highly Vulnerable Population. *JCO Glob Oncol*, 7, 873-885. doi:10.1200/go.21.00026
242. Krakauer, EL, Kwete, X, Kane, K, Afshan, G, Bazzett-Matabele, L, Bien-Aimé, DDR, Byrne-Martelli, S, Connor, S, Correa, R, Devi, CRB, Diop, M, Gafer, N, Goodman, A, Grover, S, Hasenburger, A, Irwin, K, Thanh Khanh, Q, Kumar, S, Nevzorova, D, Truong, QXN, Rajagopal, MR, Randall, T, Rassouli, M, Sessa, C, Spence, D, Torode, JS, Trimble, T, Varghese, C, &

- Fidarova, E. (2021). Cervical Cancer-Associated Suffering: Estimating the Palliative Care Needs of a Highly Vulnerable Population. *JCO Glob Oncol*, 7, 862-872. doi:10.1200/go.21.00025
243. *Krämer, I, Rosentreter, J, Fried, M, & Kühn, M. (2021). Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an osteosarcoma patient. *J Oncol Pharm Pract*, 27(4), 1000-1004. doi:10.1177/1078155220953878
 244. Kramer, R, Zaremba, A, Moreira, A, Ugurel, S, Johnson, DB, Hassel, JC, Salzmann, M, Gesierich, A, Weppler, A, Spain, L, Loquai, C, Dudda, M, Pföhler, C, Hepner, A, Long, GV, Menzies, AM, Carlino, MS, Sachse, MM, Lebbé, C, Baroudjian, B, Enokida, T, Tahara, M, Schlaak, M, Hayani, K, Bröckelmann, PJ, Meier, F, Reinhardt, L, Friedlander, P, Eigentler, T, Kähler, KC, Berking, C, Zimmer, L, & Heinzerling, L. (2021). Hematological immune related adverse events after treatment with immune checkpoint inhibitors. *Eur J Cancer*, 147, 170-181. doi:10.1016/j.ejca.2021.01.013
 245. *Krebs, FK, Trzeciak, ER, Zimmer, S, Özistanbullu, D, Mitzel-Rink, H, Meissner, M, Grabbe, S, Loquai, C, & Tuettenberg, A. (2021). Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma. *Cancer Med*, 10(5), 1562-1575. doi:10.1002/cam4.3710
 246. *Kreft, A, Hippe, K, Wagner-Drouet, EM, Ries, I, Kandulski, A, Büttner-Herold, M, Neumann, H, Weber, D, Holler, E, & Schindeldecker, M. (2021). An investigation of the diagnostic, predictive, and prognostic impacts of three colonic biopsy grading systems for acute graft versus host disease. *PLoS One*, 16(8), e0256543. doi:10.1371/journal.pone.0256543
 247. Kreissl, S, Goergen, H, Buehnen, I, Kobe, C, Moccia, A, Greil, R, Eichenauer, DA, Zijlstra, JM, Markova, J, Meissner, J, Feuring-Buske, M, Soekler, M, Beck, HJ, Willenbacher, W, Ludwig, WD, Pabst, T, Topp, MS, Hitz, F, Bentz, M, Keller, UB, Kühnhardt, D, Ostermann, H, Hertenstein, B, Aulitzky, W, Maschmeyer, G, Vieler, T, Eich, H, Baues, C, Stein, H, Fuchs, M, Diehl, V, Dietlein, M, Engert, A, & Borchmann, P. (2021). PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. *Lancet Haematol*, 8(6), e398-e409. doi:10.1016/s2352-3026(21)00101-0
 248. *Krenzlin, H, Jankovic, D, Alberter, C, Kalasauskas, D, Westphalen, C, Ringel, F, & Keric, N. (2021). Frailty in Glioblastoma Is Independent From Chronological Age. *Front Neurol*, 12, 777120. doi:10.3389/fneur.2021.777120
 249. Krenzlin, H, Zdioruk, M, Nowicki, MO, Finkelberg, T, Keric, N, Lemmermann, N, Skubal, M, Chiocca, EA, Cook, CH, & Lawler, SE. (2021). Cytomegalovirus infection of glioblastoma cells leads to NF-κB dependent upregulation of the c-MET oncogenic tyrosine kinase. *Cancer Lett*, 513, 26-35. doi:10.1016/j.canlet.2021.05.005
 250. Kretschmer, A, Mazzone, E, Barletta, F, Leni, R, Heidegger, I, Tsaur, I, van den Bergh, RCN, Valerio, M, Marra, G, Kasivisvanathan, V, Buchner, A, Stief, CG, Briganti, A, Montorsi, F, Tilki, D, & Gandaglia, G. (2021). Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. *Eur Urol Focus*, 7(6), 1247-1253. doi:10.1016/j.euf.2020.09.003
 251. Kretschmer, A, Ploussard, G, Heidegger, I, Tsaur, I, Borgmann, H, Surcel, C, Mathieu, R, de Visschere, P, Valerio, M, van den Bergh, RCN, Marra, G, Thibault, C, Ost, P, Gandaglia, G, & Tilki, D. (2021). Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. *Eur Urol Focus*, 7(4), 742-751. doi:10.1016/j.euf.2020.01.017
 252. Kretschmer, A, van den Bergh, RCN, Martini, A, Marra, G, Valerio, M, Tsaur, I, Heidegger, I, Kasivisvanathan, V, Kesck, C, Preisser, F, Fankhauser, CD, Zattoni, F, Ceci, F, Olivier, J, Chiu, P, Puche-Sanz, I, Thibault, C, Gandaglia, G, Tilki, D, & On Behalf Of The Yau Prostate Cancer Working, G. (2021). Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancer-Current State and Future Perspectives. *Cancers (Basel)*, 14(1). doi:10.3390/cancers14010147
 253. *Kreuzpointner, R, Johnner, F, Roth-Zetsche, S, Kucher, N, & Barco, S. (2021). Clinical presentation and long-term follow-up of 45 patients with Mondor disease: A single-center longitudinal study. *Vasc Med*, 1358863x211000420. doi:10.1177/1358863x211000420
 254. Kricheldorf, K, Döhner, K, Stegelmann, F, Jost, PJ, Lang, F, Radsak, M, Hansen, R, Heuer, V, Röhrig, R, Brümmendorf, TH, Koschmieder, S, & Isfort, S. (2021). Challenges of patients with myeloproliferative neoplasms (MPN) in times of COVID: First results from a patient survey by the German Study Group for MPN. *Leuk Res*, 110, 106646. doi:10.1016/j.leukres.2021.106646
 255. *Kriegsmann, M, Kriegsmann, K, Steinbuss, G, Zgorzelski, C, Kraft, A, & Gaida, MM. (2021). Deep Learning in Pancreatic Tissue: Identification of Anatomical Structures, Pancreatic Intraepithelial Neoplasia, and Ductal Adenocarcinoma. *Int J Mol Sci*, 22(10). doi:10.3390/ijms22105385

256. Kubota, N, Saito, A, Tanaka, R, Nakamura, Y, Watanabe, R, Fujisawa, Y, Ishitsuka, Y, Clausen, BE, Fujimoto, M, & Okiyama, N. (2021). Langerhans Cells Suppress CD8(+) T Cells In Situ during Mucocutaneous Acute Graft-Versus-Host Disease. *J Invest Dermatol*, 141(5), 1177-1187.e1173. doi:10.1016/j.jid.2020.09.018
257. Kudo, M, Finn, RS, Morimoto, M, Rau, KM, Ikeda, M, Yen, CJ, Galle, PR, Llovet, JM, Daniele, B, Lim, HY, McIlwain, DW, Yoshikawa, R, Nakamura, K, Liang, K, Wang, C, Abada, P, Widau, RC, & Zhu, AX. (2021). Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). *Liver Cancer*, 10(5), 451-460. doi:10.1159/000516605
258. Kudo, M, Ikeda, M, Galle, PR, Yamashita, T, Finn, RS, Liang, K, Wang, C, Sakaguchi, S, Abada, P, Widau, RC, & Zhu, AX. (2021). Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α -fetoprotein: Outcomes by treatment-emergent ascites. *Hepatol Res*, 51(6), 715-721. doi:10.1111/hepr.13638
259. *Kyyak, S, Blatt, S, Schiegnitz, E, Heimes, D, Staedt, H, Thiem, DGE, Sagheb, K, Al-Nawas, B, & Kämmerer, PW. (2021). Activation of Human Osteoblasts via Different Bovine Bone Substitute Materials With and Without Injectable Platelet Rich Fibrin in vitro. *Front Bioeng Biotechnol*, 9, 599224. doi:10.3389/fbioe.2021.599224
260. *Kyyak, S, Pabst, A, Heimes, D, & Kämmerer, PW. (2021). The Influence of Hyaluronic Acid Biofunctionalization of a Bovine Bone Substitute on Osteoblast Activity In Vitro. *Materials (Basel)*, 14(11). doi:10.3390/ma14112885
261. La Corte, E, Eldahaby, D, Greco, E, Aquino, D, Bertolini, G, Levi, V, Ottenhausen, M, Demichelis, G, Romito, LM, Acerbi, F, Broggi, M, Schiariti, MP, Ferroli, P, Bruzzone, MG, & Serrao, G. (2021). The Frontal Aslant Tract: A Systematic Review for Neurosurgical Applications. *Front Neurol*, 12, 641586. doi:10.3389/fneur.2021.641586
262. Lagorio, S, Blettner, M, Baaken, D, Feychting, M, Karipidis, K, Loney, T, Orsini, N, Rösli, M, Paulo, MS, & Elwood, M. (2021). The effect of exposure to radiofrequency fields on cancer risk in the general and working population: A protocol for a systematic review of human observational studies. *Environ Int*, 157, 106828. doi:10.1016/j.envint.2021.106828
263. *Lahnif, H, Grus, T, Pektor, S, Greifenstein, L, Schreckenberger, M, & Rösch, F. (2021). Hybrid Chelator-Based PSMA Radiopharmaceuticals: Translational Approach. *Molecules*, 26(21). doi:10.3390/molecules26216332
264. Lai, Q, Sapisochin, G, Gorgen, A, Vitale, A, Halazun, KJ, Iesari, S, Schaefer, B, Bhangui, P, Mennini, G, Wong, TCL, Uemoto, S, Lin, CC, Mittler, J, Ikegami, T, Yang, Z, Frigo, AC, Zheng, SS, Soejima, Y, Hoppe-Lotichius, M, Chen, CL, Kaido, T, Lo, CM, Rossi, M, Soin, AS, Finkenstedt, A, Emond, JC, Cillo, U, & Lerut, JP. (2021). Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. *JAMA Surg*, 156(9), e213112. doi:10.1001/jamasurg.2021.3112
265. *Lang, H. (2021). Surgical Approach to Recurrent Cholangiocarcinoma. *Visc Med*, 37(1), 26-31. doi:10.1159/000513711
266. *Lang, H, Baumgart, J, Heinrich, S, Huber, T, Heuft, LK, Margies, R, Mittler, J, Hahn, F, Gerber, TS, Foerster, F, Weinmann, A, Marquardt, JU, Kloeckner, R, Straub, BK, & Bartsch, F. (2021). Liver Resection for Intrahepatic Cholangiocarcinoma-Single-Center Experience with 286 Patients Undergoing Surgical Exploration over a Thirteen Year Period. *J Clin Med*, 10(16). doi:10.3390/jcm10163559
267. *Lang, H, Baumgart, J, Roth, W, Moehler, M, & Kloth, M. (2021). Cancer gene related characterization of patterns and point of recurrence after resection of colorectal liver metastases. *Ann Transl Med*, 9(17), 1372. doi:10.21037/atm-21-292
268. Lapa, C, Nestle, U, Albert, NL, Baues, C, Beer, A, Buck, A, Budach, V, Bütof, R, Combs, SE, Derlin, T, Eiber, M, Fendler, WP, Furth, C, Gani, C, Gkika, E, Grosu, AL, Henkenberens, C, Ilhan, H, Löck, S, Marnitz-Schulze, S, Miederer, M, Mix, M, Nicolay, NH, Niyazi, M, Pöttgen, C, Rödel, CM, Schatka, I, Schwarzenboeck, SM, Todica, AS, Weber, W, Wegen, S, Wiegel, T, Zamboglou, C, Zips, D, Zöphel, K, Zschaek, S, Thorwarth, D, & Troost, EGC. (2021). Value of PET imaging for radiation therapy. *Strahlenther Onkol*, 197(9), 1-23. doi:10.1007/s00066-021-01812-2
269. *Legscha, KJ, Antunes Ferreira, E, Chamoun, A, Lang, A, Awwad, MHS, Ton, G, Galetzka, D, Guezguez, B, Hundemer, M, Bourdon, JC, Munder, M, Theobald, M, & Echchannaoui, H. (2021). $\Delta 133p53\alpha$ enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity. *J Immunother Cancer*, 9(6). doi:10.1136/jitc-2020-001846
270. Leister, H, Luu, M, Staudenraus, D, Lopez Krol, A, Mollenkopf, HJ, Sharma, A, Schmerer, N, Schulte, LN, Bertrams, W, Schmeck, B, Bosmann, M, Steinhoff, U, & Visekruna, A. (2021). Pro- and Antitumorigenic Capacity of

Immunoproteasomes in Shaping the Tumor Microenvironment. *Cancer Immunol Res*, 9(6), 682-692. doi:10.1158/2326-6066.Cir-20-0492

271. *Li, M, Jiang, S, Haller, A, Wirsching, S, Fichter, M, Simon, J, Wagner, M, Mailänder, V, Gehring, S, Crespy, D, & Landfester, K. (2021). Encapsulation of polyprodrugs enables an efficient and controlled release of dexamethasone. *Nanoscale Horiz*, 6(10), 791-800. doi:10.1039/d1nh00266j
272. *Li, M, Jiang, S, Simon, J, Paßlick, D, Frey, ML, Wagner, M, Mailänder, V, Crespy, D, & Landfester, K. (2021). Brush Conformation of Polyethylene Glycol Determines the Stealth Effect of Nanocarriers in the Low Protein Adsorption Regime. *Nano Lett*, 21(4), 1591-1598. doi:10.1021/acs.nanolett.0c03756
273. Liang, LA, Einzmann, T, Franzen, A, Schwarzer, K, Schaubberger, G, Schriefer, D, Radde, K, Zeissig, SR, Ikenberg, H, Meijer, C, Kirkpatrick, CJ, Kölbl, H, Blettner, M, & Klug, SJ. (2021). Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies. *Cancer Epidemiol Biomarkers Prev*, 30(3), 474-484. doi:10.1158/1055-9965.Epi-20-1003
274. *Liebers, N, Duell, J, Fitzgerald, D, Kerkhoff, A, Noerenberg, D, Kaebisch, E, Acker, F, Fuhrmann, S, Leng, C, Welslau, M, Chemnitz, J, Middeke, JM, Weber, T, Holtick, U, Trappe, R, Pfannes, R, Liersch, R, Spoer, C, Fuxius, S, Gebauer, N, Caillé, L, Geer, T, Koenecke, C, Keller, U, Claus, R, Mougiakakos, D, Mayer, S, Huettmann, A, Pott, C, Trummer, A, Wulf, G, Brunnberg, U, Bullinger, L, Hess, G, Mueller-Tidow, C, Glass, B, Lenz, G, Dreger, P, & Dietrich, S. (2021). Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. *Blood Adv*, 5(13), 2707-2716. doi:10.1182/bloodadvances.2020004155
275. *Liebl, MC, & Hofmann, TG. (2021). The Role of p53 Signaling in Colorectal Cancer. *Cancers (Basel)*, 13(9). doi:10.3390/cancers13092125
276. *Liebl, MC, Moehlenbrink, J, Becker, H, Raddatz, G, Abdeen, SK, Aqeilan, RI, Lyko, F, & Hofmann, TG. (2021). DAZAP2 acts as specifier of the p53 response to DNA damage. *Nucleic Acids Res*, 49(5), 2759-2776. doi:10.1093/nar/gkab084
277. Liu, Z, Thong, MSY, Doege, D, Koch-Gallenkamp, L, Bertram, H, Eberle, A, Holleczeck, B, Waldmann, A, Zeissig, SR, Pritzkeleit, R, Brenner, H, & Arndt, V. (2021). Prevalence of benefit finding and posttraumatic growth in long-term cancer survivors: results from a multi-regional population-based survey in Germany. *Br J Cancer*, 125(6), 877-883. doi:10.1038/s41416-021-01473-z
278. Llovet, JM, Villanueva, A, Marrero, JA, Schwartz, M, Meyer, T, Galle, PR, Lencioni, R, Greten, TF, Kudo, M, Mandrekar, SJ, Zhu, AX, Finn, RS, & Roberts, LR. (2021). Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. *Hepatology*, 73 Suppl 1, 158-191. doi:10.1002/hep.31327
279. Lobato-Gil, S, Heidelberger, JB, Maghames, C, Bailly, A, Brunello, L, Rodriguez, MS, Beli, P, & Xirodimas, DP. (2021). Proteome-wide identification of NEDD8 modification sites reveals distinct proteomes for canonical and atypical NEDDylation. *Cell Rep*, 34(3), 108635. doi:10.1016/j.celrep.2020.108635
280. Lodde, G, Forschner, A, Hassel, J, Wulfken, LM, Meier, F, Mohr, P, Kähler, K, Schilling, B, Loquai, C, Berking, C, Hüning, S, Schatton, K, Gebhardt, C, Eckardt, J, Gutzmer, R, Reinhardt, L, Glutsch, V, Nikfarjam, U, Erdmann, M, Stang, A, Kowall, B, Roesch, A, Ugurel, S, Zimmer, L, Schadendorf, D, & Livingstone, E. (2021). Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients. *Cancers (Basel)*, 13(10). doi:10.3390/cancers13102319
281. Loizou, L, Demetriou, A, Erdmann, F, Borkhardt, A, Brozou, T, Sharp, L, & McNally, R. (2021). Increasing incidence and survival of paediatric and adolescent thyroid cancer in Cyprus 1998-2017: A population-based study from the Cyprus Pediatric Oncology Registry. *Cancer Epidemiol*, 74, 101979. doi:10.1016/j.canep.2021.101979
282. Lokerse, WJM, Lazarian, A, Kleinhempel, A, Petrini, M, Schwarz, P, Hossann, M, Holdt, LM, Mailänder, V, & Lindner, LH. (2021). Mechanistic investigation of thermosensitive liposome immunogenicity and understanding the drivers for circulation half-life: A polyethylene glycol versus 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol study. *J Control Release*, 333, 1-15. doi:10.1016/j.jconrel.2021.03.014
283. Lopez-Lopez, V, Robles-Campos, R, García-Calderon, D, Lang, H, Cugat, E, Jiménez-Galanes, S, Fernández-Cebrian, JM, Sánchez-Turrión, V, Fernández-Fernández, JM, Barrera-Gómez, M, de la Cruz, J, Lopez-Conesa, A, Brusadin, R, Gomez-Perez, B, & Parrilla-Paricio, P. (2021). Applicability of 3D-printed models in hepatobiliary surgery: results from "LIV3DPRINT" multicenter study. *HPB (Oxford)*, 23(5), 675-684. doi:10.1016/j.hpb.2020.09.020

284. *Lordick, F, Al-Batran, SE, Ganguli, A, Morlock, R, Sahin, U, & Türeci, Ö. (2021). Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+ gastroesophageal adenocarcinoma. *Gastric Cancer*, 24(3), 721-730. doi:10.1007/s10120-020-01153-6
285. Lüftner, D, Tesch, H, Schmidt, M, Hartkopf, AD, Streicher, S, Resch, A, Genovese, L, Rosé, C, Valenti, R, & Harbeck, N. (2021). Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study. *Eur J Cancer*, 150, 268-277. doi:10.1016/j.ejca.2021.03.045
286. Luu, M, Riester, Z, Baldrich, A, Reichardt, N, Yuille, S, Buseti, A, Klein, M, Wempe, A, Leister, H, Raifer, H, Picard, F, Muhammad, K, Ohl, K, Romero, R, Fischer, F, Bauer, CA, Huber, M, Gress, TM, Lauth, M, Danhof, S, Bopp, T, Nerreter, T, Mulder, IE, Steinhoff, U, Hudecek, M, & Visekruna, A. (2021). Microbial short-chain fatty acids modulate CD8(+) T cell responses and improve adoptive immunotherapy for cancer. *Nat Commun*, 12(1), 4077. doi:10.1038/s41467-021-24331-1
287. *Machado, TO, Beckers, SJ, Fischer, J, Sayer, C, de Araújo, PHH, Landfester, K, & Wurm, FR. (2021). Cellulose nanocarriers via miniemulsion allow Pathogen-Specific agrochemical delivery. *J Colloid Interface Sci*, 601, 678-688. doi:10.1016/j.jcis.2021.05.030
288. *Mader, L, Frederiksen, LE, Bidstrup, PE, Hargreave, M, Kjær, SK, Kuehni, CE, Nielsen, TT, Krøyer, A, Winther, JF, & Erdmann, F. (2021). Hospital Contacts for Psychiatric Disorders in Parents of Children With Cancer in Denmark. *JNCI Cancer Spectr*, 5(3), pkab036. doi:10.1093/jncics/pkab036
289. Mahnken, AH, Boulosa Seoane, E, Cannavale, A, de Haan, MW, Dezman, R, Kloeckner, R, O'Sullivan, G, Ryan, A, & Tsoumakidou, G. (2021). CIRSE Clinical Practice Manual. *Cardiovasc Intervent Radiol*, 44(9), 1323-1353. doi:10.1007/s00270-021-02904-3
290. *Mähringer-Kunz, A, Meyer, FI, Hahn, F, Müller, L, Düber, C, Pinto Dos Santos, D, Galle, PR, Weinmann, A, Kloeckner, R, & Schotten, S. (2021). Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. *United European Gastroenterol J*, 9(5), 590-597. doi:10.1002/ueg2.12098
291. *Mähringer-Kunz, A, Steinle, V, Kloeckner, R, Schotten, S, Hahn, F, Schmidtman, I, Hinrichs, JB, Düber, C, Galle, PR, Lang, H, & Weinmann, A. (2021). The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. *PLoS One*, 16(5), e0249426. doi:10.1371/journal.pone.0249426
292. Mai, EK, Miah, K, Bertsch, U, Dürig, J, Scheid, C, Weisel, KC, Kunz, C, Munder, M, Lindemann, HW, Merz, M, Hose, D, Jauch, A, Seckinger, A, Luntz, S, Sauer, S, Fuhrmann, S, Brossart, P, Elmaagacli, A, Goerner, M, Bernhard, H, Hoffmann, M, Raab, MS, Blau, IW, Hänel, M, Benner, A, Salwender, HJ, & Goldschmidt, H. (2021). Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. *Leukemia*, 35(3), 809-822. doi:10.1038/s41375-020-0976-9
293. *Mai, SS, Vogt, AR, Schmidtman, I, Maier, BO, Wagner, B, Dvir, M, & Weber, M. (2021). Sequential use of the Demoralization Scale in palliative care: feasibility, strain, and personal benefits of participation for patients at the end of life. *Support Care Cancer*, 29(2), 965-973. doi:10.1007/s00520-020-05555-1
294. *Markowitsch, SD, Juetter, KM, Schupp, P, Hauschulte, K, Vakhrusheva, O, Slade, KS, Thomas, A, Tsaor, I, Cinatl, J, Jr., Michaelis, M, Efferth, T, Haferkamp, A, & Juengel, E. (2021). Shikonin Reduces Growth of Docetaxel-Resistant Prostate Cancer Cells Mainly through Necroptosis. *Cancers (Basel)*, 13(4). doi:10.3390/cancers13040882
295. *Marron, M, Brackmann, LK, Schwarz, H, Hummel-Bartenschlager, W, Zahnreich, S, Galetzka, D, Schmitt, I, Grad, C, Drees, P, Hopf, J, Mirsch, J, Scholz-Kreisel, P, Kaatsch, P, Poplawski, A, Hess, M, Binder, H, Hankeln, T, Blettner, M, & Schmidberger, H. (2021). Identification of Genetic Predispositions Related to Ionizing Radiation in Primary Human Skin Fibroblasts From Survivors of Childhood and Second Primary Cancer as Well as Cancer-Free Controls: Protocol for the Nested Case-Control Study KiKme. *JMIR Res Protoc*, 10(11), e32395. doi:10.2196/32395
296. *Martínez-Negro, M, González-Rubio, G, Aicart, E, Landfester, K, Guerrero-Martínez, A, & Junquera, E. (2021). Insights into colloidal nanoparticle-protein corona interactions for nanomedicine applications. *Adv Colloid Interface Sci*, 289, 102366. doi:10.1016/j.jcis.2021.102366
297. *Marx, C, Sonnemann, J, Beyer, M, Maddocks, ODK, Lilla, S, Hauzenberger, I, Piée-Staffa, A, Siniuk, K, Nunna, S, Marx-Blümel, L, Westermann, M, Wagner, T, Meyer, FB, Thierbach, R, Mullins, CS, Kdimati, S, Linnebacher, M, Neri, F,

- Heinzel, T, Wang, ZQ, & Krämer, OH. (2021). Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. *Mol Oncol*, 15(12), 3404-3429. doi:10.1002/1878-0261.13060
298. Mast, MP, Modh, H, Champanhac, C, Wang, JW, Storm, G, Krämer, J, Mailänder, V, Pastorin, G, & Wacker, MG. (2021). Nanomedicine at the crossroads - A quick guide for IVIVC. *Adv Drug Deliv Rev*, 179, 113829. doi:10.1016/j.addr.2021.113829
 299. *Mayer, A, Tsiouris, A, Nölke, C, Schwinn, T, Wiltink, J, Beutel, ME, & Zwerenz, R. (2021). [Development of a Psychosocial Online Self-Help Program for Cancer Patients: A Patient-Oriented Approach]. *Rehabilitation (Stuttg)*, 60(2), 132-141. doi:10.1055/a-1361-4993
 300. Mayer, P, Fritz, F, Koell, M, Skornitzke, S, Bergmann, F, Gaida, MM, Hackert, T, Maier-Hein, K, Laun, FB, Kauczor, HU, Grenacher, L, Klauß, M, & Stiller, W. (2021). Assessment of tissue perfusion of pancreatic cancer as potential imaging biomarker by means of Intravoxel incoherent motion MRI and CT perfusion: correlation with histological microvessel density as ground truth. *Cancer Imaging*, 21(1), 13. doi:10.1186/s40644-021-00382-x
 301. *Mayer, P, & Gaida, MM. (2021). [The microarchitecture of pancreatic cancer from the point of view of the pathologist and the radiologist]. *Pathologe*, 42(5), 524-529. doi:10.1007/s00292-021-00949-2
 302. *Mayer, P, Kraft, A, Roth, W, Hackert, T, Bergmann, F, Kauczor, HU, Steinle, V, Khristenko, E, Klauss, M, & Gaida, MM. (2021). Epithelial-to-Mesenchymal Transition in Pancreatic Cancer is associated with Restricted Water Diffusion in Diffusion-Weighted Magnetic Resonance Imaging. *J Cancer*, 12(24), 7488-7497. doi:10.7150/jca.63633
 303. STARSurg Collaborative and COVIDSurg Collaborative. (2021). Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic. *British Journal of Surgery*, 108(12), 1448-1464. doi:10.1093/bjs/znab336
 304. Meier, JK, Schnetz, M, Beck, S, Schmid, T, Dominguez, M, Kalinovic, S, Daiber, A, Brüne, B, & Jung, M. (2021). Iron-Bound Lipocalin-2 Protects Renal Cell Carcinoma from Ferroptosis. *Metabolites*, 11(5). doi:10.3390/metabo11050329
 305. Meijer, AJM, Diepstraten, FA, Langer, T, Broer, L, Domingo, IK, Clemens, E, Uitterlinden, AG, de Vries, ACH, van Grotel, M, Vermeij, WP, Ozinga, RA, Binder, H, Byrne, J, van Dulmen-den Broeder, E, Garrè, ML, Grabow, D, Kaatsch, P, Kaiser, M, Kenborg, L, Winther, JF, Rechnitzer, C, Hasle, H, Kepak, T, Kepakova, K, Tissing, WJE, van der Kooi, ALF, Kremer, LCM, Kruseova, J, Pluijm, SMF, Kuehni, CE, van der Pal, HJH, Parfitt, R, Spix, C, Tillmanns, A, Deuster, D, Matulat, P, Calaminus, G, Hoetink, AE, Elsner, S, Gebauer, J, Haupt, R, Lackner, H, Blattmann, C, Neggers, S, Rassekh, SR, Wright, GEB, Brooks, B, Nagtegaal, AP, Drögemöller, BI, Ross, CJD, Bhavsar, AP, Am Zehnhoff-Dinnesen, AG, Carleton, BC, Zolk, O, & van den Heuvel-Eibrink, MM. (2021). TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. *NPJ Precis Oncol*, 5(1), 64. doi:10.1038/s41698-021-00178-z
 306. *Merzenich, H, Riccetti, N, Hoffmann, B, Blettner, M, Forastiere, F, & Gianicolo, E. (2021). Air pollution and airport apron workers: A neglected occupational setting in epidemiological research. *Int J Hyg Environ Health*, 231, 113649. doi:10.1016/j.ijheh.2020.113649
 307. *Michel, M, Hess, C, Kaps, L, Kremer, WM, Hilscher, M, Galle, PR, Moehler, M, Schattenberg, JM, Wörns, MA, Labenz, C, & Nagel, M. (2021). Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. *Sci Rep*, 11(1), 20506. doi:10.1038/s41598-021-00119-7
 308. *Michel, M, Kaps, L, Maderer, A, Galle, PR, & Moehler, M. (2021). The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. *Cancers (Basel)*, 13(10). doi:10.3390/cancers13102296
 309. *Miederer, M, Pektor, S, Miederer, I, Bausbacher, N, Keil, IS, Hefesha, H, Haas, H, Sahin, U, & Diken, M. (2021). Iodine-124 PET quantification of organ-specific delivery and expression of NIS-encoding RNA. *EJNMMI Res*, 11(1), 14. doi:10.1186/s13550-021-00753-2
 310. *Mikuličić, S, Strunk, J, & Florin, L. (2021). HPV16 Entry into Epithelial Cells: Running a Gauntlet. *Viruses*, 13(12). doi:10.3390/v13122460
 311. *Minarrieta, L, Velasquez, LN, Sparwasser, T, & Berod, L. (2021). Dendritic cell metabolism: moving beyond in vitro-culture-generated paradigms. *Curr Opin Biotechnol*, 68, 202-212. doi:10.1016/j.copbio.2020.12.010
 312. Möbus, V, Lück, HJ, Ladda, E, Klare, P, Schmidt, M, Schneeweiss, A, Grischke, EM, Wachsmann, G, Forstbauer, H, Untch, M, Marmé, F, Blohmer, JU, Jackisch, C, Huober, J, Stickeler, E, Reinisch, M, Link, T, Sinn, BV, Janni, W, Denkert, C, Furlanetto, J, Engels, K, Solbach, C, Schmatloch, S, Rey, J, Burchardi, N, & Loibl, S. (2021). Phase III randomised trial

comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). *Eur J Cancer*, 156, 138-148. doi:10.1016/j.ejca.2021.07.033

313. *Moehler, M, Dvorkin, M, Boku, N, Özgüroğlu, M, Ryu, MH, Muntean, AS, Lonardi, S, Nechaeva, M, Bragagnoli, AC, Coşkun, HS, Cubillo Gracian, A, Takano, T, Wong, R, Safran, H, Vaccaro, GM, Wainberg, ZA, Silver, MR, Xiong, H, Hong, J, Taieb, J, & Bang, YJ. (2021). Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. *J Clin Oncol*, 39(9), 966-977. doi:10.1200/jco.20.00892
314. *Moehler, M, Michel, M, Stein, A, Trojan, J, Marquardt, J, Tintelnot, J, Waidmann, O, Weinmann, A, Woerns, MA, Schroeder, H, Maenz, M, & Foerster, F. (2021). A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer. *Future Oncol*, 17(25), 3309-3319. doi:10.2217/fon-2021-0278
315. Mogensen, H, Modig, K, Talbäck, M, Erdmann, F, Heyman, M, Feychting, M, & Tettamanti, G. (2021). Number of siblings and survival from childhood leukaemia: a national register-based cohort study from Sweden. *Br J Cancer*, 125(1), 112-118. doi:10.1038/s41416-021-01374-1
316. Mori, Y, Neumann, H, Misawa, M, Kudo, SE, & Bretthauer, M. (2021). Artificial intelligence in colonoscopy - Now on the market. What's next? *J Gastroenterol Hepatol*, 36(1), 7-11. doi:10.1111/jgh.15339
317. Moser, O, Zimmermann, M, Meyer, U, Klapper, W, Oschlies, I, Schrappe, M, Attarbaschi, A, Mann, G, Niggli, F, Spix, C, Kontny, U, Klingebiel, T, Reiter, A, Burkhardt, B, & Woessmann, W. (2021). Second malignancies after treatment of childhood non-Hodgkin lymphoma: a report of the Berlin-Frankfurt-Muenster study group. *Haematologica*, 106(5), 1390-1400. doi:10.3324/haematol.2019.244780
318. *Mosler, T, Conte, F, Longo, GMC, Mikicic, I, Kreim, N, Möckel, MM, Petrosino, G, Flach, J, Barau, J, Luke, B, Roukos, V, & Bel, P. (2021). R-loop proximity proteomics identifies a role of DDX41 in transcription-associated genomic instability. *Nat Commun*, 12(1), 7314. doi:10.1038/s41467-021-27530-y
319. Mueller, M, Breuer, E, Mizuno, T, Bartsch, F, Ratti, F, Benzing, C, Ammar-Khodja, N, Sugiura, T, Takayashiki, T, Hessheimer, A, Kim, HS, Ruzzenente, A, Ahn, KS, Wong, T, Bednarsch, J, D'Silva, M, Koerkamp, BG, Jeddou, H, López-López, V, de Ponthaud, C, Yonkus, JA, Ismail, W, Nooijen, LE, Hidalgo-Salinas, C, Kontis, E, Wagner, KC, Gunasekaran, G, Higuchi, R, Gleisner, A, Shwaartz, C, Sapisochin, G, Schulick, RD, Yamamoto, M, Noji, T, Hirano, S, Schwartz, M, Oldhafer, KJ, Prachalias, A, Fusai, GK, Erdmann, JI, Line, PD, Smoot, RL, Soubrane, O, Robles-Campos, R, Boudjema, K, Polak, WG, Han, HS, Neumann, UP, Lo, CM, Kang, KJ, Guglielmi, A, Park, JS, Fondevila, C, Ohtsuka, M, Uesaka, K, Adam, R, Pratschke, J, Aldrighetti, L, De Oliveira, ML, Gores, GJ, Lang, H, Nagino, M, & Clavien, PA. (2021). Perihilar Cholangiocarcinoma - Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. *Ann Surg*, 274(5), 780-788. doi:10.1097/sla.0000000000005103
320. *Mulder, RL, Font-Gonzalez, A, van Dulmen-den Broeder, E, Quinn, GP, Ginsberg, JP, Loeffen, EAH, Hudson, MM, Burns, KC, van Santen, HM, Berger, C, Diesch, T, Dirksen, U, Giwerzman, A, Gracia, C, Hunter, SE, Kelvin, JF, Klosky, JL, Laven, JSE, Lockart, BA, Neggers, S, Peate, M, Phillips, B, Reed, DR, Tinner, EME, Byrne, J, Veening, M, van de Berg, M, Verhaak, CM, Anazodo, A, Rodriguez-Wallberg, K, van den Heuvel-Eibrink, MM, Asogwa, OA, Brownsdon, A, Wallace, WH, Green, DM, Skinner, R, Haupt, R, Kenney, LB, Levine, J, van de Wetering, MD, Tissing, WJE, Paul, NW, Kremer, LCM, & Inthorn, J. (2021). Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. *Lancet Oncol*, 22(2), e68-e80. doi:10.1016/s1470-2045(20)30595-7
321. *Müller, L, Hahn, F, Mähringer-Kunz, A, Stoeck, F, Gairing, SJ, Foerster, F, Weinmann, A, Galle, PR, Mittler, J, Pinto Dos Santos, D, Pitton, MB, Düber, C, & Kloeckner, R. (2021a). Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score? *Front Oncol*, 11, 696183. doi:10.3389/fonc.2021.696183
322. *Müller, L, Hahn, F, Mähringer-Kunz, A, Stoeck, F, Gairing, SJ, Foerster, F, Weinmann, A, Galle, PR, Mittler, J, Pinto Dos Santos, D, Pitton, MB, Düber, C, & Kloeckner, R. (2021b). Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. *Cancers (Basel)*, 13(16). doi:10.3390/cancers13163961
323. *Müller, L, Hahn, F, Mähringer-Kunz, A, Stoeck, F, Gairing, SJ, Michel, M, Foerster, F, Weinmann, A, Galle, PR, Mittler, J, Pinto Dos Santos, D, Pitton, MB, Düber, C, & Kloeckner, R. (2021). Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. *Cancers (Basel)*, 13(19). doi:10.3390/cancers13195018

324. *Müller, L, Mähringer-Kunz, A, Gairing, SJ, Foerster, F, Weinmann, A, Bartsch, F, Heuft, LK, Baumgart, J, Düber, C, Hahn, F, & Kloeckner, R. (2021). Survival Prediction in Intrahepatic Cholangiocarcinoma: A Proof of Concept Study Using Artificial Intelligence for Risk Assessment. *J Clin Med*, 10(10). doi:10.3390/jcm10102071
325. *Müller, L, Stoehr, F, Mähringer-Kunz, A, Hahn, F, Weinmann, A, & Kloeckner, R. (2021). Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. *J Hepatocell Carcinoma*, 8, 403-419. doi:10.2147/jhc.S285735
326. Muñoz-Martínez, S, Sapena, V, Forner, A, Nault, JC, Sapisochin, G, Rimassa, L, Sangro, B, Bruix, J, Sanduzzi-Zamparelli, M, Hołowko, W, El Kassas, M, Mocan, T, Bouattour, M, Merle, P, Hoogwater, FJH, Alqahtani, SA, Reeves, HL, Pinato, DJ, Giorgakis, E, Meyer, T, Villadsen, GE, Wege, H, Salati, M, Mínguez, B, Di Costanzo, GG, Roderburg, C, Tacke, F, Varela, M, Galle, PR, Alvares-da-Silva, MR, Trojan, J, Bridgewater, J, Cabibbo, G, Toso, C, Lachenmayer, A, Casadei-Gardini, A, Toyoda, H, Lüdde, T, Villani, R, Matilla Peña, AM, Guedes Leal, CR, Ronzoni, M, Delgado, M, Perelló, C, Pascual, S, Lledó, JL, Argemi, J, Basu, B, da Fonseca, L, Acevedo, J, Siebenhüner, AR, Braconi, C, Meyers, BM, Granito, A, Sala, M, Rodríguez-Lope, C, Blaise, L, Romero-Gómez, M, Piñero, F, Gomez, D, Mello, V, Pinheiro Alves, RC, França, A, Branco, F, Brandi, G, Pereira, G, Coll, S, Guarino, M, Benítez, C, Anders, MM, Bandi, JC, Vergara, M, Calvo, M, Peck-Radosavljevic, M, García-Juárez, I, Cardinale, V, Lozano, M, Gambato, M, Okolicsanyi, S, Morales-Arreaez, D, Elvevi, A, Muñoz, AE, Lué, A, Iavarone, M, & Reig, M. (2021). Assessing the impact of COVID-19 on liver cancer management (CERO-19). *JHEP Rep*, 3(3), 100260. doi:10.1016/j.jhepr.2021.100260
327. Mytilineos, D, Tsamadou, C, Neuchel, C, Platzbecker, U, Bunjes, D, Schub, N, Wagner-Drouet, E, Wulf, G, Kröger, N, Murawski, N, Einsele, H, Schaefer-Eckart, K, Freitag, S, Casper, J, Kaufmann, M, Dürholt, M, Hertenstein, B, Klein, S, Ringhoffer, M, Mueller, CR, Frank, S, Schrezenmeier, H, Fuerst, D, & Mytilineos, J. (2021). The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Analysis. *Front Immunol*, 11, 614976. doi:10.3389/fimmu.2020.614976
328. Nemes, K, Bens, S, Kachanov, D, Teleshova, M, Hauser, P, Simon, T, Tippelt, S, Woessmann, W, Beck, O, Flotho, C, Grigull, L, Driever, PH, Schlegel, PG, Khurana, C, Hering, K, Kolb, R, Leipold, A, Abbink, F, Gil-Da-Costa, MJ, Benesch, M, Kerl, K, Lowis, S, Marques, CH, Graf, N, Nysom, K, Vokuhl, C, Melchior, P, Kröncke, T, Schneppenheim, R, Kordes, U, Gerss, J, Siebert, R, Furtwängler, R, & Frühwald, MC. (2021). Clinical and genetic risk factors define two risk groups of extracranial malignant rhabdoid tumours (eMRT/RTK). *Eur J Cancer*, 142, 112-122. doi:10.1016/j.ejca.2020.10.004
329. Nettelbeck, DM, Leber, MF, Altomonte, J, Angelova, A, Beil, J, Berchtold, S, Delic, M, Eberle, J, Ehrhardt, A, Engeland, CE, Fechner, H, Geletneky, K, Goepfert, K, Holm, PS, Kochanek, S, Kreppel, F, Krutzke, L, Kühnel, F, Lang, KS, Marchini, A, Moehler, M, Mühlebach, MD, Naumann, U, Nawroth, R, Nüesch, J, Rommelaere, J, Lauer, UM, & Ungerechts, G. (2021). Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. *Viruses*, 13(8). doi:10.3390/v13081420
330. *Neu, MA, Schlecht, J, Schmidt, MF, Robinson, AL, Spix, C, Grabow, D, Kaatsch, P, Erdmann, F, Faber, J, & Urschitz, MS. (2021). Mental health and health-related quality of life in preschool-aged childhood cancer survivors. Results of the prospective cohort study ikidS-OEVA. *Pediatr Blood Cancer*, 68(8), e29039. doi:10.1002/pbc.29039
331. *Neumann, H, Kreft, A, Sivanathan, V, Rahman, F, & Galle, PR. (2021). Evaluation of novel LCI CAD EYE system for real time detection of colon polyps. *PLoS One*, 16(8), e0255955. doi:10.1371/journal.pone.0255955
332. *Neumann, H, Latorre, M, Zimmerman, T, Lang, G, Samarasekera, J, Gross, S, Brahmbhatt, B, Pazwash, H, & Kushnir, V. (2021). A multicenter, prospective, inpatient feasibility study to evaluate the use of an intra-colonoscopy cleansing device to optimize colon preparation in hospitalized patients: the REDUCE study. *BMC Gastroenterol*, 21(1), 232. doi:10.1186/s12876-021-01817-2
333. *Nguyen, A, Dzulko, M, Murr, J, Yen, Y, Schneider, G, & Krämer, OH. (2021). Class 1 Histone Deacetylases and Ataxia-Telangiectasia Mutated Kinase Control the Survival of Murine Pancreatic Cancer Cells upon dNTP Depletion. *Cells*, 10(10). doi:10.3390/cells10102520
334. Niebuhr, NI, Splinter, M, Bostel, T, Seco, J, Hentschke, CM, Floca, RO, Hörner-Rieber, J, Alber, M, Huber, P, Nicolay, NH, & Pfaffenberger, A. (2021). Biologically consistent dose accumulation using daily patient imaging. *Radiat Oncol*, 16(1), 65. doi:10.1186/s13014-021-01789-3
335. Nitschke, K, Worst, TS, von Rhade, SM, Thaqi, B, Neuberger, M, Wessels, F, Weis, CA, Porubsky, S, Gaiser, T, Kriegmair, M, von Hardenberg, J, Weidenbusch, M, Erben, P, & Nuhn, P. (2021). High IL-22RA1 gene expression is associated with poor outcome in muscle invasive bladder cancer. *Urol Oncol*, 39(8), 499.e491-499.e498. doi:10.1016/j.urolonc.2021.05.010

336. Nociarova, J, Novak, M, Polak, J, Hrudka, J, Porubsky, S, Koc, M, Rosina, J, Grebenyuk, AN, Sery, R, Gurlich, R, & Hajer, J. (2021). Development of Radiofrequency Ablation Generator and Balloon-Based Catheter for Microendoluminal Thin-Layer Ablation Therapy Using the Rat Duodenum as a Model of Low-Impedance Tissue. *J Healthc Eng*, 2021, 9986874. doi:10.1155/2021/9986874
337. Noske, A, Ammann, JU, Wagner, DC, Denkert, C, Lebeau, A, Sinn, P, Kreipe, HH, Sommer, U, Baretton, G, Steiger, K, Kiechle, M, Hieke-Schulz, S, Flores, M, Roth, W, & Weichert, W. (2021). A multicentre analytical comparison study of inter-reader and inter-assay agreement of four programmed death-ligand 1 immunohistochemistry assays for scoring in triple-negative breast cancer. *Histopathology*, 78(4), 567-577. doi:10.1111/his.14254
338. Noske, A, Wagner, DC, Schwamborn, K, Foersch, S, Steiger, K, Kiechle, M, Oettler, D, Karapetyan, S, Hapfelmeier, A, Roth, W, & Weichert, W. (2021). Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer. *Breast*, 60, 238-244. doi:10.1016/j.breast.2021.11.003
339. Obid, P, Fekete, T, Drees, P, Haschtmann, D, Kleinstück, F, Loibl, M, & Jeszenszky, D. (2021). Revision surgery for incomplete resection or recurrence of cervical spine chordoma: a consecutive case series of 24 patients. *Eur Spine J*, 30(10), 2915-2924. doi:10.1007/s00586-021-06946-6
340. *Ogorodnikov, A, & Danckwardt, S. (2021). TRENDseq-A highly multiplexed high throughput RNA 3' end sequencing for mapping alternative polyadenylation. *Methods Enzymol*, 655, 37-72. doi:10.1016/bs.mie.2021.03.022
341. Oosting, SF, Desideri, I, Staelens, D, Caballero, C, Tribius, S, Simon, C, Singer, S, Grégoire, V, Fortpied, C, & Luciani, A. (2021). Treatment patterns in older patients with locally advanced head and neck squamous cell carcinoma: Results from an EORTC led survey. *J Geriatr Oncol*, 12(8), 1261-1265. doi:10.1016/j.jgo.2021.05.007
342. Otsuka, S, Melis, N, Gaida, MM, Dutta, D, Weigert, R, & Ashwell, JD. (2021). Calcineurin inhibitors suppress acute graft-versus-host disease via NFAT-independent inhibition of T cell receptor signaling. *J Clin Invest*, 131(11). doi:10.1172/jci147683
343. *Otto, G, Pitton, MB, Hoppe-Lotichius, M, & Weinmann, A. (2021). Liver transplantation and BCLC classification: Limitations impede optimum treatment. *Hepatobiliary Pancreat Dis Int*, 20(1), 6-12. doi:10.1016/j.hbpd.2020.12.009
344. Palmieri, C, Müller, G, Kroesen, AJ, Galata, C, Rink, AD, Morgenstern, J, & Kruis, W. (2021). Perianal Fistula-Associated Carcinoma in Crohn's Disease: A Multicentre Retrospective Case Control Study. *J Crohns Colitis*, 15(10), 1686-1693. doi:10.1093/ecco-jcc/jjab057
345. *Paret, C, Lehmann, N, Bender, H, Sprang, M, Sommer, CJ, Cana, D, Seidmann, L, Wingerter, A, Neu, MA, El Malki, K, Alt, F, Roth, L, Marini, F, Ottenhausen, M, Glaser, M, Knuf, M, Russo, A, & Faber, J. (2021). Identification of an Immunogenic Medulloblastoma-Specific Fusion Involving EPC2 and GULP1. *Cancers (Basel)*, 13(22). doi:10.3390/cancers13225838
346. Pedersen, LH, Erdmann, F, Aalborg, GL, Hjalgrim, LL, Larsen, HB, Schmiegelow, K, Winther, JF, & Dalton, SO. (2021). Socioeconomic position and prediagnostic health care contacts in children with cancer in Denmark: a nationwide register study. *BMC Cancer*, 21(1), 1104. doi:10.1186/s12885-021-08837-x
347. *Pektor, S, Lawaczek, L, Tenzer, S, Bausbacher, N, Hoffmann, MA, Schreckenberger, M, & Miederer, M. (2021). Characterization of activation induced [18]F-FDG uptake in Dendritic Cells. *Nuklearmedizin*, 60(2), 90-98. doi:10.1055/a-1308-0589
348. Pfister, D, Núñez, NG, Pinyol, R, Govaere, O, Pinter, M, Szydłowska, M, Gupta, R, Qiu, M, Deczkowska, A, Weiner, A, Müller, F, Sinha, A, Friebel, E, Engleitner, T, Lenggenhager, D, Moncsek, A, Heide, D, Stirn, K, Kosla, J, Kotsiliti, E, Leone, V, Dudek, M, Yousuf, S, Inverso, D, Singh, I, Teijeiro, A, Castet, F, Montironi, C, Haber, PK, Tiniakos, D, Bedossa, P, Cockell, S, Younes, R, Vacca, M, Marra, F, Schattenberg, JM, Allison, M, Bugianesi, E, Ratzl, V, Pressiani, T, D'Alessio, A, Personeni, N, Rimassa, L, Daly, AK, Scheiner, B, Pomej, K, Kirstein, MM, Vogel, A, Peck-Radosavljevic, M, Hücke, F, Finkelmeier, F, Waidmann, O, Trojan, J, Schulze, K, Wege, H, Koch, S, Weinmann, A, Bueter, M, Rössler, F, Siebenhüner, A, De Dosso, S, Mallm, JP, Umansky, V, Jugold, M, Luedde, T, Schietinger, A, Schirmacher, P, Emu, B, Augustin, HG, Billeter, A, Müller-Stich, B, Kikuchi, H, Duda, DG, Kütting, F, Waldschmidt, DT, Ebert, MP, Rahbari, N, Mei, HE, Schulz, AR, Ringelhan, M, Malek, N, Spahn, S, Bitzer, M, Ruiz de Galarreta, M, Lujambio, A, Dufour, JF, Marron, TU, Kaseb, A, Kudo, M, Huang, YH, Djouder, N, Wolter, K, Zender, L, Marche, PN, Decaens, T, Pinato, DJ, Rad, R, Mertens, JC, Weber, A, Unger, K, Meissner, F, Roth, S, Jilkova, ZM, Claassen, M, Anstee, QM, Amit, I, Knolle, P, Becher, B, Llovet, JM, & Heikenwalder, M. (2021). NASH limits anti-tumour surveillance in immunotherapy-treated HCC. *Nature*, 592(7854), 450-456. doi:10.1038/s41586-021-03362-0

349. *Piepgras, J, Müller, A, Steffen, F, Lotz, J, Loquai, C, Zipp, F, Dresel, C, & Bittner, S. (2021). Neurofilament light chain levels reflect outcome in a patient with glutamic acid decarboxylase 65 antibody-positive autoimmune encephalitis under immune checkpoint inhibitor therapy. *Eur J Neurol*, 28(3), 1086-1089. doi:10.1111/ene.14692
350. *Pons, M, Zeyn, Y, Zahn, S, Mahendrarajah, N, Page, BDG, Gunning, PT, Moriggl, R, Brenner, W, Butter, F, & Krämer, OH. (2021). Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. *Cancers (Basel)*, 13(14). doi:10.3390/cancers13143464
351. *Porubsky, S, Nientiedt, M, Kriegmair, MC, Siemoneit, JH, Sandhoff, R, Jennemann, R, Borgmann, H, Gaiser, T, Weis, CA, Erben, P, Hielscher, T, & Popovic, ZV. (2021). The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma. *Sci Rep*, 11(1), 10926. doi:10.1038/s41598-021-90381-6
352. *Porubsky, S, Popovic, ZV, Badve, S, Banz, Y, Berezowska, S, Borchert, D, Brüggemann, M, Gaiser, T, Graeter, T, Hollaus, P, Huettl, KS, Kotrova, M, Kreft, A, Kugler, C, Lötscher, F, Möller, B, Ott, G, Preissler, G, Roessner, E, Rosenwald, A, Ströbel, P, & Marx, A. (2021). Thymic Hyperplasia with Lymphoepithelial Sialadenitis (LESA)-Like Features: Strong Association with Lymphomas and Non-Myasthenic Autoimmune Diseases. *Cancers (Basel)*, 13(2). doi:10.3390/cancers13020315
353. Puhr, M, Eigentler, A, Handle, F, Hackl, H, Ploner, C, Heidegger, I, Schaefer, G, Brandt, MP, Hoefer, J, Van der Pluijm, G, & Klocker, H. (2021). Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer. *Oncogene*, 40(17), 3087-3100. doi:10.1038/s41388-021-01754-0
354. *Rahimi-Nedjat, RK, Tuettenberg, A, Sagheb, K, Loquai, C, Rybczynski, B, Grabbe, S, Walter, C, & Al-Nawas, B. (2021). Factors accelerating recurrences and secondary tumors in cutaneous squamous cell carcinoma. *J Craniomaxillofac Surg*, 49(4), 317-322. doi:10.1016/j.jcms.2021.02.009
355. Rakauskas, A, Marra, G, Heidegger, I, Kasivisvanathan, V, Kretschmer, A, Zattoni, F, Preisser, F, Tilki, D, Tsaour, I, van den Bergh, R, Kesch, C, Ceci, F, Fankhauser, C, Gandaglia, G, & Valerio, M. (2021). Focal Therapy for Prostate Cancer: Complications and Their Treatment. *Front Surg*, 8, 696242. doi:10.3389/fsurg.2021.696242
356. Rasche, L, Wäsch, R, Munder, M, Goldschmidt, H, & Raab, MS. (2021). Novel immunotherapies in multiple myeloma - chances and challenges. *Haematologica*, 106(10), 2555-2565. doi:10.3324/haematol.2020.266858
357. *Rashid, H, Eichler, M, Hechtner, M, Gianicolo, E, Wehler, B, Buhl, R, Schmidberger, H, Stratmann, JA, Gohrbandt, B, Kortsik, C, Nestle, U, Wirtz, H, Blettner, M, & Singer, S. (2021). Returning to work in lung cancer survivors-a multi-center cross-sectional study in Germany. *Support Care Cancer*, 29(7), 3753-3765. doi:10.1007/s00520-020-05886-z
358. *Rausch, J, Windschmitt, J, Schilling, C, Butsch, F, Theobald, M, Sasca, D, & Hess, G. (2021). Treatment-Induced Aggravation of Vasculitis in Hairy-Cell Leukemia. *Clin Lymphoma Myeloma Leuk*, 21(5), e429-e431. doi:10.1016/j.clml.2020.12.019
359. Rautenberg, C, Stölzel, F, Röhl, C, Stelljes, M, Gaidzik, V, Lauseker, M, Kriege, O, Verbeek, M, Unglaub, JM, Thol, F, Krause, SW, Hänel, M, Neuerburg, C, Vucinic, V, Jehn, CF, Severmann, J, Wass, M, Fransecky, L, Chemnitz, J, Holtick, U, Schäfer-Eckart, K, Schröder, J, Kraus, S, Krüger, W, Kaiser, U, Scholl, S, Koch, K, Henning, L, Kobbe, G, Haas, R, Alakel, N, Röhnert, MA, Sockel, K, Hanoun, M, Platzbecker, U, Holderried, TAW, Morgner, A, Heuser, M, Sauer, T, Götze, KS, Wagner-Drouet, E, Döhner, K, Döhner, H, Schliemann, C, Schetelig, J, Bornhäuser, M, Germing, U, Schroeder, T, & Middeke, JM. (2021). Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. *Blood Cancer J*, 11(10), 164. doi:10.1038/s41408-021-00558-5
360. *Reddehase, MJ, Holtappels, R, & Lemmermann, NAW. (2021). Consequence of Histoincompatibility beyond GvH-Reaction in Cytomegalovirus Disease Associated with Allogeneic Hematopoietic Cell Transplantation: Change of Paradigm. *Viruses*, 13(8). doi:10.3390/v13081530
361. *Reich, TR, Schwarzenbach, C, Vilar, JB, Unger, S, Mühlhäusler, F, Nikolova, T, Poplawski, A, Baymaz, HI, Beli, P, Christmann, M, & Tomicic, MT. (2021). Localization matters: nuclear-trapped Survivin sensitizes glioblastoma cells to temozolomide by elevating cellular senescence and impairing homologous recombination. *Cell Mol Life Sci*, 78(14), 5587-5604. doi:10.1007/s00018-021-03864-0
362. Reig, M, Galle, PR, Kudo, M, Finn, R, Llovet, JM, Metti, AL, Schelman, WR, Liang, K, Wang, C, Widau, RC, Abada, P, & Zhu, AX. (2021). Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. *Liver Int*, 41(3), 598-607. doi:10.1111/liv.14731

363. Reinisch, M, Seiler, S, Hauzenberger, T, Kamischke, A, Schmatloch, S, Strittmatter, HJ, Zahm, DM, Thode, C, Furlanetto, J, Strik, D, Möbus, V, Reimer, T, Sinn, BV, Stickeler, E, Marmé, F, Janni, W, Schmidt, M, Rudlowski, C, Untch, M, Nekljudova, V, & Loibl, S. (2021). Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial. *JAMA Oncol*, 7(4), 565-572. doi:10.1001/jamaoncol.2020.7442
364. Reschke, M, Biewald, E, Bronstein, L, Brecht, IB, Dittner-Moormann, S, Driever, F, Ebinger, M, Fleischhack, G, Grabow, D, Geismar, D, Göricke, S, Guberina, M, Le Guin, CHD, Kiefer, T, Kratz, CP, Metz, K, Müller, B, Ryl, T, Schlamann, M, Schlüter, S, Schönberger, S, Schulte, JH, Sirin, S, Süsskind, D, Timmermann, B, Ting, S, Wackernagel, W, Wieland, R, Zenker, M, Zeschinig, M, Reinhardt, D, Eggert, A, Ritter-Sovinz, P, Lohmann, DR, Bornfeld, N, Bechrakis, N, & Ketteler, P. (2021). Eye Tumors in Childhood as First Sign of Tumor Predisposition Syndromes: Insights from an Observational Study Conducted in Germany and Austria. *Cancers (Basel)*, 13(8). doi:10.3390/cancers13081876
365. *Ridder, DA, Schindeldecker, M, Weinmann, A, Berndt, K, Urbansky, L, Witzel, HR, Heinrich, S, Roth, W, & Straub, BK. (2021). Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma. *Cancers (Basel)*, 13(4). doi:10.3390/cancers13040744
366. Riecke, K, Müller, V, Weide, R, Schmidt, M, Park-Simon, TW, Möbus, V, Mundhenke, C, Polasik, A, Lübke, K, Hesse, T, Laakmann, E, Thill, M, P, AF, Denkert, C, Fehm, T, Nekljudova, V, Rey, J, Loibl, S, & Witzel, I. (2021). Predicting Prognosis of Breast Cancer Patients with Brain Metastases in the BMBC Registry-Comparison of Three Different GPA Prognostic Scores. *Cancers (Basel)*, 13(4). doi:10.3390/cancers13040844
367. *Riegel, K, Yurugi, H, Schlöder, J, Jonuleit, H, Kaulich, M, Kirschner, F, Arnold-Schild, D, Tenzer, S, Schild, H, & Rajalingam, K. (2021). ERK5 modulates IL-6 secretion and contributes to tumor-induced immune suppression. *Cell Death Dis*, 12(11), 969. doi:10.1038/s41419-021-04257-8
368. *Rimassa, L, Personeni, N, Czauderna, C, Foerster, F, & Galle, P. (2021). Systemic treatment of HCC in special populations. *J Hepatol*, 74(4), 931-943. doi:10.1016/j.jhep.2020.11.026
369. *Rink, AD, Golubev, V, Vestweber, B, Paul, C, Lang, H, & Vestweber, KH. (2021). Oncologic long-term outcome of single-incision laparoscopic surgery (SILS) for colorectal cancer. *Int J Colorectal Dis*, 36(8), 1751-1758. doi:10.1007/s00384-021-03902-0
370. Rinke, A, Auernhammer, CJ, Bodei, L, Kidd, M, Krug, S, Lawlor, R, Marinoni, I, Perren, A, Scarpa, A, Sorbye, H, Pavel, ME, Weber, MM, Modlin, I, & Gress, TM. (2021). Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? *Gut*, 70(9), 1768-1781. doi:10.1136/gutjnl-2020-321300
371. Rinke, A, Maintz, C, Müller, L, Weber, MM, Lahner, H, Pavel, M, Saeger, W, Houchard, A, Ungewiss, H, & Petersenn, S. (2021). Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria. *Exp Clin Endocrinol Diabetes*, 129(7), 500-509. doi:10.1055/a-1342-2755
372. Roedig, J, Kowald, L, Juretschke, T, Karlowitz, R, Ahangarian Abhari, B, Roedig, H, Fulda, S, Beli, P, & van Wijk, SJ. (2021). USP22 controls necroptosis by regulating receptor-interacting protein kinase 3 ubiquitination. *EMBO Rep*, 22(2), e50163. doi:10.15252/embr.202050163
373. Roeschert, I, Poon, E, Henssen, AG, Garcia, HD, Gatti, M, Giansanti, C, Jamin, Y, Ade, CP, Gallant, P, Schüle-Völk, C, Beli, P, Richards, M, Rosenfeldt, M, Altmeyer, M, Anderson, J, Eggert, A, Dobbstein, M, Bayliss, R, Chesler, L, Büchel, G, & Eilers, M. (2021). Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma. *Nat Cancer*, 2(3), 312-326. doi:10.1038/s43018-020-00171-8
374. *Rosentreter, J, Alt, J, Fried, M, Chakupurakal, G, Stratmann, J, & Krämer, I. (2021). Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors. *J Oncol Pharm Pract*, 27(5), 1147-1158. doi:10.1177/1078155220946381
375. *Rosigkeit, S, Kruchem, M, Thies, D, Kreft, A, Eichler, E, Boegel, S, Jansky, S, Siegl, D, Kaps, L, Pickert, G, Haehnel, P, Kindler, T, Hartwig, UF, Guerra, C, Barbacid, M, Schuppan, D, & Bockamp, E. (2021). Definitive evidence for Club cells as progenitors for mutant Kras/Trp53-deficient lung cancer. *Int J Cancer*, 149(9), 1670-1682. doi:10.1002/ijc.33756
376. Roßwag, S, Cotarelo, CL, Pantel, K, Riethdorf, S, Sleeman, JP, Schmidt, M, & Thaler, S. (2021). Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2- Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2- Breast Cancer. *Cancers (Basel)*, 13(8). doi:10.3390/cancers13081810

377. Roth, R, Dieng, S, Oesterle, A, Feick, G, Carl, G, Hinkel, A, Steiner, T, Kaftan, BT, Kunath, F, Hadaschik, B, Oostdam, SJ, Palisaar, RJ, Koralewski, M, Beyer, B, Haben, B, Tsaar, I, Wesselmann, S, & Kowalski, C. (2021). Determinants of self-reported functional status (EPIC-26) in prostate cancer patients prior to treatment. *World J Urol*, 39(1), 27-36. doi:10.1007/s00345-020-03097-z
378. Ruzzenente, A, Bagante, F, Olthof, PB, Aldrighetti, L, Alikhanov, R, Cescon, M, Koerkamp, BG, Jarnagin, WR, Nadalin, S, Pratschke, J, Schmelzle, M, Sparrelid, E, Lang, H, Iacono, C, van Gulik, TM, & Guglielmi, A. (2021). Surgery for Bismuth-Corlette Type 4 Perihilar Cholangiocarcinoma: Results from a Western Multicenter Collaborative Group. *Ann Surg Oncol*, 28(12), 7719-7729. doi:10.1245/s10434-021-09905-z
379. Saalfeld, FC, Wenzel, C, Christopoulos, P, Merkelbach-Bruse, S, Reissig, TM, Laßmann, S, Thiel, S, Stratmann, JA, Marienfeld, R, Berger, J, Desuki, A, Velthaus, JL, Kauffmann-Guerrero, D, Stenzinger, A, Michels, S, Herold, T, Kramer, M, Herold, S, Tufman, A, Loges, S, Alt, J, Joosten, M, Schmidtke-Schrezenmeier, G, Sebastian, M, Stephan-Falkenau, S, Waller, CF, Wiesweg, M, Wolf, J, Thomas, M, Aust, DE, & Wermke, M. (2021). Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations. *J Thorac Oncol*, 16(11), 1952-1958. doi:10.1016/j.jtho.2021.06.025
380. *Sabbaghi, F, Ullner, L, Bohn, T, Hahlbrock, J, Bopp, T, Schmitt, E, Klein, M, & Stassen, M. (2021). In Activated Murine Mast Cells, NFATc2 Is Critical for the Production of Autocrine IL-3, Thereby Promoting the Expression of IL-9. *J Immunol*, 206(1), 67-76. doi:10.4049/jimmunol.1900310
381. Sadik, CD, Langan, EA, Gutzmer, R, Fleischer, MI, Loquai, C, Reinhardt, L, Meier, F, Göppner, D, Herbst, RA, Zillikens, D, & Terheyden, P. (2021). Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology Centers. *Front Immunol*, 11, 588582. doi:10.3389/fimmu.2020.588582
382. *Sahin, U, Türeci, Ö, Manikhas, G, Lordick, F, Rusyn, A, Vynnychenko, I, Dudov, A, Bazin, I, Bondarenko, I, Melichar, B, Dhaene, K, Wiechen, K, Huber, C, Maurus, D, Arozullah, A, Park, JW, Schuler, M, & Al-Batran, SE. (2021). FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. *Ann Oncol*, 32(5), 609-619. doi:10.1016/j.annonc.2021.02.005
383. Samii, A, Sorokin, M, Kar, S, Makovskaia, L, Garazha, A, Hartmann, C, Moisseev, A, Kim, E, Giese, A, & Buzdin, A. (2021). Case of multifocal glioblastoma with four fusion transcripts of ALK, FGFR2, NTRK2, and NTRK3 genes stresses the need for tumor tissue multisampling for transcriptomic analysis. *Cold Spring Harb Mol Case Stud*, 7(4). doi:10.1101/mcs.a006100
384. *Sasca, D, Gueguez, B, & Kühn, MWM. (2021). Next generation epigenetic modulators to target myeloid neoplasms. *Curr Opin Hematol*, 28(5), 356-363. doi:10.1097/moh.0000000000000673
385. Satoh, K, Kobayashi, Y, Fujimaki, K, Hayashi, S, Ishida, S, Sugiyama, D, Sato, T, Lim, K, Miyamoto, M, Kozuma, S, Kadokura, M, Wakita, K, Hata, M, Hirahara, K, Amano, M, Watanabe, I, Okamoto, A, Tuettenberg, A, Jonuleit, H, Tanemura, A, Maruyama, S, Agatsuma, T, Wada, T, & Nishikawa, H. (2021). Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. *Int Immunol*, 33(8), 435-446. doi:10.1093/intimm/dxab027
386. Schäfer, N, Bumke, E, Eberle, F, Fox, V, Gessler, F, Giordano, FA, Konczalla, J, Onken, J, Ottenhausen, M, Scherer, M, Schneider, M, Vatter, H, Herrlinger, U, & Schuss, P. (2021). Implementation, relevance, and virtual adaptation of neuro-oncological tumor boards during the COVID-19 pandemic: a nationwide provider survey. *J Neurooncol*, 153(3), 479-485. doi:10.1007/s11060-021-03784-w
387. Schaller, E, Ma, A, Gosch, LC, Klefenz, A, Schaller, D, Goehring, N, Kaps, L, Schuppan, D, Volkamer, A, Schobert, R, Biersack, B, Nitzsche, B, & Höpfner, M. (2021). New 3-Aryl-2-(2-thienyl)acrylonitriles with High Activity Against Hepatoma Cells. *Int J Mol Sci*, 22(5). doi:10.3390/ijms22052243
388. *Schattenberg, JM, Anstee, QM, Caussy, C, Bugianesi, E, & Popovic, B. (2021). Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. *Expert Rev Gastroenterol Hepatol*, 15(11), 1253-1266. doi:10.1080/17474124.2021.1974295
389. Schellhaas, B, Bernatik, T, Bohle, W, Borowitzka, F, Chang, J, Dietrich, CF, Dirks, K, Donoval, R, Drube, K, Friedrich-Rust, M, Gall, C, Gittinger, F, Gutermann, M, Haenle, MM, von Herbay, A, Ho, CH, Hochdoerffer, R, Hoffmann, T, Hüttig, M, Janson, C, Jung, EM, Jung, N, Karlas, T, Klinger, C, Kornmehl, A, Kratzer, W, Krug, S, Kunze, G, Leitlein, J, Link, A, Lottspeich, C, Marano, A, Mauch, M, Moleda, L, Neesse, A, Petzold, G, Potthoff, A, Praktikjnjo, M, Rösner, KD, Schanz, S, Schultheiß, M, Sivanathan, V, Stock, J, Thomsen, T, Vogelpohl, J, Vogt, C, Wagner, S, Wiegand, C, Wiesinger, I, Will,

- U, Ziesch, M, Zimmermann, P, & Strobel, D. (2021). Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCU LAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study. *Ultraschall Med*, 42(2), 178-186. doi:10.1055/a-1198-4874
390. Schick, S, Grosche, S, Kohl, KE, Drpic, D, Jaeger, MG, Marella, NC, Imrichova, H, Lin, JG, Hofstätter, G, Schuster, M, Rendeiro, AF, Koren, A, Petronczki, M, Bock, C, Müller, AC, Winter, GE, & Kubicek, S. (2021). Acute BAF perturbation causes immediate changes in chromatin accessibility. *Nat Genet*, 53(3), 269-278. doi:10.1038/s41588-021-00777-3
 391. *Schiegnitz, E, Kämmerer, PW, Hellwich, P, König, J, Sagheb, K, & Al-Nawas, B. (2021). Treatment concepts of horizontally deficient ridges-A retrospective study comparing narrow-diameter implants in pristine bone with standard-diameter implants in augmented bone. *Clin Oral Implants Res*, 32(10), 1159-1167. doi:10.1111/clr.13807
 392. *Schiegnitz, E, Müller, LK, Sagheb, K, Theis, L, Cagiran, V, Kämmerer, PW, Wegener, J, Wagner, W, & Al-Nawas, B. (2021). Clinical long-term and patient-reported outcomes of dental implants in oral cancer patients. *Int J Implant Dent*, 7(1), 93. doi:10.1186/s40729-021-00373-4
 393. *Schmalohr, BF, Mustafa, AM, Krämer, OH, & Imhof, D. (2021). Structural Insights into the Interaction of Heme with Protein Tyrosine Kinase JAK2*. *Chembiochem*, 22(5), 861-864. doi:10.1002/cbic.202000730
 394. Schmidt, JA, Hornhardt, S, Erdmann, F, Sánchez-García, I, Fischer, U, Schüz, J, & Ziegelberger, G. (2021). Risk Factors for Childhood Leukemia: Radiation and Beyond. *Front Public Health*, 9, 805757. doi:10.3389/fpubh.2021.805757
 395. *Schmidt, M, Edlund, K, Hengstler, JG, Heimes, AS, Almstedt, K, Lebrecht, A, Krajnak, S, Battista, MJ, Brenner, W, Hasenburger, A, Rahnenführer, J, Gehrmann, M, Kellokumpu-Lehtinen, PL, Wirtz, RM, & Joensuu, H. (2021). Prognostic Impact of Immunoglobulin Kappa C (IGKC) in Early Breast Cancer. *Cancers (Basel)*, 13(14). doi:10.3390/cancers13143626
 396. *Schmidt, M, & Heimes, AS. (2021). Immunomodulating Therapies in Breast Cancer-From Prognosis to Clinical Practice. *Cancers (Basel)*, 13(19). doi:10.3390/cancers13194883
 397. *Schmidt, M, KÜmmel, S, Ruf-Doerdelmann, A, Distelrath, A, Wacker, J, Schmatloch, S, Busch-Liles, S, & Lüdtker-Heckenkamp, K. (2021). Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin®) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin). *Anticancer Res*, 41(1), 485-496. doi:10.21873/anticancer.14799
 398. *Schmidt, M, Lenhard, H, Hoenig, A, Zimmerman, Y, Krijgh, J, Jansen, M, & Coelingh Bennink, HJT. (2021). Tumor suppression, dose-limiting toxicity and wellbeing with the fetal estrogen estetrol in patients with advanced breast cancer. *J Cancer Res Clin Oncol*, 147(6), 1833-1842. doi:10.1007/s00432-020-03472-8
 399. Schmitt, M, Silva, M, Konukiewicz, B, Lang, C, Steiger, K, Halfter, K, Engel, J, Jank, P, Pfarr, N, Wilhelm, D, Foersch, S, Denkert, C, Tschurtschenthaler, M, Weichert, W, & Jesinghaus, M. (2021). Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups. *Cancers (Basel)*, 13(24). doi:10.3390/cancers13246177
 400. Schmitz, N, Truemper, L, Bouabdallah, K, Ziepert, M, Leclerc, M, Cartron, G, Jaccard, A, Reimer, P, Wagner, E, Wilhelm, M, Sanhes, L, Lamy, T, de Leval, L, Rosenwald, A, Roussel, M, Kroschinsky, F, Lindemann, W, Dreger, P, Viardot, A, Milpied, N, Gisselbrecht, C, Wulf, G, Gyan, E, Gaulard, P, Bay, JO, Glass, B, Poeschel, V, Damaj, G, Sibon, D, Delmer, A, Bilger, K, Banos, A, Haenel, M, Dreyling, M, Metzner, B, Keller, U, Bräulke, F, Friedrichs, B, Nickelsen, M, Altmann, B, & Tournilhac, O. (2021). A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. *Blood*, 137(19), 2646-2656. doi:10.1182/blood.2020008825
 401. Schneeweiss, A, Fasching, PA, Fehm, T, Gerber, B, Jackisch, C, Loibl, S, Schmidt, M, Stickeler, E, Wöckel, A, Janni, W, & Müller, V. (2021). AGO Algorithms for the Treatment of Breast Cancer: Update 2021. *Geburtshilfe Frauenheilkd*, 81(10), 1101-1111. doi:10.1055/a-1519-7089
 402. Schoch, S, Sen, V, Brenner, W, Hartwig, A, & Köberle, B. (2021). In Vitro Nephrotoxicity Studies of Established and Experimental Platinum-Based Compounds. *Biomedicines*, 9(8). doi:10.3390/biomedicines9081033
 403. *Schüle, M, Butto, T, Dewi, S, Schlichtholz, L, Strand, S, Gerber, S, Endres, K, Schweiger, S, & Winter, J. (2021). mTOR Driven Gene Transcription Is Required for Cholesterol Production in Neurons of the Developing Cerebral Cortex. *Int J Mol Sci*, 22(11). doi:10.3390/ijms22116034

404. Schuler, E, Wagner-Drouet, EM, Ajib, S, Bug, G, Crysandt, M, Dressler, S, Hausmann, A, Heidenreich, D, Hirschbühl, K, Hoepting, M, Jost, E, Kaivers, J, Klein, S, Koldehoff, M, Kordelas, L, Kriege, O, Müller, LP, Rautenberg, C, Schaffrath, J, Schmid, C, Wolff, D, Haas, R, Bornhäuser, M, Schroeder, T, & Kobbe, G. (2021). Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. *Ann Hematol*, 100(4), 959-968. doi:10.1007/s00277-020-04321-x
405. *Schulz, L, Torres-Diz, M, Cortés-López, M, Hayer, KE, Asnani, M, Tasian, SK, Barash, Y, Sotillo, E, Zarnack, K, König, J, & Thomas-Tikhonenko, A. (2021). Direct long-read RNA sequencing identifies a subset of questionable exons likely arising from reverse transcription artifacts. *Genome Biol*, 22(1), 190. doi:10.1186/s13059-021-02411-1
406. *Schulz, S, Woerl, AC, Jungmann, F, Glasner, C, Stenzel, P, Strobl, S, Fernandez, A, Wagner, DC, Haferkamp, A, Mildenerberger, P, Roth, W, & Foersch, S. (2021). Multimodal Deep Learning for Prognosis Prediction in Renal Cancer. *Front Oncol*, 11, 788740. doi:10.3389/fonc.2021.788740
407. Schündeln, MM, Lange, T, Knoll, M, Spix, C, Brenner, H, Bozorgmehr, K, & Stock, C. (2021). Statistical methods for spatial cluster detection in childhood cancer incidence: A simulation study. *Cancer Epidemiol*, 70, 101873. doi:10.1016/j.canep.2020.101873
408. *Schupp, J, Christians, A, Zimmer, N, Gleue, L, Jonuleit, H, Helm, M, & Tuettenberg, A. (2021). In-Depth Immune-Oncology Studies of the Tumor Microenvironment in a Humanized Melanoma Mouse Model. *Int J Mol Sci*, 22(3). doi:10.3390/ijms22031011
409. *Schwab, R, Anic, K, & Hasenburg, A. (2021). Cancer and Pregnancy: A Comprehensive Review. *Cancers (Basel)*, 13(12). doi:10.3390/cancers13123048
410. *Schwab, R, Anic, K, Stewen, K, Schmidt, MW, Kalb, SR, Kottmann, T, Brenner, W, Domidian, JS, Krajnak, S, Battista, MJ, & Hasenburg, A. (2021). Pain experience and social support of endometriosis patients during the COVID-19 pandemic in Germany - results of a web-based cross-sectional survey. *PLoS One*, 16(8), e0256433. doi:10.1371/journal.pone.0256433
411. *Schwab, R, Heller, M, Pfeifer, C, Unger, RE, Walenta, S, Nezi-Cahn, S, Al-Nawas, B, Hasenburg, A, & Brenner, W. (2021). Full-thickness tissue engineered oral mucosa for genitourinary reconstruction: A comparison of different collagen-based biodegradable membranes. *J Biomed Mater Res B Appl Biomater*, 109(4), 572-583. doi:10.1002/jbm.b.34724
412. *Schwaegermann, MK, Schranz, M, Moehler, M, Labenz, C, Moringlane, A, Schmidt, M, Theobald, M, & Hess, G. (2021). Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer center. *J Cancer Res Clin Oncol*, 147(7), 2117-2126. doi:10.1007/s00432-020-03495-1
413. *Schwarzenbach, C, Tatsch, L, Brandstetter Vilar, J, Rasenberger, B, Beltzig, L, Kaina, B, Tomicic, MT, & Christmann, M. (2021). Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment. *Cancers (Basel)*, 13(14). doi:10.3390/cancers13143585
414. Sebastian, M, Eberhardt, WEE, Hoffknecht, P, Metzenmacher, M, Wehler, T, Kokowski, K, Alt, J, Schütte, W, Büttner, R, Heukamp, LC, Stenzinger, A, Jänicke, M, Fleitz, A, Zacharias, S, Dille, S, Hipper, A, Sandberg, M, Weichert, W, Groschek, M, von der Heyde, E, Rauh, J, Dechow, T, Thomas, M, & Griesinger, F. (2021). KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). *Lung Cancer*, 154, 51-61. doi:10.1016/j.lungcan.2021.02.005
415. *Seifen, C, Huppertz, T, Matthias, C, & Gouveris, H. (2021). Obstructive Sleep Apnea in Patients with Head and Neck Cancer-More than Just a Comorbidity? *Medicina (Kaunas)*, 57(11). doi:10.3390/medicina57111174
416. *Seiwert, N, Adam, J, Steinberg, P, Wirtz, S, Schwerdtle, T, Adams-Quack, P, Hövelmeyer, N, Kaina, B, Foersch, S, & Fahrner, J. (2021). Chronic intestinal inflammation drives colorectal tumor formation triggered by dietary heme iron in vivo. *Arch Toxicol*, 95(7), 2507-2522. doi:10.1007/s00204-021-03064-6
417. *Seiwert, N, Fahrner, J, Nagel, G, Frank, J, Behnam, D, & Kaina, B. (2021). Curcumin Administered as Micellar Solution Suppresses Intestinal Inflammation and Colorectal Carcinogenesis. *Nutr Cancer*, 73(4), 686-693. doi:10.1080/01635581.2020.1771384
418. Shah, MA, Bennouna, J, Doi, T, Shen, L, Kato, K, Adenis, A, Mamon, HJ, Moehler, M, Fu, X, Cho, BC, Bordia, S, Bhagia, P, Shih, CS, Desai, A, & Enzinger, P. (2021). KEYNOTE-975 study design: a Phase III study of definitive

chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. *Future Oncol*, 17(10), 1143-1153. doi:10.2217/fon-2020-0969

419. Shavlokhova, V, Goeppert, B, Gaida, MM, Saravi, B, Weichel, F, Vollmer, A, Vollmer, M, Freudlsperger, C, Mertens, C, & Hoffmann, J. (2021). Mandibular Brown Tumor as a Result of Secondary Hyperparathyroidism: A Case Report with 5 Years Follow-Up and Review of the Literature. *Int J Environ Res Public Health*, 18(14). doi:10.3390/ijerph18147370
420. *Siemer, S, Fauth, T, Scholz, P, Al-Zamel, Y, Khamis, A, Gül, D, Freudlsperger, L, Wollenberg, B, Becker, S, Stauber, RH, & Hagemann, J. (2021). Profiling Cisplatin Resistance in Head and Neck Cancer: A Critical Role of the VRAC Ion Channel for Chemoresistance. *Cancers (Basel)*, 13(19). doi:10.3390/cancers13194831
421. *Simon, J, Kuhn, G, Fichter, M, Gehring, S, Landfester, K, & Mailänder, V. (2021). Unraveling the In Vivo Protein Corona. *Cells*, 10(1). doi:10.3390/cells10010132
422. Simonetto, C, Wollschläger, D, Kundrát, P, Ulanowski, A, Becker, J, Castelletti, N, Güthlin, D, Shemiakina, E, & Eidemüller, M. (2021). Estimating long-term health risks after breast cancer radiotherapy: merging evidence from low and high doses. *Radiat Environ Biophys*, 60(3), 459-474. doi:10.1007/s00411-021-00924-8
423. *Singer, S, Rockenbach, A, Kojima, E, Reuter, K, Prinz-Zaiss, M, Petermann-Meyer, A, Schneider, E, & Lang, K. (2021). [Psycho-oncological care in private practices: a survey among psychotherapists with and without licence for reimbursement with public health insurance]. *Z Psychosom Med Psychother*, 67(2), 132-152. doi:10.13109/zptm.2021.67.0a4
424. Skardelly, M, Kaltenstadler, M, Behling, F, Mäurer, I, Schittenhelm, J, Bender, B, Paulsen, F, Hedderich, J, Renovanz, M, Gempt, J, Barz, M, Meyer, B, Tabatabai, G, & Tatagiba, MS. (2021). A Continuous Correlation Between Residual Tumor Volume and Survival Recommends Maximal Safe Resection in Glioblastoma Patients: A Nomogram for Clinical Decision Making and Reference for Non-Randomized Trials. *Front Oncol*, 11, 748691. doi:10.3389/fonc.2021.748691
425. Slater, EP, Wilke, LM, Böhm, LB, Strauch, K, Lutz, M, Gercke, N, Matthäi, E, Hemminki, K, Försti, A, Schlesner, M, Paramasivam, N, & Bartsch, DK. (2021). Combinations of Low-Frequency Genetic Variants Might Predispose to Familial Pancreatic Cancer. *J Pers Med*, 11(7). doi:10.3390/jpm11070631
426. Sonay, AY, Kalyviotis, K, Yaganoglu, S, Unsal, A, Konantz, M, Teulon, C, Lieberwirth, I, Sieber, S, Jiang, S, Behzadi, S, Crespy, D, Landfester, K, Roke, S, Lengerke, C, & Pantazis, P. (2021). Biodegradable Harmonophores for Targeted High-Resolution In Vivo Tumor Imaging. *ACS Nano*, 15(3), 4144-4154. doi:10.1021/acsnano.0c10634
427. *Sparwasser, P, Brandt, MP, Haack, M, Dotzauer, R, Boehm, K, Gheith, MK, Mager, R, Jäger, W, Ziebart, A, Höfner, T, Tsaur, I, Haferkamp, A, & Borgmann, H. (2021). Robotic surgery can be safely performed for patients and healthcare workers during COVID-19 pandemic. *Int J Med Robot*, 17(4), e2291. doi:10.1002/rcs.2291
428. *Spiecker, L, Witte, I, Mehlig, J, Shah, V, Meyerhöfer, M, Haehnel, PS, Petermann, V, Schüler, A, More, P, Cabezas-Wallscheid, N, Horke, S, Pautz, A, Daiber, A, Sasca, D, Kindler, T, & Kleinert, H. (2021). Deficiency of Antioxidative Paraoxonase 2 (Pon2) Leads to Increased Number of Phenotypic LT-HSCs and Disturbed Erythropoiesis. *Oxid Med Cell Longev*, 2021, 3917028. doi:10.1155/2021/3917028
429. Spirk, D, Sebastian, T, Barco, S, Banyai, M, Beer, JH, Mazzolai, L, Baldi, T, Aujesky, D, Hayoz, D, Engelberger, RP, Kaeslin, T, Korte, W, Escher, R, Husmann, M, Blondon, M, & Kucher, N. (2021). Clinical Outcomes of Incidental Venous Thromboembolism in Cancer and Noncancer Patients: The SWISS Venous ThromboEmbolic Registry (SWIVTER). *Thromb Haemost*, 121(5), 641-649. doi:10.1055/s-0040-1720977
430. *Sprinzl, MF, Feist, C, Koch, S, Kremer, WM, Lackner, KJ, Weinmann, A, & Galle, PR. (2021). Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B. *BMC Health Serv Res*, 21(1), 846. doi:10.1186/s12913-021-06794-6
431. Stahler, A, Heinemann, V, Holch, JW, von Einem, JC, Westphalen, CB, Heinrich, K, Schlieker, L, Jelas, I, Alig, AHS, Fischer, LE, Weiss, L, Modest, DP, von Weikersthal, LF, Decker, T, Kiani, A, Moehler, M, Kaiser, F, Kirchner, T, Jung, A, & Stintzing, S. (2021). Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3). *Int J Cancer*, 149(11), 1935-1943. doi:10.1002/ijc.33747
432. *Stamenovic, D, Hohenberger, P, & Roessner, E. (2021). Pulmonary metastasectomy in soft tissue sarcomas: a systematic review. *J Thorac Dis*, 13(4), 2649-2660. doi:10.21037/jtd-2019-pm-13

433. *Stamm, P, Kirmes, I, Palmer, A, Molitor, M, Kvandova, M, Kalinovic, S, Mihalikova, D, Reid, G, Wenzel, P, Münzel, T, Daiber, A, & Jansen, T. (2021). Doxorubicin induces wide-spread transcriptional changes in the myocardium of hearts distinguishing between mice with preserved and impaired cardiac function. *Life Sci*, 284, 119879. doi:10.1016/j.lfs.2021.119879
434. Steeb, T, Wessely, A, Alter, M, Bayerl, C, Bender, A, Bruning, G, Dabrowski, E, Debus, D, Devereux, N, Dippel, E, Drexler, K, Dücker, P, Dummer, R, Emmert, S, Elsner, P, Enk, A, Gebhardt, C, Gesierich, A, Goebeler, M, Goerdts, S, Goetze, S, Gutzmer, R, Haferkamp, S, Hansel, G, Hassel, JC, Heinzerling, L, Kähler, KC, Kaume, KM, Krapf, W, Kreuzberg, N, Lehmann, P, Livingstone, E, Löffler, H, Loquai, C, Mauch, C, Mangana, J, Meier, F, Meissner, M, Moritz, RKC, Maul, LV, Müller, V, Mohr, P, Navarini, A, Van Nguyen, A, Pfeiffer, C, Pföhler, C, Posch, C, Richtig, E, Rempel, R, Sachse, MM, Sauder, S, Schadendorf, D, Schatton, K, Schulze, HJ, Schultz, E, Schilling, B, Schmuth, M, Simon, JC, Streit, M, Terheyden, P, Thiem, A, Tüting, T, Welzel, J, Weyandt, G, Wesselmann, U, Wollina, U, Ziemer, M, Zimmer, L, Zutt, M, Berking, C, Schlaak, M, & Heppt, MV. (2021). Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG). *J Cancer Res Clin Oncol*, 147(6), 1763-1771. doi:10.1007/s00432-020-03450-0
435. *Stege, H, Haist, M, Nikfarjam, U, Schultheis, M, Heinz, J, Pempner, S, Loquai, C, & Grabbe, S. (2021). The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. *Target Oncol*, 16(5), 537-552. doi:10.1007/s11523-021-00840-3
436. *Stege, H, Haist, M, Schultheis, M, Fleischer, MI, Mohr, P, Meier, F, Schadendorf, D, Ugurel, S, Livingstone, E, Zimmer, L, Herbst, R, Pföhler, C, Kähler, K, Weichenthal, M, Terheyden, P, Nashan, D, Debus, D, Kaatz, M, Ziller, F, Haferkamp, S, Forschner, A, Leiter, U, Kreuter, A, Ulrich, J, Kleemann, J, Bradfisch, F, Grabbe, S, & Loquai, C. (2021). Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma-A Retrospective Multicenter ADOReg Study. *Cancers (Basel)*, 13(10). doi:10.3390/cancers13102312
437. *Stege, HM, Haist, M, Schultheis, S, Fleischer, MI, Mohr, P, Ugurel, S, Terheyden, P, Thiem, A, Kiecker, F, Leiter, U, Becker, JC, Meissner, M, Kleeman, J, Pföhler, C, Hassel, J, Grabbe, S, & Loquai, C. (2021). Response durability after cessation of immune checkpoint inhibitors in patients with metastatic Merkel cell carcinoma: a retrospective multicenter DeCOG study. *Cancer Immunol Immunother*, 70(11), 3313-3322. doi:10.1007/s00262-021-02925-4
438. *Stenzel, PJ, Hörner, N, Foersch, S, Wagner, DC, Tsaor, I, Thomas, A, Haferkamp, A, Macher-Goeppinger, S, Roth, W, Porubsky, S, & Tagscherer, KE. (2021). Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma. *Cancers (Basel)*, 13(18). doi:10.3390/cancers13184511
439. *Stergiou, N, Urschbach, M, Gabba, A, Schmitt, E, Kunz, H, & Besenius, P. (2021). The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response. *Chem Rec*, 21(11), 3313-3331. doi:10.1002/tcr.202100182
440. *Stockinger, M, Karle, H, Rennau, H, Sebb, S, Wolf, U, Remmele, J, Bührdel, S, Bartkowiak, D, Blettner, M, Schmidberger, H, & Wollschläger, D. (2021). Heart atlas for retrospective cardiac dosimetry: a multi-institutional study on interobserver contouring variations and their dosimetric impact. *Radiat Oncol*, 16(1), 241. doi:10.1186/s13014-021-01965-5
441. *Stratenwerth, B, Geisen, SM, He, Y, Beltzig, L, Sturla, SJ, & Kaina, B. (2021). Molecular Dosimetry of Temozolomide: Quantification of Critical Lesions, Correlation to Cell Death Responses, and Threshold Doses. *Mol Cancer Ther*, 20(10), 1789-1799. doi:10.1158/1535-7163.Mct-21-0228
442. Stratigos, AJ, Sekulic, A, Peris, K, Bechter, O, Prey, S, Kaatz, M, Lewis, KD, Basset-Seguín, N, Chang, ALS, Dalle, S, Orland, AF, Licitra, L, Robert, C, Ulrich, C, Hauschild, A, Migden, MR, Dummer, R, Li, S, Yoo, SY, Mohan, K, Coates, E, Jankovic, V, Fiaschi, N, Okoye, E, Bassukas, ID, Loquai, C, De Giorgi, V, Eroglu, Z, Gutzmer, R, Ulrich, J, Puig, S, Seebach, F, Thurston, G, Weinreich, DM, Yancopoulos, GD, Lowy, I, Bowler, T, & Fury, MG. (2021). Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. *Lancet Oncol*, 22(6), 848-857. doi:10.1016/s1470-2045(21)00126-1
443. Strübing, F, Sadick, M, Porubsky, S, Harhaus, L, Bigdeli, A, & Kneser, U. (2021). Fibroadipose Vascular Anomaly of the Upper Extremity: Case Report of Extensive Resection and Secondary Tendon Transfer. *Ann Plast Surg*, 87(5), e92-e96. doi:10.1097/sap.0000000000002792
444. *Sun, J, Xing, F, Braun, J, Traub, F, Rommens, PM, Xiang, Z, & Ritz, U. (2021). Progress of Phototherapy Applications in the Treatment of Bone Cancer. *Int J Mol Sci*, 22(21). doi:10.3390/ijms222111354

445. Šutić, M, Baranašić, J, Bilić, LK, Bilić, M, Jakovčević, A, Brčić, L, Seiwerth, S, Jakopović, M, Samaržija, M, Zechner, U, & Knežević, J. (2021). CpG islands in MyD88 and ASC/PYCARD/TMS1 promoter regions are differentially methylated in head and neck squamous cell carcinoma and primary lung squamous cell carcinoma. *Diagn Pathol*, 16(1), 17. doi:10.1186/s13000-021-01078-3
446. *Tagkalos, E, van der Sluis, PC, Berth, F, Poplawski, A, Hadzijušufovic, E, Lang, H, van Berge Henegouwen, MI, Gisbertz, SS, Müller-Stich, BP, Ruurda, JP, Schiesser, M, Schneider, PM, van Hillegersberg, R, & Grimmering, PP. (2021). Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy versus minimally invasive esophagectomy for resectable esophageal adenocarcinoma, a randomized controlled trial (ROBOT-2 trial). *BMC Cancer*, 21(1), 1060. doi:10.1186/s12885-021-08780-x
447. *Tagkalos, E, van der Sluis, PC, Uzun, E, Berth, F, Staubitz, J, Gockel, I, van Hillegersberg, R, Lang, H, & Grimmering, PP. (2021). The Circular Stapled Esophagogastric Anastomosis in Esophagectomy: No Differences in Anastomotic Insufficiency and Stricture Rates Between the 25 mm and 28 mm Circular Stapler. *J Gastrointest Surg*, 25(9), 2242-2249. doi:10.1007/s11605-020-04895-x
448. Teich, K, Krzykalla, J, Kapp-Schwoerer, S, Gaidzik, VI, Schlenk, RF, Paschka, P, Weber, D, Fiedler, W, Kühn, MWM, Schroeder, T, Mayer, K, Lübbert, M, Ramachandran, D, Benner, A, Ganser, A, Döhner, H, Heuser, M, Döhner, K, & Thol, F. (2021). Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. *Haematologica*, 106(11), 2986-2989. doi:10.3324/haematol.2021.278894
449. *Thiem, DGE, Römer, P, Blatt, S, Al-Nawas, B, & Kämmerer, PW. (2021). New Approach to the Old Challenge of Free Flap Monitoring-Hyperspectral Imaging Outperforms Clinical Assessment by Earlier Detection of Perfusion Failure. *J Pers Med*, 11(11). doi:10.3390/jpm11111101
450. *Thiem, DGE, Römer, P, Gielisch, M, Al-Nawas, B, Schlüter, M, Plaß, B, & Kämmerer, PW. (2021). Hyperspectral imaging and artificial intelligence to detect oral malignancy - part 1 - automated tissue classification of oral muscle, fat and mucosa using a light-weight 6-layer deep neural network. *Head Face Med*, 17(1), 38. doi:10.1186/s13005-021-00292-0
451. *Thol, F, Gairing, SJ, Czauderna, C, Thomaidis, T, Gamstätter, T, Huber, Y, Vollmar, J, Lorenz, J, Michel, M, Bartsch, F, Müller, L, Kloeckner, R, Galle, PR, Wörns, MA, Marquardt, JU, Moehler, M, Weinmann, A, & Foerster, F. (2022). Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer. *JHEP Rep*, 4(3), 100417. doi:10.1016/j.jhepr.2021.100417
452. *Thomas, A, do Canto Alvim, LM, Rainho, CA, Juengel, E, Blaheta, RA, Spiess, PE, Rogatto, SR, & Tsaur, I. (2021). Systemic treatment of penile squamous cell carcinoma-hurdles and hopes of preclinical models and clinical regimens: a narrative review. *Transl Androl Urol*, 10(10), 4085-4098. doi:10.21037/tau-20-945
453. *Thomas, A, Reetz, S, Stenzel, P, Tagscherer, K, Roth, W, Schindeldecker, M, Michaelis, M, Rothweiler, F, Cinatl, J, Jr., Cinatl, J, Dotzauer, R, Vakhrusheva, O, Albersen, M, Macher-Goeppinger, S, Haferkamp, A, Juengel, E, Neisius, A, & Tsaur, I. (2021). Assessment of PI3K/mTOR/AKT Pathway Elements to Serve as Biomarkers and Therapeutic Targets in Penile Cancer. *Cancers (Basel)*, 13(10). doi:10.3390/cancers13102323
454. Tjaden, C, Sandini, M, Mihaljevic, AL, Kaiser, J, Khristenko, E, Mayer, P, Hinz, U, Gaida, MM, Berchtold, C, Diener, MK, Schneider, M, Mehrabi, A, Müller-Stich, BP, Strobel, O, Hackert, T, & Büchler, MW. (2021). Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm. *JAMA Surg*, 156(9), 818-825. doi:10.1001/jamasurg.2021.0950
455. Toenges, R, Greinix, H, Lawitschka, A, Halter, J, Baumgartner, A, Simon, A, Arends, J, Jäger, P, Middeke, M, Hilgendorf, I, Klein, S, Wagner-Drouet, EM, Schmid, C, Bug, G, & Wolff, D. (2021). Current practice in nutrition after allogeneic hematopoietic stem cell transplantation - Results from a survey among hematopoietic stem cell transplant centers. *Clin Nutr*, 40(4), 1571-1577. doi:10.1016/j.clnu.2021.02.030
456. *Tomicic, MT, Dawood, M, & Efferth, T. (2021). Epigenetic Alterations Upstream and Downstream of p53 Signaling in Colorectal Carcinoma. *Cancers (Basel)*, 13(16). doi:10.3390/cancers13164072
457. *Tomicic, MT, Krämer, F, Nguyen, A, Schwarzenbach, C, & Christmann, M. (2021). Oxaliplatin-Induced Senescence in Colorectal Cancer Cells Depends on p14(ARF)-Mediated Sustained p53 Activation. *Cancers (Basel)*, 13(9). doi:10.3390/cancers13092019

458. *Tontini, GE, & Neumann, H. (2021). Artificial intelligence: Thinking outside the box. *Best Pract Res Clin Gastroenterol*, 52-53, 101720. doi:10.1016/j.bpg.2020.101720
459. Toutah, K, Nawar, N, Timonen, S, Sorger, H, Raouf, YS, Bukhari, S, von Jan, J, Ianevski, A, Gawel, JM, Olaoye, OO, Geletu, M, Abdeldayem, A, Israelian, J, Radu, TB, Sedighi, A, Bhatti, MN, Hassan, MM, Manaswiyoungkul, P, Shouksmith, AE, Neubauer, HA, de Araujo, ED, Aittokallio, T, Krämer, OH, Moriggl, R, Mustjoki, S, Herling, M, & Gunning, PT. (2021). Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. *J Med Chem*, 64(12), 8486-8509. doi:10.1021/acs.jmedchem.1c00420
460. Tsamadou, C, Engelhardt, D, Platzbecker, U, Sala, E, Valerius, T, Wagner-Drouet, E, Wulf, G, Kröger, N, Murawski, N, Einsele, H, Schaefer-Eckart, K, Freitag, S, Casper, J, Kaufmann, M, Dürholt, M, Hertenstein, B, Klein, S, Ringhoffer, M, Frank, S, Neuchel, C, Schrezenmeier, H, Mytilineos, J, & Fuerst, D. (2021). HLA-DRB3/4/5 Matching Improves Outcome of Unrelated Hematopoietic Stem Cell Transplantation. *Front Immunol*, 12, 771449. doi:10.3389/fimmu.2021.771449
461. *Tsaour, I, Brandt, MP, Juengel, E, Manceau, C, & Ploussard, G. (2021). Immunotherapy in prostate cancer: new horizon of hurdles and hopes. *World J Urol*, 39(5), 1387-1403. doi:10.1007/s00345-020-03497-1
462. *Tsaour, I, Heidegger, I, Bektic, J, Kafka, M, van den Bergh, RCN, Hunting, JCB, Thomas, A, Brandt, MP, Höfner, T, Debedde, E, Thibault, C, Ermacora, P, Zattoni, F, Foti, S, Kretschmer, A, Ploussard, G, Rodler, S, von Amsberg, G, Tilki, D, Surcel, C, Rosenzweig, B, Gadot, M, Gandaglia, G, & Dotzauer, R. (2021). A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. *Cancer Med*, 10(18), 6354-6364. doi:10.1002/cam4.4184
463. *Tsaour, I, Heidegger, I, van den Bergh, RCN, Bektic, J, Borgmann, H, Foti, S, Hunting, JCB, Kretschmer, A, Ploussard, G, Tilki, D, Gandaglia, G, & Dotzauer, R. (2021). Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment. *Eur Urol Focus*, 7(6), 1308-1315. doi:10.1016/j.euf.2020.06.018
464. *Tsaour, I, Thomas, A, Juengel, E, Maxeiner, S, Grein, T, Le, QC, Muschta, V, Rutz, J, Chun, FKH, & Blaheta, RA. (2021). Deciphering the Molecular Machinery-Influence of sE-Cadherin on Tumorigenic Traits of Prostate Cancer Cells. *Biology (Basel)*, 10(10). doi:10.3390/biology10101007
465. *Ustjanzew, A, Desuki, A, Ritzel, C, Dolezilek, AC, Wagner, DC, Christoph, J, Unberath, P, Kindler, T, Faber, J, Marini, F, Panholzer, T, & Paret, C. (2021). cbpManager: a web application to streamline the integration of clinical and genomic data in cBioPortal to support the Molecular Tumor Board. *BMC Med Inform Decis Mak*, 21(1), 358. doi:10.1186/s12911-021-01719-z
466. van Akkooi, ACJ, Haferkamp, S, Papa, S, Franke, V, Pinter, A, Weishaupt, C, Huber, MA, Loquai, C, Richtig, E, Gokani, P, Öhrling, K, Louie, KS, & Mohr, P. (2021). A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage IIIB-IVM1a Melanoma in Four European Countries. *Adv Ther*, 38(2), 1245-1262. doi:10.1007/s12325-020-01590-w
467. van den Berg, MH, van Dijk, M, Byrne, J, Berger, C, Dirksen, U, Winther, JF, Fossa, SD, Grabow, D, Grandage, VL, Haupt, R, van den Heuvel-Eibrink, MM, Kaiser, M, Kepak, T, van der Kooi, ALF, Kremer, LCM, Kruseova, J, Lambalk, CB, van Leeuwen, FE, Leiper, A, Modan-Moses, D, Spix, C, Twisk, JWR, Ronckers, CM, Kaatsch, P, & van Dulmen-den Broeder, E. (2021). Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). *Hum Reprod*, 36(6), 1561-1573. doi:10.1093/humrep/deab035
468. van der Kooi, ALF, van Dijk, M, Broer, L, van den Berg, MH, Laven, JSE, van Leeuwen, FE, Lambalk, CB, Overbeek, A, Loonen, JJ, van der Pal, HJ, Tissing, WJ, Versluys, B, Bresters, D, Beerendonk, CCM, Ronckers, CR, van der Heiden-van der Loo, M, Kaspers, GL, de Vries, ACH, Robison, LL, Hudson, MM, Chemaitilly, W, Byrne, J, Berger, C, Clemens, E, Dirksen, U, Falck Winther, J, Fosså, SD, Grabow, D, Haupt, R, Kaiser, M, Kepak, T, Kruseova, J, Modan-Moses, D, Pluijm, SMF, Spix, C, Zolk, O, Kaatsch, P, Krijthe, JH, Kremer, LC, Yasui, Y, Brooke, RJ, Uitterlinden, AG, van den Heuvel-Eibrink, MM, & van Dulmen-den Broeder, E. (2021). Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function. *Hum Reprod*, 36(4), 1120-1133. doi:10.1093/humrep/deaa342
469. van der Perk, MEM, Broer, L, Yasui, Y, Robison, LL, Hudson, MM, Laven, JSE, van der Pal, HJ, Tissing, WJE, Versluys, B, Bresters, D, Kaspers, GJL, de Vries, ACH, Lambalk, CB, Overbeek, A, Loonen, JJ, Beerendonk, CCM, Byrne, J, Berger, C, Clemens, E, Dirksen, U, Falck Winther, J, Fosså, SD, Grabow, D, Muraca, M, Kaiser, M, Kepák, T, Kruseova, J, Modan-Moses, D, Spix, C, Zolk, O, Kaatsch, P, Krijthe, JH, Kremer, LCM, Brooke, RJ, Baedke, JL, van Schaik, RHN, van den Anker, JN, Uitterlinden, AG, Bos, AME, van Leeuwen, FE, van Dulmen-den Broeder, E, van der Kooi, ALF, van den Heuvel-Eibrink, MM, & On Behalf Of The PanCare, LC. (2021). Effect of Genetic Variation in CYP450 on Gonadal Impairment in a European Cohort of Female Childhood Cancer Survivors, Based on a Candidate Gene Approach: Results from the PanCareLIFE Study. *Cancers (Basel)*, 13(18). doi:10.3390/cancers13184598

470. *van der Sluis, P, Egberts, JH, Stein, H, Sallum, R, van Hillegersberg, R, & Grimminger, PP. (2021). Transcervical (SP) and Transhiatal DaVinci Robotic Esophagectomy: A Cadaveric Study. *Thorac Cardiovasc Surg*, 69(3), 198-203. doi:10.1055/s-0040-1716323
471. *van der Sluis, PC, Tagkalos, E, Hadzijusufovic, E, Babic, B, Uzun, E, van Hillegersberg, R, Lang, H, & Grimminger, PP. (2021). Robot-Assisted Minimally Invasive Esophagectomy with Intrathoracic Anastomosis (Ivor Lewis): Promising Results in 100 Consecutive Patients (the European Experience). *J Gastrointest Surg*, 25(1), 1-8. doi:10.1007/s11605-019-04510-8
472. van Eck, I, den Hollander, D, Lidington, E, Hentschel, L, Eichler, M, Salah, S, Singer, S, Pinto, M, Fauske, L, Fiore, M, Nixon, I, Constantinidou, A, Desai, IME, Bonenkamp, JJ, van Houdt, WJ, Reuvers, MJP, Haas, RLM, Bruland Ø, S, Kasper, B, van der Graaf, WTA, & Husson, O. (2021). Health-Related Quality of Life Issues Experienced by Thoracic and Breast Sarcoma Patients: A Rare and Understudied Group. *J Clin Med*, 10(22). doi:10.3390/jcm10225334
473. *Varga, J, Kube, M, Luck, K, & Schick, S. (2021). The BAF chromatin remodeling complexes: structure, function, and synthetic lethality. *Biochem Soc Trans*, 49(4), 1489-1503. doi:10.1042/bst20190960
474. *Vehreschild, JJ, Koehler, P, Lamothe, F, Prattes, J, Rieger, C, Rijnders, BJA, & Teschner, D. (2021). Future challenges and chances in the diagnosis and management of invasive mould infections in cancer patients. *Med Mycol*, 59(1), 93-101. doi:10.1093/mmy/myaa079
475. Vogt, J, Beyer, F, Sistermanns, J, Kuon, J, Kahl, C, Alt-Epping, B, Stevens, S, Ahlborn, M, George, C, Heider, A, Tienken, M, Loquai, C, Stahlhut, K, Ruellan, A, Kubin, T, Dietz, A, Oechsle, K, Mehnert-Theuerkauf, A, van Oorschot, B, Thomas, M, Ortmann, O, Engel, C, & Lordick, F. (2021). Symptom Burden and Palliative Care Needs of Patients with Incurable Cancer at Diagnosis and During the Disease Course. *Oncologist*, 26(6), e1058-e1065. doi:10.1002/onco.13751
476. *Vogt, T, Müller, CSL, Melchior, P, Rübe, C, Ugurel, S, Schimming, TT, Utikal, J, Esser, S, Helbig, D, Hadaschik, E, Kasper, B, & Grabbe, S. (2021). S1-Guideline Cutaneous Angiosarcomas - Update 2021. *J Dtsch Dermatol Ges*, 19(12), 1801-1812. doi:10.1111/ddg.14524
477. *Vollmar, J, Kim, YO, Marquardt, JU, Galle, PR, Schuppan, D, & Zimmermann, T. (2021). Functional inhibition of Oct leads to HNF4α upregulation. *Exp Ther Med*, 21(4), 349. doi:10.3892/etm.2021.9780
478. von Hardenberg, J, Borkowetz, A, Siegel, F, Kornienko, K, Westhoff, N, Jordan, TB, Hoffmann, M, Drerup, M, Lieb, V, Taymoorian, K, Schostak, M, Ganzer, R, Höfner, T, Cash, H, & Bruendl, J. (2021). Potential Candidates for Focal Therapy in Prostate Cancer in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Large Multicenter Cohort Study. *Eur Urol Focus*, 7(5), 1002-1010. doi:10.1016/j.euf.2020.09.015
479. *Vonwirth, V, Bülbül, Y, Werner, A, Echchannaoui, H, Windschmitt, J, Habermeier, A, Ioannidis, S, Shin, N, Conradi, R, Bros, M, Tenzer, S, Theobald, M, Closs, EI, & Munder, M. (2021). Inhibition of Arginase 1 Liberates Potent T Cell Immunostimulatory Activity of Human Neutrophil Granulocytes. *Front Immunol*, 11, 617699. doi:10.3389/fimmu.2020.617699
480. *Voß, H, Scholz-Kreisel, P, Richter, C, Ringel, F, Singer, S, & Renovanz, M. (2021). Development of screening questions for doctor-patient consultation assessing the quality of life and psychosocial burden of glioma patients: an explorative study. *Qual Life Res*, 30(5), 1513-1522. doi:10.1007/s11136-021-02756-x
481. *Wagner-Drouet, E, Teschner, D, Wolschke, C, Janson, D, Schäfer-Eckart, K, Gärtner, J, Mielke, S, Schreder, M, Kobbe, G, Kondakci, M, Hilgendorf, I, von Lilienfeld-Toal, M, Klein, S, Heidenreich, D, Kreil, S, Verbeek, M, Grass, S, Ditschkowski, M, Gromke, T, Koch, M, Lindemann, M, Hünig, T, Schmidt, T, Rascle, A, Guldán, H, Barabas, S, Deml, L, Wagner, R, & Wolff, D. (2021). Standardized monitoring of cytomegalovirus-specific immunity can improve risk stratification of recurrent cytomegalovirus reactivation after hematopoietic stem cell transplantation. *Haematologica*, 106(2), 363-374. doi:10.3324/haematol.2019.229252
482. *Wagner-Drouet, E, Teschner, D, Wolschke, C, Schäfer-Eckart, K, Gärtner, J, Mielke, S, Schreder, M, Kobbe, G, Hilgendorf, I, Klein, S, Verbeek, M, Ditschkowski, M, Koch, M, Lindemann, M, Schmidt, T, Rascle, A, Barabas, S, Deml, L, Wagner, R, & Wolff, D. (2021). Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation. *Diagnostics (Basel)*, 11(2). doi:10.3390/diagnostics11020312
483. Wagner, NB, Lenders, MM, Kühl, K, Reinhardt, L, André, F, Dudda, M, Ring, N, Ebel, C, Stäger, R, Zellweger, C, Lang, R, Paar, M, Gussek, P, Richtig, G, Stürmer, SH, Kimeswenger, S, Oellinger, A, Forschner, A, Leiter, U, Weide, B, Gassenmaier, M, Schraag, A, Klumpp, B, Hoetzenecker, W, Berking, C, Richtig, E, Ziemer, M, Mangana, J, Terheyden, P,

- Loquai, C, Nguyen, VA, Gebhardt, C, Meier, F, Diem, S, Cozzio, A, Flatz, L, Röcken, M, Garbe, C, & Eigentler, TK. (2021). Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. *J Immunother Cancer*, 9(5). doi:10.1136/jitc-2021-002350
484. *Wagner, SA, Szczesniak, PP, Voigt, A, Gräf, JF, & Beli, P. (2021). Proteomic analysis of tyrosine phosphorylation induced by exogenous expression of oncogenic kinase fusions identified in lung adenocarcinoma. *Proteomics*, 21(10), e2000283. doi:10.1002/pmic.202000283
485. Walter, K, Rodriguez-Aznar, E, Ferreira, MSV, Frappart, PO, Dittrich, T, Tiwary, K, Meessen, S, Lerma, L, Daiss, N, Schulte, LA, Najafova, Z, Arnold, F, Usachov, V, Azoitei, N, Erkan, M, Lechel, A, Brümmendorf, TH, Seufferlein, T, Kleger, A, Tabarés, E, Günes, C, Johnsen, SA, Beier, F, Sainz, B, Jr., & Hermann, PC. (2021). Telomerase and Pluripotency Factors Jointly Regulate Stemness in Pancreatic Cancer Stem Cells. *Cancers (Basel)*, 13(13). doi:10.3390/cancers13133145
486. Warth, M, Koehler, F, Brehmen, M, Weber, M, Bardenheuer, HJ, Ditzen, B, & Kessler, J. (2021). "Song of Life": Results of a multicenter randomized trial on the effects of biographical music therapy in palliative care. *Palliat Med*, 35(6), 1126-1136. doi:10.1177/02692163211010394
487. Weber, L, Blachutzik, O, Vielsmeier, V, Andorfer, K, Matthias, C, & Künzel, J. (2021). [Evaluation of oesophagoscopy for staging and restaging of head and neck squamous cell carcinoma]. *Laryngorhinootologie*, 100(2), 111-119. doi:10.1055/a-1197-6978
488. Wedel, T, Heinze, T, Möller, T, van Hillegersberg, R, Bleys, R, Weijs, TJ, van der Sluis, PC, Grimminger, PP, Sallum, RA, Becker, T, & Egberts, JH. (2021). Surgical anatomy of the upper esophagus related to robot-assisted cervical esophagectomy. *Dis Esophagus*, 34(12). doi:10.1093/dote/doaa128
489. Wegener, D, Zips, D, Gani, C, Boeke, S, Nikolaou, K, Othman, AE, Almansour, H, Paulsen, F, & Müller, AC. (2021). [Primary treatment of prostate cancer using 1.5 T MR-linear accelerator]. *Radiologe*, 61(9), 839-845. doi:10.1007/s00117-021-00882-8
490. *Wegner, J, Weidenthaler-Barth, B, Engelbert, J, Knothe, M, Braun, C, Helbig, D, Sacher, C, Kreft, A, Wagner, EM, Ziemer, M, Meyer, RG, & von Stebut, E. (2021). Immunohistochemical markers for histopathological diagnosis and differentiation of acute cutaneous graft-versus-host disease. *Exp Dermatol*, 30(12), 1814-1819. doi:10.1111/exd.14416
491. Weiden, J, Schluck, M, Ioannidis, M, van Dinther, EAW, Rezaeeyazdi, M, Omar, F, Steuten, J, Voerman, D, Tel, J, Diken, M, Bencherif, SA, Figdor, CG, & Verdoes, M. (2021). Robust Antigen-Specific T Cell Activation within Injectable 3D Synthetic Nanovaccine Depots. *ACS Biomater Sci Eng*, 7(12), 5622-5632. doi:10.1021/acsbomaterials.0c01648
492. Weissinger, EM, Metzger, J, Schleuning, M, Schmid, C, Messinger, D, Beutel, G, Wagner-Drouet, EM, Schetelig, J, Baurmann, H, Rank, A, Stolz, F, Schäfer-Eckart, K, Westphal, K, Bethge, W, von Harsdorf, S, Bunjes, DW, Heidenreich, D, Klein, S, Holler, E, Kreipe, HH, Jonigk, D, Tüürüchanow, I, Raad, J, Papkalla, A, von der Leyen, H, Hambach, L, Hamwi, I, Ehrlich, S, Krauter, J, Stadler, M, & Ganser, A. (2021). A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy. *Leukemia*, 35(6), 1763-1772. doi:10.1038/s41375-020-01059-3
493. *Wellbrock, M, Spix, C, Grabow, D, Borkhardt, A, Zeeb, H, & Erdmann, F. (2021). 28-year incidence and time trends of childhood leukaemia in former East Germany compared to West Germany after German reunification: A study from the German Childhood Cancer Registry. *Cancer Epidemiol*, 73, 101968. doi:10.1016/j.canep.2021.101968
494. Wenzel, M, Borgmann, H, Von Hardenberg, J, Cash, H, Welte, MN, Bründl, J, Hoffmann, MA, Höfner, T, & Borkowetz, A. (2021). Acceptance, Indications and Chances of Focal Therapy in Localized Prostate Cancer: A Real-World Perspective of Urologists in Germany. *J Endourol*, 35(4), 444-450. doi:10.1089/end.2020.0774
495. Wenzel, M, von Hardenberg, J, Welte, MN, Doryumu, S, Hoeh, B, Wittler, C, Höfner, T, Kriegmair, MC, Michel, MS, Chun, FK, Herrmann, J, Mandel, P, & Westhoff, N. (2021). Monoprophylaxis With Cephalosporins for Transrectal Prostate Biopsy After the Fluoroquinolone-Era: A Multi-Institutional Comparison of Severe Infectious Complications. *Front Oncol*, 11, 684144. doi:10.3389/fonc.2021.684144
496. Wiegel, T, Albers, P, Bartkowiak, D, Bussar-Maatz, R, Härter, M, Kristiansen, G, Martus, P, Wellek, S, Schmidberger, H, Grozinger, K, Renner, P, Schneider, F, Burmester, M, & Stöckle, M. (2021). Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial). *J Cancer Res Clin Oncol*, 147(1), 235-242. doi:10.1007/s00432-020-03327-2

497. *Wiesmann, N, Gieringer, R, Viel, M, Eckrich, J, Tremel, W, & Brieger, J. (2021). Zinc Oxide Nanoparticles Can Intervene in Radiation-Induced Senescence and Eradicate Residual Tumor Cells. *Cancers (Basel)*, 13(12). doi:10.3390/cancers13122989
498. *Wild, J, Distelmeier, S, Keil, P, Weinmann, A, Münzel, T, Weinmann-Menke, J, & Kraus, D. (2021). Non-bacterial thrombotic endocarditis in a patient with pancreatic carcinoma. *Echocardiography*, 38(8), 1455-1458. doi:10.1111/echo.15140
499. *Wingerter, A, El Malki, K, Sandhoff, R, Seidmann, L, Wagner, DC, Lehmann, N, Vewinger, N, Frauenknecht, KBM, Sommer, CJ, Traub, F, Kindler, T, Russo, A, Otto, H, Lollert, A, Staatz, G, Roth, L, Paret, C, & Faber, J. (2021). Exploiting Gangliosides for the Therapy of Ewing's Sarcoma and H3K27M-Mutant Diffuse Midline Glioma. *Cancers (Basel)*, 13(3). doi:10.3390/cancers13030520
500. Wischnewsky, M, Schwentner, L, Diessner, JD, De Gregorio, A, Joukhadar, R, Davut, D, Salmen, J, Bekes, I, Kiesel, M, Müller-Reiter, M, Blettner, M, Wolters, R, Janni, W, Kreienberg, R, Wöckel, A, & Ebner, F. (2021). BRENDA-Score, a Highly Significant, Internally and Externally Validated Prognostic Marker for Metastatic Recurrence: Analysis of 10,449 Primary Breast Cancer Patients. *Cancers (Basel)*, 13(13). doi:10.3390/cancers13133121
501. *Witzens-Harig, M, Viardot, A, Keller, U, Wosniok, J, Deuster, O, Klemmer, J, Geueke, AM, Meißner, J, Ho, AD, Atta, J, Marks, R, La Rosée, P, Buske, C, Dreyling, MH, & Hess, G. (2021). The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatin (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial. *Hemasphere*, 5(10), e636. doi:10.1097/hs9.0000000000000636
502. *Woelfinger, P, Hauptrock, B, Kriege, O, Wagner, W, Heider, J, Schwarting, A, Birklein, F, Theobald, M, & Wagner-Drouet, EM. (2021). Alloimmune Myositis as Paraneoplastic Complication of an Oral Squamous Cell Carcinoma After Severe Chronic Graft vs Host Disease or a Manifestation of Chronic Graft vs Host Disease? A Case Report and Literature Discussion. *Transplant Proc*, 53(4), 1365-1368. doi:10.1016/j.transproceed.2020.11.010
503. *Wong, RP, Petriukov, K, & Ulrich, HD. (2021). Daughter-strand gaps in DNA replication - substrates of lesion processing and initiators of distress signalling. *DNA Repair (Amst)*, 105, 103163. doi:10.1016/j.dnarep.2021.103163
504. *Woods, K, & Guezguez, B. (2021). Dynamic Changes of the Bone Marrow Niche: Mesenchymal Stromal Cells and Their Progeny During Aging and Leukemia. *Front Cell Dev Biol*, 9, 714716. doi:10.3389/fcell.2021.714716
505. Xyländer, M, Bayer, O, Schranz, M, Ihrig, A, Flohr-Schmitt, E, Besseler, M, Bruns, G, Gelse, N, Wünsch, A, Singer, S, & Meyer, T. (2021). [Specific Contribution of Psychosocial Cancer Counselling Centers - Perspectives of the Person Seeking Advice and the Referring Professional]. *Psychother Psychosom Med Psychol*, 71(9-10), 363-369. doi:10.1055/a-1480-8037
506. Yamada, Y, Simon-Keller, K, Belharazem-Vitacolonna, D, Bohnenberger, H, Kriegsmann, M, Kriegsmann, K, Hamilton, G, Graeter, T, Preissler, G, Ott, G, Roessner, ED, Dahmen, I, Thomas, RK, Ströbel, P, & Marx, A. (2021). A Tuft Cell-Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes. *J Thorac Oncol*, 16(6), 1003-1016. doi:10.1016/j.jtho.2021.02.008
507. Yun, H, Narayan, N, Vohra, S, Giotopoulos, G, Mupo, A, Madrigal, P, Sasca, D, Lara-Astiaso, D, Horton, SJ, Agrawal-Singh, S, Meduri, E, Basheer, F, Marando, L, Gozdecka, M, Dovey, OM, Castillo-Venzor, A, Wang, X, Gallipoli, P, Müller-Tidow, C, Osborne, CS, Vassiliou, GS, & Huntly, BJP. (2021). Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. *Nat Genet*, 53(10), 1443-1455. doi:10.1038/s41588-021-00925-9
508. *Zahnreich, S, Gebrekidan, S, Multhoff, G, Vaupel, P, Schmidberger, H, & Mayer, A. (2021). Oxygen Deprivation Modulates EGFR and PD-L1 in Squamous Cell Carcinomas of the Head and Neck. *Front Oncol*, 11, 623964. doi:10.3389/fonc.2021.623964
509. *Zahnreich, S, & Schmidberger, H. (2021). Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies. *Cancers (Basel)*, 13(11). doi:10.3390/cancers13112607
510. Zaremba, A, Kramer, R, De Temple, V, Bertram, S, Salzmann, M, Gesierich, A, Reinhardt, L, Baroudjian, B, Sachse, MM, Mechttersheimer, G, Johnson, DB, Weppler, AM, Spain, L, Loquai, C, Dudda, M, Pföhler, C, Hepner, A, Long, GV, Menzies, AM, Carlino, MS, Lebbé, C, Enokida, T, Tahara, M, Bröckelmann, PJ, Eigentler, T, Kähler, KC, Gutzmer, R, Berking, C, Ugurel, S, Stadtler, N, Sucker, A, Becker, JC, Livingstone, E, Meier, F, Hassel, JC, Schadendorf, D, Hanoun, M, Heinzerling, L, & Zimmer, L. (2021). Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A

Descriptive Observational Retrospective Multicenter Analysis. *Front Oncol*, 11, 765608. doi:10.3389/fonc.2021.765608

511. Zaremba, A, Philip, M, Hassel, JC, Glutsch, V, Fiocco, Z, Loquai, C, Rafei-Shamsabadi, D, Gutzmer, R, Utikal, J, Haferkamp, S, Reinhardt, L, Kähler, KC, Weishaupt, C, Moreira, A, Thoms, KM, Wilhelm, T, Pföhler, C, Roesch, A, Ugurel, S, Zimmer, L, Stadler, N, Sucker, A, Kiecker, F, Heinzerling, L, Meier, F, Meiss, F, Schlaak, M, Schilling, B, Horn, S, Schadendorf, D, & Livingstone, E. (2021). Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases. *Eur J Cancer*, 152, 139-154. doi:10.1016/j.ejca.2021.04.032
512. Zattoni, F, Heidegger, I, Kasivisvanathan, V, Kretschmer, A, Marra, G, Magli, A, Preisser, F, Tilki, D, Tsaor, I, Valerio, M, van den Bergh, R, Kesch, C, Ceci, F, Fankhauser, C, & Gandaglia, G. (2021). Radiation Therapy After Radical Prostatectomy: What Has Changed Over Time? *Front Surg*, 8, 691473. doi:10.3389/fsurg.2021.691473
513. Zhu, AX, Finn, RS, Kang, YK, Yen, CJ, Galle, PR, Llovet, JM, Assenat, E, Brandi, G, Motomura, K, Ohno, I, Daniele, B, Vogel, A, Yamashita, T, Hsu, CH, Gerken, G, Bilbruck, J, Hsu, Y, Liang, K, Widau, RC, Wang, C, Abada, P, & Kudo, M. (2021). Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. *Br J Cancer*, 124(8), 1388-1397. doi:10.1038/s41416-021-01260-w
514. *Zilio, N, & Ulrich, HD. (2021). Exploring the SSBreakome: genome-wide mapping of DNA single-strand breaks by next-generation sequencing. *FEBS J*, 288(13), 3948-3961. doi:10.1111/febs.15568
515. Zimbelmann, M, Neppert, B, Piria, R, Babst, N, Ponto, KA, Grisanti, S, Heindl, LM, & Kakkassery, V. (2021). [Treatment and management of orbital tumors]. *Ophthalmologe*, 118(10), 1004-1011. doi:10.1007/s00347-021-01471-9
516. Zolotovskaia, M, Tkachev, V, Sorokin, M, Garazha, A, Kim, E, Kantelhardt, SR, Bikar, SE, Zottel, A, Šamec, N, Kuzmin, D, Sprang, B, Moisseev, A, Giese, A, Efimov, V, Jovčevska, I, & Buzdin, A. (2021). Algorithmically Deduced FREM2 Molecular Pathway Is a Potent Grade and Survival Biomarker of Human Gliomas. *Cancers (Basel)*, 13(16). doi:10.3390/cancers13164117
517. Zschoernack, V, Jünger, ST, Mynarek, M, Rutkowski, S, Garre, ML, Ebinger, M, Neu, M, Faber, J, Erdlenbruch, B, Claviez, A, Bielack, S, Brozou, T, Frühwald, MC, Dörner, E, Dreschmann, V, Stock, A, Solymosi, L, Hench, J, Frank, S, Vokuhl, C, Waha, A, Andreiulo, F, & Pietsch, T. (2021). Supratentorial ependymoma in childhood: more than just RELA or YAP. *Acta Neuropathol*, 141(3), 455-466. doi:10.1007/s00401-020-02260-5